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Abstract 
In view of the increasing global challenge of bacterial resistance, there exists an 
urgent need for the rationale development of antibacterial compounds with either 
novel or multiple mechanisms of action. Two chalcone-derivatives, F1 and F23, 
demonstrated MICs within the range of 16 to >512 µg/ml against two plant 
pathogens (P. caratovoram and C. michiganensis subsp. michiganensis) as well 
as important clinical bacterial species. Both compounds displayed an MIC of 32 
µg/ml against quinolone-resistant S. aureus. Whilst possessing weak activities 
individually, each semi-synthetic agent displayed notable synergistic action with 
polymyxin B against S. aureus, C. violaceum, E. coli and Ps. aeruginosa, thereby 
recording FICs within the range of <0.093 to 2 that indicated the existence of 
synergism in some instance. These chalcone compounds applied with polymyxin 
B displayed a notable FICindex of <0.093 against the Neisseriaceae C. violaceum, 
and a potential noteworthy capacity to extend the spectrum of activity of the 
latter antibiotic to include Gram-positive S. aureus species. F1 inhibited 
staphylococcal replication in broth and the combination of either of both 
chalcone-derivatives with polymyxin B instituted a metabolic blockage in S. 
aureus and other bacterial species as determined through a modified MTT 
reduction assay. The combined agents inflicted major disruptions to the S. 
aureus cytoplasmic membrane bilayer as evidenced by the release of intracellular 
potassium as well as the influx of Sytox Green fluorescent stain. Notable levels of 
cell membrane potential dissipation, leakage of intracellular potassium ions and 
blockage of reducing enzymes activities occurred within the first 30 minutes, well 
in advance of significant loss in cell viability that was recorded usually after 4 – 8 
hours, suggesting these activities were prerequisites to cell death. In erythrocyte 
lysis assay, the synergistic combinations of 128 µg/ml of either of both chalcone 
derivatives with 128 µg/ml polymyxin B displayed the lowest degree of 
haemolysis, followed by that occurring with 32 µg/ml of the chalcone-derivatives 
combined with 256 µg/ml of the polypeptide antibiotic. In conclusion, further 
structure activity modifications aimed at improving the aqueous solubility of 
these chalcone-derivatives as well as the antibacterial activity recorded for 
certain combination concentrations of polymyxin B with either of these semi-
synthetic agents may be required before considerations are made for the 
possibility for potential external formulations. Such preparations may include 
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antiseptic creams, lotions, ointments, as well as aerosols that can be applied with 
nebulizers in targeted delivery for such cases like cystic fibrosis.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
Acknowledgements 
Obviously, this fascinating but sometimes daunting as well as iconic journey is 
now coming to an end. It required a clear vision, defined purpose, sound mind 
and an unswerving focus.  
During these years, I have met and worked with several people who must be 
thanked for their invaluable support, help and encouragement. I wish to thank 
the Robert Gordon University, Institute of Social Welfare and Health Research, 
School of Pharmacy and Life Sciences as well as their staff for granting me 
access to their facilities.  
I am deeply grateful to my principal supervisor Dr. Andrew James Lamb as well 
as to my alternate supervisors, Drs. Kerr H. Matthews and Di Salvo Alberto. 
Upon my request, Andrew offered me the opportunity to work in this project, 
showing a consistently immense as well as an unsurpassable commitment, 
enthusiasm and guidance over the years. His extensive knowledge in the field of 
study, invaluable advices as well as the demonstrated willingness to meticulously 
and critically read through this dissertation is much appreciated. Furthermore, I 
wish to thank the collaborators in this project including Dr. Richard Brown, Juliet 
Wilcox and Sherif B. Abdel Ghani of the School of Chemistry, University of 
Southampton, as well as Ziddan H. Ziddan and Huessein M. Ali of the Plant 
Protection Department and Agricultural Biochemistry Department respectively, 
both within the Faculty of Agriculture, Ain Shams University, Egypt. 
I am thankful for the firm and unbiased role, as well as the comments of Dr. 
Jeanette Robertson during my transfer to PhD. process. They have indeed helped 
tremendously. 
I also wish to thank late Ms. Vivienne Hamilton, Mrs. Moira Innes, Mrs, Angela 
Ross, Mrs. Margaret Brown, Drs. Noelle O’Driscoll, Olga Labovitiadi and Tina 
Lowes for the cordial working relationship we shared in the laboratories, 
especially PA27. Upon Andrew’s request, Noelle was supportive when I needed to 
setup the first protocol for MIC determination using the micro titre plate reader. 
Thanks to Dr. Susanne Boyle for the group tutorial on the use GraphPad prism 
software and to Dr. Tina Lowes for the recent tutorial on cDNA synthesis and 
PCR. Many thanks to Dr. Colin Thompson for providing guidance on the use of 
Perkin Elmer LS Luminescence Spectrometer and to Dr. Stuart Cruickshank for 
instructions on the use of the fluorescent microscopes. I also wish to appreciate 
vii 
 
Mrs. Moira Middleton for her kindness in the chemistry laboratory as well as both 
Mr. Raymond Reid and Mrs. Maureen Byres for their assistance on the use of the 
flame emission spectrophotometer. Mr. Brian Dejonckheere was always willing to 
assist in issues related to computer hard and softwares, even when approached 
along the corridors. I really appreciate. I also acknowledge my office mates 
including Dr. Vibhu Paudyal, Dr. Maxwell Dapar, Chidinma Ibie, Oke Ndu, 
Caroline Macleod and Donald Philips. Thanks to Omo and Aakash, two of my 
contemporaries who are based in the Garthdee and St. Andrew’s campuses 
respectively. 
The most special thanks are to my friends and family members. The unexpected 
and sudden transition of my mum, Mrs. Anna Medu, 6 months into the 
commencement of this project and at a time we thought we needed her most as 
a family made me really sad. She had encouraged me to move on with the 
opportunity when it arose and I miss her dearly and daily, but pray her soul finds 
solace in the LORD’s bosom; for death is such a terrible short-changer.  My 
appreciations to my wife, Tejiri, for her prayers. I am also thankful for our 
children Ano and Rode, especially the succour and humour they provide. I also 
appreciate my siblings (especially Igho and Orho), for their encouragements and 
courage during our most trying period. I am most especially thankful for all the 
support provided by my parents (in-law), Mr. and Mrs. James Omeru, all through 
this period. They are exceptionally wonderful people. Finally, I wish to 
acknowledge Mr. and Mrs. Esse Agbasi, Mrs. Awopetu, Dr. and Mrs. Jonathan 
Alao (MD), Dr. Uvie Mafuru (MD), Dr. A.O Oyedele, Professor Onawunmi, 
Professor Wilson Erhun, Dr. Andrew Onosode and my beloved dad, Mr. Nevice U 
Medu. 
 
 
 
 
 
 
 
viii 
 
“... your main problem is that you do not think” – Professor 
Adebayor Lamikanra. 
 
“Truly, thoughts are things, and powerful things at that, 
when they are mixed with definiteness of purpose, 
persistence and a burning desire for their translation into 
riches, or other material objects.” - Napoleon Hill’s ‘think and 
grow rich’. 
 
“I am yet to know a man who stumbled into success” – 
Napoleon Hill. 
 
“Let not your heart be troubled .... In my Father’s house are 
many mansions (rooms and opportunities). For if it were not 
so, I would have told you.” – Jesus of Nazareth. 
 
 
 
 
 
 
 
 
ix 
 
 
 
 
 
 
 
In memory of my dear and caring mum, 
Mrs. Anna B. Medu – Nee Orogodo Oyibo 
 
 
 
 
 
 
 
x 
 
Table of Contents 
Abstract ................................................................................................... iv 
Aknowledgements ..................................................................................... vi 
Some quotations ...................................................................................... viii 
Dedication ................................................................................................ ix 
Table of contents ........................................................................................ x 
Index of figures ...................................................................................... xxiii 
Index of tables ..................................................................................... xxviii 
Abbreviations ......................................................................................... xxix 
Chapter 1: Introduction ............................................................................... 1 
1.1 Common causes of infections ................................................................. 1 
1.2 Common pathogenic bacterial species ..................................................... 1 
1.2.1 Staphylococcus aureus ........................................................................ 1 
1.2.1.1 Pathogenicity of S. aureus ................................................................ 1 
1.2.1.2 Phenotypes of resistant S. aureus and impact on antibiotic therapy ....... 2 
1.2.1.3 Cell wall structure and staphylococcal resistance to antimicrobial 
compounds  ............................................................................................... 3 
1.2.1.4 Genes and enzymes that regulate staphylococcal wall biosynthesis 
as potential targets for novel antibacterial compounds  ................................... 5 
1.2.2 Pseudomonas aeruginosa .................................................................... 7 
1.2.2.1 The pathogenicity of Ps. aeruginosa ................................................... 7 
xi 
 
1.2.2.2 Mechanisms of Ps. aeruginosa resistance to antimicrobial agents........... 7 
1.2.3 Other bacterial pathogens  .................................................................. 9 
1.3 Types of bacterial resistance  ............................................................... 10 
1.3.1 Bacterial resistance to antibiotics due to mutation and active efflux 
mechanisms  ........................................................................................... 10 
1.3.2 Biofilm induced resistance to antimicrobial agents  ............................... 11 
1.3.3 Effect of biofilms on bacterial susceptibility to β-lactam antibiotics ......... 12 
1.4 Influence of biofilms upon bacterial susceptibility to other 
antimicrobial compounds  .......................................................................... 13 
1.5 Mechanism of action, emergence and dissemination of bacterial 
resistance to antimicrobial compounds  ....................................................... 14 
1.5.1 Mechanism of action of antibacterial compounds  ................................. 14 
1.5.2 Bacterial resistance to antibacterial compounds ................................... 15 
1.5.2.1 β-lactams ..................................................................................... 15 
1.5.2.2 Aminoglycosides ............................................................................ 17 
1.5.2.3 Tetracyclines ................................................................................ 17 
1.5.2.4 Fluoroquinolones ........................................................................... 18 
1.5.2.5 Newer antibacterial compounds in clinical use ................................... 19 
1.5.2.5.1 Telavancin, oritavancin and vancomycin ........................................ 19 
1.5.2.5.2 Linezolid .................................................................................... 20 
1.5.2.5.3 Daptomycin ............................................................................... 21 
1.5.2.5.4 Telithromycin ............................................................................. 22 
xii 
 
1.5.2.5.5 Polymyxins ................................................................................ 22 
1.5.2.5.5.1 Adverse effects of polymyxins ................................................... 23 
1.5.3 The re-assessment and renewed clinical application of polymyxin B 
and colistin .............................................................................................. 23 
1.5.3.1 Development of modified polymyxins ............................................... 24 
1.6 Flavonoids as a potential source of antimicrobial compounds .................... 25 
1.7 Combinational antimicrobial therapy ...................................................... 27 
1.7.1 Combination of antibacterial compounds in clinical use ......................... 28 
1.7.2 Combination of antibiotics with agents that are devoid of 
antibacterial actions themselves ................................................................. 29 
1.7.3 Combination of antibiotics with cationic peptides .................................. 30 
1.8 Biological redox reactions ..................................................................... 31 
1.8.1 The electron transport chain and respiratory process in prokaryotic 
cells ........................................................................................................ 31 
1.8.2 Generating the electrochemical gradient and the electron transport 
chain ...................................................................................................... 32 
1.8.3 MTT reduction assay ......................................................................... 32 
1.8.4 Enzymes responsible for biological reduction reactions .......................... 33 
1.8.4.1 NADH dehydrogenase, Cytochrome Q, C and ATP synthase ................ 34 
1.8.4.2 Succinate dehydrogenase and other enzymes ................................... 35 
1.8.5 Tetrazolium salts reduction in eukaryotic and prokaryotic cells ............... 36 
1.8.6 Sub-cellular sites of MTT reduction ..................................................... 37 
1.8.6.1 Evidence for the sub-cellular localisation of MTT reduction .................. 37 
xiii 
 
1.8.6.2 Contrary opinions on the sub-cellular sites for MTT reduction .............. 38 
1.9 Aims and objectives of the study .......................................................... 39 
Chapter 2: Materials and Methods .............................................................. 40 
2.1: Chemicals and reagents ...................................................................... 40 
2.1.1: Dissolution of semi-synthetic chromones, and selected antimicrobial 
compounds .............................................................................................. 40 
2.1.2: Growth media and bacterial diluents .................................................. 40 
2.1.2.1: General growth media and diluents ................................................ 40 
2.1.3: Miscellaneous chemical compounds and fluorescent dye ...................... 41 
2.1.4: Laboratory equipment ..................................................................... 41 
2.2: Bacterial storage and cultivation .......................................................... 41 
2.2.1: Bacterial species and strains ............................................................ 41 
2.2.2: Bacterial storage ............................................................................. 42 
2.2.3: Bacterial sub-culture ....................................................................... 42 
2.2.3.1: Preparation of bacterial master plates ............................................. 42 
2.2.3.2: Preparation of bacterial experimental culture ................................... 42 
2.3: Preparation of bacterial enumeration graphs ......................................... 43 
2.3.1: Preparation of bacterial suspension ................................................... 43 
2.3.2: Preparation of agar plates ................................................................ 43 
2.3.3: Dilution of bacterial suspensions and plating out ................................. 43 
2.3.4: Enumeration of viable cells ............................................................... 44 
2.4: Preparing bacterial suspension with a defined density ............................ 44 
xiv 
 
2.4.1: Applying the enumeration graph to estimate bacterial density in a 
suspension .............................................................................................. 44 
2.4.2: Verifying cell density of the bacterial suspension ................................. 44 
2.5: Bacterial susceptibility testing ............................................................. 45 
2.5.1: Determination of the MIC of some antimicrobial compounds ................. 45 
2.5.2: Determination of MIC of compounds with poor aqueous solubility ......... 46 
2.5.3: Determining minimum bactericidal concentration for test 
compounds .............................................................................................. 47 
2.6: Evaluating the mode of action of chromone-derivatives in 
combination with other antibiotics .............................................................. 47 
 Chapter 3: Examination of test bacterial susceptibility to the chalcone-
derivatives and selected antimicrobial compounds ........................................ 49 
3.1: Introduction ...................................................................................... 49 
3.2: Materials and methods ....................................................................... 50 
3.2.1: Examination of bacterial sensitivity to the chalcone-derivatives 
using a modified agar dilution assay ........................................................... 50 
3.2.2: MIC determination for test compounds against test bacterial 
species .................................................................................................... 51 
3.2.3: Determination of MBCs for chalcone-derivatives and antimicrobial 
compounds against test bacterial species .................................................... 52 
3.3: Results ............................................................................................. 52 
3.3.1: Screening the series of chalcone-derivatives for antibacterial 
potency ................................................................................................... 52 
3.3.2: Susceptibility of S. aureus to the semi-synthetic chromone-
derivatives ............................................................................................... 54 
xv 
 
3.3.3: Determining the MIC of selected antimicrobial compounds ................... 62 
3.4: Discussion ........................................................................................ 65 
3.5: Conclusion ........................................................................................ 69 
 Chapter 4: Examining the antibacterial effect of chalcone-derivatives 
alone and with antibiotics .......................................................................... 70 
4.1: Introduction ...................................................................................... 70 
4.2: Materials and Methods ........................................................................ 73 
4.2.1: Evaluation of the effect of the chalcone-derivatives in combination 
with selected antibiotics ............................................................................ 73 
4.3: Results ............................................................................................. 73 
4.3.1: The antibacterial action of F1 applied in combination with either 
polymyxin B or ciprofloxacin ...................................................................... 73 
4.3.2: The antibacterial action of F23 applied in combination with 
polymyxin B ............................................................................................. 79 
4.4: Discussion ........................................................................................ 82 
4.5: Conclusion ........................................................................................ 90 
 Chapter 5: Evaluating the mode of action for polymyxin B chromone-
derivatives combinations ........................................................................... 91 
5.1: Introduction ...................................................................................... 91 
5.2: Materials and Methods ........................................................................ 93 
5.2.1: Time-course viability assay for bacterial suspensions treated with a 
single test compound ................................................................................ 93 
5.2.2: Time-course viability assay for bacterial suspensions challenged 
with polymyxin B applied with the chalcone-derivatives ................................. 94 
xvi 
 
5.2.3: Statistical analysis of data ................................................................ 95 
5.3: Results ............................................................................................. 95 
5.3.1: Examination of the activity of F1 applied alone and with polymyxin 
B upon selected strains of S. aureus species ................................................ 95 
5.3.1.1: Bactericidal activity of F1-polymyxin B combination against 
methicillin-resistant S. aureus .................................................................... 95 
5.3.1.2: Effect of F1 concentrations upon the viability of methicillin-
resistant S. aureus ................................................................................... 97 
5.3.1.3: Effect of F1 applied in combination with polymyxin B upon the 
viability of methicillin-resistant S. aureus .................................................... 99 
5.3.1.4: Effect of F1 concentrations upon the viability of quinolone-
resistant S. aureus (QRSA) under growth conditions ................................... 100 
5.3.1.5: Bactericidal activity of F1 with polymyxin B against quinolone-
resitant strain of S. aureus (QRSA) ........................................................... 102 
5.3.2: Examining the antibacterial effect of F1 with polymyxin B against 
Gram-negative bacterial species ............................................................... 103 
5.3.2.1: Bactericidal activity of sub-inhibitory concentrations of F1 with 
polymyxin B against C. violaceum ............................................................ 104 
5.3.2.2: Bactericidal activity of F1-polymyxin B combination against Ps. 
aeruginosa ............................................................................................ 105 
5.3.3: Kinetic colony counting for Gram-positive bacterial species 
challenged with F23 and polymyxin B ........................................................ 107 
5.3.3.1: Synergistic activity of F23 with polymyxin B against S. aureus 
6571 (MSSA) ......................................................................................... 108 
5.3.3.2: Synergistic activity of F23 with polymyxin B against S. aureus 
11940 MRSA .......................................................................................... 110 
xvii 
 
5.3.3.3: Antibacterial action of F23 with polymyxin B against QRSA .............. 111 
5.3.4: Kinetic colony counting for Gram-negative bacterial species 
challenged with F23 and polymyxin B ........................................................ 113 
5.3.4.1: Antibacterial action of F23 with polymyxin B against C. violaceum .... 113 
5.3.4.2: Bactericidal action of F23 with polymyxin B against Ps. 
aeruginosa ............................................................................................ 114 
5.3.5: Summary of data for the examination of the effects of the 
chalcone-derivatives in combination with polymyxin B against bacterial 
species viability ...................................................................................... 116 
5.4: Discussion ...................................................................................... 117 
5.5: Conclusion ...................................................................................... 127 
 Chapter 6: Evaluating the effect of polymyxins chalcone-derivatives 
combinations upon bacterial metabolism ................................................... 128 
6.1: Introduction .................................................................................... 128 
6.2: Materials and Methods ...................................................................... 130 
6.2.1: Preparation of Luria Bertani glycerol (LBG) broth .............................. 130 
6.2.2: Preparation of bacterial culture in LBG medium ................................. 130 
6.2.3: Establishing a correlation between bacterial density and quantity of 
formazan crystals produced ..................................................................... 131 
6.2.4: Examining the effects of polymyxins with the chalcone-derivatives 
upon bacterial metabolism ....................................................................... 131 
6.3: Results ........................................................................................... 132 
6.3.1: Calibration curves for formazan quantity produced by bacterial 
populations ............................................................................................ 132 
xviii 
 
6.3.2: Evaluating the effect of polymyxin B upon selected bacterial 
metabolism ............................................................................................ 134 
6.3.2.1: Impact of polymyxin B upon E. coli metabolism ............................. 134 
6.3.2.2: Impact of polymyxin B upon the metabolic activity of S. aureus ....... 137 
6.3.2.3: Impact of polymyxin B on the metabolic activity of Ps. aeruginosa ... 138 
6.3.3: Evaluating the effect of colistin upon the activity of reducing 
enzymes in selected bacterial species ....................................................... 140 
6.3.3.1: Effect of colistin upon the activity of reducing enzymes in E. coli ...... 140 
6.3.3.2: Examining the effect of colistin upon the reducing enzymes 
activity of MSSA ..................................................................................... 141 
6.3.3.3: Examination of the effect of colistin upon the MTT-reduction 
capacity of Ps. aeruginosa ....................................................................... 142 
6.3.4: Evaluation of the effect of F1 with polymyxin B upon the activity of 
bacterial reducing enzymes...................................................................... 143 
6.3.4.1: Effect of F1 with polymyxin B upon the biological reduction 
capacity of MSSA .................................................................................... 144 
6.3.4.2: Effect of F1 with polymyxin B upon MTT-reduction capacity of 
MRSA .................................................................................................... 145 
6.3.4.3: Effect of F1 with polymyxin B upon the biological reducing 
capacity of quinolone-resistant S. aureus .................................................. 147 
6.3.5: Evaluation of the effect of F23 with polymyxin B upon bacterial 
metabolism ............................................................................................ 148 
6.3.5.1: Effect of F1 with polymyxin B upon reducing enzymes activity of 
MSSA .................................................................................................... 148 
xix 
 
6.3.5.2: Effect of F23 with polymyxin B upon MTT-reducing capacity of 
MRSA .................................................................................................... 150 
6.3.5.3: Effect of F23 with polymyxin B upon the formazan crystals 
production capacity of quinolone-resistant S. aureus ................................... 152 
6.4: Discussion ...................................................................................... 154 
6.4.1: General observations in this protocol ............................................... 154 
6.4.2: Effect of colistin and polymyxin B upon bacterial reducing enzymes 
activity .................................................................................................. 155 
6.4.3: Partial inhibition of biological reducing enzymes activity in E. coli 
and Ps. aeruginosa ................................................................................. 163 
6.4.3.1: Effective drug combinations that impede bacterial enzymes 
activities ............................................................................................... 163 
6.5: Conclusion ...................................................................................... 169 
 Chapter 7: Examining bacterial membrane potential dissipation and 
integrity disruption by polymyxin B combined with the chalcone-
derivatives ............................................................................................. 171 
7.1: Introduction .................................................................................... 171 
7.2: Materials and Methods ...................................................................... 174 
7.2.1: Membrane potential depolarisation and cell microscopy assays ........... 174 
7.2.2: Quantifying potassium lost from bacterial cytoplasm ......................... 175 
7.2.2.1: Preparation of glassware and utencils ........................................... 175 
7.2.2.2: Calibration of atomic emission spectrophotometer .......................... 175 
7.2.2.3: Quantifying leakage of intracellular potassium ions from 
antibiotic-treated S. aureus 6571 ............................................................. 176 
xx 
 
7.2.3: Quantifying influx of Sytox Green into bacterial cytoplasm ................. 176 
7.2.3.1: Preparation of dye stock-solution ................................................. 176 
7.2.3.2: Preparation of experimental sample .............................................. 176 
7.3: Results ........................................................................................... 177 
7.3.1: Assessment of bacterial membrane potential depolarisation ............... 177 
7.3.1.1: Fluorimetry analysis of effect of test compounds upon membrane 
potential ................................................................................................ 177 
7.3.1.2: Membrane potential examination using microscopy ........................ 180 
7.3.1.2.1: Verifying dye-uptake by stained cells ......................................... 180 
7.3.1.2.2: Examining the effect of test compounds upon bacterial 
morphology through fluorescence-time lapse microscopy ............................ 181 
7.3.1.2.3: Time-course morphology assessment for stained untreated cells ... 182 
7.3.1.2.4: Morphological time-kinetics of stained gramicidin-treated cells ...... 183 
7.3.1.2.5: Time-kinetic morphology for stained S. aureus treated with 
polymyxin B ........................................................................................... 183 
7.3.1.2.6: Time-course morphology for bacterial cells stained and 
challenged with chalcone-derivatives ........................................................ 184 
7.3.1.2.7: Time-course morphology changes for stained cells challenged 
with F1 in combination with polymyxin B ................................................... 186 
7.3.1.2.8: Morphological time-kinetics for cells stained and treated with 
both F23 and polymyxin B ....................................................................... 186 
7.3.1.2.9: Summary of data findings from microscopic changes in cells 
fluorescence intensity ............................................................................. 187 
xxi 
 
7.3.2: An assessment of the effect of selected compounds upon bacterial 
membrane integrity through measurement of leaked intracellular K+ ............ 188 
7.3.2.1: Effect of benzalkonium chloride upon bacterial membrane 
integrity ................................................................................................ 188 
7.3.2.2: Effect of polymyxin B with the chalcone-derivatives upon cell 
membrane integrity ................................................................................ 191 
7.3.3: Examining cell membrane disruption with fluorimetry analysis ............ 193 
7.3.3.1: Calibration of the fluorimeter and testing of the protocol ................. 194 
7.3.3.2: Assessing the degree of membrane disruption caused by 
polymyxin B with the chalcone-derivatives ................................................. 196 
7.4: Discussion ...................................................................................... 202 
7.4.1: Membrane depolarisation and the release of S. aureus intracellular 
K+ by the combination of polymyxin B with the chalcone-derivatives ............. 202 
7.4.2: S. aureus membrane disruption and influx of Sytox Green stain.......... 206 
7.4.3: Monitoring morphological changes in S. aureus with fluorescence 
microscopy ............................................................................................ 208 
7.4.4: Combined discussion of the data in this chapter ................................ 210 
7.5: Conclusion ...................................................................................... 213 
 Chapter 8: Erythrocyte lysis assay for polymyxin B combined with either 
of the chalcone derivatives ...................................................................... 214 
8.1: Introduction .................................................................................... 214 
8.2: Materials and Methods ...................................................................... 214 
8.2.1: Erythrocyte lysis assay .................................................................. 214 
8.3: Results ........................................................................................... 215 
xxii 
 
8.3.1: Effect of the test compounds on erythrocyte membrane integrity ........ 215 
8.4: Discussion ...................................................................................... 218 
8.4.1: Haemolytic effect of polymyxin B with the chalcone-derivatives .......... 218 
8.5: Conclusion ...................................................................................... 219 
 Chapter 9: General discussion and future works ......................................... 220 
9.1: The need for new agents and combinations of antibiotics with either 
novel or multiple mechanisms of action ..................................................... 220 
9.2: Enhanced uptake may be a vital step for the synergistic actions of 
polymyxin B with the chalcone-derivatives ................................................. 225 
9.3: Inhibition of efflux mechanisms as a potential mechanism of 
polymyxin B combined with the chalcone-derivatives .................................. 228 
9.4: The semi-synthetic flavonoids (F1 and F23) demonstrated a potential 
to synergistically extend the spectrum and improve the efficacy of 
polymyxin B ........................................................................................... 229 
9.5: Conclusion ...................................................................................... 232 
10: Bibliography ..................................................................................... 234 
11: Appendices ...................................................................................... 299 
11.1: List of the examined chalcone-derivative compounds .......................... 299 
11.2: Calibration curves for S.aureus strains .............................................. 304 
12: List of Publications ............................................................................ 306 
 
 
 
 
xxiii 
 
Index of figures 
Figure 1.1: Diagrammatic representation of bacterial cell wall and 
peptidoglycan ..................................................................................... 3 
Figure 1.2: Diagrammatic representation of bacterial cell wall biosynthesis . 6 
Figure 1.3: Chemical structures of polymyxin B and colistin .................... 22 
Figure 1.4: Basic structures of flavonoids ............................................. 25 
Figure 1.5: Chemical structures of two chalcone-derivatives, F1 and F23 .. 25 
Figure 1.6: Building up the electrochemical gradient that initiates the 
process for ATP generation ................................................................. 32 
Figure 1.7: Schematic diagram of C,N-diphenyl-N-4,5-dimethyl thiazol 2 yl 
tetrazolium bromide (MTT) ................................................................. 33 
Figure 1.8: Diagrammatic representation of the ATP generation pathway 
in bacteria ........................................................................................ 34 
Figure 3.1: MIC of F1 against S. aureus ATCC 1628 (QRSA) .................... 53 
Figure 3.2: MIC of F1 against S. aureus 11940 (MRSA) .......................... 56 
Figure 3.3: MIC of F1 against C. violaceum ........................................... 57 
Figure 3.4: MIC of F23 against S. aureus 11940 (MRSA) ........................ 60 
Figure 3.5: MIC of F23 against C. violaceum ......................................... 61 
Figure 3.6: MIC of F23 against S. aureus 1628 (QRSA) .......................... 62 
Figure 3.7: MIC of polymyxin B against E. coli ....................................... 64 
Figure 4.1: Sample of a chequerboard technique showing serial dilutions 
of two drugs ..................................................................................... 71 
Figure 4.2: Data from chequerboard assays for 16 µg/ml F1 applied with 
either 32 or 64 µg/ml polymyxin B and 8 µg/ml F1 combined with 64 
µg/ml polymyxin B against MRSA ........................................................ 74 
Figure 4.2b: Data from chequerboard assays for 16 µg/ml F1 applied with 
256 µg/ml polymyxin B against MSSA .................................................. 75 
Figure 4.3: Data from chequerboard assays for 8 µg/ml F1 applied with 
either 32 or 16 µg/ml polymyxin B against QRSA .................................. 76 
Figure 4.4: Data from chequerboard assays for 16 µg/ml F1 applied with 2 
µg/ml polymyxin B against C. violaceum .............................................. 78 
Figure 4.4b: Data from chequerboard assays for 16 µg/ml F1 applied with 
0.25 µg/ml polymyxin B against Ps. aeruginosa ..................................... 79 
xxiv 
 
Figure 4.5: Data from chequerboard assays showing the synergistic 
activity of 32 µg/ml F23 applied with 64 µg/ml polymyxin B against S. 
aureus 11940 (MRSA) ........................................................................ 80 
Figure 4.6: Data from chequerboard assays showing the synergistic 
actions of 32 µg/ml F23 applied in combination with either 8 or 16 µg/ml 
polymyxin B as well as 16 µg/ml F23 combined with 16 µg/ml polymyxin 
B against C. violaceum ....................................................................... 82 
Figure 5.1: Synergistic activity for F1 applied with polymyxin B against S. 
aureus 6571 ..................................................................................... 96 
Figure 5.2: The effect of increasing concentrations of F1 applied against S. 
aureus (MRSA) in a time-kinetic assay ................................................. 98 
Figure 5.3: Synergistic activity for F1 applied with polymyxin B against 
MRSA ............................................................................................... 99 
Figure 5.4: Bacteriostatic activity of increasing concentrations of F1 
against QRSA in broth ...................................................................... 101 
Figure 5.5: Synergistic activity for F1 applied with polymyxin B against 
QRSA ............................................................................................. 103 
Figure 5.6: Bactericidal activity of sub-inhibitory concentrations of F1 
applied alone and indifferent activity of sub-inhibitory concentration of F1 
applied with sub-inhibitory concentration of polymyxin B against C. 
violaceum ....................................................................................... 104 
Figure 5.7: Synergistic activity of sub-inhibitory concentrations of F1 
applied with sub-inhibitory concentration of polymyxin B against Ps. 
aeruginosa ..................................................................................... 106 
Figure 5.8: Synergistic activity of sub-inhibitory concentrations of F23 
applied with polymyxin B concentrations against MSSA ........................ 108 
Figure 5.9: Synergistic activity of sub-inhibitory concentrations of F23 
applied with polymyxin B against MRSA .............................................. 110 
Figure 5.10: Synergistic activity of sub-inhibitory concentrations of F23 
applied with sub-inhibitory concentration of polymyxin B against QRSA .. 112 
Figure 5.11: Bactericidal activity of sub-inhibitory concentration of F23 
and indifferent activity of sub-inhibitory concentration of F23 applied with 
sub-inhibitory concentration of polymyxin B against C. violaceum .......... 113 
xxv 
 
Figure 5.12: Synergistic activity of sub-inhibitory concentration of F23 
applied with sub-inhibitory concentration of polymyxin B against Ps. 
aeruginosa ..................................................................................... 115 
Figure 6.1: Absorbance (at A550) of formazan plotted against the 
corresponding optical density (at OD600) of E. coli that produced the 
crystals .......................................................................................... 132 
Figure 6.2: Absorbance (A595) of formazan plotted against the 
corresponding optical density (OD600) of E. coli that produced the crystals134 
Figure 6.3: The effect of 1/20 x MIC, MIC and 4 x MIC of polymyxin B on 
reducing enzyme activity of E. coli ..................................................... 135 
Figure 6.4: Inhibitory effect of 20 x MIC polymyxin B upon the MTT 
reduction capacity of E. coli .............................................................. 136 
Figure 6.5: Concentration-dependent inhibitory effect of polymyxin B upon 
the reducing enzymes activity of MSSA .............................................. 137 
Figure 6.6: Concentration-dependent inhibitory effect of polymyxin B upon 
the reduction capacity of Ps. aeruginosa ............................................. 139 
Figure 6.7: Concentration-dependent inhibitory effect of colistin upon the 
activity of reducing enzymes in E. coli ................................................ 140 
Figure 6.8: Concentration-dependent inhibitory effect of colistin upon the 
reducing enzymes activity of S. aureus 6571 ...................................... 141 
Figure 6.9: Concentration-dependent inhibitory effect of colistin upon the 
MTT-reduction capacity of Ps. aeruginosa ........................................... 143 
Figure 6.10: Enhanced inhibitory effect of F1 applied with polymyxin B 
upon the MTT-reduction capacity of MSSA .......................................... 144 
Figure 6.11: Enhanced inhibitory effect of F1 with polymyxin B upon 
biological MTT-reduction by S. aureus 11940 ...................................... 146 
Figure 6.12: Enhanced inhibitory effect of F1 with polymyxin B upon the 
biological reducing power of QRSA ..................................................... 147 
Figure 6.13: Inhibitory effects of polymyxin B alone and in combination 
with sub-inhibitory concentration of F23 upon the MTT-reducing capacity 
of S. aureus 6571 ............................................................................ 149 
Figure 6.14: The effects of sub-inhibitory concentrations of polymyxin B 
and F23 applied alone as well as together upon the capacity of S. aureus 
11940 ............................................................................................ 151 
xxvi 
 
Figure 6.15: Inhibitory effect of a sub-inhibitory concentration of 
polymyxin B with a sub-inhibitory concentration of F23 applied in 
combination upon the biological reduction capacity of S. aureus 1628 
(QRSA) .......................................................................................... 152 
Figure 7.1: Depolarisation of S. aureus NCTC 11940 membrane potential 
by combined sub-inhibitory concentrations of F1 with polymyxin B in the 
presence of DiOC3(5) ....................................................................... 178 
Figure 7.2: Depolarisation of S. aureus NCTC 11940 membrane potential 
by combined sub-inhibitory concentrations of F23 with polymyxin B in the 
presence of DiOC3 (5) ...................................................................... 179 
Figure 7.3: Inverted fluorescence microscope images taken at x1000 of 
cells stained with Sytox Green and DiOC3(5) after dye-uptake............... 181 
Figure 7.4: DiOC3(5) stained and untreated MRSA cells after (a) 15 
minutes (b) 3 hours ......................................................................... 182 
Figure 7.5: DiOC3(5) stained MRSA cells treated with 256 µg/ml 
gramicidin for (a) 5 minutes  (b) 3 hours and (d) 4 hours ..................... 183 
Figure 7.6: DiOC3(5) stained MRSA cells treated with 64 µg/ml polymyxin 
B for (a) 5 minutes (b) 1 hour (c) 3 hour and (d) 4 hours ..................... 184 
Figure 7.7: DiOC3(5) stained MRSA cells treated with 32 µg/ml F1 for (a) 5 
minutes (b) 1 hour and (c) 4 hours; as well as DiOC3(5) stained MRSA 
cells treated with 32 µg/ml F23 for (d) 5 minutes (e) 1 and (f) 4 hours .. 185 
Figure 7.8: DiOC3(5)-stained MRSA cells treated with 32 µg/ml F1 applied 
with 64 µg/ml polymyxin B for (a) 5 minutes (b) 1 hour and (c) 4 hours 186 
Figure 7.9: DiOC3(5) stained MRSA cells treated with 32 µg/ml F23 with 
64 µg/ml polymyxin B for (a) 5 minutes (b) 1 hour (c) 3 hour and (d) 4 
hours ............................................................................................. 187 
Figure 7.10: Intracellular potassium ion leakage from 1 x 108 cfu/ml S. 
aureus 6571 cells treated with benzalkonium chloride and analysed with 
the flame emission analysis .............................................................. 189 
Figure 7.11: Time-kinetic viability assay for the 1 x 108 cfu/ml S. aureus 
6571 suspension exposed to concentrations of the quaternary ammonium 
compound ...................................................................................... 190 
Figure 7.12: Inducement of potassium ion leakage in S. aureus 6571 
populations challenged with 128 µg/ml of both F1 and polymyxin B ....... 191 
xxvii 
 
Figure 7.13: Inducement of potassium ion leakage in S. aureus 6571 
populations challenged with 128 µg/ml of both F23 and polymyxin B ..... 192 
Figure 7.14: An assessment of the impact of representative antibacterial 
compounds upon membrane integrity of S. aureus 6571 (MSSA) 
populations ..................................................................................... 194 
Figure 7.15: Data from a complementary time-course viability assay for 
the S. aureus 6571 populations challenged with representative 
antibacterial compounds and examined for membrane integrity ............ 195 
Figure 7.16: Determination of the membrane integrity of S. aureus 6571 
(MSSA) challenged with various concentrations of benzalkonium chloride 
and polymyxin B ............................................................................. 197 
Figure 7.17: Determination of the membrane integrity of S. aureus 6571 
(MSSA) challenged with concentrations of benzalkonium chloride, 
polymyxin B, F1 alone and F1 applied in combination with polymyxin B at 
varying strengths ............................................................................ 199 
Figure 7.18: Determination of the membrane integrity of S. aureus 6571 
(MSSA) challenged with concentrations of benzalkonium chloride, 
polymyxin B, F23 alone and F23 in combination with polymyxin B ......... 200 
Figure 8.1: Data for erythocyte cells treated with various concentrations of 
polymyxin B applied alone and in combination with F1 ......................... 215 
Figure 8.2: Data for erythocyte cells treated with various concentrations 
polymyxin B applied alone and in combination with F23 ....................... 216 
Figure 12.1: Calibration curves for S. aureus 6571 (MSSA) ................... 304 
Figure 12.2: Calibration curves for S. aureus 11940 (MRSA) ................. 305 
 
 
 
 
 
 
 
 
 
xxviii 
 
Index of tables 
Table 1.1: Major antibacterial compounds in clinical use and their primary 
mechanism of action .......................................................................... 15 
Table 3.1: Sensitivity of selected test bacterial species to the chalcone-
derivatives, reported as MIC of these compounds from an antibiotic-agar 
dilution assay .................................................................................... 52 
Table 3.2: Susceptibility of S. aureus NCTC 6571 (MSSA) and S. aureus 
NCTC 11940 (MRSA) to the chalcone-derivatives reported as MIC and MBC 
values for these compounds obtained from an antibiotic-broth micro 
dilution assay .................................................................................... 54 
Table 3.3: Susceptibility of test bacterial species to F1 and F23 reported 
as MIC and MBC values for these compounds obtained from an antibiotic-
broth micro dilution and MBC determination assays ............................... 55 
Table 3.4: Susceptibility of S. aureus NCTC 6571 (MSSA) to selected 
antimicrobial compounds reported as MIC and MBC values of these 
compounds ....................................................................................... 63 
Table 3.5: Susceptibility of test bacterial species to polymyxin B and 
colistin (polymyxin E) reported as the MICs and MBCs ........................... 63 
Table 4.1: The data (FICindexes) obtained from a chequerboard assay for F1 
applied in combination with polymyxin B against test bacterial species ..... 73 
Table 4.2: The data (FICindexes) obtained from a chequerboard assay for 
F23 applied in combination with polymyxin B against test bacterial species80 
Table 11.1: Chemical structure, molecular weight and scientific names of 
the examined chalcone derivatives .................................................... 299 
 
 
 
 
 
 
 
xxix 
 
Abbreviations 
A Absorbance 
ATP Adenosine triphosphate 
ATCC American type culture collection 
BZK Benzalkonium chloride 
cAMPs Cationic antimicrobial peptides 
cfu/ml Colony forming units per millilitre 
DNA Deoxyribonucleic acid 
DMSO Dimethyl sulphoxide 
FDA     Food and Drug Administration 
FMN Flavin mononucleotide 
FAD Flavin adenine dinucleotide 
K+   Potassium ions 
LPS   Lipopolysaccharide 
MBC   Minimum bactericidal concentration 
MIC Minimum inhibitory concentration 
MTT C,N-diphenyl-N-4,5-dimethyl thiazol 2 yl tetrazolium bromide 
NADH Nicotinamide adenine dinucleotide  
NAD(P)H Nicotinamide dinucleotide phosphate  
NCTC National collection of type culture 
ND Not determined 
OD Optical density 
RNA Ribonucleic acid 
RGU Robert Gordon University 
rpm Revolution per minute 
SDS Sodium dodecyl sulphate 
SEM Standard error of mean 
SDH succinate dehydrogenase  
UK United Kingdom 
USA United States of America 
XTT 
 
WHO 
2, 3-bis [2-methoxy-4-nitro-5-sulphophophenyl] -2H-
tetrazolium-5-carboxanilide 
World Health Organisation 
xxx 
 
 
1 
 
Chapter 1  
1.0 Introduction 
1.1 Common causes of Infection 
The WHO 2008 health statistics report on infectious, communicable and parasitic 
diseases confirms that such ailments remain the leading cause of morbidity and 
mortality globally (Mathers, Fat and Boerma  2008). The disease conditions 
include diarrhoea, HIV/AIDs, tuberculosis, pneumonia, endocarditis, urinary tract 
infections, malaria, trypanosomiasis and leishmaniasis (Goossens et al. 2005, 
Angulo et al. 2009). Diverse species are responsible for infectious diseases of 
bacterial origin and often include species of common pathogens such as 
Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli. Infections 
are often deep-sited within tissues and as such require treatment with 
antibacterial compounds that are bactericidal in action but also show an excellent 
safety profile towards uninfected host tissues (Liu et al. 2011). Such attributes 
enable the use of long term dosage regiments in order to access deep sites of 
infection, eradicate the pathogen, while at the same time cause  minimal adverse 
effects for the host. Examples of such compounds are ceftriazone, vancomycin, 
teicoplanin, ceftaroline and telavancin, all of which have been used extensively in 
the past with positive outcomes (Liu et al. 2011). 
1.2 Common pathogenic bacterial species 
1.2.1 Staphylococcus aureus  
1.2.1.1 Pathogenicity of S. aureus 
More than 100 years ago, S. aureus was identified as an important pathogenic 
bacterial species (Lowy 1998). This bacterium was first recovered from surgical 
abscess in 1880 and has hitherto been isolated from diverse clinical conditions. 
S. aureus can cause minor skin infections, inflammations, septicaemia, 
respiratory tract and lung infections, endocarditis as well as chronic bone 
infections when in contact with these sites, under conditions that promote cell 
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survival and replication (Liu et al. 2011, Sheagren 1984, Smith et al. 1999, 
Tenover and Moellering 2007, Hersh et al. 2008).  
1.2.1.2 Phenotypes of resistant S. aureus and impact on antibiotic 
therapy 
The evolution, acquisition and dissemination of antibiotic resistance in S. aureus 
have been accompanied by changing disease pathology, epidemiology and 
prognosis (Liu et al. 2011, Bishop and Howden 2007). S. aureus species initially 
developed resistance to penicillin and subsequently to methicillin (Liu et al. 2011, 
Rivera and Boucher 2011). Methicillin-resistant S. aureus (MRSA) is now 
pandemic and has become a major cause of hospital acquired infections globally 
(Enright et al. 2002). More than 19,000 MRSA-related mortalities per annum are 
reported in the U.S.A alone and 70 % of all strains of S. aureus in hospitals are 
methicillin-resistant (Leung et al. 2011). Subsequent emergence of community 
acquired MRSA with genes expressing increased virulence has also been reported 
(Vandenesch et al. 2003, Charlebois et al. 2004, Chambers and DeLeo 2009).  
Teicoplanin and vancomycin are glycopeptides that are reserved for MRSA 
infections because of these drugs effectiveness and the need to preserve their 
clinical utility by reducing the chances for the development of resistance against 
these agents by pathogens (Liu et al. 2011, Enright et al. 2002). But the clinical 
use of these antibiotics has been accompanied by the emergence of glycopeptide 
intermediate- (GISA/VISA) and heterogeneous- resistant S. aureus (h.VISA) 
since about 1993 (Appelbaum  2007). MRSA strains with reduced sensitivity to 
teicoplanin were first reported in 1995 (Mainardi et al. 1995) and was followed in 
1997 by the isolation of S. aureus strains in Japan with reduced sensitivity and 
heterogeneous resistance to vancomycin (Hiramatsu et al. 1997). These two 
incidences increased the volume of international medical debate on the impact of 
evolving bacterial resistance upon the future prospects of antibiotic therapy 
(Hiramatsu et al. 1997). Currently, controversy still exists in the medical 
community on the future role of vancomycin in the treatment of serious 
infections caused by methicillin-resistant S. aureus (Howden et al. 2010).  
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1.2.1.3 Cell wall structure and staphylococcal resistance toantimicrobial 
compounds  
The cell wall of Gram-positive bacteria consists of an inner cytoplasmic 
membrane and a thick outer peptidoglycan (murein) layer with teichoic and 
lipoteichoic acids, as well as cell wall proteins (figure 1.1) (Navarre and 
Schneewind 1999, Heilmann and Götz 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Diagrammatic representation of bacterial cell wall and peptidoglycan (Bugg and Walsh 
1992). 
Peptidoglycan is a semi-flexible exoskeleton required to withstand the internal 
cytoplasmic turgor and osmotic pressure, as well as to function like elastic 
scaffolding that gives shape to the cell (Vollmer and Höltje 2004, Lorian 2005). 
This structure consists of alternating units of uridine diphosphate-N-
acetylglucoseamine and uridine diphosphate-N-acetylmuramic acid that are 
cross-linked with short peptide chains (Paradis-Bleau et al. 2008), thereby 
forming a mesh-like polymeric structure that surrounds the cytoplasmic 
membrane (Vollmer 2007, Vollmer and Born 2009). The continuously cross-
linked mesh forms a polyionic and amphoteric network (Lorian 2005). This 
network is relatively coarse and porous with an exclusion limit of up to 100 000 
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Da that enables antimicrobial compounds (usually 300 to 700 Da in size) to 
readily diffuse through this layer (Lorian 2005).   
Peptidoglycan is an essential component for bacterial viability, growth and 
replication (Goehring and Beckwith 2005) with a conserved composition for 
different strains of S. aureus (Tomasz 2006). The peptidoglycan layer from the 
same strains consists of identical patterns of linear oligo (GlcNac-MurNAc) glycan 
strands when examined with high performance liquid chromatography, 
suggesting that cell wall composition may be strain-specific (Tomasz 2006). This 
may partly explain why different strains of S. aureus express different sensitivity 
to distinct antimicrobial compounds (Howden et al. 2010). 
The bacterial cell wall also contains teichoic acids, long chain polymers made of 
either ribitol or glycerol residues with phosphodiester links and uronic acids. 
These acids are bound to the cell wall as lipoteichoic acid with one end of their 
chain anchored to either phospholipids in the cytoplasmic membrane or attached 
to N-acetylmuramyl residues in the peptidoglycan layer. In both instances, the 
free ends of the teichoic acids protrude at the staphylococcal surface (Bertsche 
2009). The protruding teichoic acids are linked together by hydrophilic 
polysaccharides (various hexose stereoisomers and linkages), that can absorb 
water and transform the layer into a gel known as either glycocalyx, slime, 
alginate or capsule (Lorian  2005, Bertsche  2009). Teichoic acids in the capsule 
contribute to staphylococcal-host cells attachment (Heilmann and Götz 2010, 
Greenberg, Fischer and Joiner 1996). For instance, there is reduced nasal 
colonisation, reduced binding to endothelial cells and attenuated virulence in 
staphylococcal strains with reduced cell wall teichoic acids and in strains with 
gene-mediated annihilation of teichoic acids (Weidenmaier et al. 2005).  The 
mechanism by which S. aureus develops resistance to β-lactams and 
glycopeptides is associated with mutational modifications leading to inactivation 
of penicillin-binding proteins (Howden et al. 2010) and increased thickness of the 
cell wall (Sieradzki, Pinho and Tomasz 1999). Both factors reduce the capacity of 
antibiotics to access and interact with their primary cell wall targets. Resistant 
bacterial species are thought to have developed peptidoglycans with altered 
composition, allowing for a reduced fraction of highly cross-linked muropeptide 
alongside a proportionate increase in the occurrence of muropeptide monomers 
and dimers (Sieradzki, Pinho and Tomasz 1999). Organisms with such altered 
peptidoglycan structures can express reduced susceptibility to antibiotics whose 
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primary target is the impairment of cell wall biosynthesis and may continue to 
replicate in the presence of these compounds. 
1.2.1.4 Genes and enzymes that regulate staphylococcal wall 
biosynthesis as potential targets for novel antibacterial compounds 
An array of genes is known to code for precursors in the biosynthesis of 
staphylococcal cell wall components (De Lencastre et al. 1999). During cell wall 
formation (figure 1.2), these genes therefore code for the stepwise synthesis of 
the pentaglycine bridge that gets attached to the lysine residue of the stem 
peptide (Tomasz 2006, KOPP et al. 1996). Such genes include femX, femA, femB 
and femC (Berger-Bächi and Rohrer 2002). The gene femX, is also referred to as 
fmhB and codes for enzymes responsible for interpeptide formation as well as 
the addition of the 1st glycine interbridge residue to the stem peptide. As would 
be expected, the inactivation of this gene leads to cell death (Rohrer et al. 
1999). The genes femA and femB code for proteins that are responsible for 
interpeptide formation, addition of the 2nd, 3rd, 4th and 5th glycine to the stem 
peptide and their inactivation either abolishes or reduces methicillin resistance 
(Berger-Bächi and Rohrer 2002). The femC codes for glutamine synthetase 
repression and the inactivation of this gene reduces the amidation of glutamate 
of the stem peptide as well as the cell resistance to methicillin (Berger-Bächi and 
Rohrer 2002, Figueiredo et al. 2012). These genes are therefore essential for 
bacterial survival (Hübscher et al. 2007) and could be possible targets for the 
design of novel antibacterial compounds (KOPP et al. 1996). MurF enzyme 
(figure 1.2) catalyses the formation of a peptide bond between D-alanine-D-
Alanine (D-Ala-D-Ala) and the cell wall precursor, uridine 5’-diphosphoryl N-
acetylmuramoyl-L-alanyl-D-glutamyl-meso-diaminopimelic acid (UDP-MurNAc-
Ala-Glu-meso-A2pm) accompanied by the hydrolysis of ATP to ADP and inorganic 
phosphate to produce UDP-N-acetylmuramylpentapeptide. 
A potential antibiotic, MurFp1, in the form of a phage display-derived inhibitor for 
this essential cell wall biosynthesis enzyme (MurF) (figure 1.2) has been 
developed (Paradis-Bleau et al. 2008). MurFp1 enforces a blockage of the 
bacterial wall synthesis by interfering with the utilisation of MurF amide ligase 
enzyme (Paradis-Bleau et al. 2008). 
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Figure 1.2: Diagrammatic representation of bacterial cell wall biosynthesis involving the 
cytoplasmic, membrane as well as periplasmic segments of the pathway. The formed peptidoglycan 
consists of alternating units of uridine diphosphate-N-acetylglucosamine and uridine diphosphate-
N-acetylmuramic acid that are cross-linked with short peptide chains. Adapted from Paradis-Bleau 
et al. 2008. 
In cell wall biosynthesis, Pbp1, Pbp2 and Pbp3 are high molecular weight 
penicillin binding proteins that carry out both transglycosidase and 
transpeptidase functions. In other words, they are essential enzymes for the 
formation of β-1, 4-glycosidase bonds between N-acetyl glucosamine (NAG) and 
N-acetylmuramic acid (NAMA), as well as for the peptide bond linkage of the 
penultimate D-alanine to a glycine receptor on the interbridge, in actively 
An essential enzyme 
inhibited by MurFp1 
antibiotic (Paradis-
Bleau et al. 2008). 
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dividing staphylococcal bacterial species (Maranan et al. 1997, Pinho and 
Errington 2005). Pbp2a encoded by mecA is responsible for S. aureus resistance 
to methicillin (Pinho and Errington 2005). 
 1.2.2 Pseudomonas aeruginosa 
1.2.2.1 The Pathogenicity of Ps. aeruginosa 
Ps. aeruginosa is an ubiquitous and opportunistic Gram-negative bacterium with 
capacity to either cause or contribute to infections in animal hosts (Bais et al. 
2006, Weir 2008). Ps. aeruginosa is the main cause of lung infections in patients 
with cystic fibrosis (Smith et al. 1996) and is also  a leading cause of chronic 
lung infections (Maciá et al. 2005), nosocomial infections that include pneumonia 
(Rello et al. 1996, Gales et al. 2001) and septic shock (Kurahashi et al. 1999). 
The virulence of this bacterium contributes to the aetiology and pathogenesis of 
physical injuries and wounds in burn patients (Lyczak, Cannon and Pier 2000b, 
Lyczak, Cannon and Pier 2000a, Estahbanati, Kashani and Ghanaatpisheh 2002). 
Ps. aeruginosa is a major cause of secondary infection in immune compromised 
patients and nosocomial infections caused by other pathogens (Hill et al. 2005, 
Rowe and Clancy 2006, Bonomo and Szabo 2006). Primary infections caused by 
Ps. aeruginosa and disease conditions associated with this organism are difficult 
to treat because of its inherent and adaptive resistance to antimicrobial 
compounds (Hirakata et al. 2002). 
1.2.2.2 Mechanisms of Ps. aeruginosa resistance to antimicrobial agents 
An effective antimicrobial compound must be able to penetrate the bacterial 
envelope, interact with the target site in sufficiently high concentration and for a 
long enough duration. In Gram-negative bacteria (such as E. coli, Ps. aeruginosa, 
and Chromobacterium violaceum), the degree of permeation of hydrophilic 
antimicrobial agents can be restricted by the lipopolysaccharide layer of the outer 
cell membrane and the underlying phospholipids (Savjani, Gajjar and Savjani 
2009); whilst the translocation of hydrophobic antibiotics is deregulated by over-
expression of outer membrane proteins (Cloete  2003). Ps. aeruginosa is 
intrinsically resistant to many antimicrobial compounds such as macrolides, 
rifampicin and aminoglycosides because of its intact and highly effective outer 
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membrane barrier (Cloete  2003, Hancock  1997a, Normark and Normark 2002), 
thereby causing infections with a high rate of morbidity and mortality (Emerson 
et al. 2002, Kang et al. 2003).  
In addition, this organism has an array of effective multi-drug resistant efflux 
pumps that include MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-OprM 
(Hirakata et al. 2002, Lomovskaya et al. 2001a) which are particularly effective 
against the fluoroquinolones, whose mechanism of uptake is through facilitated 
diffusion (Lewis  1999). However, both MexAB-OprM and MexXY-OprM are broad 
specific multi-drug resistant efflux systems, which can extrude a wide range of 
antibiotics, including hydrophobic as well as amphiphilic antimicrobial compounds 
(Hancock 1997a, Normark and Normark 2002). The over expression of MexCD-
OprJ and MexEF-OprN promotes acquisition of multi-drug resistance through 
mutational hyper expression of efflux mechanisms (Li, Nikaido and Poole 1995, 
Gotoh et al. 1998, Köhler et al. 1999). The mexR and nfxB genes in Ps. 
aeruginosa act as repressors for MexAB-OprM and MexCD-OprJ efflux pumps 
respectively. Mutation in these genes can lead to over expression of these pumps 
with consequent resistance to antimicrobial substrates to which this organism 
was previously susceptible (Evans, Adewoye and Poole 2001). Similarly, 
mutations of these genes can lead to over expression of chromosomal AmpC β-
lactamase causing increased resistance to all β-lactam antibiotics, except 
carbapenems (Quale et al. 2006, Livermore and Woodford 2006). 
Although the outer membrane was previously thought to slow the permeation of 
hydrophobic substrates, findings from other studies show that the efflux systems 
play a more prominent role in the extrusion of hydrophobic antimicrobial 
compounds (Hancock 1997a). Mutant bacterial species defective in specific efflux 
pathways, but without any outer membrane barrier alterations, are considerably 
more susceptible to hydrophobic antibacterial agents than are species with 
effective efflux systems but with altered outer barriers or those possessing 
effective efflux systems with intact outer membrane barriers (Hancock 1997a). 
Hydrophilic antimicrobials permeate the outer membrane through the activated 
porins, which are integral proteins located in the outer membrane (Bayley and 
Jayasinghe 2004). A strain of Ps. aeruginosa that lacks OprD, an outer 
membrane porin selective for certain carbon sources, demonstrates resistance to 
imipenem (Ochs et al. 1999, Tamber, Ochs and Hancock 2006), a reserve 
antibiotic for penicillinase- and β-lactamase- producing bacteria (Rolinson and 
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Geddes 2007). The absence of a 35 kDa outer membrane protein, suggested as 
the port of entry for isothiazolone, is responsible for Ps. aeruginosa resistance to 
this agent (Huang and Hancock 1993, Wolter et al. 2004).  
1.2.3 Other bacterial pathogens  
Chromobacterium violaceum is an organism usually found in mesophilic 
environments (soils and water with temperature within the range of 20 to 45 oC, 
suitable for bacterial species growth), predominantly in the tropics (Ke et al. 
2012). This bacterium belongs to the same family Neisseriaceae along with 
Neisseria meningitidis and Neisseria gonorrhoeae; the causative organisms for 
meningitis and gonorrhoeae respectively (Gillis and Logan 2005, Zinger-Yosovich 
et al. 2006). C. violaceum demonstrates the same antimicrobial susceptibility 
pattern as Neisseria species (to polycationic antimicrobial peptides), although the 
former bacterium is a saprophyte that thrives harmlessly upon their host (Tzeng 
et al. 2005), and a safer organism to work with in the laboratory. The isolation of 
a new strain of N. gonorrhoeae that is untreatable with almost all available 
antibiotics (Bolan, Sparling and Wasserheit 2012) provides further rationale 
justification for the need for continuous development of new potentially effective 
antimicrobial agents, as well as synergistic combinations. 
Pectobacterium caratovoram (formerly Erwinia carotovora) a is a Gram-negative, 
non-sporing facultative anaerobe characterised by the production of large 
amounts of extracellular pectic enzymes applied in the degradation of plant cell 
walls, especially in potatoes (Wegener and Jansen 2007). These enzymes include 
pectinase, cellulase, proteases and xylanases. P. caratovoram is the primary 
cause of tuber decay in store and black leg (stem root) in the field (Czajkowski et 
al. 2011). P. caratovoram is opportunistic with pathogenicity principally in 
potatoes that have compromised immunity (Pérombelon 2002). This organism 
takes advantage of the interplay between the host’s weakened immunity, 
exposure to adverse weather conditions and environmental elements, microbial 
competition and genetic makeup of the cell strain, such as the phage-selected 
lipopolysaccharide mutants with increased bacterial virulence (Pérombelon 2002, 
Evans et al. 2010).  
Clavibacter michiganensis subsp. michiganensis is a Gram-positive, aerobic 
bacterium with corniform morphology. Cl. michiganensis is responsible for 
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tomato canker and therefore regarded as a quarantine bacterium within the 
European Union (Smith, Hennessy and Stead 2001, Van der Wolf et al.  2005, 
Hukkanen et al. 2005). This phytopathogenic bacterium secretes proteases 
employed in the degradation of the polysaccharides in plant cell wall (Gartemann 
et al. 2003). 
1.3 Types of bacterial resistance 
1.3.1 Bacterial resistance to antibiotics due to mutation and active efflux 
mechanisms 
Various mechanisms exist, including adaptive resistance (sometimes known as 
tolerance) in bacteria, which are triggered by either environmental factors or the 
presence of antimicrobial compounds through selective pressure (Albrich, Monnet 
and Harbarth 2004, Alanis 2005). This form of resistance can be both transient 
and non-inheritable, in which case, the affected bacterial populations revert to 
their normal level of sensitivity to compounds upon the removal of the triggering 
agent (Langsrud, Sundheim and Borgmann‐Strahsen 2003, Fernandez et al. 
2010, Fernández, Breidenstein and Hancock 2011). In addition, bacteria can 
demonstrate the expression of either acquired or intrinsic resistance to 
antimicrobial compounds (Normark and Normark 2002). Intrinsic resistance is 
encoded and expressed as part of the genetic make-up of the wild type bacterial 
species or strain (Fernández, Breidenstein and Hancock 2011). Intrinsic bacterial 
resistance is inheritable, stable and independent of exposure to environmental 
factors. Each bacterium in the population is resistant to the compound without 
the need for any additional genetic alterations (Normark and Normark 2002). For 
instance, mycoplasma is resistant to β-lactam antibacterial compounds due to 
the absence of peptidoglycan and a conventional bacterial cell wall (Lamoth and 
Greub 2010). On the other hand, acquired bacterial resistance can occur either 
by mutation (point mutation, deletion, insertion, inversion and duplication) within 
the genome or through horizontal transfer of resistant genes (Normark and 
Normark 2002). The hydrolytic action of β-lactamase to β-lactams and the 
structural modification induced by aminoglycosidase to aminoglycosides are 
classified as acquired resistance (Normark and Normark 2002). Mutated porins 
can express reduced up-take of antibacterial compounds (Livermore, Winstanley 
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and Shannon 2001). Mutations at ribosomal protein level (either methylation or 
mutation of ribosomal rRNA) and mutation in penicillin-binding proteins can 
cause the modification and consequent inactivation of the drug’s target site, 
leading to reduced antibiotic binding and the development of resistance (Davies 
1996, Connell et al. 2003a, Guardabassi and Courvalin 2006). Bacterial 
horizontal acquisition of mecA genes leads to expression of resistance to 
methicillin (Charlebois et al. 2004, Diep et al. 2008) and plasmid coded 
quinolone-resistant (Qnr) proteins confer resistance to fluoroquinolones in Gram-
negative species (Jacoby  2005, Robicsek, Jacoby and Hooper 2006). Once the 
extra chromosomal element (plasmids, transposons or integrons) that harbours 
the resistant genes have been taken up by the actively dividing cells, the 
acquired resistance becomes inheritable, stable, and can be expressed regardless 
of exposure to environmental factors (such as changes in pH and the presence of 
particulate matter), as is also the case with intrinsic resistance (Lewis  2008). 
The expression of up-regulated efflux causes increased dislodgement and 
removal of the antibacterial compounds through actively re-oriented and aligned 
tripartite channels that consist of a transporter in the inner membrane, a 
periplasmic linker protein and a channel protein in the outer membrane of Gram-
negative species (Normark and Normark 2002). 
1.3.2 Biofilm induced resistance to antimicrobial agents 
Structurally, biofilms are arranged such that they consist of an external matrix 
made of polysaccharides, proteins and nucleic acid (Moscoso, García and López 
2006, Flemming and Wingender 2010). This matrix acts as both a scaffolding 
that supports and strengthens the indigenous bacterial cells and as a protective 
barrier that inhibits the penetration of foreign noxious agents. The consequent 
diminished penetrating capacity of antibacterial compound reduces antibiotic 
access to bacterial target sites of action thereby causing either sub-optimal 
efficacy or therapeutic failure (Fernández, Breidenstein and Hancock 2011, Lees 
et al. 2009). The sub-lethal doses to which bacterial cells are exposed can 
promote the development of resistant bacterial strains through selective pressure 
that stimulates mutation. Within bacterial biofilms, concentration gradients occur 
in the distribution of metabolic substrates and products (Wimpenny and 
Kinniment 1995). Cells are differentially exposed to nutrients and oxygen (Singh, 
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Paul and Jain 2006). Consequently, biofilms consist of cells in different metabolic 
and growth phases, such as either slow-growing/stationary or actively dividing 
cells. Even biofilms formed from a homogenous species exhibit heterogeneous 
growth phases within the population (Molin et al. 2000). Cells that are embedded 
deep within the matrix can exist in near anaerobic conditions and adopt slow 
growth modes due to oxygen and nutrient deprivation; an adaptation that is in 
contrast to the cells nearer the matrix surface. Cells in different zones of a 
biofilm will therefore express different sensitivity patterns to various 
antimicrobial compounds, depending on the drug’s mechanism of action (Ito et 
al. 2009). 
In the process of aggregating to form a biofilm, bacterial cells express 
phenotypic traits that differ from their planktonic counterparts (Varnam and 
Evans 2000, Stoodley et al. 2002, Hall-Stoodley, Costerton and Stoodley 2004). 
A major problem associated with bacterial biofilms in infectious diseases is the 
emergence of bacterial resistance to antimicrobial compounds and the immune 
system. Bacterial biofilms can demonstrate resistance due to reduced 
permeability of antimicrobial compounds (Mah and O'Toole 2001, Stewart 2002, 
Burmølle et al. 2010,  Burmølle et al. 2010), while nutrient and oxygen 
distribution gradients that lead to heterogeneous growth phases within the 
matrix (Wimpenny and Kinniment 1995) can cause adaptive stress responses 
(Molin et al. 2000). These adaptive responses together with the over expression 
of efflux pumps, target mutations and existence of persister cells (which take 
longer to get killed), can lead to the resistance of biofilms to antimicrobial agents 
(Stewart 2002). This often results in treatment complications as biofilms can be 
a 1000-fold more resistant to antibiotics than their planktonic counterparts 
(Hoyle and Costerton 1991). For instance, urinary tract infections associated with 
the use of catheters caused by multi-resistant S. epidermidis and Ps. aeruginosa 
are more difficult to treat due to the formation of biofilms on the surfaces of the 
prosthetic devices (Taylor, Prosser and Cleeland 1988, Obst et al. 1989).  
1.3.3 Effect of biofilms on bacterial susceptibility to β-lactam antibiotics 
Biofilms that consist of actively growing homogenous cells are more susceptible 
to applied antibacterial compounds rather than those with heterogeneous growth 
phases of constituent bacteria population (Xu, McFeters and Stewart 2000). 
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Bacteria in the stationary growth zones of a biofilm are strategically positioned to 
survive antimicrobial challenges (Gilbert and Brown 1995). For β-lactam 
antibiotics to be effective, it is required that bacterial cells are in an actively 
dividing mode (Rothstein et al. 2005). Consequently, these compounds are 
unable to eradicate dormant, nutrient- and oxygen-deprived cells in bacterial 
biofilms. Cells in the stationary growth phase in E. coli biofilms have been shown 
to be insensitive to ampicillin but sensitive to ofloxacin and kanamycin (Ito et al. 
2009), probably because of the slower pace of cell wall synthesis during this 
phase.                
The therapeutic application of ampicillin leads to the emergence of a spared 
population that acts as an inoculum after the cessation of antibiotic treatment, 
causing a relapse of infection and re-occurrence of clinical symptoms (Gilbert et 
al. 2002). In addition to the biofilm matrix forming a penetration barrier, should 
the native cells be β-lactamase secreting, the enzyme will accumulate within the 
biofilm causing a large fraction of administered β-lactam antibiotics to be broken 
down, even before being able to access their primary target site (Anderl, Franklin 
and Stewart 2000, Smith  2005). Hence, biofilms of K. pneumonia from β-
lactamase negative strains are more sensitive to ampicillin than biofilms from β-
lactamase-producing strains (Anderl, Franklin and Stewart 2000) due to the 
absence of drug-inactivation in the former instance.  
1.4 Influence of biofilms upon bacterial susceptibility to other 
antimicrobial compounds 
Metabolically active cells in Ps. aeruginosa biofilms are able to develop 
insensitivity to the polymyxins through activation of a lipopolysaccharide-
modification operon and MexAB-OprM efflux pump (Pamp et al. 2008). 
Polymyxins are normally bactericidal to cells displaying either dormant or slow 
growth phase in the biofilms. In contrast, ciprofloxacin and tetracycline exercise 
bactericidal activity only against the metabolically active cells in biofilms of the 
same bacterial species. Consequently, it has been suggested that either two or 
more antibacterial compounds should be used as a combination therapy, which 
includes a polymyxin, in cystic fibrosis patients with pulmonary infections that 
consist of biofilms from multi-resistant Ps. aeruginosa (Chernish and Aaron 
2003). Cells exposed to lower oxygen concentrations in Ps. aeruginosa and E. 
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coli biofilms demonstrate decreased sensitivity to vancomycin, tobramycin, 
ciprofloxacin, carbenicillin, ceftazidime, chloramphenicol and tetracycline (Ito et 
al. 2009, Evans et al. 1991). The distribution of oxygen along a gradient also 
modulates the antibacterial action of the aminoglycosides (Stewart 2002). 
Bacterial cells exposed to anaerobic conditions in biofilms are differentially 
protected from the action of various antimicrobial agents even when capable of 
fermentative growth (Davey and O'toole 2000, Shirtliff, Mader and Camper 
2002). 
1.5 Mechanism of action, emergence and dissemination of bacterial 
resistance to antimicrobial compounds 
Antibiotics are chemical entities (penicillin, streptomycin) either produced by or 
derived from fungi, bacteria and other micro-organisms and plants, possessing 
the capacity to either kill or inhibit the growth of other pathogenic organisms 
(Singh and Pelaez 2008, James, Vignesh and Muthukumar 2012). Currently, 
synthetic and semi-synthetic compounds with antimicrobial actions are also 
commonly referred to as antibiotics (Giuliani, Pirri and Nicoletto 2007, Harvey 
2008). 
1.5.1 Mechanism of action of antibacterial compounds 
The primary mechanism of action for the major classes of antibacterial 
compounds in clinical use is summarised in the table 1.1. Different classes of 
antibiotics can interfere with essential cell maintenance processes including the 
inhibition of cell wall synthesis by the β-lactam antibiotics (Paradis-Bleau et al. 
2008, Silver  2003, Hao et al. 2012), blockage of protein synthesis by the 
tetracyclines (Hilliard et al. 1999, Connell et al. 2003a, Zapun, Contreras‐Martel 
and Vernet 2008) and the inhibition of the activities of vital metabolic pathways 
such as folic acid synthesis reported with the sulphonamides (Bermingham and 
Derrick 2002). The interference with DNA replication by the fluoroquinolones has 
been extensively studied (Drlica and Malik 2003, Owens and Ambrose 2005). 
Meanwhile, the disruption of cell membrane integrity by colistin and polymyxin B 
(Fernandez et al. 2010, Fernandez et al. 2010, Zavascki et al. 2007) is another 
recognised mechanism of antibacterial action. 
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Class of antibacterial 
compound 
Mechanism of action 
Fluoroquinolone 
(ciprofloxacin) 
Inhibition of DNA synthesis 
Aminoglycoside (gentamicin), 
tetracycline, ketolide, 
macrolide, chloramphenicol, 
lincosamide 
Inhibition of protein synthesis 
 
Rifampin Inhibition of RNA synthesis 
Trimethoprim, sulphonamide Inhibition of folic acid synthesis 
Penicillin, daptomycin, 
cephalosporin, carbapenem, 
vancomycin 
Inhibition of cell wall synthesis 
 
Polymyxins Disruption of cell membrane 
integrity 
Table 1.1 Major antibacterial compounds in clinical use and their primary mechanism of action 
(Cottarel and Wierzbowski 2007). 
1.5.2 Bacterial resistance to antibacterial compounds 
The incidence of pathogenic bacterial resistance to antibacterial compounds is 
increasing globally (Silbergeld, Graham and Price 2008). The indiscriminate and 
wide-spread use of antimicrobial compounds (β-lactams, aminoglycosides, 
tetracyclines, fluoroquinolones, etc.) in the agro-allied industry and inappropriate 
dosing regiments in humans has led to the emergence and dissemination of 
bacterial strains resistant to a wide array of antimicrobial compounds (Levy and 
Marshall 2004). Major classes of antibacterial compounds to which bacteria have 
developed resistance include the β-lactams, carbapenems, aminoglycosides, 
tetracyclines and fluoroquinolones. 
1.5.2.1 β-lactams 
The β-lactams (penicillins, carbapenems, cephalosporins, and monobactams) are 
bactericidal compounds that prevent the formation of bacterial cell walls through 
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inhibition of peptidoglycan bio-synthesis in actively dividing cells. These 
compounds impede the formation of cross-linkages upon the linear N-acetyl 
glucosamine (NAG) and N-acetylmuramic acid (NAMA) strands 
(transglycosylation) during peptidoglycan biosynthesis; a critical step essential 
for bacterial survival (Silver  2003). Inappropriate use of β-lactam antibiotics led 
to the emergence and spread of penicillin-resistant and later on, methicillin-
resistant S. aureus (MRSA) (Levy and Marshall 2004, Goldmann et al. 1996, 
O'Brien 2002). Data collected between 1992 and 2004 show that more than 50 
% of pathogens identified in intensive care units within this same period were 
MRSA (Zhang, Rozek and Hancock 2001b, Cardo et al. 2004). The emergence of 
bacterial strains that are resistant to β-lactam antibiotics can occur through 
induced synthesis of β-lactamase enzymes (Bonomo and Rice 1999). This 
enzyme has the capacity to break the β-lactam ring thereby rendering these 
antibiotics ineffective (Fernández, Breidenstein and Hancock 2011). In addition, 
alteration in penicillin-binding proteins (PBP) in the cell wall of MRSA that was 
previously mentioned is an alternative mechanism of resistance to this class of 
antibiotics (Sieradzki, Pinho and Tomasz 1999). Penicillin binding proteins are the 
binding sites for β-lactam antibacterial compounds. Bacterial strains with altered 
binding proteins have been proposed to exhibit resistance to β-lactam antibiotics 
due to diminished binding capacity for β-lactam antibiotics (Zapun, 
Contreras‐Martel and Vernet 2008). 
Carbapenems (imipenem, meropenem, ertapenem, doripenem, etc.) belong to a 
sub-class of broad spectrum β-lactam antibacterial compounds with a peculiar 
backbone structure that renders them highly resistant to β-lactamase enzymes 
(Fonseca 2011). Carbapenems are the choice antibacterial compounds in 
instances of bacterial infections caused by resistant E. coli and Klebsiella 
pneumoniae (Johnson 2008). Bacterial resistance to carbapenems due to 
acquired carbapenemases emerged in 2000 and has been disseminated globally 
since then (Corbella et al. 2000, Rolain, Parola and Cornaglia 2010). There are 
different carbapenemases including enzymes from class A, B (metallo-beta 
lactamases (MBL)) and D (serine carbapenemases) (Miriagou et al. 2010).  The 
New Delhi metallo-beta-lactamase 1 (NDM-I) is a novel type of MBL (Struelens et 
al. 2010) disseminated by plasmids encoding carbapenem-resistant metallo-
beta-lactamase (PCM) and bacterial strains carrying this genetic element were 
previously named NDM-1 (Rai et al. 2011). This extra genetic segment encodes 
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for bacterial resistance to a broad range of β-lactam antibiotics (Moriarty, Elborn 
and Tunney 2005). The antibiotic resistance activity mediated by this plasmid-
borne gene upon diverse and unrelated species compromises their susceptibility 
to carbapenems, thereby disqualifying this antibiotic as the reserved antibiotic of 
choice in instances of bacterial resistance to β-lactams (Johnson 2008). The 
plasmid encoding carbapenem-resistant metallo-beta-lactamase gene was first 
recovered from a Klebsiella pneumoniae strain isolated from a Swedish patient of 
Indian origin in 2009 (Rolain, Parola and Cornaglia 2010). The following year, the 
strain had become prevalent in the United States, Asia, United Kingdom, Israel 
and southern Europe (Wilson and Chen 2012). The rapid global dissemination of 
this plasmid encoding carbapenem-resistant metallo-beta-lactamase gene in 
enterobacteriaceae, via horizontal gene transfer, exemplifies the speed with 
which resistant bacterial strains can emerge and be disseminated due to 
globalisation and wide-spread travel (Jacqueline et al. 2005, Jacqueline et al. 
2005). 
1.5.2.2 Aminoglycosides 
Aminoglycosides (such as gentamicin, amikacin, kanamycin and neomycin) 
consist of hydrophilic amino sugar residues bound to a central six-member 
aminocyclitol ring by glycosidic bonds that function as polycations (Vicens and 
Westhof 2002). Their polycationic nature facilitates binding to the polyanionic 
16S rRNA of the bacterial ribosome (Knowles et al. 2002), thereby blocking 
bacterial synthesis of proteins. Plasmids such as pXZL34 can encode diminished 
membrane permeability and up-regulation of membrane efflux pumps (OprM) for 
the extrusion of aminoglycosides, thereby expressing resistance to these 
compounds (Westbrock-Wadman et al. 1999). This mechanism of resistance also 
prevails for β-lactams and tetracyclines (Walsh 2000, Li and Nikaido 2004). 
Additionally, in enterococci, the aminoglycoside-inactivating enzyme 
aminoglycoside 2’ phosphodiesterase is another mechanism for the expression of 
bacterial resistance to aminoglycoside antibiotics (Takahashi et al. 2002). 
1.5.2.3 Tetracyclines 
Tetracyclines (such as tetracycline, doxycycline and minocycline) are broad 
spectrum antibacterial compounds that consist of a tetracene nucleus with four 
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fused rings (Lorian 2005). They demonstrate activity against Gram-positive and 
Gram–negative bacteria, chlamydia, mycoplasmas, rickettsia and some 
protozoan parasites (Chopra and Roberts 2001). Tetracyclines inhibit protein 
synthesis through disruption of codon-anticodon interaction between tRNA and 
mRNA thereby preventing the binding of amino acyl tRNA to the ribosomal 
acceptor A site. Bacterial mechanisms of resistance against the tetracyclines 
include the use of efflux-based systems, enzymatic inactivation and ribosomal 
protection strategies (Chopra and Roberts 2001, Poole 2000, Trieber and Taylor 
2002, Trieber and Taylor 2002). However, the up-regulation of outer as well as 
the cytoplasmic membrane efflux pumps is the primary mechanism by which 
bacteria express resistance to tetracycline antibiotics (Kumar and Schweizer 
2005). Resistance mediated through the use of efflux proteins has been 
extensively studied leading to the identification of over 300 genes that belong to 
the major facilitator super-family (MFS) (De Rossi et al. 2002). Bacterial 
resistance to tetracycline through ribosomal protection was demonstrated by the 
isolation of Tet(O) and Tet(M) ribosomal protection proteins (RPPs) from 
Campylobacter jejuni and Streptococcus species respectively (Aminov et al. 
2004, Alfredson and Korolik 2007). In the presence of both proteins, aminoacyl 
tRNA binding to the A site, normally inhibited by tetracycline, is protected and 
the drug is released and removed thereby freeing the ribosomes from the 
antibiotic’s inhibitory effect. This action enables aminoacyl-tRNA to continue to 
bind to the A site for on-going protein synthesis (Burdett 1996, Connell et al. 
2003b).  Other mechanisms of resistance are the expression of enzymatic 
degradation of tetracyclines in Bacteriodes species and rRNA mutations in 
Propionibacterium acnes and Helicobacter pylori (Trieber and Taylor 2002, Ross 
et al. 1998, Gerrits et al. 2002).  
1.5.2.4 Fluoroquinolones 
The fluoroquinolones include nalidixic acid, ciprofloxacin and sparfloxacin and are 
synthetic bactericidal compounds that inhibit either or both topoisomerases II 
(DNA gyrase) and IV (Hooper 2000). DNA gyrase catalyses the introduction of 
negative superhelical twists in circular DNA of actively growing cells (Drlica and 
Malik 2003, Drlica and Hooper 2003). This is an important step for bacterial 
replication and survival as separation of DNA strands must precede DNA 
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transcription and replication, which results in excessive positive super-coiling of 
the DNA in front at the point of separation. The introduction of negative super-
coiling by DNA gyrase prevents this excessive positive twisting (Lorian 2005). 
The wide-spread misuse of fluoroquinolones has also been accompanied by the 
emergence and dissemination of strains of bacterial species resistant to this class 
of antibiotic (Levy  2002), especially because of their direct inhibitory action 
against DNA synthesis (Hooper  2001). Fluoroquinolones are currently ineffective 
in most cases of shigellosis, cholera and camphylobacteriosis due to bacterial 
resistance (Sack and World Health Organization 2001). Quinolone resistant S. 
aureus (QRSA) is associated with chromosomal mutations either in genes 
encoding for subunits of the drug’s target enzymes (DNA gyrase and 
topoisomerase IV), diffusion channels in the outer membrane, or multi-drug 
resistant efflux systems (Hilliard et al. 1999).  
1.5.2.5 Newer antibacterial compounds in clinical use 
Newer clinically effective antibacterial compounds should target either novel or 
multiple sites as their mechanisms of action in order to address the challenges 
associated with the rapidity with which resistant strains emerge to newly 
introduced antibiotics (Chopra et al. 1997). This will increase the clinical life-span 
and utility of such newly developed antibacterial agents (Bais et al. 2006), since 
bacterial species will require longer time to develop resistance mechanisms 
against either novel or multiple patterns of assault. Some recently developed 
antimicrobial agents in clinical use are as follow. 
1.5.2.5.1 Telavancin, oritavancin and vancomycin 
Telavancin is available for use clinically as an alternative glycopeptide for 
vancomycin-resistant bacterial species (Aksoy and Unal 2008). This new 
antibacterial agent demonstrates a pronounced depolarisation of membrane 
potential, disrupts cell membrane integrity and inhibits the biosynthesis of lipid 
II, a precursor required for the production of peptidoglycan during bacterial cell 
wall formation (Rashid, Weintraub and Nord 2011, Moellering Jr 2011). Likewise, 
oritavancin (a lipoglycopeptide) is also effective against vancomycin-resistant 
organisms (Guskey and Tsuji 2010). Oritavancin’s mechanism of action is by the 
sequestration of lipid II, through which the peptidoglycan repeat unit is 
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covalently linked to a C55-lipid transporter (Kim et al. 2008). This sequestration 
leads to inhibition of cell wall synthesis (Kim et al. 2008). In addition, oritavancin 
has the capacity to collapse membrane potential, increase membrane 
permeability and eventually induces loss of membrane integrity (Domenech et al. 
2009). This agent has also been shown to inhibit RNA synthesis (Zhanel et al. 
2010) and is active against slow growing cells as well as staphylococcal biofilms 
challenged in vitro (Belley et al. 2009). Oritavancin demonstrates a rapid 
bactericidal activity greater than that of vancomycin (Kim et al. 2008). A notable 
bactericidal action can be achieved after 15 minutes in the former agent; unlike 
the latter antibiotic that requires about 24 hours with activity restricted to 
actively dividing cells (McKay et al. 2009a).  
Vancomycin also possesses a narrow therapeutic window that discourages 
routine use especially because inaccurate dosing often results in sub-optimal 
concentrations of the drug and a loss of clinical effectiveness (Hall et al. 2009). 
On the other hand, patients receiving more than 50 mg/kg body weight 
vancomycin have been increasingly diagnosed with severe nephrotoxicity (Lodise 
et al. 2008, Hazlewood et al. 2010). Connected to this concern, is the fact that 
treatment of MRSA infections with sub-optimal vancomycin concentrations leads 
to the emergence of S. aureus strains with intermediate sensitivity to 
vancomycin, typically characterised by their thickened cell walls (Hiramatsu 
2001). The presence of these strains is associated with the failure of vancomycin 
therapy in MRSA infections, as much of the administered dose are entrapped 
within the enlarged cell wall and consequently denied access to their molecular 
target sites (Hiramatsu et al. 1997, Soriano et al. 2008). 
1.5.2.5.2 Linezolid 
Linezolid is an oxazolidinone bacteriostatic antibacterial compound developed for 
Gram-positive organisms that inhibits protein synthesis in susceptible pathogens 
(Stefani et al. 2010). Linezolid is also effective in vitro against both methicillin-
resistant S. aureus and vancomycin-resistant enterococci. Linezolid retains FDA 
approval for specific infections caused by vancomycin-resistant E. faecium, S. 
aureus, S. pneumoniae, S. pyogenes and S. agalactiae (Stefani et al. 2010, 
McNeil et al. 2000). Such infections include nosocomial and community-acquired 
pneumonia, uncomplicated to complicated skin and soft tissue infections as well 
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as diabetic foot infections devoid of supine-state induced ulcers and 
oesteomyelitis (Falagas, Siempos and Vardakas 2008). However, despite the 
limitations of vancomycin therapy previously mentioned, linezolid is not a 
significantly more effective than vancomycin for the treatment of Gram-positive 
infections and both compounds have comparable resistance profiles (Falagas, 
Siempos and Vardakas 2008). A combination of linezolid with sub-inhibitory 
doses of imipenem has been applied for the improved efficacy against methicillin-
resistant S. aureus (Jacqueline et al. 2005). 
1.5.2.5.3 Daptomycin 
Daptomycin is a cyclic lipopeptide with rapid bactericidal activity against both 
methicillin- and vancomycin-sensitive as well as resistant staphylococci and 
enterococci (Castanheira, Jones and Sader 2008). Daptomycin’s rapid 
bactericidal activity against Gram-positive bacteria is associated with the 
lipopeptide’s capacity to competitively bind staphylococcal membrane-bound 
calcium ions and be inserted into the cytoplasmic membrane after structural 
modifications thereby leading to membrane-pore formation (Jung et al. 2004a). 
In addition, daptomycin also kills bacteria via depolarisation of cytoplasmic 
membrane potential, inhibition of amino acid transport and blockade of 
peptidoglycan cross-linkages in cell wall formation of actively dividing cells 
(Allen, Alborn Jr and Hobbs Jr 1991). 
Daptomycin is approved for skin and soft tissue infections, bacteraemia and 
right-sided endocarditis caused by methicillin-resistant S. aureus and other 
sensitive Gram-positive pathogens except vancomycin-resistant pathogens 
(Arbeit et al. 2004, Fowler Jr et al. 2006). Vancomycin-intermediate strains of S. 
aureus demonstrate diminished sensitivity to daptomycin because of the 
entrapment of daptomycin within the thickened cell wall and the consequent 
reduced availability of the antibiotic at the target sites (Wootton, MacGowan and 
Walsh 2006). Also, daptomycin is not recommended for pulmonary infections (in 
community-acquired pneumonia) because of inactivation by pulmonary 
surfactant (Silverman et al. 2005). In this instance, ceftriazone is a preferred 
option (Pertel et al. 2008). 
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1.5.2.5.4 Telithromycin 
The ketolide, telithromycin is a semi-synthetic derivative of macrolide antibiotics 
with amplified binding capacity to bacterial ribosomes (Lonks and Goldmann 
2005). Ketolides bind simultaneously to domains II and V of the 23S rRNA in 
bacterial ribosomes, unlike macrolides that are only bound to domain V (Jenkins, 
Brown and Farrell 2008). Hence, telithromycin demonstrates in vitro activity 
against macrolide-resistant and multi-drug resistant isolates of S. pneumoniae 
and other common respiratory tract pathogens (Lonks and Goldmann 2005, 
Jenkins, Brown and Farrell 2008). Other relatively new antibacterial compounds 
include tigecycline, which belongs to same class as tetracycline (Peterson et al. 
2006); moxifloxacin and gemifloxacin are ciprofloxacin (Pletz et al. 2004); whilst 
ertapenem is a once daily parenteral β-lactam carbapenem (Vetter et al. 2002, 
Shah and Isaacs 2003) and cefditoren is a streptogramin (Spangler, Jacobs and 
Appelbaum 1996). 
1.5.2.5.5 Polymyxins 
Polymyxins (figure 1.3) are effective against Acinetobacter  species, 
Pseudomonas aeruginosa, Klebsiella species and Enterobacter species (Bonomo 
and Szabo 2006, Falagas, Kasiakou and Saravolatz 2005).  
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Figure 1.3: Chemical structures of polymyxin B and colistin (polymyxin E), showing five positive 
charges. Adapted from Tsubery et al. 2000. 
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These peptide antibiotics are clinically ineffective against most Gram-positive 
bacterial species at tolerable therapeutic doses, most probably due to the 
absence of their primary target - the outer membrane lipopolysaccharide (LPS) 
structure (Zhang, Rozek and Hancock 2001a, Hancock and Rozek 2002a, Vaara 
et al. 2008, Martti 2010). The polymyxins primarily target the LPS of the outer 
membrane structure of Gram-negative bacterial species (Hancock and Sahl 
2006). These compounds competitively displace Mg2+ and Ca2+ from the anionic 
LPS surface (Thompkins 2010), leading to some degree of disturbances and 
formation of blebs (multiple protrusions) on the membrane bilayer surface 
(Hancock 1997c). Permeability of the cell envelope is increased, permitting the 
self-promoted uptake of these polypeptide antibiotics (Hancock 1997b), leakage 
of intracellular potassium (O'Driscoll 2011), loss of osmotic integrity and cell 
death (Falagas, Kasiakou and Saravolatz 2005, Hancock and Sahl 2006, 
O'Driscoll  2011, Wu and Hancock 1999).  
1.5.2.5.5.1 Adverse effects of polymyxins 
Polymyxin B and colistin interfere with the membrane integrity of the linings of 
the nephron, thereby causing nephrotoxicity, an adverse side effect of polymyxin 
B and colistin treatment (Bonner 2011). Polymyxins can bind to megalin in the 
apical membrane of the nephron’s proximal tubules, as well as to isolated brush 
border membranes, with higher affinity than other antibiotics such as gentamicin 
(Vaara et al. 2008). Furthermore, extensive re-absorption due to continually 
administered high (intravenous) doses can lead to the accumulation of 
polymyxins in the tubular cells of the nephron, thereby causing dose-related 
nephrotoxicity (Vaara and Vaara 2010, Zavascki et al. 2008). There is therefore 
a strong rationale to investigate other measures whereby the safer clinical use of 
the polymyxins can be achieved, such as the application of these compounds at 
lower concentrations through synergistic combinations with other established 
antibiotics. 
1.5.3 The re-assessment and renewed clinical application of polymyxin B 
and colistin 
The clinical use of polymyxins (figure 1.3) as antimicrobial therapeutic agents 
was abandoned in the 1970s because of concerns relating to their dose-
24 
 
dependent adverse effects of nephrotoxicity and neurotoxicity (Falagas, Kasiakou 
and Saravolatz 2005). However, due to the dearth in discovery and development 
of new effective as well as clinically useful antimicrobial agents, these concerns 
were re-evaluated. It was noted that these adverse events and the issues 
surrounding such concerns were valid but seemingly over-stated. Polymyxins 
were therefore re-introduced in 2002 as an antibiotic, reserved for conditions 
involving multi-resistant Gram-negative bacterial species (Hirsch and Tam 2010). 
Currently most multi-resistant Gram-negative bacterial strains are commonly 
susceptible to polymyxin B and colistin (polymyxin E) (Zavascki et al. 2007, 
Falagas, Kasiakou and Saravolatz 2005). However, if both antibiotics are not 
used appropriately, such susceptible bacterial species could mutate into new 
strains that are resistant to these compounds due to selective pressure. 
Clinicians must therefore be urged to discourage the use of polymyxin B and 
colistin as monotherapeutic agents, especially when applied as an antibiotic of 
last resort (Vaara and Vaara 2010, Hirsch and Tam 2010). 
1.5.3.1 Development of modified polymyxins  
In view of the toxicity concerns previously raised about colistin and polymyxin B, 
attempts are being made to develop newer polymyxins with improved safety 
profile and bactericidal action against multi-resistant Gram-negative organisms 
(Martti 2010). Newer polymyxins are being developed from polypeptide 
derivatives that carry only three cationic charges instead of the conventional five 
(figure 1.3) (Tsubery et al. 2000, Martti 2010). As a result of this structure-
activity manipulation, some recently developed CAPs such as NAB739 and 
NAB7061, demonstrate a reduction in their capacity to get bound to the acidic 
phospholipid sites of the brush-border membrane in the proximal tubular cells of 
the kidneys (Vaara and Vaara 2010), leading to reduced likelihood for the 
occurrence of their dose-related nephrotoxicity adverse event. Some of these 
new compounds such as NAB739 have direct antibacterial activity whilst others 
such as NAB7061 demonstrate the capacity to sensitize bacteria to the effects of 
other antibacterial compounds (Vaara et al. 2012).  
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1.6 Flavonoids as a potential source of antimicrobial compounds 
Flavonoids are polyphenolic organic compounds each possessing about 15 carbon 
atoms and usually 2 benzene rings joined by a linear 3 carbon atoms (figures 1.4 
and 1.5).   
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Figure 1.4: Basic structures of flavonoids; adapted from Cushnie and Lamb 2011. 
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Figure 1.5: Diagrams of the chemical structures of [2-(cyclohexymethyl)-6-methoxy-4H-chromen-
one] (F1) and 2-cyclohexyl-6-methoxy-4H-chromen-4-one (F23); adapted from Abdel Ghani et al. 
2008 and Ghani et al. 2012. 
These polyphenolic compounds are characteristically present in higher plants, 
especially in angiosperms where they function as flowering pigments. Flavonoids 
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have demonstrated a wide range of activities including antileishmanial (Wong et 
al. 2007), antitrypanosomial (VA 2010), cancer chemo-preventive (Heo, Sohn 
and Au 2001) and antibacterial (Cushnie and Lamb 2005a) potentials. Flavonoids 
from Glycyrrhiza glabra extract demonstrate antibacterial activity against 
methicillin-resistant S. aureus (Fukai et al. 2002b) and Helicobacter pylori (Fukai 
et al. 2002a).  In vitro susceptibility studies of the antibacterial activities of 
flavonoids and their semi-synthetic analogues suggest that they may have 
potential as lead compounds for the development of novel antimicrobial agents 
(Fukai et al. 2002b). The flavonol galangin demonstrates bactericidal action 
against species of S. aureus through cell aggregation (Cushnie et al. 2007) and 
also induces cytoplasmic damage that leads to the leakage of intracellular 
potassium (Cushnie and Lamb 2005b).  
The 2 semi-synthetic chalcone-derivatives (F1 and F23) (figure 1.5), are 
flavonoid compounds produced by the micro-wave assisted closure of the 
heterocyclic ring (Abdel Ghani et al. 2008) and both were shown to demonstrate 
weak antibacterial as well as antifungal activities (Ghani et al. 2012). Beside 
investigations covering their potentials for direct antimicrobial activity, flavonoids 
of natural origin, their synthetic and semi-synthetic counterparts have been 
assessed for synergistic actions with established antibiotic as well as the 
suppression of bacterial virulence (Cushnie and Lamb 2011). (-)-Epicatechin 
gallate reduces the MICs of the β-lactam antibiotic, oxacillin, against species of 
MRSA by as much as 512-fold (Hamilton-Miller and Shah 2000); but like other 
flavon-3-ols, demonstrates susceptibility to bacterial esterases, thereby 
diminishing its chances as a candidate for further development for potential 
useful clinical applications (Hamilton-Miller and Shah 2000, Stapleton et al. 2004, 
Stapleton et al. 2004). However, (-)-epicatechin gallate displays broad-spectrum 
inhibitory activity against the growth of both Gram-positive as well as Gram-
negative bacterial species and has therefore been considered for possible 
applications in the control of common oral infections such as dental carries and 
periodontal disease (Taylor, Hamilton-Miller and Stapleton 2005, Shah, Stapleton 
and Taylor 2008). Interestingly, a semi-synthetic analogue of (-)-epicatechin 
gallate with improved stability against esterification as well as hydrolysis due to 
amide substitution (for an ester linkage) demonstrates a similar degree of 
previously recorded synergistic action with oxacillin (Anderson et al. 2005) and 
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will therefore be more likely considered for further development for potential 
clinical applications. 
1.7 Combinational antimicrobial therapy   
Combination antimicrobial therapy involves the simultaneous application of 
compounds with different molecular mechanisms of action and target sites within 
the bacterial pathogen (Silver and Bostian 1993). Hence, an effective 
combination therapy leads to either additive or synergistic activity (Lorian 2005). 
Such effective combinations of compounds also leads to a reduction in the 
required dose for each of the ‘synergistic’ or ‘additive’ compounds, which in turn  
leads to a reduction in the potential for the occurrence of dose-related adverse 
events by each compound (Rybak and McGrath 1996). A reduction in the 
potential for toxicity would enhance the chances for the clinical development of 
such new compounds combination, which have already been found to be 
effective (Owens and Ambrose 2005). This has been demonstrated for the 
combination of either streptomycin or dihidrostreptomycin with rifampicin, which 
is clinically effective for the treatment of brucellosis especially in the tropics (Asif 
2012, Dooley et al. 2012). In addition, with the application of combinational 
antibacterial therapy, it becomes more difficult for the treated pathogen to 
evolve into mutant strains that are resistant to multiple compounds (Lomovskaya 
et al. 2001a, Xilin and Drlica 2002). The simultaneous antibacterial activity at 
diverse molecular sites hinders the organism from recuperating and prolongs the 
time required for bacterial species to develop resistant strains against the 
antibacterial compounds used, especially through mutation (Levin and Harris 
1975). It is recommended that certain antibiotics such as isoniazid should not be 
administered alone for the treatment of bacterial infections because bacterial 
resistance against such compounds can emerge very rapidly (Zhao and Drlica 
2001). Also, infectious diseases caused by hetero-pathogens are better treated 
with combinational antibacterial therapy considering that different molecular 
targets are affected simultaneously (Levin and Harris 1975).  
Finally, in emergency situations that do not permit time for the conduct of 
bacterial susceptibility testing, the combination of antibacterial compounds is 
often applied to achieve an effective broad-spectrum and empirical management 
of life-threatening infectious disease conditions.  Overall, an effective antibiotic 
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combination therapy may ultimately lead to a reduction in the time required for a 
complete therapeutic regimen, an improvement in patient compliance and a 
more effective therapeutic outcome (Rello et al. 1997, Niederman 2003, Dellit et 
al. 2007). 
1.7.1 Combination of antibacterial compounds in clinical use  
Some antibiotic combination therapies have achieved therapeutic success 
already, such as the combined application of either streptomycin or 
dihidrostreptomycin with rifampicin, described above (Dooley et al. 2012). In 
addition, co-amoxiclav consists of a novel combination of clavulanic acid with 
amoxicillin, an amino penicillin with improved oral bioavailability and half-life 
(Cottarel and Wierzbowski 2007, Gisbert et al. 2006). Herein, the β-lactamase 
enzyme in resistant Gram-positive bacteria is irreversibly bound to clavulanic 
acid thereby preventing the enzyme from degrading the β-lactam ring and 
enhancing the capacity of amoxicillin to inhibit cell wall formation (Craig and 
Ebert 1992, Navarro 2005). Following a similar mechanism of action as the one 
detailed above, ampicillin sodium has been successfully combined with salbutam 
sodium, another β-lactamase inhibitor, to achieve improved activity against β-
lactamse secreting Gram-positive species, such as in the treatment of 
Stenotrophomonas maltophilia and Acinetobacter baumannii (Miller, Ratnam and 
Payne 2001). 
Synercid is a commercial product containing types A and B streptogramin 
bacteriostatic compounds, dalfopristin and quinupristin as a 70:30 bactericidal 
combination respectively (Manfredi and Sabbatani 2010). Although both 
compounds are individually bacteriostatic in action (Vouillamoz et al. 2000), the 
combined product  synercid is predominantly bactericidal against Gram-positive 
multi-resistant organisms including vancomycin-resistant and multi-resistant 
Enterococcus faecium, S. epidermidis and S. aureus (McNeil et al. 2000, 
Karageorgopoulos and Falagas 2009). The FDA approved the combined 
streptogramins for complicated skin and soft tissue infections caused by 
methicillin-susceptible S. aureus, Streptococcus pyogenes as well as infections 
caused by vancomycin-resistant E. faecium. In S. aureus, resistance to 
quinupristin and dalfopristin combinations seems to be due to a mutation in the 
L22 ribosomal protein (Malbruny et al. 2002). 
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The combination of trimethoprim and sulphamethoxazole provides a synergistic 
bactericidal product that inhibits the folic acid metabolism in two independent 
and specific steps of the folic acid biosynthesis pathway (Kavatha et al. 2003). 
Trimethoprim competitively inhibits dihydrofolate reductase and blocks the 
conversion of dihydrofolic acid to tetrahydrofolic acid (Kalan and Wright 2011). 
The accumulation of dihydrofolate reductase leads to the inhibition of the 
synthesis of polyglutamylfolates by folylpoly- γ-glutamate synthase (Kesavan et 
al. 2001, Liani et al. 2002). Simultaneously, sulphamethoxazole can stand in as a 
surrogate substrate for dihydropteroate synthase, resulting in a compound that 
cannot be further metabolised to dihydrofolate (Kalan and Wright 2011). The 
combination of trimethoprim and sulphamethoxazole has been a viable option for 
the treatment of MRSA (Grim et al. 2005). However, allergy to sulphonamides 
could sometimes result in toxic epidermal necrolysis and has been noted as a 
major concern (Glasser and Burroughs 2003, Lee et al. 2004). 
In the management and treatment of tuberculosis, the causative organism, 
Mycobacterium tuberculosis, is treated with a combination of isoniazid, rifampicin 
and pyrazinamide or ethambutol simultaneously for approximately 6 months 
(Ginsberg and Spigelman 2007). Rifampicin inhibits DNA-dependent RNA 
polymerase, preventing protein synthesis whilst the other 3 antibacterial 
compounds disrupt M. tuberculosis membrane and wall through direct as well as 
indirect mechanisms (Cottarel and Wierzbowski 2007). There are reports of the 
emergence of M. tuberculosis strains resistant to this standard combinational 
therapy which has heightened the concerns for the development and introduction 
of new compounds into the regime (Pletz et al. 2004). Sparfloxacin and 
moxifloxacin have been considered as antibacterial compounds in the antibiotic 
combinational treatment and management of tuberculosis, especially in 
HIV/AIDS patients because of their long half-lives (Pletz et al. 2004, Grosset 
1992). These examples demonstrate that the combination of different 
antibacterial compounds could be effective in vivo. 
1.7.2 Combination of antibiotics with agents that are devoid of 
antibacterial actions themselves  
The adjuvant (clavulanic acid) is devoid of significant antibacterial activity but 
prevents the degradation and modification of the antibacterial compound 
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(amoxicillin) (Cottarel and Wierzbowski 2007). The combination of the latter 
antibiotic with the former agent therefore yields a synergistic antibacterial action 
(Vree, Dammers and Exler 2003). In another instance, an adjuvant may enhance 
the accumulation and retention of the antibacterial compound by inhibiting the 
efflux of the latter. For instance, MPex Pharmaceuticals have developed various 
combinational antibacterial compounds, one of which involves the combined 
application of a non-antimicrobial compound, MC-207,110 with known antibiotics 
thereby producing new effective treatment combinations. MC-207,110 is a 
repressor for bacterial outer membrane efflux pumps, such as MexAB-OprM, 
MexCD-OprJ and MexEF-OprN in Ps. aeruginosa and their homologue AcrAB-TolC 
in E. coli (Lomovskaya et al. 2001a, Lomovskaya and Bostian 2006, Poole and 
Lomovskaya 2006).  In the combination, MC-207,110 potentiates the 
antibacterial activity of laevofloxacin against Ps. aeruginosa, by preventing the 
efflux of laevofloxacin from the periplasmic space (Kriengkauykiat et al. 2005). 
This combination reduces the modal MIC of laevofloxacin against Ps. aeruginosa 
strains (with over expressed efflux pumps and mutants with gyrA and parC 
genes, that confer resistance to laevofloxacin) by 32- to 64-fold (Lomovskaya et 
al. 2001a). In addition, the intrinsic resistance of Ps. aeruginosa towards 
laevofloxacin is decreased 8-fold and the frequency of emergence of new 
resistant strains to fluoroquinolones is repressed (Lomovskaya et al. 2001a, 
Lomovskaya and Bostian 2006).  
1.7.3 Combination of antibiotics with cationic peptides 
Polymyxins are amphipatic compounds with hydrophobic regions at their amino 
terminus (Giacometti et al. 2000). The polymyxin-like peptide, ranalexin, 
enhances the entry of several hydrophobic substrates into both Gram–positive 
and Gram–negative bacterial cells (Giacometti et al. 2000). The application of a 
hydrophilic cationic antimicrobial peptide in combination with a hydrophilic 
fluorescent compound increased the outer membrane porin diameter and influx 
of the hydrophobic fluorescent probe (Delcour 2009). Either ranalexin or 
polymyxins can synergistically promote enhanced antimicrobial actions of 
lipophilic and amphiphilic agents like rifampin, macrolides, fusidic acid and 
novobiocin against Ps. aeruginosa (Hancock 1997c, Giacometti et al. 2000, Vaara 
and Porro 1996). The combined application of ranalexin with polymyxins yields 
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synergistic antimicrobial activity (Giacometti et al. 2000). This is understandable 
considering that both compounds exhibit similar mechanisms of interaction 
towards the phospholipids present on the cell membrane thereby increasing 
bacterial membrane permeability and disrupting osmotic integrity (Hancock 
1997b, Giacometti et al. 1999, Giacometti et al. 2000, Giacometti et al. 2000, 
Vaara and Porro 1996). 
1.8 Biological redox reactions  
1.8.1 The electron transport chain and respiratory process in prokaryotic 
cells  
The electron transport chain couples the electron transfer between a donor (such 
as either nicotinamide adenine dinucleotide (NADH), flavin adenine dinucleotide 
(FADH2), etc. and an acceptor such as oxygen (O2), for the transfer of H+ ions 
(protons) across bacterial membranes (Krebs et al. 1999). This proton transport 
leads to the build-up of an electrochemical gradient (potential difference) which 
is utilised in the generation of chemical energy in the form of adenosine 
triphosphate (ATP) (Kröger et al. 1992). This process defines the cellular 
mechanism for extracting energy from redox reactions, such as the oxidation of 
sugars and fats during respiration and extraction of energy from sunlight in 
photosynthesis (Kröger et al. 1992, Berridge and Tan 1998). Bacterial respiratory 
systems are similar in many respects to those present in mitochondria of higher 
organisms, such as eukaryotes or plants. For instance, both are membrane-
bound, with similar respiratory carriers and capacity to conserve energy to be 
used either for ATP synthesis or to drive mechanical work (Kröger et al. 1992). 
In the mitochondria of multi-cellular organisms, the reduction of oxygen to 
water, NAD+ to NADH and succinate to fumarate (as shown in figure 1.6) 
generates the electrochemical proton gradient required for these processes.  
Also, bacteria have electron transport chains similar to that demonstrated in 
plant chloroplasts through photosynthesis (Bolton and Hall 1979, Kramer and 
Crofts 2004, Boghossian et al. 2011). Therefore, in all domains of life, the 
electron transport chain oxidises NADH and succinate produced from the citric 
acid cycle and thereby provides energy required to power ATP synthase. ATP 
synthase facilitates the provision of energy in the form of ATP - the currency 
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expended for the performance of all cellular reactions. Finally, bacteria can use 
NADH and succinate as electron donors in the presence of an organic matter as 
energy source. These are inducible enzymes, selected from the bacterial DNA 
library and are synthesized only when needed for growth (Guerin et al. 1982, 
Muffler et al. 2002). 
1.8.2 Generating the electrochemical gradient and the electron transport 
chain 
An electrochemical potential gradient required to initiate biological redox 
reactions and it is usually generated in the cell membrane. Translocation of 4 
protons across the cell membrane occurs during the oxidation of every molecule 
of NADH, thereby building up an electrochemical potential used for the 
production of ATP. NADH binds to dehydrogenase to form NADH dehydrogenase 
complex (complex I). The transferred electrons are received by the isoalloxazine 
ring of FMN, which is identical to flavin adenine dinucleotide (FAD) (Berridge et 
al. 1996). Electrons are then transferred again through a second prosthetic group 
of NADH dehydrogenase through a series of Fe-S clusters and finally to co-
enzyme Q (CoQ) (ubiquinone), as shown in figure 1.6.  
 
NADH + H+ + CoQ + 4H+ in → NAD+ + CoQH2 + 4H+ out 
 
FAD + succinate  → Fumarate + FADH2 
 
FAD + 2H+ + 2e ↔ FADH2 
Figure 1.6: Building up the electrochemical gradient that initiates the process for ATP generation. 
Ubiquinone (CoQ) accepts 2 electrons and is reduced to ubiquinol (CoQH2), as a 
result. This final transfer leads to expulsion of 4H+ (Berridge, Herst and Tan 
2005a).   
1.8.3 MTT reduction assay 
An assay involving C,N-diphenyl-N′-4,5-dimethyl thiazol 2 yl tetrazolium bromide 
salt (MTT) salt (figure 1.7) reduction to formazan by the normal physiological 
processes in bacterial species can be used to evaluate the potential capacity of 
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antimicrobial agents to cause a blockage to cell metabolism, as a potential 
mechanism of action.  
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Figure 1.7 Schematic diagram of C,N-diphenyl-N-4,5-dimethyl thiazol 2 yl tetrazolium bromide 
(MTT). 
Bacteria (Wang et al. 2010a), fungi (Bernas and Dobrucki 2002), plant 
(Bruggisser et al. 2002) as well as mammalian (Morgan 1997) cells have the 
capacity to reduce this salt into insoluble formazan crystals (Morgan 1997). 
Substances that can cause the cessation of this reaction in the midst of viable 
organisms may be seen as capable of blocking the metabolism of such cells, an 
event that likely precedes their death. A similar assay has been used to examine 
the susceptibility of Mycobacterium tuberculosis strains to rifampicin (Abate, 
Mshana and Miorner 1998). 
1.8.4 Enzymes responsible for biological reduction reactions 
The biological breakdown of various tetrazolium salts, including 2, 3-bis [2-
methoxy-4-nitro-5-sulphophophenyl] -2H-tetrazolium-5-carboxanilide (XTT), 
MTS and MTT, is achieved through the activities of various cell reducing enzymes 
(Berridge, Herst and Tan 2005a). For mammalian cells, data gleaned from 
fractionation studies suggest the reduced pyridine nucleotide cofactor NADH, is 
responsible for most MTT reduction (Berridge, Herst and Tan 2005a). Other 
enzymes include succinate dehydrogenase (Wang et al. 2010b). The reduction of 
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MTT salt can occur in the mitochondria, endosome, lysosome, plasma membrane 
as well as cytoplasm (Bernas and Dobrucki 2002). 
1.8.4.1 NADH dehydrogenase, Cytochrome Q, C and ATP synthase  
Nicotinamide adenine dinucleotide (NADH) dehydrogenase is a metabolic enzyme 
also referred to as either “NADH:quinolone reductase” or “complex I”. This 
cofactor, alongside “complex II” are important enzymes in reduction activities in 
cell physiology (figure 1.8).  
 
  
 
 
 
 
Figure 1.8: Diagrammatic representation of the ATP generation pathway in bacteria, showing the 
important steps, I to V. 
The actions of these enzymes are required for the biological reduction reactions 
and the reduction of dimethyl thiazolyl diphenyl tetazolium salt (MTT) in vivo 
(Stoward, Campbell and Al-Sarraj 1982, Bigliardi et al. 1994). 
In eukaryotic cells, complex I is located in the inner mitochondrial membrane 
catalysing the transfer of electrons from NADH to coenzyme Q (CoQ) as the rate-
limiting enzyme required for oxidative phosphorylation (electron transport chain) 
in the mitochondria (Stoward, Campbell and Al-Sarraj 1982). NADH 
dehydrogenase is the largest and most complex enzyme of all the electron 
transport chain enzymes (Janssen et al. 2007) containing 45 independent 
polypeptide chains in mammals; 7 of which are encoded by the mitochondrial 
genome. The functionally most important subunit of this complex contains flavin 
prosthetic groups (i.e. flavin mononucleotides) and 8 Fe-S clusters (Aydin and 
Altunbasak 2006, Carroll et al. 2006). Complex I is L-shaped, consisting of a long 
membrane embedded domain with approximately 60 helixes and a hydrophilic 
peripheral domain containing all the known redox centres as well as binding sites 
for NADH. This peripheral hydrophilic centre has been crystallized from Thermus 
thermophilus and the disfunction of this centre is associated with aging and 
many degenerative diseases in humans (Sazanov and Hinchliffe 2006, Beal 
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1995). Other additional enzymes required for oxidative phosphorylation are 
complexes III, IV and V (ATP synthase) (Liu et al. 1997).  
1.8.4.2 Succinate dehydrogenase and other enzymes 
The reduction of MTT by the normal physiological processes has also been 
associated with a flavin-containing enzyme, succinate dehydrogenase (SDH) 
(Abe and Saito 1998, Huet et al. 2005). Succinate is an effective substrate for 
MTT reduction, especially in the presence of mitochondrial fractions (Berridge et 
al. 1996). But, there are other non-mitochondrial enzymes required for cellular 
MTT reduction such as nicotinamide dinucleotide phosphate (NAD(P)H)-
dependent oxido-reductases like NQOI, cytochrome P450, non-mitochondrial 
dehydrogenases and flavin oxidases (Berridge and Tan 1998, Berridge, Herst and 
Tan 2005a, Liu et al. 1997). In addition, non-mitochondrial pyridine nucleotide-
dependent enzymes and other terminal electron-acceptors, some of which need 
the assistance of intermediate electron acceptors, are also involved in the 
reduction of MTT (Vistica et al. 1991, Abate, Mshana and Miorner 1998, Wang et 
al. 2010a) However, the intracellular rate of MTT reduction correlates with 
intracellular NAD(P)H concentration (Berridge, Herst and Tan 2005a). In 
addition, sub-cellular fractionation studies have shown that NADH and NAD(P)H 
are more efficient in promoting the reduction of MTT than succinate (Liu et al. 
1997, Berridge and Tan 1993). Such studies have also shown that reduced 
pyrimidine nucleotides (>90%) and succinate (<10%) account for the non-
mitochondrial reduction of intracellular MTT (Berridge, Herst and Tan 2005a). 
This finding contradicts previously published opinion that succinate 
dehydrogenase is responsible for most cellular MTT reduction which led to the 
pseudonym “succinate dehydrogenase inhibition” assay (Van Noorden and 
Butcher 1989). Nonetheless, in eukaryotic cells, 77 % of the <10% MTT 
reduction credited to succinate dehydrogenase occurs within the mitochondria, 
under the auspices of complex II (Berridge and Tan 1993, Christmas and Turrens 
2000). But the fact that the succinate dehydrogenase inhibitor, 
thenoyltrifluoracetone (TTFA), demonstrates a negligible effect upon intracellular 
reduction of MTT strengthens the argument that NAD(P)H is the major electron 
donor in MTT reduction (Berridge and Tan 1998, Berridge and Tan 1993a, 
Berridge, Horsfield and Tan 1995). Other oxido-reductase enzymes such as 
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intracellular dehydrogenases, oxidases and peroxidases are also capable of 
catalysing electron transfers from an electron donor to an acceptor tetrazolium 
salt (Berridge, Herst and Tan 2005a).  
1.8.5 Tetrazolium salts reduction in eukaryotic and prokaryotic cells 
Eukaryotic cell viability has been studied by the regulation of their cellular 
metabolic activities using the MTT assay. The water soluble yellow C,N-diphenyl-
N′-4,5-dimethyl thiazol 2 yl tetrazolium bromide (MTT) salt is reduced to water-
insoluble purple formazan crystals by the dehydrogenase system, (complex I), of 
viable cells (Carmichael et al. 1987). The crystals can be dissolved in an organic 
solvent like DMSO and quantitatively analysed using spectrophotometry. Usually, 
the concentration of formazan is directly proportional to the density of 
metabolically active cells in the culture (Gabrielson et al. 2002, Tunney et al. 
2004).   
The mono-tetrazolium salt, MTT is especially suitable for end-point determination 
assays because of its capacity to form water-insoluble formazan crystals. One 
main application of cellular tetrazolium dye reduction is the assessment of cell 
proliferation on the basis that the dye reduction is a function of the density of 
viable cells in the exponential growth phase (Cook and Mitchell 1989). Cell 
growth conditions, cell source and type of dye must be defined (Cook and 
Mitchell 1989). In other words, for both eukaryotic and bacterial cell 
proliferation/metabolic assay, the experiments are influenced by species, density 
of inoculum, growth phase and growth conditions. Therefore, in the presence of 
growth modifying compounds (like noxious or antibacterial compounds), 
especially those to which the organisms are sensitive, tetrazolium salt reduction 
will be influenced by the sensitivity of cells to the foreign substance. Such 
substances, depending on the onset and sub-cellular site of action, may affect 
cell respiration, metabolism, replication and density. In turn, this will have an 
effect on the rate of reduction of MTT salt to formazan. 
The intracellular reduction of tetrazolium salts is not restricted to the 
mitochondria in eukaryotes as components of the cytoplasm, non-mitochondrial 
membranes, endosomal as well as lysosomal organelles and plasma membranes 
are all involved in the reduction of MTT salt to formazan crystals (Berridge, Herst 
and Tan 2005a). Reduction of the salt also occurs at the cells’ external surface 
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and periphery of the plasma membrane through trans-plasma membrane 
electron transport (Berridge, Herst and Tan 2005a).  
1.8.6 Sub-cellular sites for MTT reduction 
MTT has a positively charged quaternary tetrazole ring core (figure 1.7) that 
contains four nitrogen atoms surrounded by three phenyl moieties. Reduction 
disrupts the tetrazoline ring leading to colour transformation from yellow to 
purple and the generation of formazan crystals (Berridge et al. 1996, Berridge 
and Tan 2000, Bruggisser et al. 2002). The net positive charge on the tetrazole 
ring facilitates uptake of MTT across the plasma membrane of viable cells 
through the membrane potential (¥m -30 to -60 mV, negative inside) and if not 
reduced in the cytoplasm, also crosses the mitochondrial inner membrane (¥m -
150 to -170 mV, negative inside) in eukaryotic cells (Berridge and Tan 1998, 
Berridge and Tan 1993, Berridge and Tan 2000, Berridge, Herst and Tan 2005b). 
MTT alongside rhodamine B has been applied in the determination of 
mitochondrial membrane potential (Reungpatthanaphong et al. 2003). 
Altogether, intracellular NAD(P)H from the Krebb’s cycle and electron transport 
chain in mitochondria, NADH from ubiquinone cycle within the plasma membrane 
and various substrates that are freely dispersed within the cytoplasm reduce the 
salt to water-insoluble formazan crystals. 
1.8.6.1 Evidence for the sub-cellular localisation of MTT reduction 
One of the findings that revealed the non-mitochondrial and extra-cellular 
reduction of tetrazolium salts was the development of a new generation of water 
soluble tetrazolium salts with their prototype as WST-I. WST-I bears a net 
negatively charged disulphonated inner salt containing iodine residue.  This 
water-soluble salt can be reduced extracellularly to soluble formazan by electron 
transport across the plasma membrane of actively dividing cells (Herst et al. 
2004). The net negative charge exists because of its possession of two 
negatively charged sulphonated groups and one positively charged phenyl ring. 
This arrangement generates an inner salt, with a net negative charge that 
excludes it from uptake by plasma membranes (Herst et al. 2004). Therefore, 
the net positive charge on the MTT salt and the plasma membrane potential 
appear to be the main factors influencing the cellular up-take and sites of 
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reduction (Wang et al. 2010a, Murphy 2007). Further on, WST-I is reduced 
extracellularly, most likely by electron transport across plasma membrane from 
intracellular NADH to WST-I with 1-methoxy-5-methyl-phenazinium methyl 
sulphate (mPMS) as an intermediate (Herst et al. 2004). Hence, contrary to 
previous beliefs, WST-I is not reduced by succinate dehydrogenase in the 
mitochondria of metabolically active cells (Berridge, Herst and Tan). And, unlike 
many other newer generation water-soluble salts, WST-1 can also be reduced 
extracellularly in the absence of an intermediate electron acceptor (Berridge, 
Herst and Tan). Finally, evidence obtained from confocal imaging has shown that 
MTT-formazan crystals are found outside the mitochondria, in the cytoplasm and 
around the plasma membrane in viable cells with intact membrane integrity 
(Bernas and Dobrucki 2002, Bernas and Dobrucki 2000). In fact, epi-
fluorescence microscopy studies have shown that sub-cellular reduction of 5-
cyano-2,3-ditolyl tetrazolium chloride (CTC), a fluorescent cyano-tetrazolium salt 
similar to MTT and also bearing a net positive charge, occurs slowly in the 
periphery of plasma membrane in HepG2 cells (Berridge, Herst and Tan 2005b, 
Bernas and Dobrucki 1999, Roslev and King 1993, Smith and McFeters 1997). 
1.8.6.2 Contrary opinions on the sub-cellular sites for MTT reduction  
Liu et. al. published in 1997 that MTT is membrane-impermeable when it was 
incorporated into large unilamella liposomes and consequently suggested that 
the salt is taken up across the plasma membrane through endocytosis 
(Bruggisser et al. 2002, Larm, Cheung and Beart 1997). However, this view has 
been discredited by three valid and superior arguments. Firstly, synthetic 
liposomes are completely devoid of membrane potential and are therefore 
incomparable to plasma membranes of viable cells. Secondly, the suggestion 
that MTT readily undergoes cellular up-take and gets reduced intracellularly has 
been supported by imaging studies using HepG2 cells (Bernas and Dobrucki 
2002, Bernas and Dobrucki 2000). And thirdly, MTT in combination with 
rhodamine B has been applied to quantify mitochondrial membrane potential 
wherein the formazan crystals formed within the mitochondria acted as a 
fluorescence quencher for rhodamine inside this organelle (Reungpatthanaphong 
et al. 2003). 
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1.9 Aims and objectives of the study  
In summary, the prevailing global incidence of bacterial resistance makes it 
rational for newer, more effective antibiotics and strategies for combating these 
organisms to be developed. The mechanisms of action of either agents with 
promise or newly found effective combinations of compounds, should be 
elucidated at the early stages of development with a view to giving priority to 
compounds that belong to classes other than the ones to which currently used 
antibiotics belong and possessing either novel or multiple mechanisms of action.  
The aims and objectives of this study include: 
1. To screen for in vitro antibacterial activity from a series of semi-synthetic 
flavones. 
2. To examine the antibacterial mode of action of these semi-synthetic 
flavones. 
3. To investigate the existence of either additive or synergistic antibiotic 
action between these semi-synthetic flavones and known antibiotics, 
including polymyxin B; using a chequerboard as well as time-kinetic 
viability assays for possibility of extending the antimicrobial spectrum and 
efficacy of the decapeptide agent against Gram-positive bacterial species. 
The organisms examined include S. aureus species, C. violaceum, E. coli 
and Ps. aeruginosa. 
4. To elucidate the potential mechanisms of action for the effective combined 
application of the chalcone-derivatives with polymyxin B using a modified 
bacterial MTT-reduction assay and an evaluation of the impact of the 
combined antibacterial activity upon cytoplasmic membrane integrity 
through measurement of the leakage of intracellular potassium ions. Visual 
examination of the capacity of the combined agents to induce changes in 
the fluorescence intensity of applied stains in S. aureus over a time-course 
was also undertaken using microscopy. 
5. Finally, an attempt will be made to examine the in vitro haemolytic effect 
of the chalcone-derivatives with polymyxin B. The capacity of the effective 
combinations to disrupt the plasma membrane will be examined in order 
to have an insight into the utility of potential future formulations, 
especially in the form of external applications.  
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Chapter 2 
Materials and Methods  
2.1 Chemicals and reagents 
2.1.1 Dissolution of semi-synthetic chalcones, and selected  
antimicrobial compounds 
The semi-synthetic chalcone-derivative compounds (supplied by Professor 
Richard C. D. Brown, University of Southampton, UK.) were used to prepare 
stock 5-10 mg/ml solutions in neat dimethyl sulfoxide (DMSO) using 1.5 ml 
centrifuge tubes (Fisher Scientific UK. Ltd., Loughborough, UK.). Aqueous stock 
solutions of 10 to 50 mg/ml penicillin G, polymyxin B, colistin, gentamicin, 
benzalkonium chloride, ciprofloxacin and ascorbic acid (all purchased from 
Sigma-Aldrich, Poole, UK.) were also prepared. A stock solution of acetyl salicylic 
acid (purchased from Aldrich) was prepared to yield 25 mg/ml in 20 % v/v DMSO. 
All stock solutions were stored at -20 oC. On the other hand, ascorbic acid and 
acetyl salicylic acid solutions were prepared daily when required because of 
aqueous instability. 
2.1.2 Growth media and bacterial diluents 
2.1.2.1 General growth media and diluents 
Nutrient broth, nutrient agar and Mueller-Hinton broth were purchased from 
Oxoid Ltd. (Basingstoke, UK.). All media suspensions were prepared following the 
manufacturer’s label instructions and were autoclaved at 121 oC for 15 minutes 
by moist heat sterilisation. Agarose was purchased from Fisher Scientific UK. Ltd. 
and was autoclaved by moist heat as described above. Also, general purpose 
grade sodium chloride was purchased from Fisher Scientific UK. Ltd. and was 
used to prepare 0.9 % w/v sodium chloride. Finally, tablets used to prepare 
phosphate buffer saline (PBS) were purchased from Sigma-Aldrich Company Ltd., 
Poole, UK. 
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2.1.3 Miscellaneous chemical compounds and fluorescent dye 
Sodium dodecyl sulphate and 20 % v/v chlorhexidine digluconate were purchased 
from Fisher Scientific UK. Ltd. Dimethyl thiazolyl diphenyl tetrazolium (MTT) and 
dimethyl sulphoxide (DMSO) were purchased from Sigma-Aldrich. An aliquot of 5 
mg/ml MTT stock solution in 0.9 % w/v sodium chloride solution was prepared 
weekly and stored at the same temperature stated in section 2.1.1 above. 
Ethanol was purchased from Hayman Ltd., Witham, UK. Finally, the intact 
bacterial membrane-impermeant dye, Sytox Green, 5 mM was purchased from 
Molecular Probes (Invitrogen Ltd., Paisley, UK.). 
2.1.4 Laboratory equipment 
All disposable plastic utensils and materials were purchased from Fisher 
Scientific. Plastic tips for pipettes and 1.5 ml centrifuge tubes were sterilised by 
moist autoclaving at 134 oC for 3¼ minutes as a porous load. Separately, all 
glassware were sterilised by dry heat sterilisation at 160 oC for 2 hours. 
2.2 Bacterial storage and cultivation 
2.2.1 Bacterial species and strains 
 Bacterial strains were Staphylococcus aureus, National Collection of Type 
Cultures (NCTC) 6571 (methicillin-sensitive, MSSA); Staphylococcus aureus 
NCTC 11940 (methicillin-resistant, MRSA); Staphylococcus aureus, American 
Type Culture Collection (ATCC) 1628 (quinolone-resistant, QRSA); Escherichia 
coli NCTC 4174; Pseudomonas aeruginosa NCTC 6750 and Chromobacterium 
violaceum CV026 that was received as a gift from Nottingham University, UK. All 
NCTC strains were obtained from National Collection of Type Cultures (NCTC, 
Porton Down, Salisbury, UK.) and the ATCC strain was from American Type 
Culture Collection (Manassas, Virginia, USA.). In addition, the plant pathogens 
Pectobacterium caratovoram, National Collection of Plant Pathogenic Bacteria 
(NCPPB) 312 and Clavibacter michiganensis subsp. michiganensis NCPPB 2979 
were obtained from the National Collection of Plant Pathogenic Bacteria, Food 
and Environment Research Agency (Sand Huton, York, UK.).  
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2.2.2 Bacterial storage 
Bacterial stock cultures were stored using Protect Bacterial Preserver beads in 
cryotubes (Technical Service Consultants Ltd., Lancashire, UK.) at -80 oC 
(Upright freezer TS80-140; Life Sciences International, Colchester, UK.). 
2.2.3 Bacterial sub-culture  
2.2.3.1 Preparation of bacterial master plates 
When required, a 10 ml volume of Mueller-Hinton broth (Oxoid Ltd., Basingstoke, 
England) was inoculated with a bead from the bacterial stock culture obtained 
from the Protect Bacterial Preserver cryotube. The broth was incubated at 37 oC 
for 24 hours in an orbital incubator set at 100 rpm (Sanyo Gallenkamp PLC, 
Loughborough, UK.). The bacterial culture obtained for each species was 
streaked on a pre-dried Mueller-Hinton agar plate (Oxoid Ltd., Basingstoke, 
England) and incubated at 37 oC for 24 hours. Equivalent 10 ml volumes of 
Mueller-Hinton broth inoculated with beads from stock cultures of the plant 
pathogens Pectobacterium caratovoram and Clavibacter michiganensis were 
incubated at 25 and 18 oC respectively in a shaking water bath set at 100 rpm. 
The bacterial culture obtained from each sample was streaked on a pre-dried 
Mueller-Hinton agar plate and incubated at 25 oC for 48 hours. All master plates 
were stored at 4 oC and each bacterial species was sub-cultured on a monthly 
basis.  
2.2.3.2 Preparation of bacterial experimental culture 
For routine experimental purposes, a single colony from each master plate 
(except the plant pathogens) was used to inoculate a sterile 50 ml Mueller-
Hinton broth. The broth was incubated for 24 hours as described above. 
Meanwhile, bacterial broth cultures prepared from beads of the plant pathogens, 
Pectobacterium caratovoram and Clavibacter michiganensis were incubated in a 
shaking water bath set at 100 rpm for both organisms and temperatures of 25 
and 18 oC respectively, for 48 hours. 
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2.3 Preparation of bacterial enumeration graphs 
Graphs of optical density plotted against concentration of bacterial cells (colony 
forming unit per ml (cfu/ml) (shown in appendix 11.2) were prepared by 
following the viable count dilution method described below. 
2.3.1 Preparation of bacterial suspension  
Fifteen ml of a 24 hours incubated 50 ml Mueller-Hinton broth culture was 
centrifuged at 4,000 rpm for 10 minutes in a MSE Chilspin (Fisons, 
Loughborough, UK.). The supernatant was decanted carefully and the pellet was 
washed once in 10 ml of 0.9 % w/v sodium chloride by centrifugation at 4,000 
rpm for 10 minutes. The pellet was then re-suspended in 10 ml of 0.9 % w/v 
sodium chloride and diluted to yield a range of bacterial populations with 7 
different optical density readings within 0.1 to 0.2 units at OD500 (Helios 
spectrophotometer, Thermo spectronic Corporation, Madison, USA.). 
2.3.2 Preparation of agar plates 
A batch of fourteen surface dried nutrient agar plates (90 mm diameter) were 
prepared by keeping them upright with lids open in a sterile cabinet 
(Horizonzatal Laminar Flow Cabinet, %HLF B/U; Hepaire Manufacturing Ltd., 
Avon, UK.) at room temperature, for 1 hour. The base of the plates were labelled 
into four quadrants and labelled for dilutions of 1 x 10-5 to 1 x 10-8 
2.3.3 Dilution of bacterial suspensions and plating out 
Each of the seven bacterial densities prepared in section 2.3.1 above was diluted 
ten-fold serially down to 1 x 10-8 in 0.9 % w/v sodium chloride. Five aliquotes of 
20 µl from 10-5, 10-6, 10-7 and 10-8 dilutions were carefully pipetted onto each 
quadrant of the pre-dried agar plate respectively. Duplicate agar plates were 
prepared for each density. Following absorption of the inoculum into the agar, 
the plates were incubated for 24 hours at 37 oC. 
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2.3.4 Enumeration of viable cells 
At the end of the incubation period, all agar plates were examined. The colonies 
from all 10 volumes (duplicate plates) of the appropriate dilution were counted 
and the mean value calculated and recorded. However, the quadrants that 
yielded bacterial colonies in the range of 5 to 50 were preferably used to assess 
the level of bacterial growth and to calculate the population of cells in the original 
suspensions. A graph of cell densities (cfu/ml) against corresponding optical 
densities (at OD500) was plotted for the bacterial suspension. Such enumeration 
graphs were prepared for each of the bacterial strains employed in this project. 
2.4 Preparing bacterial suspension with a defined density 
2.4.1 Applying the enumeration graph to estimate bacterial density in a 
suspension 
Following on from section 2.2.3.2 above, 15 ml of a 24 hours culture was 
centrifuged at 4000 rpm in an MSE Chilspin for 10 minutes. The pellet recovered 
was washed once by re-centrifuging with 15 ml of 0.9 % w/v sodium chloride as 
described above, and re-suspended in 5 ml of 0.9 % w/v NaCl solution. 
Approximately a 100-fold dilution of the suspension was then made with 0.9 % 
w/v saline as diluent. The density of the bacterial suspension was estimated by 
adjusting the spectrophotometer (Cecil CE 3021, Cecil instruments Ltd., Milton 
Technical Centre, Cambridge, UK.) reading to correlate with the desired cell 
density in a previously prepared enumeration graph of the bacterial species. 
2.4.2 Verifying cell density of the bacterial suspension 
A ten-fold serial dilution and plating out of the density of the adjusted bacterial 
suspension were performed as described previously in section 2.3.3. Following 
on, the mean colony count from the plates were recorded as described in section 
2.3.4 and the actual viable population of the test bacterial suspension was 
calculated as colony forming unit per millilitre (cfu/ml). 
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2.5 Bacterial susceptibility testing 
The screening of some semi-synthetic chalcone-derivatives (flavonoids) for 
potential antibacterial activity was conducted using a modified agar-test-
compound two-fold serial dilution assay. Bacterial susceptibility testing for the 
chalcone-derivatives and selected compounds was conducted using the micro-
titre broth antibiotic two-fold serial dilution assay. 
2.5.1 Determination of the MIC of some antimicrobial compounds 
The minimum inhibitory concentration (MIC) of the antibacterial compounds was 
determined against the selected pathogenic bacterial species and strains stated 
in section 2.2.1 above. The MIC was determined using a micro broth two-fold 
serial dilution assay adapted from the recommendations of the Clinical and 
Laboratory Standards Institute (CLSI) (CLSI 2009). A Versamax Microplate 
Reader (Molecular Devices Ltd., Wokingham, Berkhire, UK.) was optimised to 
read statically incubated plates, after a round of orbital oscillation, every 30 
minutes, for 24 hours at OD650 and 37 oC. A final cell density of 1 x 106 cfu/ml in 
a final volume of 200 µl Mueller-Hinton broth per well was used. 
The stock antibacterial compound solution was subject to two-fold serial dilution 
to yield a desired range of test concentrations within the wells of a  96-well 
micro-titre plate (gamma-irradiated; Bibby Sterilin Ltd., Stone, UK.). To achieve 
this, volumes of 40 µl sterile water were transferred into wells 2 to 8 of rows C, 
D, E and F. Then, 80 µl of a suitable concentration of the antibiotic under 
examination was transferred into the first wells of same rows. A two-fold serial 
dilution was carried out by transferring 40 µl from the first column into the 
second. The procedure was repeated up to the 8th column of these rows wherein 
the extra 40 µl volume was discarded. Following on, 60 µl water and 100 µl 
double strength Mueller-Hinton broth, containing 2 x 106 cfu/ml bacterial 
suspension, were added to the wells from the 1st to the 8th columns in order to 
ensure that only the wells that received an even distribution of temperature were 
engaged. Wells for positive (containing broth and inoculum density of the 
bacteria) and negative (containing broth devoid of inoculum density bacteria and 
broth devoid of bacteria containing the test range of antibacterial concentration) 
controls were included.  
46 
 
The micro-titre plate was then covered with an optically clear and gas 
impermeable seal (Fisher Scientific) to avoid evaporation and inconsistent well 
volumes. The plate was incubated at the set conditions described above. The MIC 
was determined as the lowest concentration of test antibacterial compound that 
inhibited growth of the bacterial species, under investigation, after incubation at 
37 oC for 24 hours (Andrews 2001). Data reported were obtained from at least 
three separate assays that gave at least two identical data. 
2.5.2 Determination of MIC of compounds with poor aqueous solubility  
The MICs of the chalconederivatives against the test bacterial species mentioned 
in section 2.2.1 above was determined with a micro broth dilution assay. The 
plate reader was set as described in section 2.5.1.2 above. However, the test 
chalcone derivatives were subject to two-fold serial dilution to yield a suitable 
range of test concentration in 2.5 % v/v DMSO within Mueller-Hinton broth. In 
order to achieve this, volumes of 40 µl 12.5 % v/v DMSO were transferred into 
wells 2 to 8 of rows C, D, E and F in the micro-titre plate. Then, 80 µl of a 
suitable concentration of the chalcone derivative dissolved in 12.5 % v/v DMSO 
was transferred into the first wells of the same rows. A two-fold serial dilution 
was carried out by transferring 40 µl from the first column into the second. The 
procedure was repeated up to the 8th column of these rows wherein the extra 40 
µl volume was discarded. At this point, 60 µl water and 100 µl double strength 
Mueller-Hinton broth containing 2 x 106 cfu/ml bacterial suspensions were added 
to the wells from the 1st to the 8th column of the rows mentioned above. The 
controls were extended to include a positive solvent (Mueller-Hinton broth with 
2.5 % v/v DMSO and inoculum population of the bacterial species) and a negative 
solvent (Muller-Hinton broth containing 2.5 % v/v DMSO with no inoculum 
bacterial species) controls respectively. The micro-titre plate was then sealed and 
incubated at the set conditions previously described in section 2.5.2.1 above. 
Similarly, the MIC was determined as previously described in the same section 
above. The reported data were obtained from at least three separate assays that 
gave at least two identical data. 
47 
 
2.5.3 Determining minimum bactericidal concentration for test 
compounds 
The minimum bactericidal concentration (MBC) for the test antimicrobial 
compounds against the selected bacterial species was determined by a replica 
plating procedure using a 96-pin multi-point replicator (Boekel Scientific, 
Feasterville PA, USA.). Approximately one micro litre inoculum was transferred 
from each well to the surface of chalcone derivative-free and antibiotic-free 
nutrient agar in a 13.5 cm diameter plate. The plate was left to sit on the bench 
top for approximately 3 minutes, to allow time for the agar to absorb the 
inoculum and then incubated at 37 oC for 24 hours. Following on, the MBC was 
determined as the least concentration of the compound under examination that 
prevented the bacterial growth (Lorian 2005). The reported data were obtained 
from at least three separate assays that gave at least two identical data. 
2.6 Evaluating the mode of action of chalcone-derivatives in combination 
with other antibiotics  
The existence of synergism between the chalcone-derivatives and selected 
antimicrobial compounds was determined with a chequerboard method. A 96-
well micro plate containing chequered concentrations of the compounds being 
examined in Mueller-Hinton broth was prepared. The protocol for preparing the 
plate was adapted from Lorian et. al., Antibiotics in Laboratory Medicine (Lorian 
2005, Pillai et al. 2005a, Petersen et al. 2006). Bacterial culture and suspension 
with a defined density were prepared as previously described in sections 2.2.3.2 
and 2.4.1 respectively. Dispensing of media, bacterial suspension, diluents and 
test compounds under examination were conducted with an 8-tip 10 - 100 µl 
variable multi-channel pipette (Calibra 852, Socorex Isba S.A, Ecublens, 
Switzerland). 
The column 1, wells A to F in the micro-titre plate was taken to be the y-axis and 
row G, with wells in column 2 to 7 was taken to be x-axis. An 80 µl volume of 
12.5 % v/v DMSO was added to the wells in the micro-titre plate from column 1 
to 7, rows A to F. Then 80 µl volume of chalcone-derivative solution with a 
known concentration in 12.5 % v/v DMSO was added to the first two rows of 
column 1 to 7. As described in section 2.2.7, serial two-fold dilutions were 
carried out in a decreasing order down the rows A to F, as the y-axis, in order to 
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obtain a chalcone-derivative concentration equal to either MIC or 2 x MIC in the 
row A, wells 1 to 7 and the lowest dilution concentration in row F, wells 1 to 7.  
Similarly, in another micro-titre plate, 30 µl sterile water was introduced into 
each well in the first 6 columns using rows A to G. Then, 30 µl of aqueous 
antibiotic solution with known concentration was added to columns 6 and 7. Two-
fold serial dilutions were carried out backward, from column 6 to 2 of wells A to 
G, as described in section 2.5.2.1. A concentration equal to either MIC or 2 x MIC 
was obtained in column 7 and the lowest dilution concentration in column 2. 
Aliquots of 20 µl of the serial dilutions of the selected compounds were 
withdrawn from the 30 µl from the wells of the second micro-titre plate and 
transferred into the exact replicate well number in the first micro plate containing 
80 µl chalcone-derivative solutions. This was followed by the addition of 20 µl 
volumes of sterile water to wells A to F of column 1, and 80 µl sterile water to 
wells A to G of column 7 in order to make up the volumes of all the wells to a 
100 µl each.  Then, 100 µl double strength Mueller-Hinton broth, containing 2 x 
106 cfu/ml bacterial suspension, was added to each well of the micro-titre plate. 
Final volume was 200 µl in all the wells and inoculum density was 1 x  106 
cfu/ml. Wells in row H (1 to 7) and column 8 (A to H) were used for positive and 
negative controls. The plate was sealed and incubated in the Versmax reader set 
as previously described in section 2.5.2.1 above. 
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Chapter 3 
Examination of test bacterial species susceptibility to the 
chalcone-derivatives and selected antimicrobial compounds  
3.1 Introduction  
Bacterial susceptibility testing is the recommended first step in defining the most 
suitable antimicrobial agent when dealing with organisms that contribute to an 
infectious disease (Liu et al. 2011, Clinical and Laboratory Standards Institute 
2009). This testing is necessitated by the continuous emergence of resistant 
bacterial strains to available antimicrobial agents, to which such organisms were 
previously sensitive (Clinical and Laboratory Standards Institute 2009). The 
standard test involves culturing an inoculum of the test bacterial isolate 
individually in the presence of a range of antibiotics for a defined time period. 
The relative sensitivity of the pathogenic organism to the antimicrobial 
compounds in vitro is then ascertained. Data obtained from these susceptibility 
assays, along with the classification and mechanism of action of the various 
antimicrobial compounds, clinical experience and knowledge of local pathogens, 
as well as the expected potential adverse effects and costs are some factors that 
influence the choice of drug selection for antibacterial therapy (Rex et al. 1997, 
Tsuji and Rybak 2006).  
The potency of a newly developed antimicrobial compound can also be 
ascertained by examining the sensitivity and susceptibility of a range of 
pathogenic organisms to the compound. The antibacterial potency of a series of 
structurally related semi-synthetic chalcone-derivatives against selected bacterial 
species was therefore undertaken. The organisms employed were a 
representation of Gram-positive antibiotic-sensitive and resistant strains of S. 
aureus. Others included C. michiganensis and P. caratovoram both of which are 
serious plant pathogens. The Gram-negative species, E. coli and Ps. aeruginosa 
were also considered alongside the saprophyte C. violaceum (that belongs to the 
same family of neisserheae with N. gonorrhoea) (Zinger-Yosovich et al. 2006). 
Considering that it is safer to work with a saprophyte and that C. violaceum 
belongs to the same family (Neisseriaceae) as N. gonorrhoea, the presumption 
was that data obtained from assays conducted with this organism may give an 
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indication of the sensitivity of N. gonorrhoea to the chalcone-derivatives. 
Infections caused by this latter bacterial species was recently declared as being 
at the verge of being re-classified as an untreatable organism with available 
antibiotics in the clinics (Bolan, Sparling and Wasserheit 2012). 
 Unfortunately, these chalcone-derivatives demonstrated poor aqueous solubility 
and in addition, were only available in very limited quantities. Both factors made 
it extremely difficult for their preliminary antibacterial properties to be 
established using either conventional broth or agar dilution assays. We therefore 
developed a novel method that enabled the use of reduced quantities for the 
determination of their minimum inhibitory concentrations against a range of test 
bacteria assayed simultaneously, whilst dealing with the challenges posed by 
these compounds inherent poor aqueous solubility.  
The objectives of the work detailed in this chapter were to screen for in vitro 
antibacterial activity of a series of structurally related family of chalcone-
derivatives and some commercial antimicrobial agents against selected strains of 
human and plant pathogenic bacterial species. 
3.2 Materials and methods 
3.2.1 Examination of bacterial sensitivity to the chalcone-derivatives 
using a modified agar dilution assay 
The sensitivity of test bacterial species to the chalcone-derivatives was 
ascertained by a newly developed modified antibiotic-agar micro dilution 
technique. A 2.4 ml aliquot of 2.56 mg/ml stock chalcone-derivative solution (in 
12.5 % v/v DMSO as solvent) and 3.6 ml molten Mueller-Hinton agar were mixed 
in a McCartney bottle (maintained at 50 - 55 oC in a water bath) to obtain 
flavonoid-agar solution in 5 % v/v DMSO. After suitable mixing, 3 ml of the 
flavonoid-agar solution was withdrawn and transferred to another McCartney 
bottle containing 3 ml molten agar previously equilibrated with 5 % v/v DMSO and 
also held at same condition stated above. The content of the second bottle was 
mixed thoroughly and the process of two-fold serial dilutions was continued to 
yield flavonoid concentrations in a range from 1.024 mg/ml to 4 μg/ml, in molten 
agar containing 5 % v/v DMSO. 
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Then, 300 µl of each dilution was introduced into separate wells (8 wells used for 
each concentration) of a 96 multi-well flat bottom micro-titre plate (Fisher 
Scientific, Loughborough, UK.) in a descending concentration order, beginning 
from the first column. The agar in the micro-titre plate was allowed to set at 
room temperature and then surface-dried under laminar air flow for 15 minutes. 
A sterile 96 pin stainless steel multi-point inoculator (140500 Boekel Scientific, 
Feasterville PA, USA.) was used to carefully transfer a 1 µl volume of the test 
bacterial suspensions (5 x 107 cfu/ml), contained in a replicate micro-titre wells 
in duplicate, onto the agar surface. Therefore, inoculum density was 
approximately 5 × 104 cfu/ml for each bacterial species. Each bacterial species 
was applied to duplicate rows of the agar.  
The actual bacterial density in each bacterial sample was established by colony 
count determination (section 2.4.2) in order to verify the actual inoculum density 
and bacterial purity. Negative controls (sterile agar and sterile agar containing 5 
% v/v DMSO); and positive controls (inoculated agar and inoculated agar 
containing 5 % v/v DMSO) were included (4 columns). The inoculated plates were 
allowed to stand for 3 minutes to enable the applied bacterial suspensions to 
soak into the agar. The plates were incubated at 37 oC for 24 hours. The MIC (in 
units of µg/ml) was determined as the lowest concentration of test antibacterial 
compound that inhibited visible growth of the bacterial species under 
investigation (Andrews 2001). The reported data were obtained from at least 
three separate assays. 
3.2.2 MIC determination for test compounds against test bacterial 
species 
The antibacterial potency of these chalcone-derivatives was verified by 
determining their minimum inhibitory concentration against the test bacterial 
species with the antibiotic-broth micro dilution protocol described in section 
2.5.2. The minimum inhibitory concentration of some selected antimicrobial 
compounds was also determined as described in section 2.5.1.  
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3.2.3 Determination of MBCs for chalcone-derivatives and antimicrobial 
compounds against test bacterial species 
The minimum bactericidal concentration for the semi-synthetic compounds and 
antimicrobial compounds were determined by the multi-inoculator replica method 
described in section 2.5.3. 
3.3 Results  
3.3.1 Screening the series of chalcone-derivatives for antibacterial 
potency 
The sensitivity of the test bacterial species to the chalcone-derivatives was 
reported in the form of the minimum inhibitory concentration of the compound 
being examined against the test organism. The MICs for the chalcone-derivatives 
obtained from a modified antibiotic-agar dilution assay against selected strains of 
S. aureus and an E. coli species are reported in table 3.1.  
Compound MIC against bacterial species (μg/ml) 
MSSA MRSA QRSA E. coli 
F1 64 128 32 256 
F5 128 128 >512 256 
F6 >512 128 >512 >512 
F7 256 64 >512 128 
F9  >512 >512 >512 ND 
F12 >512 >512 >512 ND 
F17 128 64 >512 128 
Table 3.1: Sensitivity of selected test bacterial species to the chalcone-derivatives, reported as MIC 
of these compounds from an antibiotic-agar dilution assay. The data represent two consistent 
results from three replicates. MSSA: methicillin-sensitive S. aureus NCTC 6571; MRSA: methicillin-
resistant S. aureus NCTC 11940; QRSA: quinolone-resistant S. aureus ATCC 1628; and E. coli 
NCTC 4174. ND: Not determined. Structures and chemical names of these semi-synthetic 
chalcone-derivatives are provided in appendix 11.1. Solvent was 5 % v/v DMSO and inoculum 
density was 5 x 104 cfu/ml.  
The antibacterial activity displayed by these chalcone-derivatives was modest, 
with the reported MIC values from this modified agar dilution technique within 
the range of 32 to >512 μg/ml. Data presented in table 3.1 also show QRSA was 
most sensitive to F1 by displaying an MIC value of 32 μg/ml (as is also displayed 
in figure 3.1), but was insensitive to the presence of F5, F6, F7, F9, F12 and F17. 
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All these 6 compounds were considered inactive against this strain of quinolone-
resistant S. aureus because they displayed MIC values that were >512 μg/ml.  
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Figure 3.1: MIC of F1 against S. aureus ATCC 1628 (QRSA) in Mueller-Hinton broth at 37 oC. 
Inoculum density was 1 x 106 cfu/ml.  The mean cell density readings over time were plotted for 
the outcomes of two experiments with three replicates each. 
The data in figure 3.1 also show the pronounced adverse effect of 2.5 % v/v 
DMSO on the growth kinetic of QRSA cells in the solvent control sample relative 
to the untreated and DMSO-free populations. This solvent-effect is however 
overwhelmed by the antibacterial action of 32 µg/ml F1 against this bacterial 
species. Likewise, F1 showed an MIC value of 64 µg/ml whilst F5 and F17 
demonstrated an MIC value of 128 μg/ml against MSSA respectively. MRSA was 
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most sensitive to F7 and F17 as both compounds displayed an MIC value of 64 
μg/ml while F5 and F6 yielded an MIC value of 128 μg/ml against this bacterial 
species with F1 demonstrating an MIC value of 256 μg/ml. Results presented in 
table 3.1 also show that F1, F5, F7 and F17 demonstrated antibacterial activity 
against E. coli in the range of 128 - 256 μg/ml. Therefore, compounds F1, F5, F7 
and F17 demonstrated only modest broad-spectrum antibacterial activity in the 
antibiotic-agar micro dilution assay. 
3.3.2 Susceptibility of S. aureus to the semi-synthetic chalcone-
derivatives  
The MIC and MBC values for a number of the semi-synthetic chalcone-derivatives 
obtained from the antibiotic-broth micro dilution assay against MSSA and MRSA 
are shown in table 3.2.  
Compounds MIC against staphylococcal species (μg/ml) 
MSSA MRSA 
MIC MBC MIC MBC 
F2 97.5 ›400 400 ›400 
F6 256 ›512 ND ND 
F8 ND ND 400 ›400 
F12 128 ›512 ND  ND 
F13 200 ›400 400 ›400 
F14 ND ND 400 ›400 
F15 ND ND 400 ›400 
F17 200 ›400 400 ›400 
F21 200 ›400 400 ›400 
Table 3.2: Susceptibility of S. aureus NCTC 6571 (MSSA) and S. aureus NCTC 11940 (MRSA) to the 
chalcone-derivatives reported as MIC and MBC values for these compounds obtained from an 
antibiotic-broth micro dilution assay. The data represents at least 2 consistent readings from 3 
replicates. Solvent was 2.5 % v/v DMSO. MSSA: methicillin-sensitive S. aureus and MRSA: 
methicillin-resistant S. aureus. ND: Not determined. 
F2 and F12 demonstrated modest antibacterial activity with MIC values of 97.5 
and 128 µg/ml respectively against MSSA. F13, F17 and F21 demonstrated weak 
MICs of 200 and 400 µg/ml against MSSA and MRSA respectively. However, 
approximately 75 % of the reported MBC values are greater than 400 μg/ml and 
none is less than 90 μg/ml reflecting the general poor antibacterial activity of 
these chalcone-derivatives. F1 and F23 however demonstrated better activity 
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(MIC of 64 µg/ml) against MSSA and were therefore further examined against 
other selected human and plant pathogens, using the antibiotic-broth micro-
dilution as well as the minimum bactericidal concentration (MBC) determination 
assay. The MIC (µg/ml) and MBC values obtained from both assays are 
presented in table 3.3.  
Bacterial species F1 F23 
MIC 
(μg/ml) 
MBC 
(μg/ml) 
MIC 
(μg/ml) 
MBC 
(μg/ml) 
P. caratovoram 16 32 64 64 
Cl. michiganensis 16 16 32 32 
C. violaceum >512 512 >512 512 
MSSA 64 128 64 128 
MRSA 128 512 >1024 1024 
QRSA 32 32 32 64 
E. coli 256 512 512 >512 
Ps. aeruginosa 512 512 256 512 
Table 3.3: Susceptibility of test bacterial species to F1 and F23 reported as MIC and MBC values for 
these compounds obtained from an antibiotic-broth micro dilution and MBC determination assays. 
The data were 2 consistent readings obtained from 3 replicates. Solvent was 2.5 % v/v DMSO. 
MSSA: methicillin-sensitive S. aureus NCTC 6571; MRSA: methicillin-resistant S. aureus NCTC 
11940 and QRSA: quinolone-resistant S. aureus ATCC 1628. 
The MIC and MBC values were in the range of 16 to >1024 μg/ml indicating a 
range of modest to very weak activity. The plant pathogens P. caratovoram and 
C. michiganensis were most sensitive to F1, as this compound demonstrated the 
same MIC value of 16 μg/ml against both strains. This was followed by MIC 
values of 32, 64 and 128 μg/ml demonstrated by F1 against QRSA, MSSA and 
MRSA (figure 3.2) respectively. C. violaceum, Ps. aeruginosa and E. coli 
displayed lower degrees of sensitivity to F1 with demonstrated MIC values of 
>512, 512 and 256 μg/ml respectively (table 3.3).  
The chalcone compounds (F1 and F23) formed a true solution with neat DMSO, 
even at very high concentrations, which upon initial aqueous dilution becomes 
cloudy, forming a milk-white suspension that retains this opaque characteristic 
even upon the introduction of Mueller-Hinton broth containing bacterial cells. This 
is evidenced by initial high optical density readings at OD650 that seem to support 
the suggestion that the milk-white suspension is neither translucent nor 
transparent as reflected by the elevated initial reading of more than 0.4 units 
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(figure 3.2) at OD650 for the sample containing 128 µg/ml concentration of this 
semi-synthetic agent in 2.5 % v/v of the solvent. 
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Figure 3.2: MIC of F1 against S. aureus 11940 (MRSA) in Mueller-Hinton broth at 37 oC. Inoculum 
density was 1 x 106 cfu/ml.  The mean OD readings were plotted against time (hours) for the 
outcomes of two experiments with three replicates each. 
On the other hand, the optical density of the bacterial suspension treated with a 
two-fold dilution of the above strength was reduced to less than 0.2 unit at the 
same OD650 value whilst a four-fold dilution displayed a value of 0.1 unit.  
With the use of a much higher initial F1 concentration of 512 µg/ml in 2.5 % v/v 
DMSO for the determination of the MIC of this chalcone-derivative against C. 
violaceum, the initial OD reading was seen to be elevated to about 1.5 unit at 
OD650 as demonstrated in the data recorded in figure 3.3.  
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Figure 3.3: MIC of F1 against C. violaceum in Mueller-Hinton broth at 37 oC. Inoculum density was 
1 x 106 cfu/ml.  The mean OD readings were plotted against time (hours) for the outcomes of two 
experiments with three replicates each. 
 A two and four-fold dilutions reduced these optical density (absorbance) 
readings to about 1 and 0.5 units respectively at OD650 indicating that further 
dilutions lowered the opacity of this suspension. Hence, although F1 formed a 
true and lucid solution with neat DMSO at extremely high concentrations (such 
as 5 to 20 mg/ml), initial aqueous dilutions produced quite opaque suspensions 
(reflected by the high initial absorbance readings). A reduction in this opacity 
was obtained as further dilutions were made for the compound such that the 
lower strengths displayed lower initial absorbance readings due to the attainment 
of more translucent suspensions by the desired lower F1 concentrations, even in 
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the presence of Mueller-Hinton broth and bacterial cells, as evidenced by the 
lower initial optical density readings at OD650. On the other hand, although 
Mueller-Hinton broth is opaque to the naked eye, control wells containing either 
this broth alone or with bacterial suspensions did not give high initial optical 
density readings at OD650. However, the data also show a rapid drop in the 
elevated optical density readings within the first 2 hours thereby demonstrating 
the effect of an increase in temperature upon the opacity of suspensions 
constituted with DMSO and water. The OD650 of the cell suspension containing 
the highest concentration of the semi-synthetic flavonoid in 2.5 % v/v DMSO had 
dropped from an initial value of 1.5 units at OD650 that was recorded at the on-
set of the experiment (and obviously at room temperature as well) to 0.5 within 
2 hours upon incubation at 37 oC. Hence, contrary to a previous opinion, the data 
presented in the figure 3.3 rather than suggesting either a coalescence or 
precipitation of the chalcone-derivatives from suspension, actually indicates an 
incubation of the final suspension at elevated temperature increased the lucidity 
and translucency of suspensions contained in the wells within 2 hours. 
The explanation above is also applicable for the observation made in figure 3.3, 
wherein a reduction of the initially raised OD650 readings in the wells of each 
bacterial population treated with ≥ 64 µg/ml F1 concentrations  was noted within 
the first 6 hours following an extensive dilution of the suspension containing the 
chalcone-derivatives in DMSO with water. The effect of extreme dilution coupled 
with an increase in temperature following incubation at 37 oC probably led to a 
decline in the initial opacity recorded for such highly concentrated suspensions 
within this period. This observation may also be verifying that F1 formed a 
completely true solution at concentrations lower than 64 µg/ml (in 2.5 % v/v 
DMSO), as the data presented in figure 3.1 show 1 to 32 µg/ml F1 displaying an 
initial optical density reading of 0.1 to 0.2 unit at OD650. However, one-step 
dilution of stock F1 (as well as F23) solutions prepared in 12.5 % v/v DMSO in 1.5 
ml centrifuge tubes were stable (and did not coalesce), for more than 6 weeks 
when stored at -20 oC. But, in order to avoid the negative effect of repeated 
thawing upon the potency of the tested chalcone compounds, their stock 
solutions were prepared with neat DMSO in 1.5 ml centrifuge tubes and stored in 
the dark at -20 oC. In most cases (except for the solvent negative control) and as 
seen in figure 3.3, the initial rapid decline in the opacity readings recorded for 
wells containing relatively higher concentrations of the chalcone-derivatives were 
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overtaken at a point by the growth kinetic curves of the suspended cells if the 
strengths of the compounds were unable to inhibit the bacterial replication. 
The MBC values were within the range of 16 and >1024 μg/ml against these test 
bacterial species; also indicating a range of modest activity to inactivity. F1 
demonstrated MBC values of 32, 128 and 512 μg/ml against QRSA, MSSA and 
MRSA respectively. Although the 512 µg/ml F1 was infective at inhibiting the 
growth of C. violaceum in the data presented in figure 3.3, a 1 µl volume of this 
suspension sub-cultured onto an antibiotic-free freshly prepared agar after 24 
hours and incubated for another 24 hours had no bacterial colony on the plate, 
unlike samples obtained from all the other wells. This explains how the MBC 
value of 512 µg/ml for this agent against C. violaceum was achieved. 
Another observation to note is that the MIC reported for F1 against MSSA and 
MRSA (64 and 128 μg/ml) from the antibiotic-broth micro dilution assay were 
one dilution step lower than values reported from the antibiotic-agar micro 
dilution assay, which were within the range of 128 – 256 µg/ml respectively. This 
is despite the higher inoculum density of 1 x 106 cfu/ml used in the former 
assay. This is probably accounted for by the fact that the organisms have greater 
contact with the test antimicrobial agents in liquid broth media than they do on a 
solid agar surface. This phenomenon has been previously identified in similar 
studies (Wiegand, Hilpert and Hancock 2008). The data presented in table 3.3 
also show that F23 was modestly active against C. michiganensis, P. 
caratovoram and QRSA with MIC values of 32, 64 and 32 μg/ml respectively. 
This agent may however be considered as being inactive against MRSA because 
of the very high MIC value of >1024 µg/ml demonstrated against this bacterial 
species (figure 3.4). 
This assertion is also applicable to C. violaceum given that this chalcone-
derivative likewise displayed a high MIC value of >512 µg/ml against this latter 
bacterial species (figure 3.5).  
However, it can be observed from the data presented in figure 3.4 that the 
tested concentrations of F23 within the range of 16 to 1024 µg/ml appeared to 
have inhibited the growth of MRSA for the first 18 hours in comparison to the 
untreated control and to a degree surpassing the solvent-only control, until these 
strengths of the agent became apparently overwhelmed by cell replication. But 
surprisingly, a 1 µl volume of 1024 µg/ml F23 sample sub-cultured onto a freshly 
prepared antibiotic and chalcone-derivative-free agar had no bacterial colony 
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after 48 hours unlike those from all other wells containing challenged inoculum 
populations. This observation is similar to that previously made for C. violaceum 
suspension challenged with 512 µg/ml F1.  
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Figure 3.4: MIC of F23 against S. aureus 11940 (MRSA) in Mueller-Hinton broth at 37 oC. Inoculum 
density was 1 x 106 cfu/ml.  The mean optical density readings over time were plotted for the 
outcomes of two experiments with three replicates each. 
This semi-synthetic agent (F23) was also suggested to be weakly active against 
E. coli and Ps. aeruginosa by displaying MIC values of 512 and 256 μg/ml 
respectively, recorded in table 3.3. 
Comparing data presented in table 3.2 to those in 3.3, it can be observed that 
F23 and F1 demonstrated comparable degrees of antibacterial activity against C. 
violaceum (figures 3.3 and 3.5), and QRSA (figures 3.1 and 3.6) by showing the 
same MIC values of >512, 64 and 32 μg/ml respectively against these species.  
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Figure 3.5: MIC of F23 against C. violaceum in Mueller-Hinton broth at 37 oC. Inoculum density was 
1 x 106 cfu/ml.  The mean optical density readings over time were plotted for the outcomes of two 
experiments with three replicates each. 
However, MRSA was more than 8 times more sensitive to F1 than F23.  Likewise, 
the plant pathogens P. caratovoram and Cl. michiganensis were 2 times more 
sensitive to F1 than F23. These data therefore suggest F1 demonstrated more 
potent antibacterial activity than F23. 
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Figure 3.6: MIC of F23 against S. aureus 1628 (QRSA) in Mueller-Hinton broth at 37 oC. Inoculum 
density was 1 x 106 cfu/ml.  The mean optical density readings over time were plotted for the 
outcomes of two experiments with three replicates each. 
3.3.3 Determining the MIC of selected antimicrobial compounds  
In view of the generally weak antibacterial action demonstrated by the chalcone-
derivatives against the test bacterial species above, consideration was given for 
their activity to be assessed in combination with known antimicrobial 
compounds. There was therefore the prerequisite to determine the susceptibility 
of these test bacterial strains to these antibiotics. Representative antibiotics with 
activity targeted at disrupting bacterial membrane integrity, cell wall formation, 
inhibition of protein synthesis and inhibition of DNA replication were chosen. 
Examples of such agents are polymyxin B, penicillin, gentamicin and ciprofloxacin 
respectively (Cottarel and Wierzbowski 2007). The MIC and MBC values obtained 
from antibiotic-broth micro dilution assay for the selected antimicrobial 
compounds against the test bacterial species are shown in tables 3.4 and 3.5. 
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Antimicrobial 
agents 
MSSA MRSA 
MIC 
(μg/ml) 
MBC 
(μg/ml) 
MIC 
(μg/ml) 
MBC 
(μg/ml) 
Penicillin G 0.03125 0.03125 ND ND 
Chlorhexidine 1 2 ND ND 
Benzalkonium 
chloride 
1 1 ND ND 
Gentamicin 1.6 1.6 ND ND 
Ciprofloxacin 32 32 1 1 
Gramicidin ND ND 64 64 
Table 3.4: Susceptibility of S. aureus NCTC 6571 (MSSA) to selected antimicrobial compounds 
reported as MIC and MBC values of these compounds. The data were obtained from at least 3 
replicates. MSSA: Methicillin-sensitive S. aureus. 
Bacterial species Polymyxin B Colistin 
MIC (μg/ml) MBC (μg/ml) MIC (μg/ml) MBC (μg/ml) 
MSSA 256 256 140 140 
MRSA 128 512 ND ND 
QRSA 256 256 ND ND 
E. coli 0.03125 0.03125 0.28 0.28 
Ps. aeruginosa 0.5 1 1.5 1.5 
C. violaceum 32 64 ND ND 
Cl. michiganensis 16 32 ND ND 
P. caratovoram 2 2 ND ND 
Table 3.5: Susceptibility of test bacterial species to polymyxin B and colistin (polymyxin E) 
reported as the MICs and MBCs. ND: Not determined. The data were at least 2 consistent readings 
from 3 replicates. MSSA: Methicillin-sensitive S. aureus NCTC 6571; MRSA: Methicillin-resistant S. 
aureus NCTC 11940 and QRSA: quinolone-resistant S. aureus ATCC 1628. 
In table 3.4, both chlorhexidine and benzalkonium chloride displayed an MIC 
value of 1 μg/ml against MSSA whilst ciprofloxacin displayed an MIC value of 32 
and 1 μg/ml against MSSA and MRSA respectively. Similarly, an MIC of 64 µg/ml 
was recorded for gramicidin against MRSA. The lowest recorded MIC as well as 
MBC value in this study was 0.03125 μg/ml for penicillin G against MSSA in table 
3.4 and polymyxin B against E. coli as shown in table 3.5 as well as figure 3.7 
respectively. 
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Figure 3.7: MIC of polymyxin B against E. coli in Mueller-Hinton broth at 37 oC. Inoculum density 
was 1 x 106 cfu/ml.  The mean optical densities were plotted against time (hours) for the outcomes 
of two experiments with three replicates each. 
Unlike data presented in figures 3.2, 3.3, 3.4, 3.5 and 3.6 for the activity of the 
chalcone-derivatives, the initial optical density readings (OD650) for cells treated 
with polymyxin B in the results reported in figure 3.7 were a much lower value of 
about 0.1 unit probably because this antibiotic forms a true and lucid solution 
with water as solvent. As would be expected, polymyxin B demonstrated 
relatively higher MIC values of 256, 512 and 256 μg/ml against MSSA, MRSA and 
QRSA respectively, being a Gram-negative specific antibiotic, given that these 
organisms are Gram-positive. Similarly, the MIC and MBC values of colistin 
against MSSA were both 140 µg/ml.  
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3.4 Discussion 
All the chalcone-derivative compounds investigated demonstrated poor solubility 
in aqueous medium. Compounds F1, F2 and F23 formed milk-white suspensions, 
indicating chemical incompatibility and poor solubility in aqueous medium. The 
modified antibiotic-agar dilution technique was therefore developed and applied 
to enable the evaluation of the antibacterial activity of these compounds whilst 
dealing with the challenge posed by their poor aqueous solubility. In addition, 
considering that the chalcone-derivatives were supplied in very limited 
quantities, there was the need to develop an assay that enabled the 
simultaneous screening of multiple bacterial species with reduced quantities 
whilst dealing with their poor aqueous solubility. In the assay developed, molten 
agar-antibiotic mixture in a pre-heated (≤ 55 oC) static water-bath (to avoid 
thermal degradation of the test compound) was adjusted to a desired final 
antibiotic as well as solvent concentration. The suspended chalcone compounds 
were unable to coalesce out of the agar once the agar became solidified and their 
presence affected the growth of the bacterial species, if the organism was 
sensitive to the compound. 
The data presented in table 3.1 from the modified antibiotic-agar dilution assay 
show that F1, F5, F7 and F17 demonstrated activity in the range of modest to 
very weak broad-spectrum antibacterial action against MSSA, MRSA and E. coli. 
This observation is consistent with findings from our earlier studies which 
established the poor antibacterial as well as antifungal actions of a series of 
these chalcone and chalcone-derivatives (Ghani et al. 2012). 
Nonetheless, data obtained from the investigations made in this report show that 
in comparison to the other semi-synthetic agents examined, F1 and F23 were 
most active against P. caratovoram, Cl. michiganensis, MSSA and QRSA, with 
MIC values within the range of 16 to 64 µg/ml. Both compounds had been noted 
for further antibacterial and antifungal studies (Ghani et al. 2012). Both 
compounds displayed some degree of antibacterial activity against Gram-
negative (P. caratovoram, C. violaceum, E. coli and Ps. aeruginosa) and Gram-
positive (C. michiganensis, MSSA, MRSA and QRSA) with MIC values in the range 
of 16 to 512 and 32 to 1024 µg/ml respectively. These compounds did not 
therefore exhibit preference for any class of bacteria, irrespective of the absence 
of an outer membrane consisting of an anionic lipopolysaccharide in Gram-
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positive bacterial species (Wu and Hancock 1999). This is understandable given 
that the chemical structures of these chalcone compounds presented in figure 
1.5 show the absence of a net charge. The presence of a net positive charge (as 
seen with the polymyxins in figure 1.3) is likely to have influenced these agents 
binding affinity for the lipopolysaccharide structure in Gram-negative bacterial 
species, as with the former polycationic antibiotic (Falagas, Kasiakou and 
Saravolatz 2005, Jenssen, Hamill and Hancock 2006a, Hale and Hancock 2007), 
although investigational emphasis is now shifting from pore formation and outer 
membrane disruption to other alternative intracellular sites, as additional 
potentential targets of such cationic antimicrobial peptides (Hale and Hancock 
2007). It is therefore possible that these chalcone-derivatives can interact with 
teichoic as well as lipoteichoic acids in the wall of Gram-positive bacterial 
species. Although the potential mechanisms of action of these chalcone-
derivatives are yet to be explored, a similar flavonoid compound (-)-epicatechin 
demonstrates weak antibacterial action (Anderson et al. 2005, Stapleton et al. 
2007). But with some structural activity modifications, (-)-epicatechin gallate 
(ECg) is more active and is thought to sensitize MRSA to the action of β-lactam 
antibiotics by mediating alterations to the cytoplasmic membrane, promoting the 
release of lipoteichoic acid from this bilayer structure and thereby enforcing 
architectural changes to the cell wall teichoic acid that modulates the wall 
properties to make them more susceptible to such antibiotics (Stapleton et al. 
2007). This action of ECg is also thought to be neither related to the expression 
of decreased penicillin-binding proteins (PBP) 2a nor to the binding of this 
flavonoid compound to peptidoglycan. Rather, similar to the antistaphylococcal 
action of galangin, ECg promotes cell aggregation (Cushnie et al. 2007) and in 
addition, increases the thickness of cell wall whilst decreasing peptidoglycan 
cross-linking by 5 – 10 %; which is thought to be of little significant effect upon 
the overall mechanism of action (Stapleton et al. 2007). Therefore, further 
structural activity modifications aimed at improving the aqueous solubility and 
enhancing the antimicrobial potency of both F1 and F23 should be undertaken. 
This will hopefully lead to a reduction in their MIC values against bacterial 
species. It is desirable for antibacterial compounds to demonstrate strong activity 
against pathogenic organisms, with MICs ≤4 to 8 µg/ml against sensitive strains 
and ≤8 to 16 µg/ml against intermediate and resistant strains of S. aureus, as 
has been noted for vancomycin (Tenover et. al. 2007). Antibiotics with MIC 
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values at sub-microgram levels are more likely to display reduced potential to 
cause concentration-related adverse effects in vivo at therapeutically 
administered doses (Van Bambeke et al. 2004). The relatively small doses 
administered will exhibit minimal impact upon other sites that are not the 
primary target, eliciting insignificant degrees of unwanted effects (Tzeng et al. 
2005, Van Bambeke et al. 2004). Unlike the values obtained from this study for 
the chalcone-derivatives that suggested weak antibacterial activity and verified 
previously published data for these chalcone-derivatives (Ghani et al. 2012), 
panduratin A and isobavachalcone display desirably low MIC values of 0.06 to 2.0 
and 0.3 to 0.6 µg/ml against species of S. aureus, using the same broth micro 
dilution assay applied in this report, although with a cell density of 5 x 105 and 
3.75 x 104 cfu/ml respectively (Mbaveng et al. 2008, Rukayadi et al. 2009).  
Comparing data presented in tables 3.1, 3.2 and 3.3, the MIC values for F1 
obtained from the antibiotic-broth micro dilution assay were 32, 64, 128 and 256 
μg/ml against QRSA, MSSA, MRSA and E. coli respectively. The reported MIC 
values of 32 and 256 μg/ml for F1 against QRSA and E. coli are the same from 
the two different techniques. Hence, the data from the conventional micro broth 
dilution assay validated the results obtained from the modified antibiotic-agar 
dilution assay. Meanwhile, the MIC values for F1 from antibiotic-agar dilution 
assay against the same bacterial species above were 32, 128, 256 and 256 
μg/ml respectively. Although the antibiotic-agar micro dilution technique was 
conducted with a lower inoculum density of 1 x 104 cfu/ml, some of the MIC 
values from this modified technique were either the same or one to two dilution 
steps values higher than those obtained from the antibiotic-broth micro dilution 
assay. This is most probably because there was increased contact and therefore 
enhanced interaction between the test compound and the challenged bacterial 
species in the liquid milieu than occurs upon the solid agar surface (Wiegand, 
Hilpert and Hancock 2008, Mann and Markham 1998). Organisms that were 
challenged in a planktonic environment have a greater surface area of interaction 
with the test antimicrobial agent than those placed upon the agar surface and 
this may explain why the former exhibits lower MIC values, given the greater 
contact surface area. 
Results recorded in table 3.5 show that polymyxin B demonstrated MIC values of 
2 and 16 µg/ml against the plant pathogens P. caratovoram and C. 
michiganensis respectively. Understandably, the MIC value of polymyxin B 
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against P. caratovoram is much lower than that obtained for C. michiganensis 
because the latter organism is a Gram-positive bacterium devoid of outer 
membrane, the primary target for polymyxins (Hancock and Chapple 1999). In 
the same table mentioned above, colistin and polymyxin B were approximately 
90 to 8000-fold more active against Gram negative E. coli and Ps. aeruginosa 
than Gram-positive MSSA. With an MIC value of 32 μg/ml, polymyxin B 
demonstrated what may be regarded as a clinically weak activity against C. 
violaceum, a Gram-negative organism, in an antibiotic-broth micro dilution 
assay. Although this reported activity is much better than the activity of this 
polypeptide antibiotic against Neisseria species, the availability of other 
antibiotics that demonstrate far lower MIC values in-vivo along with excellent 
safety profiles makes polymyxin B to be considered as clinically ineffective 
against N. gonorrhoea (Res 2003) and even some subspecies of N. meningitides 
are intrinsically resistant to this antibiotic, with MICs ≥512 μg/ml (Tzeng et al. 
2005). Hence, despite this wide margin in the susceptibilities of N. gonorrhoea, 
N. meningitides and C. violaceum to polymyxin B, the latter organism was 
employed as a model in this project because it is a saprophyte and the MIC of 32 
µg/ml would still be unacceptable clinically. F1 and F23 demonstrated a higher 
MIC value of 512 µg/ml against C. violaceum indicating a much weaker activity. 
This organism might be thought of as being insensitive to the presence of F1 and 
F23 and that by speculation, probably so would N. gonorrhoea. 
The data presented in table 3.3 suggest that both compounds demonstrated 
weak activity against P. caratovoram, MSSA and QRSA and poor activity against 
C. violaceum, Ps. aeruginosa and E. coli. In addition F23 could be considered 
inactive to MRSA at concentrations lower than 512 μg/ml. Effective plant 
antimicrobial compounds are required to show MICs in the range of 100 to 1,000 
μg/ml to their target pathogens in practice (Tegos et al. 2002). Therefore the 
MIC values of 2 and 16 μg/ml reported for polymyxin B against P. caratovoram 
and Cl. michiganensis and 32 and 64 μg/ml against P. caratovoram by F1 and 
F23 respectively are noteworthy. It may be worthwhile for the antibacterial 
activity of F1 and F23 to be evaluated against other phytopathogenic organisms.  
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3.5 Conclusion  
A novel method that permits evaluation of the antimicrobial activities of 
hydrophobic antibiotics against an array of organisms simultaneously, with a 
limited quantity of compound was developed and validated. Some data obtained 
from this modified assay technique and antibiotic-broth dilution assay indicates 
that F1, F2, F12, F13, F17 and F23 were the most active of the chalcone-
derivatives examined, in view of their MIC values against the test bacterial 
species. F1 and F2 demonstrated the lowest MIC values against the plant 
pathogens, P. caratovoram and C. michiganensis, both of which are Gram-
positive and Gram-negative respectively. Although continuous collaborations with 
medicinal chemists on the possible approaches that could be adopted to improve 
the antimicrobial activities of these chalcone-derivatives are on-going (Abdel 
Ghani et al. 2008, Ghani et al. 2012), the options of combinational assays must 
be explored. This may be a viable alternative especially given that a similar 
compound (ECg) demonstrates synergistic antibacterial activities with β-lactam 
antibiotics (Stapleton et al. 2004, Stapleton et al. 2007) and an increasing 
number of flavonoids with direct as well as synergistic actions with antibiotics 
have been noted (Cushnie and Lamb 2011). 
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Chapter 4 
Examining the antibacterial effect of chalcone-derivatives alone 
and with antibiotics 
4.1 Introduction 
Due to the poor output from the developmental process of new antibiotics in the 
past three decades (Booth and Zemmel 2004), an option with several 
advantages to combat the continued emergence of resistant pathogenic bacterial 
strains is the use of combinational therapy. The combination of either two 
antibiotics or an antibiotic with an adjuvant is considered as a therapeutic 
alternative strategy with promise because of the potential for an extended 
spectrum of activity, synergistic action and a longer useful clinical life-span for 
such antibiotics due to delay in the emergence of resistant bacterial 
strains(Cottarel and Wierzbowski 2007). Although polymyxins are clinically 
effective against most Gram-negative multi-resistant pathogens such as 
Acinetobacter species, Pseudomonas aeruginosa, Klebsiella species, and 
Enterobacter species (Falagas, Kasiakou and Saravolatz 2005), a leading and 
current opinion is that polymyxins should be applied in combination with other 
antimicrobial compounds (Kasiakou et al. 2005). It is thought that this approach 
will enhance the safety and effectiveness of polymyxins as well as increase their 
useful clinical life-span by reducing the potential for the emergence of resistant 
bacterial strains. The safety profile of polymyxins applied in combination with 
other antibiotics is likely to improve due to the use of lower doses to achieve 
synergy and consequent lower chances for their dose-related nephrotoxicity 
adverse effect to occur. 
The antibacterial activity of the chalcone-derivatives applied in combination with 
selected antibiotics was undertaken. Attempts to use the agar disc-diffusion 
method to examine the occurrence of synergism between the chalcone-
derivatives and known antimicrobial compounds were unsuccessful due to the 
poor aqueous solubility of the semi-synthetic chalcone-derivatives. The 
chequerboard assay is an effective in vitro technique frequently applied for 
investigating the existence of synergism between two or more compounds 
(Sánchez-Gómez et al. 2011). This assay applies a simple rational technique that 
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enables the assessment of the antibacterial activity of varying concentrations of 
chalcone-derivative in combination with varying concentrations of a known 
antimicrobial compound in a 96-well micro-titre (Lorian 2005). The pattern of 
distribution of the various test concentrations for the two compounds is shown in 
figure 4.1. 
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Figure 4.1 Sample of a chequerboard technique showing serial dilutions of two drugs performed 
with concentrations proportional to MICs of the compounds against the test bacterial species.  
A single growth-inhibitory end-point for the challenged inoculum population may 
then be obtained at any given point, representing the combined synergistic 
concentration of both compounds (Lorian 2005, Lewis et al. 2002, Roling et al. 
2002a). The occurrence of either synergistic or additive action between both 
compounds can be traced along the shaded 45o axis, although it could occur in 
wells containing concentrations of compounds that are located well off this line 
(Pillai et al. 2005a). 
The selected antibacterial agents chosen for inclusion in the investigation of 
potentiated action when applied with the chalcone-derivatives were ciprofloxacin, 
gentamicin, polymyxin B and penicillin, which all have distinct primary 
mechanisms of action (table 1.1) (Walsh  2003, Hancock  2005, Bradley and 
Jones 2006). Ciprofloxacin inhibits DNA replication, gentamicin blocks ribosomal 
protein synthesis, polymyxins disrupt membrane integrity and penicillin inhibits 
peptidoglycan synthesis in actively dividing bacterial cells (Cottarel and 
Wierzbowski 2007). This report will focus only on the data obtained for assays 
conducted with polymyxin B and ciprofloxacin. Although polymyxins are only 
clinically useful against Gram-negative organisms (Res 2003), the test bacterial 
species were selected to include Gram-positive bacterial species (S. aureus 6571 
(MSSA), S. aureus 11940 (MRSA) and S. aureus 1628 (QRSA), representing 
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different strains of antibiotic-sensitive and resistant S. aureus species) in an 
attempt to potentially extend the spectrum of activity of polymyxins. Bearing in 
mind that polymyxin B is clinically effective against Gram-negative bacterial 
species (Fernandez et al. 2010), a concomitant activity against these 
representative Gram-positive species by the combination of this latter antibiotic 
with any of these semi-synthetic flavonoids may attract further consideration for 
formulation of a potential antibacterial preparation with a view to eliciting a 
broader spectrum of action. 
Overall antibacterial effect can be rated as either antagonistic, indifferent, 
additive or synergistic. When the MIC value of either of two compounds in a 
combination was lower than half the MIC value of any of the individual 
compounds applied against a test bacterial species, it was suggestive of the 
existence of either an additive or synergistic relationship between the two 
compounds (Petersen et al. 2006). The fractional inhibitory concentration (FIC) 
for the combination doses can be calculated by dividing the MIC value for each of 
the compounds in the combination by the MIC value obtained for each agent 
when applied alone and adding the two quotients as shown in the formulas 
below:  
 
FIC of compound A (FICA) = (MICA in combination)/(MICA alone) 
FIC of compound B (FICB) = (MICB in combination)/(MICB alone) 
The FICindex = FICA + FICB 
Where: FICA, MICA, FICB and MICB are FICs and MICs for antibiotic A and B 
respectively (Chen et al. 2004).  The FIC indices were used to characterize the 
overall antibacterial activity between the chalcone-derivatives and the 
established antibiotics applied together, as follows: Synergy, FICindex ≤ 0.5; 
additive, 0.5 ‹ FICindex ‹ 1; indifference, 1 ‹ FICindex ≤ 4 and antagonism, FICindex  › 
4 (Chen et al. 2004, Eliopoulos and Moellering 1996). Therefore, the objective for 
this aspect of the project was the examination of the overall antibacterial effect 
of the chalcone-derivatives F1 and F23 when each was applied in combination 
with selected antibiotics against some test bacterial pathogens. 
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4.2 Materials and Methods 
4.2.1 Evaluation of the effect of the chalcone-derivatives in combination 
with selected antibiotics  
The examination of the antibacterial activity of the chalcone-derivatives each 
applied in combination with selected antibiotics was undertaken in vitro in a 
standard chequerboard assay, as previously described in section 2.6.  
4.3 Results 
4.3.1 The antibacterial action of F1 applied in combination with either 
polymyxin B or ciprofloxacin 
The data obtained from the assay were interpreted as described above, 
permitting the determination of the FICs for the effective combination 
concentrations of either polymyxin B or ciprofloxacin with the semi-synthetic 
agents in table 4.1.  
Bacterial 
species 
 
MIC (µg/ml) 
MBC (μg/ml) of F1 
with polymyxin B  
FICindex Interpretation 
    
F1 Polymyxin  
B 
F1 with 
polymyxin B 
MSSA 64 1024 16/256 16/256 0.5 synergism 
MRSA 128 128 16 /32 16 /32 0.375 synergism 
QRSA 32 256 8/32 8/32 0.375 synergism 
E. coli 256 0.03125 256/0.03125 512/0.03125 2 indifferent 
C. violaceum >512 32 16/2 32/2 <0.093 synergism 
Ps.aeruginosa 256 0.5 16/0.25 64/0.25 0.53125 additive 
Table 4.1: The data (FICindexes) obtained from a chequerboard assay for F1 applied in combination 
with polymyxin B against test bacterial species. The data were at least 2 consistent readings from 3 
replicates conducted on separate days. MIC: minimum inhibitory concentration; MBC: Minimum 
bactericidal concentration; MSSA: S. aureus 6571; MRSA: Methicillin-resistant S. aureus 11940 and 
QRSA: quinolone-resistant S. aureus 1628. Note that the MIC of polymyxin B applied alone against 
MSSA had changed from the previously reported 256 to 1024 µg/ml. Inoculum density was 1 x 106 
cfu/ml. 
The data presented in table 4.1 demonstrate that in the in vitro combinations, the 
MICs of F1 and polymyxin B against S. aureus 6571 (MSSA) were synergistically 
reduced from 64 and 1024 (when applied separately) to 16 and 256 μg/ml (when 
applied in combination) respectively, thereby yielding a FICindex of 0.5. As shown in 
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both table 4.1 and figure 4.2, the combination also synergistically reduced the 
MICs of both compounds against S. aureus 11940 (MRSA) from 128 and 128 to 16 
and 32 μg/ml respectively, with a FICindex of 0.375.  
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Figure 4.2: Data from chequerboard assays for 16 µg/ml F1 applied with either 32 or 64 µg/ml 
polymyxin B and 8 µg/ml F1 combined with 64 µg/ml polymyxin B against MRSA. The mean cell 
densities values at OD650 were plotted against time (hours) for the outcomes of two experiments 
repeated on separate days. 
The data presented in figure 4.2 further show that the combinations of 64 µg/ml 
polymyxin B with either 8 or 16 µg/ml F1 were also synergistic against MRSA, 
giving an indication that several different combinations of these agents can display 
bactericidal actions at lower concentrations than would either of the compounds 
applied separately. The inability of the combination of 64 µg/ml polymyxin B with 
2.5 % v/v DMSO, used as a control, to inhibit the growth of the organism suggests 
the activity reported for the synergistic combinations of F1 with polymyxin B 
cannot be attributed to the presence of the solvent. 
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For MSSA, the MICs of both compounds were reduced from 64 and 1024 µg/ml to 
16 and 256 µg/ml under a combined application as shown in figure 4.2b. 
0 2 4 6 8 10 12 14 16 18 20 22 24
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
Negative control
4 µg/ml F1 in 0.156 % v/v DMSO
8 µg/ml F1
16 µg/ml F1
256 µg/ml polymyxin B + 2.5 % v/v DMSO
256 µg/ml polymyxin B
16 µg/ml F1+ 256 µg/m polymyxin B
2.5 % v/v DMSO negative control
Untreated MSSA in 2.5 %v/v DMSO
Untreated MSSA
Time (hours)
Ce
ll 
de
ns
ity
 a
t O
D
65
0
 
Figure 4.2b: Data from chequerboard assays for 16 µg/ml F1 applied with 256 µg/ml polymyxin B 
against MSSA. The mean cell densities values at OD650 were plotted against time (hours) for the 
outcomes of two experiments repeated on separate days. 
Although the 3 concentrations of 4, 8 and 16 µg/ml of F1 demonstrated increasing 
activity against MSSA, none of them was bactericidal unlike the combination of the 
latter strength with polymyxin B. With the quinolone-resistant S. aureus 1628 
(QRSA), the MICs of both compounds were synergistically reduced from 32 and 
256 to 8 and 32 μg/ml respectively (figure 4.3), yielding the same FICindex value of 
0.375 as shown in the table 4.1. 
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Figure 4.3: Data from chequerboard assays for 8 µg/ml F1 applied with either 32 or 16 µg/ml 
polymyxin B against QRSA. The mean OD650 values were plotted against time (hours) for the 
outcomes of two experiments repeated on separate days. 
The results presented in figure 4.3 corroborates with data in table 4.1 which 
showed that the application of 8 µg/ml F1 with 16 µg/ml polymyxin B was also 
synergistic against the challenged inoculum and yielded an FICindex of 0.3125. 
The two consecutive previous figures show that both MRSA and QRSA cells 
expressed a some levels of sensitivity to the presence of DMSO as solvent 
relative to all other bacterial species examined in this study. As previously noted 
in figures 3.1 and 3.6, the result presented in figure 4.3 also clearly shows the 
growth kinetic of QRSA suspension treated with only 2.5 v/v DMSO as solvent 
control were adversely affected in comparison to the untreated positive control 
cells. The solvent control cells exhibited a longer lag time and a slower growth 
rate that peaked at an OD650 of 1 unit. Whilst the growth kinetic of the cells 
treated with sub-inhibitory concentrations of 8 and 16 µg/ml polymyxin B but 
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devoid of DMSO were faster in onset, exhibiting optical density readings of <1.4 
unit, the untreated solvent-free control cells demonstrated the fastest onset and 
rate of growth that peaked at about 1.5 unit at OD650. These polymyxin-treated 
cells had a growth kinetic curve that was higher in rate and extent than those 
treated with the chalcone-derivatives containing DMSO as solvent and therefore 
displayed curves that were separated from those obtained from either the latter 
or DMSO solvent control samples. However, the degree of the bactericidal action 
of the combination of F1 with polymyxin B makes this solvent effect insignificant. 
In addition, cells treated with 64 µg/ml polymyxin B in the presence of 2.5 % v/v 
DMSO demonstrated uninhibited growth suggesting the augmentative 
antibacterial action recorded for the 2 synergistic combinations of F1 and 
polymyxin B against QRSA above may not be attributable to the presence of the 
solvent.  
With E. coli, both F1 and polymyxin B were indifferent in their combined 
antibacterial action with a FICindex of 2, as both retained their original MIC values 
of 256 and 0.03125 μg/ml when applied in combination. Of note, with the in vitro 
combined application of both compounds against C. violaceum, the MICs of both 
compounds were reduced from 512 and 32 to 16 and 2 μg/ml respectively as 
shown in figure 4.4.  
This combination demonstrated considerable antibacterial synergism, with a 
FICindex of 0.094, in this instance. This FICindex gave an indication that C. 
violaceum was the most susceptible organism to the combination of F1 with 
polymyxin B amongst the test bacterial species. The data presented in the figure 
suggests an extension of the endpoint time from 24 to 48 hours may have been 
more revealing as the effective combination strengths began to become 
overwhelmed by cell growth after 20 hours of incubation. To corroborate this 
point, results presented in table 4.1 also show that the combination of 32 µg/ml 
F1 with 2 µg/ml polymyxin B, which were higher than the former mentioned 
strengths, were recorded as the bactericidal concentration against C. violaceum, 
thereby verifying the observation being reported for the action of 16 µg/ml F1 
with 2 µg/ml polymyxin B in figure 4.4. As was previously shown in figure 3.5, 
the impact of 2.5 % v/v DMSO on C. violaceum was comparatively minimal in that 
the solvent treated cells were seen to demonstrate a rate and an extent of 
growth kinetic that is comparable to the untreated population. In figure 4.4b, F1 
applied in combination with polymyxin B demonstrated an additive action against 
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Ps. aeruginosa with a FICindex of 0.53. The MICs of F1 and polymyxin B against 
this bacterial species was reduced from 256 and 0.5 μg/ml (when applied alone) 
to 16 and 0.25 μg/ml (when applied in combination) respectively. 
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Figure 4.4: Data from chequerboard assays for 16 µg/ml F1 applied with 2 µg/ml polymyxin B 
against C. violaceum. The mean cell densities at OD650 from two experiments repeated on separate 
days were plotted against time (hours). 
Therefore F1 and polymyxin B demonstrated a 16 and a 2-fold reduction in MIC 
values respectively. Such a disproportionate reduction in the MICs of both 
compounds with bactericidal action against Ps. aeruginosa often makes the well 
containing the best synergistic combination concentrations to fall outside (farther 
away from) the 45o axis previously described. The MICs obtained when 
methicillin-sensitive S. aureus 6571 was challenged with a range of F1 and 
ciprofloxacin concentrations independently applied were 64 and 32 µg/ml 
respectively. Both MIC values were however synergistically reduced to 4 and 8 
µg/ml respectively when both compounds were applied in combination, yielding a 
FICindex of 0.313 that indicated these compounds were synergistic in action.  
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Figure 4.4b: Data from chequerboard assays for 16 µg/ml F1 applied with 0.25 µg/ml polymyxin B 
against Ps. aeruginosa. The mean cell densities at OD650 from two experiments repeated on 
separate days were plotted against time (hours). 
4.3.2 The antibacterial action of F23 applied in combination with 
polymyxin B  
The antibacterial effect of F23 applied in combination with polymyxin B against 
test bacterial species is shown in table 4.2. The data presented in the table 
demonstrate that in the in vitro combination, the MICs of F23 and polymyxin B 
against MSSA were synergistically reduced from 64 and 1024 (when applied 
separately) to 16 and 256 μg/ml (when applied in combination) respectively, 
thereby yielding a FICindex of 0.5. The combination reduced the MICs of both 
compounds against MRSA from >1024 and 128 to 32 and 64 μg/ml respectively 
yielding a FICindex of <0.53 that indicated both compounds were additive in action 
against this bacterial species (figure 4.5). Similarly, both compounds applied in 
combination were also additive in action against QRSA populations, by having 
their MICs reduced from 32 and 256 (when applied alone) to 16 and 64 µg/ml 
(when applied together), thereby yielding a FICindex of 0.75.  
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Bacterial 
species 
 
MIC (µg/ml) 
MBC (μg/ml) of 
F23 with 
polymyxin B  
FICindex Interpretation 
    
F23 Polymyxin 
B 
F23 with 
polymyxin B  
MSSA 64 1024 16/256 16/256 0.5 synergism 
MRSA >1024 128 32/64 32/64 <0.53125 additive 
QRSA 32 256 16/64 16/64 0.75 additive 
E. coli 512 0.03125 32/0.03125 32/0.03125 0.1625 synergism 
C. violaceum >512 32 32/8 64/4 0.3125 synergism 
Ps.aeruginosa 256 0.5 32/0.125 32/0.125 0.375 synergism 
Table 4.2: The data (FICindexes) obtained from a chequerboard assay for F23 applied in combination 
with polymyxin B against test bacterial species. The data were at least 2 consistent readings from 3 
replicates conducted on separate days. MIC: minimum inhibitory concentration; MBC: Minimum 
bactericidal concentration; MSSA: S. aureus 6571; MRSA: Methicillin-resistant S. aureus 11940 and 
QRSA: quinolone-resistant S. aureus 1628. Note that the MIC of polymyxin B applied alone against 
MSSA had changed from the previously reported 256 to 1024 µg/ml. Inoculum density was 1 x 106 
cfu/ml. 
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Figure 4.5: Data from chequerboard assays showing the synergistic activity of 32 µg/ml F23 
applied with 64 µg/ml polymyxin B against S. aureus 11940 (MRSA). The mean ODs are plotted for 
the outcomes of two experiments repeated on separate days. 
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The antibacterial activity of F23 applied in combination with polymyxin B against 
E. coli was synergistic but conspicuously outside the imaginary 45o axis, as 
obtained for F1 applied in combination with polymyxin B against Ps. aeruginosa. 
In this instance, whilst the MIC of F23 was reduced 16-fold from 512 to 32 
μg/ml, that of polymyxin B was retained at the initial value of 0.03125 μg/ml. 
There was another observation in the antibacterial actions of either F1 or F23 
applied in combination with polymyxin B against E. coli. When F1 was applied in 
combination with polymyxin B against E. coli, the MICs of both F1 and polymyxin 
B were retained at their initial values of 256 and 0.0313 μg/ml respectively. 
Whereas with F23 was applied in combination with polymyxin B against E. coli, 
the MIC of F23 was reduced from 512 to 32 μg/ml whilst that of polymyxin B was 
also retained at the initial value of 0.03125 μg/ml.  
The antibacterial activity of F23 applied in combination with polymyxin B against 
C. violaceum is once again noteworthy. The MICs of F23 and polymyxin B were 
synergistically reduced from 512 and 32 to 32 and 8 μg/ml respectively, yielding 
a FICindex of 0.313 (figure 4.6). 
In this same assay, the combination of either 16 or 32 µg/ml F23 each with 16 
µg/ml polymyxin B were equally bactericidal against C. violaceum, thereby 
exposing the various bactericidal flexibilities from different concentration 
combination of both compounds against this bacterial species that can be further 
explored. 
Finally, in contrast to the additive activity of F1 applied in combination with 
polymyxin B against Ps. aeruginosa, the MICs of F23 and polymyxin B were 
synergistically reduced from 256 and 0.5 to 32 and 0.125 μg/ml respectively, 
yielding a FICindex of 0.375. 
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Figure 4.6: Data from chequerboard assays showing the synergistic actions of 32 µg/ml F23 
applied in combination with either 8 or 16 µg/ml polymyxin B as well as 16 µg/ml F23 combined 
with 16 µg/ml polymyxin B against C. violaceum. The mean ODs are plotted for the outcomes of 
two experiments repeated on separate days. 
4.4 Discussion 
Antibiotics applied in combination in a chequerboard assay are assumed to 
possess an identical dose response and to contribute equally to the overall 
outcome of their collective effect upon the challenged bacterial population (Roling 
et al. 2002a). Such is the case in an ideal situation and if the combined effect of 
both compounds was synergistic, the most effective concentrations would be 
contained in wells positioned along the imaginary 45o axis on the micro-titre 
plate (Lorian 2005). An observation with the chequerboard assay is that although 
dilutions of concentrations of the chalcone-derivatives applied in combination 
with the established antibiotics were made on this premise; both compounds 
could possess dissimilar dose responses at the single growth-inhibitory endpoint 
(Lewis, Klepser and Pfaller 1999). But a limitation of this in vitro assay is that 
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even if the growth inhibitory end-point concentration wells were located along 
the 45o line, the information obtained could be misleading if extrapolated and 
applied presumptuously in an in vivo condition, as the ratios of the two 
compounds may not remain constant upon administration in doses that are 
proportional to their MICs due to differences in their biological half-lives as well 
as susceptibility to metabolic degradation (Lorian  2005). This is connected to 
differences in pharmacodynamic and pharmacokinetic parameters for varying 
chemical substrates (Owens and Ambrose 2007). It is therefore important to 
take note of additive and synergistic actions that occur outside the 45o axis as 
further in vivo assays may be required to guarantee the usefulness of the most 
effective combination concentrations. 
The data presented in table 4.1 indicate that the combination of F1 with 
polymyxin B was synergistic in action against MSSA, MRSA, QRSA, E. coli and C. 
violaceum and additive against Ps. aeruginosa respectively in the chequerboard 
assays. Similar data presented in table 4.2 indicate that F23 applied in 
combination with polymyxin B was synergistic in action against MSSA, E. coli, C. 
violaceum and Ps. aeruginosa; and additive against MRSA and QRSA 
respectively. None of the combinations gave indications that were suggestive of 
the occurrence of antagonism. 
The synergisms demonstrated by F1 when applied with polymyxin B against 
MSSA, MRSA, QRSA and C. violaceum were displayed along the midline 
suggesting both compounds were exhibiting a similar dose-response against 
these bacterial species. This observation may suggest the cells were equally 
sensitive to the combined presence of these agents and an inhibition of either a 
common target site or metabolic pathway in these organisms by both 
compounds, as seen with the application of trimethoprim with sulphonamides 
(Grim et al. 2005). Trimethoprim and sulphonamides are individually 
bacteriostatic agents applied as a combinational antibiotic to achieve a 
synergistic outcome due to their capacity to inhibit at two separate points 
simultaneously the folic acid synthetic pathway, a small component of a very 
broad and complex metabolic process known as the aromatic biosynthesis 
pathway (Jain 2012). Sulphonamides being derivatives of p-
aminobenzenesulphonamide are structural analogues and competitive 
antagonists of p-aminobenzoic acid, probably upon the attachment of the sulpha 
molecule to the benzene ring (Hanson 2006). Sulphonamides are therefore able 
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to inhibit dihydropteroate synthase, an enzyme responsible for the incorporation 
of p-aminobenzoic acid into dihydropteroic acid which is an immediate precursor 
of folic acid (Goldstein and Proctor 2008, Lumb et al. 2009).   
F1 and polymyxin B applied in combination demonstrated synergism against 
MSSA, MRSA and QRSA by displaying a ≥4-fold reduction in their MICs.  The 
most profound antibacterial activity reported from the combination assay was 
that of F1 applied in combination with polymyxin B against C. violaceum, which 
yielded a FICindex of 0.094. This combination demonstrated a 32 and 16-fold 
reduction in the MICs of both compounds. Considering that C. violaceum is a 
member of the Neisseriaceae family, this response would make the examination 
of the antibacterial activity of this combination of compounds against antibiotic 
resistant strains of Neisseria species very worthwhile; as recently, a strain of N. 
gonorrhoea that is resistant to all available antimicrobial agents in the clinic was 
recovered indicating a possibility for the emergence of untreatable gonorrhoea 
shortly (Bolan, Sparling and Wasserheit 2012). 
The activities of F1 and polymyxin B reported against E. coli and Ps. aeruginosa 
were indifferent and additive respectively, with both organisms, which 
incidentally are Gram-negative, showing either little or no further sensitivity to 
the presence of the combined agents than they would to polymyxin B alone. This 
may indicate that the degree of bactericidal action of polymyxin B, a Gram-
negative specific antibiotic (Zavascki et al. 2008) surpasses that of the 
combination against both pathogens and that the presence of the chrome-
derivatives is not required to facilitate the activity of this polycationic agent 
against the anionic lipopolysaccharide structure, which is considered the primary 
target site in the outer membrane bilayer of this class of organisms for this 
antibiotic (Fernandez et al. 2010, Martti  2010). Although the combination of F1 
with polymyxin B was additive in action against Ps. aeruginosa, the application of 
F23 with the latter antibiotic was synergistic in activity, with this organism 
displaying greater sensitivity to polymyxin B in the presence of this latter 
chalcone-derivative, as the MIC shifted from 0.5 to 0.125 µg/ml (table 4.2). The 
data presented show that the additive and synergistic actions of F1 and F23 each 
in combination with polymyxin B against Ps. aeruginosa respectively also 
required a relatively smaller fraction of both chalcone derivatives. For in table 
4.1, the MIC of F1 was reduced from 256 to 16 µg/ml and in table 4.2 that of 
F23 was reduced from 256 to 32 µg/ml respectively. In the combination, 
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although F1 and F23 demonstrated a 16 and an 8-fold reduction in MIC, 
polymyxin B only showed a 2-fold reduction.  
It was reported in chapter 3 that both F1 and F23 displayed poor activity against 
C. violaceum, Ps. aeruginosa and E. coli at concentrations lower than 256 μg/ml 
and that F23 was inactive against MRSA at concentrations lower than 1024 
μg/ml. With the chequerboard assay, F1 applied in combination with sub-
inhibitory concentrations of polymyxin B was additive in action against Ps. 
aeruginosa. Generally, tolerance seemed to be expressed to compound F1 by the 
3 Gram-negative bacterial species of E. coli, C. violaceum and Ps. aeruginosa by 
the demonstration of either a one or two steps increment in the MBC values 
recorded in table 4.1 against these organisms. This observation was indeed not 
made for polymyxin B, although both agents were applied in combination. This 
occurrence may be partly due to difficulties associated with both permeability 
and efflux (Walsh et al. 2003, Cottell et al. 2009). A possibility for the 
development of tolerance by Gram-negative bacterial species to hydrophobic 
agents through both above mentioned mechanisms is well established (Hancock 
1997, Hancock and Rozek 2002). In fact, structurally unrelated antimicrobial 
agents, including biocides are sometimes ineffective due to efflux-mediated 
resistance mechanism (Walsh et al. 2003, Poole 2000).  
In table 4.2, F23 applied in combination with sub-inhibitory concentrations of 
polymyxin B was synergistic against these same Gram-negative organisms. And, 
the occurrence of tolerance for the action of F23 was also noted when this agent 
was applied in combination with polymyxin B against C. violaceum by a one-step 
increment in the MBC value recorded against this organism. Meanwhile, the 
reported value for polymyxin B reduced by a factor of one-step dilution. On the 
other hand, all the reported MIC values were retained as the MBC values for the 
combination of F23 with polymyxin B against all three Gram-positive bacterial 
species of S. aureus (MSSA, MRSA and QRSA respectively). Ps. aeruginosa is a 
Gram-negative bacterium possessing a capacity for both intrinsic and adaptive 
resistance to antimicrobial peptides (Hocquet et al. 2003, Fernandez et al. 2010) 
and harbouring numerous virulence factors (Schurek, Breidenstein and Hancock 
2012). The intrinsic resistance and virulence of Ps. aeruginosa are hugely up-
regulated in response to sub-inhibitory concentrations of polymyxin B, colistin 
and some naturally occurring peptides (Gooderham and Hancock 2009). Hence, 
it would be worthwhile to examine the mechanism by which these chalcone-
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derivatives are able to demonstrate enhanced synergistic activity with sub-
inhibitory concentrations of polymyxin B against Ps. aeruginosa. 
There are on-going attempts to achieve a better understanding of the 
mechanisms by which antimicrobial peptides induce adaptive resistance 
responses in Ps. aeruginosa. It has been shown that the two-component 
response regulator proteins PhoP-PhoQ and PmrA-PmrB are up-regulated when 
treated with polymyxin B and influence the expression of the arnBCADTEF 
lipopolysaccharide modification operon (Fernandez et al. 2010, Zavascki et al. 
2006). In so doing, these regulatory systems activate resistance to polymyxin B 
and other cationic peptides in this organism (Fernandez et al. 2010, McPhee, 
Lewenza and Hancock 2003). It would therefore be sensible to examine whether 
either F1 or F23 down-regulates these resistance genes in Ps. aeruginosa, in the 
presence of sub-inhibitory concentrations of polymyxin B within the course of 
their combined synergistic activity in the combination assay. 
In the presence of polymyxin B, the MICs of both F1 and polymyxin B against E. 
coli were retained at their individual values; an indication that both compounds 
neither enhanced nor interfered with the activity of each other against this 
bacterial strain. This may suggest the anionic lipopolysaccharide outer 
membrane in this organism was a highly effective barrier against the permeation 
of F1 especially considering the absence of a net (positive) charge on the 
molecular structure of this compound.  However, F23 applied in combination with 
polymyxin B was synergistic in action against E. coli (like this same agent did 
against Ps. aeruginosa and C. violaceum, all of which are Gram-negative 
bacterial species) with the former chalcone compound displaying a 16-fold 
reduction in MIC whilst the latter retained the previous individual MIC value of 
0.0313 µg/ml. This may suggest that polymyxin B promoted the translocation of 
F23 across the outer membrane bilayer barrier of E. coli (these organisms), 
thereby enhancing the antibacterial action of this chalcone-derivative in their 
combined applications against this class of bacterial species. This speculation 
could be explored further to guide the development of polymyxins combinations 
that would be potentially effective for the treatment of infections mediated by 
both Gram-positive and Gram-negative bacterial species simultaneously. The 
lipopolysaccharide (LPS) layer in Gram-negative species accounts to a great 
degree for their low permeability to hydrophobic compounds, including certain 
antibiotics (Kumar and Schweizer 2005). The LPS is composed of lipid A (a 
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polysaccharide) and an O-antigen. Fatty acid substituents of the LPS form a 
thick, impermeable gel because of complete saturation and the O-antigen is 
strongly anionic with cross-bridging of the core region with phosphate groups 
and divalent cations (Wiese et al. 1999). All these factors enhance the low 
permeability of the LPS, especially in E. coli as well as Ps. aeruginosa, wherein 
the LPS is most highly phosphorylated in comparison to other Gram-negative 
bacterial species, resulting in a stronger diffusion barrier (Sadovskaya et al. 
1998, Sadovskaya et al. 2000) and may explain why combined applications of F1 
with polymyxin B were indifferent and additive to both organisms in the data 
presented in table 4.1.  
However, although the outer membrane is an effective barrier against 
hydrophobic substrates, the fraction of these compounds that could permeate 
barrier membranes are actually extruded by efflux pumps at a rate faster than 
that with which such compounds entered (Hancock  1997a, Nikaido and 
Takatsuka 2009). Molecules of polymyxins (and antibacterial peptides generally) 
are capable of self-translocation and thereby also promoting the entry of other 
hydrophobic substrates across bacterial outer and cytoplasmic membranes 
(Jenssen, Hamill and Hancock 2006a), a process commonly termed self-
promoted uptake (Hancock 1997a). Molecules of polymyxins consist of 
hydrophobic and hydrophilic regions and can aggregate to span the lipid bilayer 
with micelle-like complexes made up of peptides and lipids. These molecules can 
also insert themselves at a 90o angle to the plane of the bilayer by the 
interaction of their hydrophilic regions with the phospholipid head groups of the 
outer membrane structure whilst their hydrophobic region is associated with the 
lipid core. The membrane then curves inward allowing more of the polymyxins 
molecules to line the formed pore to permit the creation of a free entry route for 
both itself and other molecules (Jenssen, Hamill and Hancock 2006a). This 
strategy is more pronounced in the “barrel-stave” peptides entry model (Zhang, 
Rozek and Hancock 2001a, Bradshaw  2003) wherein the polymyxins orientate 
and insert themselves at an angle of 90o to the bilayer plane forming staves 
(holes that extend from outward to inward) with their hydrophilic region facing 
the inner open space of the pore and their hydrophobic region interacting with 
the lipid bilayer (Jenssen, Hamill and Hancock 2006a). The latter two 
mechanisms have a capacity to promote the entry of polymyxins and other 
molecules, even hydrophobic compounds. Such hydrophobic molecules are likely 
88 
 
to begin their transition by interacting with the outer hydrophobic regions of the 
peptide molecules already in association with the lipid bilayer (Hancock 1997a, 
Wu and Hancock 1999, Hancock 1997d). This self-promoted uptake can occur in 
both Gram-positive and negative organisms (Falagas, Kasiakou and Saravolatz 
2005, Hancock and Chapple 1999, Hancock and Lehrer 1998a) and is often 
accompanied by an increased permeability of the bacterial membrane to a 
variety of compounds, including hydrophobic agents. For Gram-negative cells, 
the preliminary electrostatic bonding occurs between the cationic peptides and 
negatively charged phosphate groups within the lipopolysaccharide in the outer 
membrane (Zhang et al. 2000) whilst lipoteichoic acids occurring on the surfaces 
of Gram-positive bacteria interacts with these compounds. Therefore, it can be 
speculated that polymyxin B possibly acts in a manner that promotes the 
enhanced translocation of both F1 and F23 across both Gram-positive and Gram-
negative bacterial membrane barriers leading to a continued accumulation and 
retention of both compounds (due to a simultaneous down-regulation of efflux 
mechanisms), within the cytoplasm and periplasmic spaces, for potential 
targeting of other intracellular sites and enzymes.  
In both San Diego and Kingston in Ontario, MPex Pharmaceuticals have been 
developing some combinational antibacterial compounds (Lomovskaya and 
Bostian 2006, Kriengkauykiat et al. 2005). One of their strategies is to combine 
compounds, one of which is sometimes an adjunct that can interfere with the 
bacterial efflux pump, with an antimicrobial agent (Poole and Lomovskaya 2006). 
The compound MC-2077,110 and its analogues MC-002595 as well as  MC-
004124 are dibasic peptide-like agents that are competitive inhibitors of multiple 
resistance-nodulation-division (RND) transporters in Gram-negative bacterial 
species, especially in Ps. aeruginosa (Lomovskaya and Bostian 2006). These 
compounds being substrates of their target efflux-pumps compromise the 
extrusion of fluoroquinolone and macrolide antibiotics when applied in 
combination by competitively inhibiting the binding of such antibiotics to a 
common site on the pumps (Pagès, Masi and Barbe 2005). Such a combinational 
formulation has demonstrated an enhanced antibacterial activity for laevofloxacin 
against Ps. aeruginosa, by preventing the efflux of laevofloxacin from the 
cytoplasmic space (Kriengkauykiat et al. 2005). 
QacA is a member of the small multi-drug resistant family (Paulsen et al. 1996) 
and NorA belongs to the major facilitator super-family that are multi-drug and 
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toxic compound extrusion pumps prevalent in Gram-positive bacterial species, 
especially S. aureus (Yoshida et al. 1990, Yamagishi et al. 1996).  Whilst QacA is 
plasmid encoded, NorA is chromosomally encoded and responsible for 
intermediate fluoroquinolone resistance in S. aureus (Poole 2000). Considering 
that the data presented in this section indicated a synergism for the combined 
antibacterial activity of F1 with ciprofloxacin, it might be worthwhile to examine 
whether these extrusion pumps are down-regulated in S. aureus by the 
combination of the chalcone-derivative with a fluoroquinolone. Likewise, it may 
also be worthwhile examining whether either F1 or F23 in combination with 
polymyxin B inhibit QacA and NorA in Gram-positive as well as the multiple 
resistance-nodulation-division pumps in Gram-negative bacterial species in 
achieving their synergistic action. 
Tackling the efflux systems may not be the only potential mechanism by which 
the combination of the chalcone-derivatives with polymyxins elicited their 
antimicrobial synergistic action. The loss of the MexAB-OprM efflux system (RND) 
family in strains of Ps. aeruginosa that are resistant to fluoroquinolones and 
macrolides did not induce susceptibility of this pathogenic organism to these 
antibiotics (Masuda et al. 2000); an indication that a capacity to overcome the 
activity of the latter enzymes is a more important factor in determining the 
potency of a given antibiotics. Although the mechanisms of action of these 
chalcone-derivatives have not been explored, some similar flavonoid compounds 
are known to function as adjuncts, modifying the activities of established 
antibiotics. As mentioned in chapter 3, (-)-epicatechin gallate (ECg) sensitizes 
MRSA to the actions of β-lactam antibiotics, reducing the oxacillin MICs as much 
as 512-fold (Cushnie and Lamb 2011) through mechanisms that are neither 
related to the occurrence of decreased penicillin binding protein nor the binding 
of the flavonoid to same sites on the peptidoglycan with this class of antibiotic 
(Stapleton et al. 2004). This flavonoid (ECg) is now thought to potentiate the 
actions of β-lactams by inflicting structural changes to the cell wall teichoic acid, 
promoting the release of lipoteichoic acid from the cytoplasmic membrane 
thereby inducing an enhanced susceptibility of MRSA to the β-lactams (Stapleton 
et al. 2007). Clavulanic acid acts synergistically as an adjunct with amoxicillin, in 
a combinational formulation called co-amoxiclav, by rendering strains that are β-
lactamase expressing susceptible to amoxicillin through a competitive binding of 
the former compound to the enzyme (Vree, Dammers and Exler 2003). A 
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reversible complex is formed initially upon the binding that progresses into an 
irreversible inactivation of the β-lactamase enzyme and clavulanic acid (Drawz 
and Bonomo 2010). Both compounds share similar pharmacokinetic properties 
and a biological half-life of 1 hour illustrating an ideal antimicrobial combination 
(Vree, Dammers and Exler 2003, Petitpretz et al. 2002). The combination of the 
chalone-derivatives with polymyxin B may be eliciting their potentiated activity 
against these bacterial species in a manner comparable to that of co-amoxiclav 
although it is yet to be ascertained which of the two compounds may be 
augmenting the antimicrobial activity of the other. Both compounds may 
collectively potentially inhibit the activities of bacterial metabolic enzymes such 
as NADH and succinate dehydrogenase that are very significant for bacterial 
respiratory chain and viability (Wang et al. 2010a). 
4.5 Conclusion  
The fact that F1 and F23 applied in combination with polymyxin B are synergistic 
against different species of S. aureus, C. violaceum, Ps. aeruginosa and E. coli 
suggest these combinations should be further evaluated as leads for the 
development of potentially useful antimicrobial compounds. Combinational 
therapy targeted at enhancing the antibacterial activity of polymyxin B and other 
established antibiotics can support their clinical re-evaluation and a re-
assessment of their combined spectrum of activity (Owens and Ambrose 2005, 
Owens and Ambrose 2007). Although the antibacterial activities of F1 and F23 
were of low individual potency, the combination of these compounds with 
polymyxin B clearly demonstrated synergistic bactericidal activities against a 
wide range of test bacterial species. The synergism demonstrated by the 
combination of polymyxin B with the chalcone-derivatives, if further evaluated, 
could lead to smaller doses of polymyxins being required to achieve more 
effective and extended spectrum of therapeutic goals against pathogenic 
organisms. This can also lead to a reduction in the potential for polymyxin B to 
elicit its dose-dependant adverse effect of nephrotoxicity.  
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Chapter 5 
Evaluating the mode of action for polymyxin B chalcone-
derivatives combinations  
5.1 Introduction 
In order to gain some insight to the influence of time upon the nature of the 
antibacterial activity for polymyxin B applied with the chalcone derivatives, 
colony counting experiments were undertaken using selected strains of 
antibiotic-sensitive and resistant bacterial species. The data obtained from 
chequerboard and MBC analysis for the effective combination concentrations in 
the latter assay suggesting this polypeptide was either additive or synergistic in 
action with either F1 or F23 were re-assessed. Such information was further 
verified by examining either the bacteriostatic or bactericidal concentrations of 
such combinations in a time-course viability assay. Although the chequerboard 
technique is very useful, the assay is not as sensitive and discriminatory as a 
time-course viability analysis to accurately detect synergism (Lewis et al. 2002). 
The time-course viability assay remains the most reliable technique to verify an 
antibiotic’s mode of action (Lin et al. 2010). This latter assay can elucidate the 
rate and extent of action of antimicrobial compounds and is therefore still 
considered most suitable for the characterisation of newly developed agents 
(McKay et al. 2009b), being able to clearly differentiate bacteriostatic from 
bactericidal action in vitro. Bactericidal effect was defined as ≥ 3 log 10 cfu/ml 
(99.9 %, equivalent to a 3 log cfu/ml decline in exposed cell density) of the 
initial bacterial population whilst a bacteriostatic effect was defined as <3 log 
depletion of the inoculum population within 24 hours (Mangili et al. 2005).  
At the moment, most multi-resistant Gram-negative bacterial strains remain 
susceptible to polymyxin B and colistin (Evans, Feola and Rapp 1999, Li et al. 
2005a). Serious concerns have been raised about the potential capability of 
these Gram-negative pathogens to develop resistance to polymyxins (Vaara and 
Porro 1996). Clinicians are therefore being discouraged from using polymyxins as 
a monotherapy, especially when applied as an antibiotic of last resort (Falagas, 
Kasiakou and Saravolatz 2005) in order to decrease the likelihood for the 
emergence of resistant bacterial strains due to selective pressure (Vaara and 
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Vaara 2010). When a given bacterial population is continually exposed to lethal 
(and especially sub-inhibitory) doses of an antibiotic, a small fraction may evade 
the killing-effect due to mutation and transfer the resistant gene to the next 
generation onward (Pond and Frost 2005). There is therefore a strong rationale 
for continuous development of new antibacterial compounds and more effective 
synergistic combination of compounds against pathogenic bacterial species 
(Gunderson et al. 2003, Hogardt et al. 2004). It is thought the development of 
effective synergistic combinations will permit the use of lower strengths, leading 
to lower potential for toxicity to the host, an extended spectrum of activity and 
an extension of the clinical life-span for both agents, as has been demonstrated 
with (Navarro  2005, Alou et al. 2004) co-amoxiclav (Navarro  2005) and 
mupirocin with amoxicillin-clavulanate formulation (Alou et al. 2004).  
The capacity of some novel synthetic antibacterial peptides to increase the 
permeability of bacterial membranes and act synergistically with hydrophobic 
compounds has been demonstrated (Wu and Hancock 1999, Vaara and Porro 
1996). Many of the peptides that were developed show some form of 
resemblance to the polymyxins by having a cyclic structural conformation in 
common (Vaara and Porro 1996, Reddy, Yedery and Aranha 2004). The capacity 
of polymyxin B to act synergistically with each of two hydrophobic semi-synthetic 
chalcone-derivatives (F1 and F23) against selected bacterial species (Gram-
positive and Gram-negative) was studied to understand how both classes of 
compounds promote each other’s antimicrobial activity. Polymyxins are 
ineffective against Gram-positive organisms (MSSA, MRSA and QRSA) probably 
due to the absence of an outer membrane, which is the primary target of these 
agents (Hancock 1997b, Jenssen, Hamill and Hancock 2006a, Hancock and 
Lehrer 1998b). The occurrence of a much thicker peptidoglycan layer in this class 
of bacterial species may also be facilitating the insusceptibility of this class of 
bacterial species to these polycationic antimicrobial agents (Lorian 2005). The 
activity of polymyxin B in combination with the chalcone derivatives against 
strains of S. aureus was investigated in an attempt to overcome the obstacle 
responsible for the inactivity of polymyxins against Gram-positive bacterial 
species and potentially extend their spectrum of activity. On the other hand, the 
activity of both compounds applied together against C. violaceum and Ps. 
aeruginosa was evaluated in an attempt towards developing potentially effective 
formulations with improved antibacterial activity at lower concentrations of 
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polymyxins against Gram-negative bacterial species in the presence of low 
amounts of chalcone-derivatives. Considering that polymyxin B is the antibiotic 
of reserve for ailments like cystic fibrosis mediated by multi-resistant Gram-
negative organisms, especially Ps. aeruginosa (Kasiakou et al. 2005, Schurek, 
Breidenstein and Hancock 2012, Bjarnsholt et al. 2009), a reduction in the 
effective concentrations of polymyxins administered against this group of 
organisms will lower the potential for the dose-related adverse events of 
nephrotoxicity associated with the use of these agents and promote their use as 
antibiotics of choice in the clinics (Vaara and Vaara 2010). The objectives in this 
chapter were to: 
i. verify the data that indicated either an additive or synergistic antibacterial 
activity for either F1 or F23 applied in combination with polymyxin B 
against MSSA, MRSA, QRSA, C. violaceum and Ps. aeruginosa  
ii. establish whether the mode of action for polymyxin B in combination with 
the chalcone derivatives is either bacteriostatic or bactericidal 
iii. compare and contrast the antibacterial activity of F1 and F23 applied alone 
and each in combination with polymyxin B against the test bacterial 
species. 
5.2 Materials and Methods  
5.2.1 Time-course viability assay for bacterial suspensions treated with 
a single test compound 
A bacterial suspension containing ~2 x 107cfu/ml in 0.9 % w/v saline solution in a 
conical flask was prepared as described in section 2.4.1 above. A suitable volume 
of the stock test compound was added to a 20 ml volume of the bacterial 
suspension in order to obtain the desired final concentration. The flask was 
incubated in a Clifton shaking water bath, set at 37 oC and 100 rpm. At time 
intervals of usually 0, 2, 4, 8 and 24 hours, 100 µl of the suspension was 
withdrawn for viable count determination in order to ascertain the viable 
bacterial population in the suspension, as previously described in section 2.3.3 
and 2.3.4. Bacteriostatic and bactericidal activities were defined as <3 log10 and 
≥3 log10 reductions in bacterial population (cfu/ml) respectively, within 24 hours 
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(CLSI 2009, (Yamagishi et al. 1996). Data reported were obtained from at least 
2 independent assays. 
5.2.2 Time-course viability assay for bacterial suspensions challenged 
with polymyxin B applied with the chalcone-derivatives  
The data obtained from a chequerboard technique described in chapter 4 that 
indicated either additive effects or synergism for polymyxin B applied in 
combination with chalcone-derivatives were verified in a bacterial time-course 
viability assay. Bacterial suspension containing ~2 x 107cfu/ml in 0.9 % w/v 
sodium chloride solution in a conical flask was prepared as described in section 
2.4 above. A suitable volume of the stock concentration of the chalcone-
derivative was added to 4 ml of the bacterial suspension in a conical flask, in 
order to obtain the desired final concentration. The chalcone- derivative was 
combined with polymyxin B either at MIC proportion or an effective combination 
concentration previously determined by the chequerboard assay (against the 
selected bacterial species). Then, the test tube was kept in a suitable glass 
beaker containing water  and incubated in a shaking water bath as described in 
section 2.6. Also, as described in the same section, at the set intervals, 100 µl 
samples were withdrawn for colony plate count determination. Graphs of 
bacterial density (log10 cfu/ml) against time (hours) were plotted. Controls 
containing the bacterial suspension treated with suitable concentrations of the 
chalcone-derivative, the antibiotic, untreated bacterial suspension and solvent 
treated bacterial suspension were included. The antibacterial activities in this 
assay were further described as either antagonistic, indifferent or synergistic. 
Antagonism was defined as a ≥ 2 log10 cfu/ml decrease in the antibacterial 
activity of the combination of compounds in comparison to the action of the most 
potent agent applied alone; indifference was defined as a < 2log10 cfu/ml 
decrease in the action displayed by the combination in comparison to the activity 
of the most potent single agent (Clinical and Laboratory Standards Institute  
2009, Roling et al. 2002a). The activity characterised as synergistic (bactericidal) 
were those where the combination of compounds demonstrated ≥ 2 log10 cfu/ml 
increase in antibacterial activity in comparison to the activity demonstrated by 
the most potent single agent (Clinical and Laboratory Standards Institute  2009, 
Roling et al. 2002a). The data reported were obtained from assays conducted in 
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duplicate with at least three independent replicates carried out on separate days 
(n = 6). 
5.2.3 Statistical analysis of data 
The data obtained from the methods described in section 5.2.1 and 5.2.2 above 
were subjected to statistical analysis for standard error of mean and standard 
deviation using a GraphPad Prism 4. The software was used to plot graphs of the 
bacterial population (cfu/ml) against sampling time (hours). The graphs were 
interpreted as previously described in sections above. The limit of sensitivity of 
the assay was also determined. 
5.3 Results  
5.3.1 Examination of the activity of F1 applied alone and with polymyxin 
B upon selected strains of S. aureus species 
5.3.1.1 Bactericidal activity of F1-polymyxin B combination against 
methicillin-sensitive S. aureus 
Figure 5.1 represents the data from a time-course viability assay for F1 applied 
in combination with polymyxin B against methicillin-sensitive S. aureus (MSSA). 
In conducting the time-course viability assays, the MIC value of polymyxin B 
against MSSA was regarded as 256 µg/ml based on the data previously recorded 
from a micro-broth dilution assay in chapter 2. In the current technique, this 
strength of polymyxin B demonstrated about 1 log reduction in the population of 
the challenged S. aureus (MSSA), with reference to the solvent-treated control. 
With reference to both the solvent and untreated controls, it appears the 
presence of F1 seem to have had no effect upon the viability of MSSA in the 
presence of DMSO, as the bacterial population challenged with only 64 µg/ml F1 
had a slightly higher colony count than the solvent after 24 hours suggesting this 
bacterial species demonstrated a slightly higher sensitivity to the presence of 
DMSO alone (in the absence of the chalcone-derivatives). 
Considering that S. aureus 6571 (MSSA) samples challenged with 5 and 10 % v/v 
DMSO in some preliminary investigations showed appreciable sensitivity to the 
presence of these strengths of the solvent, the DMSO concentration used for the 
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dissolution of the test compounds as well as the solvent control were reduced to 
1.28 % v/v DMSO.  MSSA also demonstrated sensitivity to this strength of DMSO 
by the display of an approximately 2 log reduction in the challenged inoculum 
population after 24 hours as shown in figure 5.1. 
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Figure 5.1: Synergistic activity for F1 applied with polymyxin B against S. aureus 6571 (MSSA). 
Inoculum density was ~1 x 107 cfu/ml. The data were mean values obtained from 3 replicates and 
repeated on separate days. 
The untreated positive control demonstrated about 1.5 log cfu/ml reduction in 
cell density attributable to the poor survival capacity of S. aureus in 0.9 % w/v 
sodium chloride solution over time. Therefore, the effects of DMSO solvent and 
0.9 % w/v sodium chloride upon this bacterial species may have been cumulative 
in the solvent treated sample. The bacterial population challenged with 64 µg/ml 
(MIC) F1 in combination with 256 µg/ml (MIC) polymyxin B was reduced by more 
than 4 log cfu/ml to below detectable limit within 8 hours indicating their 
combined killing-effect surpassed the action of the most potent single compound, 
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polymyxin B. A profound synergism was therefore displayed over the 24 hours 
period that greatly surpassed the antibiotic action of the polypeptide and the 
solvent-effect that were recorded. Given that at least 1 colony forming unit (cfu) 
can be obtained from 20 µl of a 10-fold dilution, 50 cfu were obtainable from 1 
ml of same dilution and 500 cfu from 1 ml of the neat suspension. Therefore, the 
limit of sensitivity of this assay was 5 x 102 cfu/ml, which is approximately log 
2.69. This limit is applicable for all the assays performed in this section using this 
same technique. A 2 way analysis of variance with the Bonferroni post test sow 
that a significant difference existed between the activity of the single polymyxin 
B concentration and the untreated sample at 24 hours at p < 0.0001. With the 
same analysis, there is a significant difference between the activity of polymyxin 
B-treated and the solvent-treated bacterial suspension from 2 to 24 hours. 
Although, the synergistic action of the combination of F1 with polymyxin B 
against the bacterial suspension was significantly different in comparison to the 
untreated sample at the same conditions, such a difference only occurred 
between the activity recorded for the synergistic combination and the solvent-
only treated samples after 8 and 24 hours respectively affirming that the 
cumulative negative effect of both solvent and 0.9 % w/v NaCl upon MSSA was 
enormous.  
5.3.1.2 Effect of F1 concentrations upon the viability of methicillin-
resistant S. aureus 
Data for the viability of equivalent densities of MRSA suspensions treated with 
increasing strengths of F1 in a time-kinetic assay is shown in figure 5.2. 
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Figure 5.2: The effect of increasing concentrations of F1 applied against S. aureus (MRSA) in a 
time-kinetic assay. Inoculum population was ~1 x 107 cfu/ml. The data were mean of values 
obtained from experiments conducted in duplicate and repeated on three separate days. 
Bearing in mind that cell suspension exposed to only 5 % v/v DMSO as a control 
displayed a 99 % (2 log cfu/ml) depletion in colony count after 24 hours, 
obviously concentrations within the range of MIC (128 µg/ml) to 4 x MIC (512 
µg/ml) F1 demonstrated no apparent antibacterial effect against MRSA, in 
relation to the untreated and solvent-treated controls, when applied alone.  
Relative to the solvent-treated control, 8 x MIC (1024 µg/ml) F1-treated 
bacterial sample demonstrated a 1.5 log cfu/ml reduction in density within 24 
hours; indicating a bacteriostatic action at best with such a high concentration of 
the chalcone-derivative. As previously explained, the limit of sensitivity for the 
assay results was log 2.69. 
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5.3.1.3 Bactericidal activity of F1-polymyxin B combination against 
methicillin-resistant S. aureus  
The data presented in figure 5.3 were obtained from a time-course viability assay 
for methicillin-resistant strain of S. aureus challenged with 128 µg/ml (MIC) F1 
with 128 µg/ml (MIC) polymyxin B. 
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Figure 5.3: Synergistic activity for F1 applied with polymyxin B against MRSA. Inoculum density 
was ~1 x 107 cfu/ml. The data were mean of values obtained from experiments conducted in 
duplicate and repeated on three separate days. 
In comparison to the solvent treated control, MRSA population challenged with 
128 µg/ml (MIC) polymyxin B demonstrated less than 1 log cfu/ml reduction in 
viability after 24 hours. The independently applied 128 µg/ml F1 was ineffective 
against this bacterial species, in this assay, as had been previously demonstrated 
in the data presented in figure 5.2. Any appreciable loss in cell viability was not 
recorded in bacterial suspension treated with this concentration of the chalcone-
compound in relation to the solvent-treated cells. The ~1.5 log cfu/ml reduction 
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in the viability of the solvent-treated MRSA population may be attributable to the 
weak survival potential of S. aureus in 0.9 % w/v sodium chloride coupled with 
the sensitivity of these cells to DMSO. As before, the loss in the viability in both 
control samples over 24 hours is greatly surpassed by the rapid and profound 
synergism demonstrated by F1 with polymyxin B. The application of 128 µg/ml 
(MIC) F1 with 128 µg/ml (MIC) polymyxin B reduced MRSA population by more 
than 4 log cfu/ml within 8 hours, although the limit of cell density detection for 
this technique was 500 cfu/ml. In relation to the activity recorded for the 
independent application of 128 µg/ml polymyxin B (which is considered the most 
active single compound), the F1-polypeptide combination displayed a > 4 log 
cfu/ml depletion to the inoculum population similar to the recorded values 
against MSSA thereby indicating a profound synergism in both instances. 
5.3.1.4 Effect of F1 concentrations upon the viability of quinolone- 
resistant S. aureus under growth conditions 
The effect of F1 upon the viability of QRSA suspension in a growth (Mueller-
Hinton broth) rather than a buffer medium was undertaken in order to 
investigate the antibiotic property of this semi-synthetic chalcone compound 
under an environment that permits cell wall synthesis and cell replication. This 
assay was also intended to give an insight into the influence of F1’s interaction 
with broth on the antibacterial action of the chalcone-derivative. The choice of 
QRSA was based on the fact that the relatively low MIC value of 32 µg/ml 
demonstrated by the chalcone-derivative against this species will enable the 
examination of the effects of very high multiple-folds of this inhibitory 
concentration whilst consuming a relatively small cumulative quantity of the 
compound, since the supply was limited. On this occasion (figure 5.4), the 
untreated and solvent controls manifested unhindered growth over the time-
course suggesting that unlike in previous assays conducted under buffer 
medium, the deleterious effect of DMSO and 0.9 % w/v sodium chloride on S. 
aureus viability were absent.  
The cell sample challenged with 32 µg/ml F1 (equivalent to the MIC) displayed a 
1 log cfu/ml growth within 2 hours and this density was maintained for 8 hours. 
Due to cell replication, the inhibitory effect of this strength of F1 was 
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overwhelmed with time as the cell population multiplied to equate with those of 
the untreated and solvent-treated samples after 24 hours. The QRSA population 
challenged with either 64 (2 x MIC), 128 (4 x MIC 128), 256 (8 x MIC) or 1024 
µg/ml (32 x MIC) F1 demonstrated growth inhibitory activity in broth, impeding 
the capacity of these cells to multiply. 
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Figure 5.4: Bacteriostatic activity of increasing concentrations of F1 against QRSA in broth. 
Inoculum density was ~1 x 106 cfu/ml. The data were mean of values obtained from experiments 
conducted in duplicate and repeated on three separate days. 
It is unclear whether either the inoculum populations were being replaced by new 
cells at an almost equal rate of proliferation or the original cell densities were 
simply retained within the assay duration. But given that the untreated as well as 
the solvent treated suspensions exhibited unimpeded cell replication over the 
same time duration, it can be inferred that the data gleaned from the challenged 
cell suspensions cannot be attributed to the effect of depletion in nutrient supply 
102 
 
with time. These data suggest that given a high enough concentration (≥2 x 
MIC), F1 has capacity to inhibit S. aureus growth in broth. A comparative view of 
data presented in this section with that previously recorded in figure 5.2 
suggests F1 is only at best bacteriostatic against S. aureus at a concentration up 
to 8 x MIC, in both buffer and growth media. A much higher concentration of 32 
x MIC did not show any additional activity in the growth medium. Bearing in 
mind that the effect of F1 appears to be independent of concentration, 
subsequent time-kinetic assays were conducted under buffer condition with low 
concentrations of the chalcone-derivatives in order to verify this compound’s 
lowest synergistic concentrations with polymyxin B against selected bacterial 
species in combinational assays.   
5.3.1.5 Bactericidal activity of F1 with polymyxin B against quinolone- 
resistant strain of S. aureus 
Figure 5.5 shows data for a time-course viability assay for a quinolone-resistant 
strain of S. aureus challenged with F1 with polymyxin B. A concentration of 128 
µg/ml polymyxin B applied independently did not demonstrate any appreciable 
activity whilst 32 µg/ml (MIC) F1 was bacteriostatic against QRSA by 
demonstrating a 1 log cfu/ml reduction to an equivalent population with respect 
to the solvent-treated sample over 24 hours. As observed with the other strains 
of S. aureus reported earlier, the loss of some degree of viability with the 
controls is likely due to the combined adverse effects of DMSO and 0.9 w/v 
sodium chloride. 
This loss is however not comparable to the synergistic outcome recorded from 
the combined application of the same concentrations of both compounds above 
against an equivalent cell density of the same bacterial species, wherein a rapid 
and complete loss of viability was reported after only 8 hours of exposure 
although the reliable limit of detection of this assay was 500 cfu/ml, which 
approximates to log 2.69 on the y-axis.  The three strains of S. aureus employed 
in the investigations discussed were thought to have given adequate 
representation of the activity of F1 against this Gram-positive bacterial species 
necessitating the use of other species in subsequent examinations in this assay. 
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Figure 5.5: Synergistic activity for F1 applied with polymyxin B against QRSA. Inoculum density 
was ~1 x 107 cfu/ml. The data were mean of values obtained from experiments conducted in 
duplicate and repeated on three separate days. 
5.3.2 Examining the antibacterial effect of F1 with polymyxin B against 
Gram-negative bacterial species 
The antibacterial activity of polymyxin B applied with the chalcone-derivative 
against E. coli was not investigated using a time-kinetic colony counting 
technique because data from prerequisite chequerboard assay suggested the 
combination of F1 with polymyxin B was indifferent in antibacterial action against 
this Gram-negative bacterial species (table 4.1). The antibiotic activities from the 
chequerboard assay that indicated the existence of either additive or synergistic 
actions were especially considered for re-assessment using the time-course 
colony counting technique.  
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5.3.2.1 Bactericidal activity of sub-inhibitory concentrations of F1 with 
polymyxin B against C. violaceum 
The data presented in figure 5.6 was obtained from a time-course viability assay 
for C. violaceum suspensions challenged with F1 applied alone and in 
combination with polymyxin B.  
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Figure 5.6: Bactericidal activity of sub-inhibitory concentrations of F1 applied alone and indifferent 
activity of sub-inhibitory concentration of F1 applied with sub-inhibitory concentration of polymyxin 
B against C. violaceum. Inoculum density was ~2 x 106 cfu/ml. The data were mean of values 
obtained from experiments conducted in duplicate and repeated on three separate days. 
The concentrations of both compounds employed was based upon guidance from 
data obtained from the chequerboard assay previously undertaken (table 4.1). 
Although 16 µg/ml (1/32nd MIC) F1 applied in combination with 2 µg/ml (1/16th) 
MIC polymyxin B was synergistic against C. violaceum in the previously reported 
technique, 2 to 4 times the effective chequerboard combination concentrations 
were used considering that this species is a Gram-negative organism which can 
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display greater insusceptibility because of the additional drug permeation barrier 
posed by the presence of an outer membrane structure.  
Considering that 5 % v/v DMSO demonstrated appreciable deleterious effect 
against the viability of S. aureus populations, the solvent concentration in this 
assay was reduced to 0.3125 v/v DMSO which was tolerable to this bacterial 
species within the 24 hours period. It can also be seen that in comparison to S. 
aureus species, C. violaceum showed a lesser sensitivity to the presence of 0.9 
% v/v sodium chloride by demonstrating a lower degree of loss in cell viability in 
the unchallenged control suspension over time. The C. violaceum sample 
challenged with 4 µg/ml (1/8 MIC) of polymyxin B demonstrated only a < 1 log 
reduction with reference to the unchallenged suspension in DMSO. 
Both densities of C. violaceum populations challenged with the 64 µg/ml sub-
inhibitory concentration of F1 alone and together with polymyxin B were reduced 
from ~2 x 106 to ~250 cfu/ml within 120 minutes (although the limit of detection 
of the assay was 500 cfu/ml). Although this 1/8 MIC concentration of F1 
displayed a rapid and profound bactericidal action against C. violaceum, F1 with 
polymyxin B demonstrated indifference in their combined antibiotic effect since 
the addition of the latter agent did not improve the recorded action of the former 
compound alone within 24 hours. The activity of agents applied together is 
described as indifferent if their combined antibiotic effect amounts to a < 2 log 
cfu/ml depletion of the challenged inoculum density.  
5.3.2.2 Bactericidal activity of F1-polymyxin B combination against Ps. 
aeruginosa 
The result from a time-course viability assay for Ps. aeruginosa population 
challenged with 64 µg/ml (1/4 MIC) F1 applied in combination with 0.25 µg/ml 
(1/2 MIC) polymyxin B is presented in figure 5.7. As with other instances, the 
selection of strengths of both compounds to be used was informed by data 
previously obtained from a chequerboard assay presented in table 4.1. Although 
16 µg/ml (1/16 MIC) F1 applied with 0.25 µg/ml (1/2 MIC) polymyxin B had 
recorded an additive antibacterial action against Ps. aeruginosa in the former 
technique, this combination was eventually not bactericidal in action upon the 
inoculation of a freshly prepared antibiotic and chalcone-derivative-free agar with 
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a 1 µl volume obtained from a well containing this sample. The agar plate 
displayed bacterial growth following incubation at 37 oC, for 24 hours.  
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Figure 5.7: Synergistic activity of sub-inhibitory concentrations of F1 applied with sub-inhibitory 
concentration of polymyxin B against Ps. aeruginosa. Inoculum density was ~1 x 107 cfu/ml. The 
data were mean of values obtained from experiments conducted in duplicate and repeated on three 
separate days. 
The data presented in table 4.1 however also shows that the application of 64 
µg/ml F1(4 x the former concentration) with 0.25 µg/ml polymyxin B was 
bactericidal against this bacterial species in both of the previously conducted 
techniques. Bearing this in mind and especially considering that an increased 
inoculum density (1 x 107 cfu/ml) of this Gram-negative bacterial suspension was 
to be used for the re-assessment, the latter more effective combination was 
chosen to be applied for the investigation. This choice is also supported by 
findings from other researchers as previously published data show that the action 
of polymyxin B (as well as colistin) against Ps. aeruginosa is both concentration-
dependent and influenced by inoculum population (Li et al. 2001b, Tam et al. 
2005), such that restricting the amount of the chalcone-derivative whilst 
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increasing the strengths of polymyxin B would be expected to demonstrate an 
increasing antibiotic effect against this bacterial species. 
In comparison to the DMSO-bacterial control, 0.25 µg/ml (1/2 MIC) polymyxin 
expressed a less than 1 log reduction to population of Ps. aeruginosa suspension 
over 24 hours and 64 µg/ml (1/4 MIC) F1 showed no appreciable activity against 
this organism. Both compounds applied together at the same strengths against 
an equivalent bacterial density demonstrated a synergistic outcome by reducing 
the bacterial density from ~1 x 107 to ~1 x 103 cfu/ml within the first 8 hours 
and further down to ~20 cfu/ml (considered to be below the detection limit of 
500 cfu/ml for the assay) after 24 hours. 
An overview of the results presented so far in this chapter indicate F1 is at best 
only bacteriostatic against species of S. aureus in both buffer and growth media 
even at concentrations as high as 8 x MIC whilst polymyxin B demonstrated no 
appreciable antibacterial action against Gram-positive S. aureus species, 
especially methicillin-resistant strains. The combined applications of both 
compounds demonstrated a profoundly bactericidal action against all tested S. 
aureus species and Ps. aeruginosa but were indifferent in their antibacterial 
effect against C. violaceum since the activity demonstrated by F1 alone was not 
surpassed by that of the combination. Of note however is the immense degree of 
activity demonstrated by F1 against this organism. 
5.3.3 Kinetic colony counting for Gram-positive bacterial species 
challenged with F23 and polymyxin B 
Using the same inoculum densities for the five bacterial species employed in the 
evaluation of the antibacterial potential of polymyxin B in combination with F1, 
the antibiotic effect of polymyxin B in the presence of F23 was examined and the 
findings are presented below. Given that the data presented in tables 4.1 and 4.2 
suggest neither of the chalcone-derivatives alone had activity against the 
examined bacterial species in chequerboard assays and that this was verified 
when single applications of F1 concentrations were previously tested against 
QRSA, the action of F23 in combination with polymyxin B was examined against 
the selected bacterial species based on guidance from the findings recorded in 
table 4.2. 
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5.3.3.1 Synergistic activity of F23 with polymyxin B against MSSA 
The data presented in figure 5.8 was obtained from a time-course viability assay 
for MSSA suspensions challenged with 256 µg/ml polymyxin B, 16 µg/ml (1/4 
MIC) F23, the latter concentration of F23 with either 64 or 256 µg/ml polymyxin 
B and twice this F23 strength with 256 µg/ml (MIC) polymyxin B.  The selection 
of concentrations of both compounds examined was based on information 
previously gleaned from both chequerboard and MBC determination assays (table 
4.2) wherein an application of 16 µg/ml F23 with 256 µg/ml polymyxin B was 
synergistic against MSSA.  
0 2 4 6 8
2
3
4
5
6
7
8 24
16 µg/ml (1/4 MIC) F23
256 µg/ml (MIC) polymyxin B
16 µg/ml (1/4 MIC) F23 + 64 µg/ml (1/4 MIC)
polymyxin B
0.078 % v/v DMSO
Untreated MSSA control
16 µg/ml (1/4 MIC) F23 + 256 µg/ml (MIC)
polymyxin B
32 µg/ml (1/2 MIC) F23 + 256 µg/ml (MIC)
polymyxin B
Time (hours)
Vi
ab
le
 M
SS
A 
po
pu
la
tio
n
(lo
g 
cf
u/
m
l)
 
Figure 5.8: Synergistic activity of sub-inhibitory concentrations of F23 applied with polymyxin B 
concentrations against MSSA. Inoculum density was ~1 x 107 cfu/ml. The data were mean of 
values obtained from experiments conducted in duplicate and repeated on three separate days. 
Bactericidal activity was also observed in the well containing 16 µg/ml F23 with 
64 µg/ml (1/4 MIC) polymyxin B as well as that containing the cell suspension 
treated with 32 µg/ml (1/2 MIC) F23 plus 256 µg/ml (MIC) polymyxin B. The 
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data previously reported in chapter 3 that indicated MIC of polymyxin B against 
MSSA was 256 µg/ml was used in conducting the time-course viability assay. 
Considering that the data recorded in figure 5.1 shows that viability of 
unchallenged S. aureus suspension was negatively affected by the combination 
of 0.9 % w/v sodium chloride with 1.28 % v/v DMSO over a 24 hours period, a 
lower strength of 0.078 % v/v final DMSO was used to dissolve F23 and also 
employed in a control. Although the degree of loss in viability for both controls 
were lesser in this instance than in the former occasion, the 0.078 % v/v DMSO 
control still demonstrated a > 1 log reduction in cell density that became more 
pronounced between 8 to 24 hours. The loss of cell viability observed in the 
untreated and solvent-treated samples re-emphasized the poor capacity of S. 
aureus to remain viable in 0.9 % w/v sodium chloride over a 24 hours period. 
Within 24 hours, 256 µg/ml (MIC) polymyxin B demonstrated bacteriostatic 
activity against MSSA by causing a ~1.5 log reduction to the inoculum population 
whilst suspension treated with 16 µg/ml (1/4 MIC) F23 had the same colony 
count as the solvent control after 24 hours clearly expressing the lack of potency 
of this semi-synthetic agent against this species at the applied strength.  
All the three applications containing sub-inhibitory concentrations of F23 with two 
varying strengths of polymyxin B were synergistic against MSSA,  demonstrating 
extents of action that were at least 2 log greater than that of polymyxin B alone. 
Of all the three combinations, the combined application of 16 µg/ml (1/4 MIC) 
F23 with 64 µg/ml (1/4 MIC) polymyxin B appeared to have shown the lowest 
degree of antibiotic action by demonstrating a > 3 log reduction to the MSSA 
suspension within 24 hours. A concentration of 16 µg/ml F23 applied with 64 
µg/ml (1/4 MIC) polymyxin B reduced the inoculum population by ~2 log within 
2 hours and further down to below detectable limits within 24 hours indicating 
synergism when viewed with reference to the activity of a higher concentration 
256 µg/ml polymyxin B that was singly applied. This recorded level of activity 
was followed by the action of the combination containing 16 µg/ml F23 plus 256 
µg/ml polymyxin B that caused a depletion of the density of an equivalent 
bacterial population by 2 log cfu/ml within 4 hours and further down to below 
detectable levels after 24 hours.  
As would be expected from the combination containing the highest 
concentrations of both compounds, the application of 32 µg/ml (1/2 MIC) F23 
with 256 µg/ml polymyxin B was the most potent. This latter combination 
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instituted a 3 log loss in the viability of the challenged cell suspension within 4 
hours and a further reduction to below the detectable limit of log 2.69 after 24 
hours. This combination therefore demonstrated the most rapid onset and rate of 
action against MSSA. An increase in the concentration of F23 in the combination 
therefore translated to a corresponding increase in onset, rate and extent of 
these compounds antibacterial synergism against MSSA. 
5.3.3.2 Synergistic activity of F23 with polymyxin B against MRSA 
With an MIC of 1024 µg/ml, F23 was considered inactive against MRSA. 
However, the chequerboard assay had demonstrated that 32 µg/ml (1/32 MIC) 
F23 applied with 64 µg/ml (1/2 MIC) polymyxin B was synergistic against MRSA 
(table 4.2). The technique for MBC determination confirmed the bactericidal 
property of this combination against MRSA. This combination was therefore 
applied at the same strength in a time course viability assay whose results are 
presented in figure 5.9.  
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Figure 5.9: Synergistic activity of sub-inhibitory concentrations of F23 applied with polymyxin B 
against MRSA. Inoculum density was ~1 x 107 cfu/ml. The data were mean of values obtained from 
experiments conducted in duplicate and repeated on three separate days. 
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Over a 24 hours period, 64 µg/ml (1/2 MIC) polymyxin B was the most active 
single agent displaying a bacteriostatic action with an approximately 1 log loss in 
colony count of MRSA that became conspicuous between the 8 and 24 hours with 
reference to the untreated solvent control. Another aliquot of the bacterial 
suspension treated with 32 µg/ml (1/32 MIC) of this semi-synthetic agent singly 
as well as the untreated positive and solvent controls showed no appreciable 
decline in colony count after 24 hours. 
An equivalent density of the bacterial suspension challenged with a combination 
of the same strengths of both compounds above displayed 2.5 and >4 log losses 
in viability after 8 and 24 hours respectively, indicating synergism in view of the 
activity of the most potent compound in the application. The loss in viability 
recorded for the latter combination was more pronounced and exceeded the 
detection limit of 500 cfu/ml for the employed technique. The outcome of this 
assay confirmed the data recorded from the two other techniques that signalled 
the existence of synergism between both compounds at the examined strengths.  
5.3.3.3 Antibacterial action of F23 with polymyxin B against QRSA 
The data from a time-course viability assay wherein a QRSA population was 
challenged with 16 µg/ml (1/2 MIC) F23 with 64 µg/ml (1/4 MIC) of polymyxin B 
is presented in figure 5.10. 
Previous data obtained from chequerboard and MBC determination techniques 
had shown that this combination of compounds, at the strengths stated above, 
was bactericidal against QRSA (table 4.2). The polypeptide antibiotic was the 
most active single agent in the combination since quinolone-resistant S. aureus 
suspension treated with 64 µg/ml (1/4 MIC) polymyxin B demonstrated a 2 log 
loss in viability within 24 hours, indicating a bacteriostatic action whilst 16 µg/ml 
F23 alone caused only about 0.5 log depletion to the colony count of an 
equivalent cell density. When both compounds were applied together against 
another equivalent QRSA population at the strengths defined above, more than a 
4 log reduction in colony count, below the detection limit of log 2.69, was seen 
after 24 hours with reference to the solvent control whilst only an additional 2 
log loss in viability was recorded with reference to the most potent single 
compound of the combination. This outcome suggests the existence of synergism 
between polymyxin B and F23 at the evaluated concentrations. 
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Figure 5.10: Synergistic activity of sub-inhibitory concentrations of F23 applied with sub-inhibitory 
concentration of polymyxin B against QRSA. Inoculum density was ~2 x 107 cfu/ml. The data were 
mean of values obtained from experiments conducted in duplicate and repeated on three separate 
days. 
However, the onset of action for this combination was comparatively slow as 
there was negligible activity within the first 4 hours and only about a 1 log 
depletion in viability was reported after 8 hours. In a previous time-course assay 
wherein the activity of F1 applied with polymyxin against QRSA was evaluated in 
0.9 % v/v sodium chloride (figure 5.5), 5 % v/v DMSO final concentration was the 
solvent for F1 and was also applied as a control. This solvent control sample was 
seen to have displayed a 2 log loss in the viability of QRSA suspension. The data 
presented in figure 5.10 however shows a 1 log depletion in viability of the 
solvent control cells which suggests the organism was less sensitive to the 
presence of 0.078 % v/v DMSO in saline. 
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5.3.4 Kinetic colony counting for Gram-negative bacterial species 
challenged with F23 and polymyxin B 
5.3.4.1 Antibacterial action of F23 with polymyxin B against C. 
violaceum 
The data presented in figure 5.11 were obtained from C. violaceum suspensions 
treated with either 64 µg/ml (1/8th MIC) F23 only or 4 µg/ml (1/8th MIC) 
polymyxin B for 24 hours.  
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Figure 5.11: Bactericidal activity of sub-inhibitory concentration of F23 and indifferent activity of 
sub-inhibitory concentration of F23 applied with sub-inhibitory concentration of polymyxin B 
against C. violaceum. Inoculum density was ~2 x 106 cfu/ml. The data were mean of values 
obtained from experiments conducted in duplicate and repeated on three separate days. 
The choice of strengths of both compounds to be evaluated was based on data 
previously obtained from a chequerboard and MBC determination techniques. 
The MBC determination assay verified the effectiveness of these combined 
concentrations of compounds that indicated either an additive or synergistic 
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outcome in the chequerboard assay in that bacterial re-growth did not occur 
within 48 hours in treated samples of C. violaceum that were sub-cultured onto 
fresh antibiotic-free agar media (table 4.2).  
In the present technique, with respect to the solvent control, 64 µg/ml (1/8th 
MIC) F23 was on its own bactericidal against C. violaceum by demonstrating 
approximately a 3 log depletion to the density of the treated cell suspension 
within 2 hours. An equivalent cell density treated with 4 µg/ml (1/8 MIC) 
polymyxin B was seen to have lost only about 0.5 log in viability within 24 hours. 
When the chalcone-derivative and polypeptide antibiotic were applied together at 
the strengths defined above against another standard sample containing an 
equivalent density of the same bacterial species, the same end-point reduction in 
colony count previously recorded for the cell suspension treated with 64 µg/ml 
F23 alone, was obtained. This observation suggested the collective application of 
both compounds acted indifferently. Therefore, F23 applied singly as well as in 
combination with polymyxin B demonstrated a rapid onset of antibacterial action 
by reducing the density of the treated C. violaceum from ~2 x 106 to ~400 
cfu/ml, below the detection limit of the assay, within 2 hours. This action is 
comparable to the activities of sub-inhibitory concentration of F1 applied alone 
and with polymyxin B against this bacterial species. Between 2 and 24 hours, the 
cell suspension challenged with F23 plus polymyxin B showed a slight further 
drop in colony count suggesting that this combination is relatively more potent 
with increasing time of exposure than the single application of polymyxin B. Both 
the solvent and untreated samples demonstrated no appreciable loss in viability, 
indicating as previously mentioned, that C. violaceum is less sensitive to the 
presence of sodium chloride. 
5.3.4.2 Bactericidal action of F23 with polymyxin B against Ps. 
aeruginosa 
Figure 5.12 represents the data obtained from a kinetic colony count assay for a 
Ps. aeruginosa suspension challenged with 64 µg/ml (1/4 MIC) F23 with 0.25 
µg/ml (1/2 MIC) polymyxin B.  
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Figure 5.12: Synergistic activity of sub-inhibitory concentration of F23 applied with sub-inhibitory 
concentration of polymyxin B against Ps. aeruginosa. Inoculum density was ~1 x 107 cfu/ml. The 
data were mean of values obtained from experiments conducted in duplicate and repeated on three 
separate days. 
Bearing in mind that this organism is a recalcitrant Gram-negative organism, the 
applied concentrations were twice the values of bactericidal strengths recorded 
for these agents during a previously conducted chequerboard assay and verified 
by an MBC determination technique (table 4.2). 
Although the untreated positive and solvent-treated controls showed no 
appreciable reduction in cell viability within the 24 hours period, cell samples 
treated with either 0.25 µg/ml (1/2 MIC) polymyxin B or 64 µg/ml (1/4 MIC) F23 
demonstrated less than a 1 log reduction in their population. 
In contrast, an equivalent cell density challenged with 64 µg/ml (1/4 MIC) F23 
and 0.25 µg/ml (1/2 MIC) polymyxin B showed a rapid 4 log depletion in colony 
count (from ~2 x 107 to ~800, which was within the detection sensitivity limit of 
the technique) within 4 hours. The ~800 cfu/ml Ps. aeruginosa density was 
maintained after 24 hours. The displayed action of both compounds combined 
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viewed with reference to that of the most potent single agent, polymyxin B, 
indicates synergism in that the collective action induced > 3 log depletion in the 
cell viability more than that caused by the former. 
5.3.5 Summary of data for the examination of the effects of the 
chalcone-derivatives in combination with polymyxin B against bacterial 
species viability 
F1 and polymyxin B acted in a synergistic manner against MSSA, MRSA, QRSA 
and Ps. aeruginosa; whilst both agents were indifferent in activity against C. 
violaceum as the application of effective concentrations of both compounds 
determined by a chequerboard assay expressed no significant additional action to 
the killing effect of the chalcone-derivative alone. Similarly, F23 concentrations 
applied with different strengths of polymyxin B were synergistic in action against 
MSSA, MRSA, QRSA and Ps. aeruginosa but also acted indifferently against C. 
violaceum. The results obtained for F1 and F23 each applied with polymyxin B 
verified the data previously reported from the chequerboard assay (tables 4.1 
and 4.2) suggesting such combinations were either additive or synergistic 
against MSSA, MRSA, QRSA and Ps. aeruginosa. Although the chequerboard 
assay indicated 16 µg/ml F23 applied with 64 µg/ml polymyxin B was additive 
against QRSA, data recorded from the time-kinetic assay suggested the same 
combination was synergistic against this species.  
After 24 hours of exposure, all the applied combinations (at various 
concentrations) demonstrated a ≥ 2  log reduction to the challenged cell 
populations with reference to the density of equivalent cell suspensions  singly 
treated with the most potent agent for the various test bacterial species; 
indicating synergism in all instances. 
Finally, figure 5.8 also shows that concentrations of both F23 and polymyxin B in 
the combination could be adjusted to influence the potency and onset of action 
for the antibacterial action of the combination against MSSA. Although 1/4 MIC 
(16 µg/ml) of F23 applied with 1/4 MIC (64 µg/ml) polymyxin B was effectively 
bactericidal against MSSA, the highest examined strengths of both compounds 
were half the MIC (32 µg/ml) of F23 applied with the MIC (256 µg/ml) of 
polymyxin B which as expected demonstrated the most profound and rapid onset 
of bactericidal action indicating a concentration-dependent potency.  
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5.4 Discussion 
It is an established fact that the outcome and interpretation of a set of data as 
being either bacteriostatic or bactericidal in a chequerboard assay may not 
always be consistent with findings from a time-kinetic colony counting assay 
(Lewis et al. 2002). The latter assay is the most reliable in vitro technique for 
verifying the activity of combination of agents recorded from the former method 
(Alou et al. 2004). In this chapter, given that 10 to 106 –fold dilutions were 
plated out on agar for incubation and colony counting, the limit of detection for 
this assay was actually 500 cfu/ml. Although S. aureus 6571 (MSSA) 
demonstrated relatively poor survival capacity in 0.9 % w/v NaCl used as buffer, 
the viability of C. violaceum (figure 5.6) as well as Ps. aeruginosa (figure 5.7) in 
same medium were much better and may not be unconnected with the fact that 
both are Gram negative organisms with outer membrane barriers. The tenacious 
ability of Ps. aeruginosa to survive in very adverse conditions as well as to 
persist under antibiotic treatments has been extensively discussed in the 
literatures (Evans, Adewoye and Poole 2001, Kasiakou et al. 2005, Bjarnsholt et 
al. 2009, Schurek, Breidenstein and Hancock 2012). 
The in vitro bactericidal activities of the chalcone-derivatives (F1 and F23) 
applied with polymyxin B against MSSA, MRSA, QRSA, C. violaceum and Ps. 
aeruginosa were significant when compared to the single application of each 
compound. The combined concentrations of both compounds examined in this 
assay, which in most cases were found to be synergistic in action, were 
estimated from previous chequerboard and MBC determination techniques. These 
results therefore verified the data gleaned from the previous micro broth MIC 
determination, chequerboard and MBC determination assays. In addition, the 
time-course viability technique displayed the mode of bacterial killing over time 
for these agents, showing in some cases, a more extensive action than had been 
earlier reported. For instance, certain combination concentrations thought to be 
additive in action in the chequerboard assay were currently reported as 
synergistic, even in the presence of a higher inoculum population. This is clearly 
exemplified for Ps. aeruginosa suspensions treated with concentrations of F1 in 
combination with polymyxin B (table 4.1 and figure 5.7). The most likely 
explanation for these minor discrepancies would be that the time-course assay 
exposes some of the weaknesses inherent in the other techniques (Pankey and 
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Ashcraft 2005). The inability to sometimes align findings from time-kinetic colony 
counting assays with those from a chequerboard and the often irreproducible 
nature of data from the latter technique has been previously established 
(Petersen et al. 2006, Lewis et al. 2002). Therefore, data obtained from 
chequerboard assays often need to be verified by other techniques of which the 
most recommended is the time-kinetics colony counting experiment (Petersen et 
al. 2006).However, the data obtained from in vitro assays conducted with 
effective strengths of compounds that were previously determined by either 
chequerboard or time-course viability assay are some times neither mirrored nor 
comparable with results from in vivo methods due to interference from body 
fluid. A depletion of the applied strengths of compounds to either below the 
minimum effective concentrations of both compounds or to an ineffective 
combination ratio can occur due to the activity of biological enzymes coupled 
with the existence of a variation in these agents individual half-lives (Reddy 
2000, Jacqueline et al. 2005, Pinto et al. 2005, Johnson 2008). 
The data presented from assays carried out with an inoculum density of 1 x 106 
cfu/ml in the published manuscript of V. H. Tam show that polymyxin B is rapidly 
bactericidal against various antibiotic sensitive and resistant strains of Ps. 
aeruginosa in growth medium, albeit with extensive re-growth after 2 to 4 hours 
(Tam et al. 2005). This polypeptide antibiotic is effective against many other 
Gram-negative bacterial species (Fernandez et al. 2010, Martti  2010, Hogardt et 
al. 2004, Hermsen, Sullivan and Rotschafer 2003) and notably demonstrates a 
rapid in vitro action against multi-drug resistant A. baumanii and K. 
pneuomoniae (Zavascki et al. 2007) yet considered ineffective against most 
Gram-positive organisms including S. aureus (Res  2003). Single applications of 
polymyxin B were at best only weakly bacteriostatic against species of S. aureus 
in this report. 
The findings that F1 applied together with polymyxin B demonstrated an 
enhanced activity against MSSA, MRSA, QRSA, C. violaceum as well as Ps. 
aeruginosa in time-course colony counting assays is consistent with reports 
presented in the previous chapter and is very remarkable. But a weakness in this 
study is the fact that it could not be verified whether any of the combinations 
were antagonist in action as all the assays were carried out in a buffer medium 
which can not permit the demonstration of increment in population over time due 
to the inability of organisms to replicate therein. 
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The data presented in figure 5.2 suggest F1 concentrations up to 512 µg/ml (4 x 
MIC) were ineffective against MRSA populations and at 1024 µg/ml (8 x MIC) 
was only bacteriostatic with a 1.5 log cfu/ml reduction to the inoculum 
population. Meanwhile, under growth conditions (figure 5.4), a concentration of 
F1 equivalent to the 32 µg/ml (MIC) demonstrated some degree of blockage to 
the ability of the quinolone-resistant strains of S. aureus to multiply in 
comparison to the untreated and solvent-treated controls. At higher 
concentrations in the range of (64 to 1024 µg/ml) 2 to 32 x MIC, this compound 
successfully impeded the ability of the quinolone-resistant cells to replicate 
within 24 hours. The information gleaned from both assays presented in figures 
5.2 and 5.4 appears to strongly suggest that F1 is more active under growth 
media than in buffer conditions and may have the capacity to cause a blockage 
to the biosynthesis of peptidoglycan in S. aureus species. Within the range of 
concentrations used in the growth medium above, the capacity of QRSA cells to 
develop new structures (e.g. cell wall, proteins, DNA, etc.) and to replicate were 
apparently being impeded. Penicillin inhibits cell wall formation by blocking 
peptidoglycan biosynthesis in viable cells especially under growth conditions 
(Lewis 2001).  This antibiotic is bactericidal under growth conditions but 
ineffective against most bacterial species suspended in buffer; except 
mycoplasma, which is inherently resistant to the activity of penicillin due to the 
absence of peptidoglycan and conventional cell wall (Normark and Normark 
2002).  
Figures 5.8 to 5.10 and 5.12 similarly show that sub-inhibitory concentrations of 
F23 applied alone were devoid of antibacterial activity against the entire test 
bacterial species (except C. violaceum in figure 5.11). These results are 
comparable to those obtained from bacterial populations challenged with F1 
alone in figures 5.1 to 5.7. At best therefore, single applications of F1 were only 
bacteriostatic against methicillin-sensitive and antibiotic resistant strains of 
Gram-positive S. aureus while F23 was also bacteriostatic against Ps. aeruginosa. 
Both compounds were each bactericidal against C. violaceum at the applied 
concentrations that were seen to be sub-inhibitory and ineffective in the 
chequerboard technique.  
Considering that F1 and F23 demonstrated weak antibacterial action when 
applied alone, both compounds were examined for potential augmentative effect 
upon the antibacterial action of established agents like that provided by 
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clavulanic acid (Navarro 2005). Clavulanic acid is devoid of appreciable 
antibacterial activity when applied alone (Rolinson 1998, Kim et al. 2009) but 
can greatly potentiate the antibacterial activity of penicillin and amoxicillin 
against β-lactamase producing bacterial strains (Therrien and Levesque 2000, 
Bremner, Ambrus and Samosorn 2007). This compound has demonstrable 
capacity to competitively inhibit the activity of β-lactamase enzymes, thereby 
preventing the cleavage of the β-lactam ring and allowing amoxicillin to exert 
maximum effect upon susceptible pathogens (Mark, Vocadlo and Oliver 2011). 
In these last two chapters, F1 and F23 have shown demonstrable capacity to 
potentiate the antibacterial action of polymyxin B (or vice-versa), leading to 
enhanced activity against both Gram-positive and negative bacterial species. Just 
like (-)-epicatechin gallate that reduces the MIC of oxacillin by as much as 512-
fold (Cushnie and Lamb 2011) by the enforcement of structural changes upon 
the cell wall teichoic acid, which is a component of peptidoglycan as well as 
inducing the release of lipoteichoic acid from the cytoplasmic membrane of MRSA 
(Stapleton et al. 2007). It is yet to be investigated how the combination of 
polymyxin B with the chalcone-derivatives act to synchronise and amplify their 
action against S. aureus species but many antibiotics that are effective against 
Gram-positive cells such as the β-lactams - penicillins, carbapenams, etc. usually 
primarily block cell replication by inhibiting the capacity of these organisms to 
expand their peptidoglycan layer as well as develop new cell wall structures 
(Pinho and Errington 2005). There is a speculation that epicatechin gallate is able 
to increases the susceptibility of MRSA to β-lactam antibiotics in MRSA either 
through binding to penicillin binding proteins at target locations distinct from the 
normal penicillin-binding sites or by intercalation into the cytoplasmic membrane 
thereby causing the dislodgement of lipoteichoic acid from the phospholipid 
structure (Stapleton et al. 2007). Newer antibiotic agents that can inhibit the 
biosynthesis of peptidoglycan by novel mechanisms such as either binding to 
new targets within penicillin-binding proteins or essential enzymes such as Mur, 
lipid I and II, in the cell wall biosynthesis pathway, are still being sought after 
(Hao et al. 2012).  
At the moment, one speculation is that the chalcone-derivatives may be having 
some form of activity against the formation of new peptidoglycan structures 
which manifested as inhibition of cell replication under growth conditions. Upon 
single applications, this semi-synthetic agent may have been unable to access its 
121 
 
primary target site at sufficient concentrations leading to the poor antibiotic 
action. During combined application with polymyxin B, it is speculated that this 
polypeptide promotes the entry of these semi-synthetic agents and their capacity 
to reach their active sites thereby facilitating the establishment of their 
antibacterial action. On the other hand, polymyxins can competitively bind to the 
anionic lipopolysaccharide, undergo self-translocation and disrupt the outer 
membrane integrity in Gram-negative bacterial species (Hancock and Sahl 2006, 
Jenssen, Hamill and Hancock 2006a, Hancock 2001). For this group of bacterial 
cells, a second speculation is that the synergistic action recorded from the 
combined application of the chalone-derivatives with polymyxin B is either 
through the augmentation of this latter mechanism of action or and in addition, 
the blockage of other intracellular enzyme activity, such as that of the bacterial 
reducing enzymes, NADH and succinate dehydrogenases. Their combined effect 
is extended against Gram-positive cells probably due to the action of the 
chalcone-derivatives against the thicker peptidoglycan layer and cell wall 
development. The inhibition of certain enzymes activities and defined 
biosynthetic pathways can culminate in the blockage of cell wall formation. The 
impairment of transpeptidation and transglycosylation steps, which are the 
cross-linking stages of cell wall biosynthesis, are known to halt cell wall 
formation (Kahne et al. 2005). Penicillin can inhibit transpeptidase enzyme by 
the formation of slowly hydrolysing covalent acyl enzyme intermediates whilst 
vancomycin causes a complexation of the D-ala-D-ala termini of growing 
peptidoglycan by making five hydrogen bonds to this dipeptide structure of each 
uncrosslinked peptidoglycan pentapeptide side chain (Walsh 2000). Further 
assays will be required to determine whether an application of these chalcone-
derivatives either by themselves or in combination with the polypeptide 
antibiotics blocks essential enzymes required for biosynthetic and metabolic 
pathways in the examined bacterial species. 
Based on the information previously gathered from the chequerboard and MBC 
determination assays, sub-MIC concentrations of both compounds were some 
times re-assessed in the current assay, in order to verify, in some instances, the 
lowest most effective concentrations of the chalcone-derivatives required to 
potentiate the action of polymyxin B (or vice versa), against the test bacterial 
species. For instance, table 4.1 and figure 5.7 show that only a relatively small 
fraction of F1 (1/4 MIC) was needed to augment the antibacterial activity of 
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polymyxin B against Ps. aeruginosa, a recalcitrant Gram-negative bacteria. This 
observation is comparable to the action of clavulanic acid, as only a small 
amount of this agent is required to potentiate the antibacterial action of 
amoxicillin against β-lactamase producing strains of S. aureus when applied as 
co-amoxiclav (Navarro  2005).  
The fact that F1 applied with polymyxin B was synergistic in action against both 
methicillin-sensitive (MSSA) and resistant strains (MRSA) of S. aureus may be 
suggesting a relative reduction in the thickness of the peptidoglycan wall as well 
as a depletion in the binding capacity of penicillin-binding proteins were having 
little impact on the combined action of both agents. Mutant strains of MRSA 
grown in the presence of oxacillin and examined under scanning electron 
microscope were seen as having enlarged, malformed and rough surface cells 
(Raju et al. 2007). The increase in cell size was compensated for by a decline in 
the size of this cell envelope which translates to a reduction in the binding site 
(capacity) as well as the antibiotic effect of oxacillin on these cells. 
Colonies of MRSA used in this project were seen to have a larger morphology on 
agar plate than their MSSA and QRSA counterparts. This suggests they may well 
have had a smaller cell envelope and a reduction in the binding site for agents 
that have the peptidoglycan as primary target. The data presented however 
showed the combination of polymyxin B with the chalcone-derivative 
demonstrated comparable antibiotic action against all three strains of S. aureus 
irrespective of their morphology. 
Resistance of S. aureus to penicillin has in some cases been proven to be due to 
a reduction in the ability of the binding proteins in the cell wall to interact with 
penicillin, as well as this compound’s derivatives such as the beta-lactams 
(Enright et al. 2002, Dowson, Coffey and Spratt 1994). Such cells could also be 
seen to be having thickened cell walls as is observable with clinical strains Mu3 
and Mu5 of MRSA with varying degrees of resistance to vancomycin (Hanaki et 
al. 1998). The demonstration of resistance to vancomycin and teicoplanin by 
some strains of MRSA is some times due to the inactivation of penicillin-binding-
protein (pbp4) (Sieradzki, Pinho and Tomasz 1999) and a thickening of the cell 
wall, otherwise described as activated peptidoglycan synthesis (Appelbaum 
2007). This latter increase in peptidoglycan biosynthesis leads to a decrease in 
the capacity of certain antibiotics like vancomycin to gain access to required 
target active sites as the molecules end up entrapped within the wall (Sieradzki, 
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Pinho and Tomasz 1999). In MRSA that express intermediate resistance to 
vancomycin (VISA), glycopeptides are unable to gain access to cell wall synthesis 
sites permitting the continued expansion of existing cell wall structures and the 
development of new ones even in the presence of this antibiotic unlike in those 
strains that are sensitive to vancomycin (Appelbaum 2007). As previously 
speculated, the findings in this study suggest that polymyxin B promotes the 
translocation of either of these chalcone derivatives across bacterial membrane 
bilayers thereby providing them unhindered access to the cell wall synthesis sites 
of both antibiotic sensitive and resistant strains of S. aureus. A suitable 
formulation of both compounds may be a potentially effective alternative against 
glycopeptide-sensitive and resistant MRSA strains. Further laboratory work 
involving the use of polymyxin B with either of these semi-synthetic compounds 
against such MRSA strains, that are CLSI recommended, is however required to 
verify this speculation. It is known that MRSA grown in the presence of (-)-
epicatechin gallate demonstrates a decline in the substitution of wall teichoic acid 
backbone by D-alanine (D-ala) and ratios of N-acetyl glucosamine to D-ala are 
reduced by as much as about 50 %, which translates to a decrease in the 
positive charge of the bacterial wall during molecular simulations, and confirmed 
by an increase in cationized ferritin binding (Bernal, Zloh and Taylor 2009). 
These observations have given further insight into the mechanisms by which this 
latter semi-synthetic flavonoid compound increases the susceptibility of MRSA to 
β-lactam antibiotics. 
The findings in this study also suggest that either of the two compounds is 
capable of promoting the trans membrane up-take of the other or both and 
thereby facilitating the inhibition of some form of metabolic activities in both 
Gram-positive and negative bacterial species. This latter speculation is because 
of the rapidity with which the combination was bactericidal against the 
challenged bacterial species, despite the high biological load of the inoculum 
population. Antibiotics that manifest such a high speed at the killing of micro-
organisms are thought to be able to inhibit essential metabolic processes, such 
as the activities of NADH dehydrogenase and ATP synthase in bacterial 
respiration (Zhang, Rozek and Hancock 2001a, Tam et al. 2005), as well as 
cause the impairment of protein synthesis to stop cell replication. Bacterial 
membrane de-energization (Zhang, Rozek and Hancock 2001a), depolarisation 
and disruption for which polymyxin is known (Hancock and Rozek 2002a) can 
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initiate processes that lead to impairment of metabolism as well as leakage of 
intracellular materials. The synergistic activity of both compounds is therefore 
thought of at the moment as being most probably initiated by the presence of 
this polypeptide antibiotic both as a bilayer-barrier translocation agent and as 
the catastrophic element initiating the augmented blockade of yet to be verified 
processes.  
The data presented in figure 5.6 also showed that although F1 applied alone was 
bactericidal against C. violaceum; F1 applied in combination with polymyxin B 
demonstrated the same rapid and profound quantitative reduction in colony 
count. This is suggestive of indifference in action for both compounds applied 
together contrary to the report in table 4.1 from the chequerboard assay in 
which F1 applied in combination with polymyxin B was outstandingly synergistic 
with a FICindex of 0.09375. But the more reliable time-course viability assay 
(Petersen et al. 2006) clearly showed both compounds were indifferent in activity 
when examined under buffer conditions. Considering that the chequerboard 
assay was conducted under growth medium, additional time-kinetic assays for C. 
violaceum populations challenged with polymyxin B together with each of the 
chalcone-derivatives is required to give more insight to the mode of action of 
both compounds against this organism and enable a more appropriate 
comparison of the data from the two different assays. The mechanism of action 
by which either of the chalcone-derivatives alone, as well as polymyxin B, were 
able to display rapid bactericidal actions against C. violaceum should be 
investigated in future studies. At the moment, the available data seemingly 
suggest either of the chalcone-derivatives, as well as polymyxin B, were capable 
of self-translocation across the membrane-barriers of this Gram-negative 
organism and had unimpaired access to either their primary target site or 
enzymes. 
In the data presented, despite the high starting inoculum densities of 
approximately 1x107 cfu/ml for all the test species (1x106 cfu/ml for C. 
violaceum), all combinations examined demonstrated bactericidal activities. 
Either F1 or F23 applied in combination with polymyxin B demonstrated ≥3 log 
cfu/ml reduction (equivalent to 99.9 % loss in viability) to the bacterial 
populations of C. violaceum with at least 2 log reduction more than the activity 
of the most active agent in the combination at 24 hours for challenged 
populations of Ps. aeruginosa, MRSA and QRSA. The combinations usually 
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demonstrated remarkable activity within the first 4 hours (except with MSSA) 
and after the 8th hour, bacterial viability for the various species were reduced to 
below detectable limits for all the S. aureus strains that were evaluated. The 
rapidity of bactericidal action for these combinations is comparable to that 
published for the combination of two concentrations (48 and 144 x MIC) of 
colistin each with (1.5 x MIC) ceftazidime against a clinical isolate of Ps. 
aeruginosa (Gunderson et al. 2003). In the published report however, despite 
the high concentrations of colistin used, all the bacterial populations challenged 
with both single or a combination of antibiotics expressed re-growth at different 
times within 24 hours (Gunderson et al. 2003). It is certainly worth verifying 
whether the killing effect of the chalcone-derivatives applied with polymyxin B 
against these bacterial species reported in this study will be permanent by 
repeating the time-course colony counting assays of challenged cell densities in 
growth media. 
Other published reports indicate the killing effect of both colistin and polymyxin B 
against Ps. aeruginosa in kinetic colony counting experiments is concentration-
dependent (Gunderson et al. 2003, Tam et al. 2005, Li et al. 2001a) and greatly 
diminished by a high inoculum load (Tam et al. 2005). Data from this study 
presented in figure 5.8 showed that higher concentrations of both F1 and 
polymyxin B applied together displayed increased extents and rates of synergistic 
effect suggesting their activity was concentration-dependent as well. But despite 
the high inoculum populations used all through this study, the combinations were 
effectively bactericidal. For although an increase in inoculum density from log 105 
to 107 cfu/ml of Ps. aeruginosa samples causes a reduction in the antibiotic 
action of polymyxin B when applied alone (Tam et al. 2005) the data presented 
in this report show that at 8 hours, either F1 or F23 applied in combination with 
polymyxin B demonstrated a ≥ 3 log cfu/ml reduction to the high biological 
populations. Their combined action also caused a greater ≥ 2 log cfu/ml 
reduction to the starting inoculum density of this bacterial species in comparison 
to the activity of the polypeptide only, which was the most potent individual 
compound in the assay thereby indicating both agents were synergistic in action 
(Pillai et al. 2005b).  
It appears that Ps. aeruginosa was more sensitive to the application of F1 with 
polymyxin B than to the same strengths of F23 with the polypeptide antibiotic as 
the challenged populations were reduced down to a lower colony count after 24 
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hours by the former combination. The antibacterial activity of F23 can be further 
compared and contrasted with that of F1 using the data presented in tables 4.1 
and 4.2, as well as figures 5.8 to 5.12. Despite the high inoculum densities of 
1x107 cfu/ml, concentrations of F23 and polymyxin B in combination 
demonstrated synergistic activity, with ≥4 log cfu/ml reduction to the population 
of MSSA within the first 4 hours. After 8 hours, concentrations of F23 applied in 
combination with polymyxin B were bactericidal against MSSA and Ps. aeruginosa 
with approximately 5 and 4 log cfu/ml reductions in population densities of the 
bacterial species above respectively; and an approximately ≥3 log cfu/ml 
reduction to the population density of MRSA. At the 24th hour, the combinations 
had demonstrated ≥4 log reductions to the population densities of MSSA, MRSA, 
QRSA and Ps. aeruginosa. This confirms the existence of synergism following the 
definition given to this concept by Eliopoulos and Moellering (Pillai et al. 2005b) 
between either of the chalcone-derivatives applied in combination with polymyxin 
B against the aforementioned 4 bacterial species.  
On the other hand, the chequerboard assay had indicated F1 applied with 
polymyxin B was synergistic against MSSA, MRSA, QRSA and C. violaceum; but 
additive against Ps. aeruginosa respectively. The latter kind of assay had also 
indicated F23 applied together with polymyxin B was synergistic against MSSA, 
C. violaceum and Ps. aeruginosa although additive against MRSA as well as QRSA 
respectively. But when applied independently at the selected strengths, figures 
5.1 to 5.12 suggest polymyxin B had no appreciable activity under buffer 
conditions against the challenged bacterial populations except QRSA to which this 
agent appears to be bacteriostatic. This report is mindful that colistin and 
polymyxin B are reported to be bactericidal against Ps. aeruginosa with extensive 
re-growth under growth conditions (Gunderson et al. 2003, Tam et al. 2005). 
The activities of sub-inhibitory concentration of F23 applied alone and with sub-
inhibitory concentration of polymyxin B against C. violaceum are comparable to 
those obtained for F1. The application of either F1 or F23 was rapidly and 
profoundly bactericidal against C. violaceum. Considering that the singly applied 
effective concentrations were lower than the MIC values for these compounds 
previously recorded from broth micro-dilution and chequerboard assays, it 
becomes expedient for the time-course colony count for these semi-synthetic 
agents against C. violaceum to be repeated in broth in follow-up experiments. 
Sub-inhibitory concentrations each of F1 and F23 singly applied in combination 
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with sub-inhibitory concentrations of polymyxin B were indifferent in action 
against C. violaceum, given the conventional definition for this terminology (Pillai 
et al. 2005a, Petersen et al. 2006); as neither combinations displayed a 
significant reduction to the colony count of challenged inoculum populations, at 
least not to an extent ≥ 2 log cfu/ml more than the most active agent (in this 
instance F1 and F23). However, after 2 hours, F23 applied alone was slightly less 
active over time than F23 applied together with polymyxin B against C. 
violaceum.  
The table 4.2, figures 5.9 and 5.12 also show that with MRSA and Ps. 
aeruginosa, only a relatively small fraction (1/32 and 1/4 MIC respectively) of 
F23 was required to potentiate the antibacterial action of polymyxin B. Therefore 
another comparison of F23 to F1 is that both compounds were required in 
relatively smaller quantities to augment the antibacterial potency of polymyxin B 
against some of the tested bacterial species. In a given in vivo model for the 
evaluation of the antimicrobial efficacy of cefepime against E. coli in mouse, 
magainin 2 was inactive but only a small fraction was required to potentiate the 
activity of cefepime against this bacterial strain (Krieger et al. 2007, Darveau et 
al. 1991). This is also true for the combined action of clavulanic acid with 
amoxicillin as only a relatively smaller amount of the former compound is 
required to potentiate the action of the latter antibiotic in different formulations 
(Navarro  2005, Vree, Dammers and Exler 2003).  
5.5 Conclusion 
The results from the time-course viability assay presented in this chapter verified 
the data previously obtained from a chequerboard assay recorded in tables 4.1 
and 4.2. The data presented in this chapter verified the existence of synergism 
for selected concentrations of either F1 or F23 applied in together with polymyxin 
B against the test bacterial species. 
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Chapter 6  
Evaluating the effect of polymyxins chalcone-derivatives 
combinations upon bacterial metabolism 
6.1 Introduction 
Cationic amphiphilic peptides have been studied for a wide range of potential 
mechanisms that could account for their antibacterial action, in particular 
membrane depolarisation, disruption and blockade of molecular energization 
activity (Zhang, Rozek and Hancock 2001a, Vaara et al. 2008, Vaara 2010).  
Polymyxin B and colistin were investigated for their ability to interfere with the 
activity of metabolic enzymes essential for normal functioning of the electron 
transport chain that facilitate adenosine triphosphate (ATP) production. The 
enzymes nicotinamide adenine dinucleotide (NADH) dehydrogenase and 
succinate dehydrogenase are involved in bacterial metabolism of carbon sources 
such as glucose, for the generation of ATP required as the currency for 
regeneration and synthesis of new proteins (Bernas and Dobrucki 2002). 
Considering that the inhibition of these fundamental reduction enzyme could lead 
to the blockage of a cascade of metabolic processes, the assay is often also 
described as examination of the effect of antibiotics upon bacterial metabolism. 
In prokaryotic cells, NADH generated from the ubiquinone cycle attached to the 
periphery of the bacterial cytoplasmic membrane and the enzymes obtained as a  
primary product from Krebb’s cycle, combine to reduce 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium (MTT) salt to water-insoluble purple formazan 
crystals (Berridge, Herst and Tan 2005a). Therefore, the capacity of a given 
bacterial population to reduce MTT salt through their electron transport chain can 
be used to assess their metabolic potential (respiratory capacity) (Wang et al. 
2010a). The effect of polymyxin B, the chalcone-derivatives and both compounds 
applied in combination upon the activity of bacterial reducing enzymes, NADH 
dehydrogenase and succinate dehydrogenase, was assessed. The growth phase 
to which the bacterial population belongs can influence the rate and 
reproducibility of the reduction reaction (Wang et al. 2010b). Cells in their 
exponential growth phase are employed in the assay because of the need for the 
abundance of nutrients required to support the rapid structural development, cell 
129 
 
proliferation and a high rate of metabolism (Koutny et al. 2006). Considering 
that the levels of dissolved /available oxygen, nutrient and temperature can 
influence the biological reduction reaction of MTT salt (Takahashi et al. 2002), 
the experimental centrifuge tubes should be left open and incubated at 37 oC to 
allow for optimum bacterial growth and metabolism. This factor also necessitates 
the need for a surplus supply of energy reserve, in the form of glycerol and an 
abundant oxygen supply (Wang et al. 2010a). All these factors should be 
guaranteed in order to achieve optimum efficiency of the electron transport chain 
required for the conversion of MTT into formazan crystal by bacteria, catalyzed 
by several dehydrogenases enzymes most of which are located in the respiratory 
chain (Berridge, Herst and Tan 2005b, Smith and McFeters 1997, Berridge and 
Tan 1993b).  
For a fixed population of viable cells, until enzyme saturation is achieved, a 
higher MTT concentration would yield more formazan crystals production over 
time (Gabrielson et al. 2002, Stentelaire et al. 2001). Therefore, a fixed 
concentration of MTT solution in the final volume of the reaction mixture should 
be applied to avoid variability in the rate and quantity of formazan crystal 
production by a given cell density. Considering that growth media type, volume 
and strength can influence the rate of the reaction, a fixed volume of Luria 
Bertani glycerol (LBG) broth should always be inoculated with a known density of 
the test bacterial species. Background absorbance can be caused by the 
interaction of incompletely removed culture medium, residual MTT and entrapped 
bacterial cells before the addition of DMSO (Wang et al. 2010b). To deal with 
this, the formazan crystals should be immediately washed upon recovery with 
0.9 % w/v sodium chloride solution before the introduction of DMSO solvent.  To 
avoid inconsistency in the absorbance readings due to an incomplete dissolution 
of formazan crystal precipitates as a result of aggregation and formation of 
complexes with bacterial cells (Wang et al. 2010b), the recovered crystals should 
be dissolved in DMSO, in the dark, at room temperature overnight.  In addition, 
the solution should be mixed/swirled in a rotary mixer before readings are taken 
with a spectrophotometer. 
Unlike in mammalian culture (Wang et al. 2010b), bacterial cells assayed with 
the MTT reduction protocol did not form needle-like formazan crystals on cell 
surfaces and in the broth medium. Formazan crystals instead covered the 
bacterial cells, forming complexes that led to an entrapment of the substrate. 
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Each bacterium functions as a unit of dehydrogenase system and the rapid 
precipitation of formazan crystals upon them leads, as well as the formation of 
complexes with individual units of these cells causes a decline in the amount of 
available dehydrogenase enzymes, which is incidentally required to progress the 
reaction infinitely (Berridge, Herst and Tan 2005a, Wang et al. 2010a). This 
assay cannot therefore progress infinitely and generally a period of 20 to 30 
minutes is required for completion of the reaction (Morgan 1997).  
The objectives of this chapter were to: 
i.     Develop, as well as standardise, an MTT protocol for evaluating the 
biological reducing enzymes capacity of unchallenged viable bacterial 
populations by establishing a relationship between fixed density of cell 
populations and the quantity of formazan crystals produced  
ii.      Examine the effect of polymyxin B, colistin and combinations of 
these compounds with the chalcone-derivatives upon the capacity of 
bacterial species to reduce MTT salt into formazan crystals. 
6.2 Materials and Methods 
6.2.1 Preparation of Luria Bertani glycerol (LBG) broth  
Five grams of tryptone T (Oxoid LP0043), 2.5 g yeast extract (Oxoid LP0021) 
and 2.5 g sodium chloride (Aldrich) were weighed, the powders suspended in 
distilled water and the volume made up to 500 ml using a volumetric flask. A 250 
ml stock solution of 0.5 % v/v glycerol stock solution was prepared. The bottles 
containing the media suspension and glycerol solution were autoclaved by moist 
heat sterilisation as previously described in section 2.1.2.1  When required, the 
sterile broth and glycerol solutions were combined in a 5:1 ratio. 
6.2.2 Preparation of bacterial culture in LBG medium 
Using 30 ml of LBG medium in a 100 ml Erlenmeyer conical flask, an 18 hour 
culture was prepared as previously described in section 2.2.3.2. A 500 µl aliquot 
of the overnight culture was transferred into fresh LBG and incubated at 37 oC 
for 4 - 6 hours in an orbital incubator set at 100 rpm (Sanyo Gallenkamp PLC, 
Loughborough, UK.). 
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6.2.3 Establishing a correlation between bacterial density and quantity 
of formazan crystals produced 
The bacterial suspension in LBG was adjusted using a spectrophotometer to 
obtain 5 samples with densities within the wavelength range of 0.1 to 1.0 units 
at OD600. Colony plate count was carried out for each density as previously 
described in sections 2.3.3 and 2.3.4, in order to verify the actual number of 
viable cells (cfu/ml). Suitable volumes of the defined cell densities and stock MTT 
solution (5 mg/ml dissolved in 0.9 % w/v sodium chloride solution) were mixed 
and incubated for 20 minutes, in a static water bath previously set at 37 oC. Each 
sample was centrifuged at 14,000 rpm for 2 minutes and the recovered insoluble 
formazan crystals washed once with 0.9 % w/v sodium chloride solution and re-
centrifuged at the conditions described above. After supernatant removal, the 
crystals were dissolved in 1 ml DMSO and optically quantified with a 
spectrophotometer (Cecil CE 3021, Cecil instruments Ltd., Milton Technical 
Centre, Cambridge, UK.) at OD550. The assay was conducted in duplicate with at 
least three independent experiments. A graph consisting of absorbance (A550) of 
formazan crystals produced against the optical density (OD600) of the bacterial 
population that yielded the formazan was plotted and statistically analysed for 
standard error of mean and standard deviation with GraphPad prism 4 software.  
6.2.4 Examining the effects of polymyxins with the chalcone-derivatives 
upon bacterial metabolism 
A defined volume of stock (5 mg/ml) MTT solution and a suitable volume of 0.3 
units OD600 bacterial suspension in LBG as well as antibiotic solutions required to 
prepare the desired final concentration were added together and mixed. The 
mixture was incubated in a static water bath pre-set to 37 oC. At time intervals of 
0, 20, 40, 60 and 80 minutes, samples were collected and centrifuged at 14, 000 
rpm for 2 minutes. The recovered pellets were washed once and re-centrifuged 
at 14,000 rpm. A solution of the recovered formazan crystals was prepared in 1 
ml DMSO and the absorbance determined with either a DTX 880 (Molecular 
Devices, California, USA.) at A595 or a with a spectrophotometer (Cecil 7400 UV-
Visible), set at A550. The assay was repeated with at least three independent 
experiments on separate days. A graph of optical density of the broth culture (at 
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OD600) against absorbance of formazan produced (at A550) was prepared and 
statistically analysed for standard error of mean as well as standard deviation 
with GraphPad prism 4 software. 
6.3 Results 
6.3.1 Calibration curves for formazan quantity produced by bacterial 
populations 
The sensitivity of the assay as a measure of detecting the capacity of untreated 
bacterial cells to reduce MTT salt into formazan crystals was initially established. 
The assay was then standardised by determining the relationship between 
quantity of formazan produced and bacterial density. On this premise, figure 6.1 
shows that as the optical density of the viable E. coli suspensions were increasing 
from 0.1 to 1.0 unit at OD600, the quantity of formazan crystals obtained as yield 
increased proportionately, indicating an increase in enzyme activity. 
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Figure 6.1: Absorbance (at A550) of formazan plotted against the corresponding optical density (at 
OD600) of E. coli that produced the crystals. The data were mean values obtained from experiments 
conducted in duplicate and repeated thrice on separate days. 
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Upon establishing the assay on a macro-scale, the substrate concentrations 
employed in the analysis were reduced to microgram levels and the formazan 
crystals obtained as yield were quantified in a micro-titre plate using a DTX-880 
reader at A595. The assay from which data for figure 6.1 were obtained was 
designed to standardise the protocol for bacterial MTT metabolic assay. The 
figure indicates the existence of a direct correlation between the quantity of 
formazan crystals and bacterial density when E. coli population was within the 
range of 0.1 to 1.0 units at OD600. A fixed cell population selected from this range 
could therefore be used to assess the effect of antibiotics upon the reducing 
capacity of bacterial enzymes. Using this as a guide, all further analysis for 
polymyxins and the chalcone-derivatives were carried out using a fixed cell 
density of 0.3 unit at OD600 which can produce measurable quantities of 
formazan crystals whilst maintaining a correlation between absorbance of 
formazan and bacterial density. Having established the sensitivity and reliability 
of the assay at a macro-scale level, a scaled down technique was employed in 
most cases such that the reduced/smaller amount of formazan crystals obtained 
as yield was quantified using a micro-titre plate in a pre-calibrated DTX-880 
reader. This explains why subsequent data may have been presented using a 
different absorbance of 595 nm on the y-axis. The use of varying absorbance for 
the measurement of formed formazan did not affect the data analysis as the 
results were normalised in terms of percentage with reference to the control 
samples. 
Figure 6.2 shows data for the calibration curve of absorbance of formazan at A595 
obtained as yield from the biological reduction of MTT salt against that of the 
optical density (at OD600) of the corresponding E. coli population, using a micro-
titre plate incubated in a DTX-880 reader at 37 oC. A linear correlation exists 
between the amount of formazan produced and the cell density from which 
crystals were obtained. As the bacterial population was increasing from 0.1 to 
0.2 unit at OD600, the absorbance for the quantities of formazan produced were 
seen to be increasing in a proportionate manner from 0.5 to 0.85 unit at A595.  
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Figure 6.2: Absorbance (A595) of formazan plotted against the corresponding optical density (OD600) 
of E. coli that produced the crystals. The data were mean values obtained from experiments 
conducted in duplicate and repeated thrice on separate days. 
The readings demonstrate a direct correlation between the quantity of formazan 
produced and the cell density, even within a smaller range of 0.1 to 0.2 units at 
OD600, indicating the sensitivity of MTT salt to the presence of NADH and 
succinate dehydrogenase enzymes. This assay can therefore be used to assess 
the effect of either new or established antimicrobial compounds upon bacterial 
metabolism.  
6.3.2 Evaluating the effect of polymyxin B upon selected bacterial 
metabolism 
6.3.2.1 Impact of polymyxin B upon E. coli metabolism 
The effect of polymyxin B upon the activity of E. coli reducing enzymes was 
assessed with the bacterial MTT reduction protocol and the data obtained is 
presented in figure 6.3.  
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Figure 6.3: The effect of 1/20 x MIC, MIC and 4 x MIC of polymyxin B on reducing enzyme activity 
of E. coli. The data were mean values obtained from experiments conducted in duplicate and 
repeated three times on separate days. 
In comparison to the untreated bacterial sample, E. coli challenged with 1/20 
MIC of polymyxin B demonstrated no remarkable blockage to the biological 
production of formazan crystals from MTT salt, whilst cells treated with 
concentrations of the polypeptide equivalent to MIC and 4 x MIC both displayed 
about 20 % inhibition. The LBG medium containing an equivalent amount of the 
MTT salt but devoid of the inoculum bacterial population displayed no optically 
detectable quantity of formazan crystals thereby giving an indication that the 
presence of active biological reducing enzymes from viable organisms is required 
for the salt reduction to occur. 
Concentrations of polymyxin B equivalent to 0.0313 µg/ml (MIC) and 0.125 
µg/ml (4 x MIC) also had no notable influence upon formazan production from 
MTT by E. coli within 80 minutes. Considering that concentrations of polymyxin B 
within the range of 1/20 to 4 x MIC only weakly affected the metabolic activity of 
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E. coli, a higher concentration 0.625 µg/ml (20 x MIC) of this polypeptide 
antibiotic was subsequently applied in the data presented in figure 6.4.  
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Figure 6.4: Inhibitory effect of 20 x MIC polymyxin B upon the MTT reduction capacity of E. coli. 
The data were mean values obtained from experiments conducted in duplicate and repeated on 3 
separate days. 
The data presented in figure 6.4 were obtained from MTT reduction analysis of 
untreated, sonicated and viable E. coli suspensions challenged with 20 x MIC 
polymyxin B. This experiment had been conducted using the macro-protocol as is 
being reflected on the scale for the absorbance values recorded on the y-axis for 
formazan production. The production of formazan crystals from MTT salt by E. 
coli was gradually inhibited within 80 minutes. The activity of the biological 
reducing enzymes was however still partially affected by the presence of a higher 
concentration of this polypeptide antibiotic. The treated bacterial population 
demonstrated approximately 25 % reduction in the quantity of formazan 
produced in comparison to the untreated bacterial population after 80 minutes of 
incubation. The capacity of sonicated E. coli cells to produce formazan crystals 
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was initially completely inhibited but the cells in this sample eventually produced 
about 10 % of the amount of crystals yielded by the untreated bacterial control 
after 80 minutes. This observation indicates that the sonication process probably 
did not completely destroy 100 % of the reducing enzymes. As expected, there 
were no formazan crystals in the LBG medium devoid of inoculum populations of 
E. coli over the same time period. 
6.3.2.2 Impact of polymyxin B upon the metabolic activity of S. aureus  
S. aureus 6571 (MSSA) populations were challenged with polymyxin B 
concentrations within the range of 12.8 µg/ml (1/20 MIC) to 2.56 mg/ml (10 x 
MIC) in the presence of MTT salt and examined for the rate and quantity of 
formazan production. The data obtained from the assay is presented in figure 6.5 
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Figure 6.5 Concentration-dependent inhibitory effect of polymyxin B upon the reducing enzymes 
activity of MSSA.  The data were mean values obtained from experiments conducted in duplicate 
and repeated on 3 separate days. 
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In comparison to the untreated MSSA suspension, the bacterial samples 
challenged with 1.024 (4 x MIC) and 2.56 mg/ml (10 x MIC) polymyxin B 
demonstrated almost 95 and 100 % inhibition of formazan production 
respectively within 80 minutes. This strongly suggests the presence of both 
concentrations of this polypeptide antibiotic halted the activities of NADH and 
succinate dehydrogenase enzymes even in the presence of glycerol, broth and 
oxygen. As can be seen from the figure, the bacterial population challenged with 
256 µg/ml (MIC) polymyxin B demonstrated approximately 75 % reduction in the 
quantity of formazan produced suggesting the activity of this antibiotic against 
the biological reducing enzymes in MSSA was concentration-dependent. 
To further reinforce this point, the MSSA population challenged with 12.8 µg/ml 
(1/20 MIC) polymyxin B demonstrated approximately only a 15 % reduction in 
the quantity of formazan recovered, indicating a reduction in the enzyme 
inhibitory capacity of this antibiotic with a lesser concentration. The effect of 
polymyxin B upon the reducing enzymes of Gram-positive S. aureus (MSSA) and 
Gram-negative E. coli is therefore concentration-dependent. Although 0.625 
µg/ml (20 x MIC) polymyxin B only partially affected (by about 25 %) the 
metabolising enzymes activity in the latter Gram-negative organism, 1.024 
mg/ml (4 x MIC) and 2.56 mg/ml (10 x MIC) polymyxin B completely inhibited 
the capacity of reducing enzymes to convert MTT salt into formazan in Gram-
positive MSSA. But as observed with E. coli previously, the negative control 
devoid of MSSA did not produce formazan crystals within the assay duration. 
6.3.2.3 Impact of polymyxin B on the metabolic activity of Ps. 
aeruginosa 
The result presented in figure 6.6 was obtained from Ps. aeruginosa populations 
challenged with polymyxin B concentrations and examined for the rate and 
quantity of formazan production. The Ps. aeruginosa population challenged with 
0.05 µg/ml (1/20 MIC) of polymyxin B demonstrated a comparable rate and 
quantity of formazan production with the unchallenged population after 80 
minutes. The close proximity of the curves recorded from both samples gives an 
indication that such a sub-inhibitory concentration of polymyxin B had very little 
inhibitory effect on the capacity of the biological reduction enzymes, NADH and 
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succinate dehydrogenases, to convert MTT salt to the reduced form. Meanwhile, 
Ps. aeruginosa samples challenged with the polypeptide concentrations 
equivalent to 1 µg/ml (MIC), 4 µg/ml (4 x MIC) and 20 µg/ml (20 x MIC) 
demonstrated a 25, 40 and 50 % reduction in the quantity of formazan crystals 
produced and thereby manifested a concentration-dependent blockade of the 
reducing capacity of the biological enzymes in this bacterial species. This 
systematic quantitative decrease in recoverable formazan shows the biological 
system is sensitive to the presence of this antibiotic.  
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Figure 6.6: Concentration-dependent inhibitory effect of polymyxin B upon the reduction capacity 
of Ps. aeruginosa. The data were mean values obtained from experiments conducted in duplicate 
and repeated on 3 separate days. 
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6.3.3 Evaluating the effect of colistin upon the activity of reducing 
enzymes in selected bacterial species  
The ability of colistin to influence the activity of the reducing enzymes in selected 
bacterial species was examined using the MTT metabolic assay. 
6.3.3.1 Effect of colistin upon the activity of reducing enzymes in E. coli 
Figure 6.7 shows the varying effect of different concentrations of colistin upon 
the metabolic activity of E. coli.  
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Figure 6.7: Concentration-dependent inhibitory effect of colistin upon the activity of reducing 
enzymes in E. coli. The data were mean values obtained from experiments conducted in duplicate 
and repeated on three separate days. 
There was a demonstration of a concentration-dependent inhibitory effect by 
colistin upon the capacity of E. coli to produce formazan crystals from MTT salt. 
In comparison to the untreated population, E. coli suspensions challenged with 
0.014 µg/ml (1/20 MIC), 0.28 µg/ml (MIC), 1.12 µg/ml (4 x MIC) and 2.8 µg/ml 
(20 x MIC) of colistin demonstrated approximately 2.5, 10, 25 and 50 % 
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reduction in the quantity of formazan produced respectively. The inhibitory effect 
demonstrated by 1.12 µg/ml (4 x MIC) colistin was almost equivalent to that 
shown by 0.625 µg/ml (20 x MIC) polymyxin B against this same species, 
suggesting colistin was demonstrating more impact upon bacterial reducing 
enzymes than polymyxin B. As with the inhibitory effect of polymyxin B, 20 x 
MIC colistin demonstrated the greatest impairment to the activity of the 
biological reducing enzymes in E. coli, with the highest recorded inhibition to the 
reduction of MTT salt to formazan. As expected, the LBG medium devoid of 
bacterial inoculum had no formazan crystals. 
6.3.3.2 Examining the effect of colistin upon the reducing enzymes 
activity of MSSA 
The data presented in figure 6.8 was obtained from populations of S. aureus 
6571 (MSSA) that were challenged with different concentrations of colistin in the 
range of 7 µg/ml (1/20 MIC) to 1.4 mg/ml (10 x MIC).  
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Figure 6.8: Concentration-dependent inhibitory effect of colistin upon the reducing enzymes 
activity of S. aureus 6571 (MSSA). The data were mean values obtained from experiments 
conducted in duplicate and repeated 3 times on separate days. 
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The information provided in the figure suggests the occurrence of a 
concentration-dependent inhibitory effect of colistin upon the metabolising 
capacity of MSSA in the MTT reduction analysis. In comparison to the untreated 
population, the bacterial densities challenged with 7 µg/ml (1/20 MIC), 140 
µg/ml (MIC), 560 µg/ml (4 x MIC) and 1.4 mg/ml (10 x MIC) of colistin 
demonstrated a proportionate sensitivity to the presence of this antibiotic. 
There was an approximately 2, 30, 55 and 70 % cessation respectively to the 
quantity of formazan crystals produced after 80 minutes of incubation, 
suggesting that NADH as well as succinate dehydrogenase enzymes were being 
inhibited to a varying degree that is dependent upon the concentration of the 
polypeptide antibiotic. As would be expected, the LBG medium devoid of 
inoculum bacteria had no formazan crystals. 
6.3.3.3 Examination of the effect of colistin upon the MTT-reduction 
capacity of Ps. aeruginosa 
The effect of a range of concentrations from 0.075 µg/ml (1/20 MIC) to 15 µg/ml 
(10 x MIC) of colistin upon the respiratory capacity of Ps. aeruginosa was 
assessed and the information obtained is presented in figure 6.9.  
The data obtained demonstrate a concentration-dependent inhibitory effect of 
colistin upon the capacity of Ps. aeruginosa to produce formazan crystals from 
MTT salt. Compared to the untreated population, the Ps. aeruginosa populations 
challenged with 0.075 µg/ml (1/20), 1.5 µg/ml (MIC), 6 µg/ml (4 x MIC) and 15 
µg/ml (10 x MIC) of colistin demonstrated approximately 0, 25, 50 and 68 % 
impairment to the quantity of formazan produced within 80 minute, again giving 
the impression that the biological reducing enzymes in these cells were 
demonstrating a dose-dependent inhibitory response to the presence of colistin.  
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Figure 6.9: Concentration-dependent inhibitory effect of colistin upon the MTT-reduction capacity of 
Ps. aeruginosa. The data were mean values obtained from experiments conducted in duplicate and 
repeated 3 times on separate days. 
6.3.4 Evaluation of the effect of F1 with polymyxin B upon the activity of 
bacterial reducing enzymes  
This analysis should have begun by considering the effect of the combined 
application of F1 with polymyxin B upon the reducing enzymes activity of E. coli. 
This was however not carried out since the data obtained from the chequerboard 
assay indicated indifference in the antibacterial action of both compounds 
combined against this organism. As already stated, the examination of the effect 
of polymyxin B upon the metabolic activity of E. coli reported previously was 
conducted for the purpose of standardising the protocol using bacterial cells. The 
effect of polymyxin B with F1 upon bacterial metabolism was investigated for 
species wherein either an additive or synergistic action had been recorded during 
a chequerboard and time-kinetic colony counting assay in an attempt to have an 
insight into these agents potential mechanism of action. 
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6.3.4.1 Effect of F1 with polymyxin B upon the biological reduction 
capacity of MSSA 
Figure 6.10 shows the effect of F1 applied with polymyxin B upon the activity of 
reducing enzymes in S. aureus 6571 (MSSA).  
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Figure 6.10: Enhanced inhibitory effect of F1 applied with polymyxin B upon the MTT-reduction 
capacity of MSSA. The data were mean values obtained from experiments conducted in duplicate 
and repeated three times on separate days. 
The concentrations applied in this technique were based on guidance received 
from the activity of both compounds in the chequerboard (table 4.1) and time-
course colony counting (figure 5.1) assays. 
The untreated MSSA population, the solvent treated and the sample challenged 
with 64 µg/ml (MIC) F1 all demonstrated comparable and uninhibited production 
of formazan. Comparatively, the MSSA density that was challenged with 256 
µg/ml (MIC) polymyxin B demonstrated approximately 60 % inhibition to the 
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quantity of formazan produced. Whilst, the MSSA populations that were 
challenged with 64 µg/ml (MIC) F1 or 32 µg/ml (1/2 MIC) F1 in combination with 
256 µg/ml (MIC) or 64 µg/ml (1/4 MIC) of polymyxin B respectively, 
demonstrated approximately 90 % decline in the quantity of formazan produced. 
This reported action suggests a pronounced inhibition of the activity of NADH and 
succinate dehydrogenase in MSSA by the combined action of these compounds. 
 
This data complements the results recorded from the kinetic colony counting 
assay wherein a 7 log cfu/ml MSSA inoculum population challenged with 64 
µg/ml F1 and 256 µg/ml polymyxin B demonstrated a decline in cell viability to 
below detectable limits after 8 hours (figure 5.1). It follows therefore that timing 
for the impairment of cell metabolic activity preceded that of the loss in viability 
for the challenged bacterial species. 
The LBG broth without bacteria to which MTT solution was added did not produce 
formazan; an indication that the combination of the salt with the media alone 
cannot reduce the salt to water insoluble purple crystals. As reflected by the 
results in the figure, the lack of inhibitory activity in the solvent treated control 
suggests the absence of interference with the assay by the presence of 1 % v/v 
DMSO (solvent for F1) in the activity recorded for the combinations of F1 with 
polymyxin B against bacterial NADH and succinate dehydrogenase enzymes. 
6.3.4.2 Effect of F1 with polymyxin B upon MTT-reduction capacity of 
MRSA 
Figure 6.11 demonstrates the effect of F1 applied with polymyxin B upon the 
metabolic enzymes of S. aureus 11940 (MRSA). As for S. aureus 6571 (MSSA), 
the concentrations of both compounds applied were chosen based on information 
already gleaned from a chequerboard (table 4.1) and time-course viability (figure 
5.3) assays. 
The untreated MRSA population, the solvent treated and the sample challenged 
with 128 µg/ml (MIC) F1 demonstrated comparable and unhindered production 
of formazan crystals within 80 minutes. 
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Figure 6.11: Enhanced inhibitory effect of F1 with polymyxin B upon biological MTT-reduction by S. 
aureus 11940 (MRSA). The data were mean values obtained from experiments conducted in 
duplicate and repeated three times on separate days. 
In comparison to the untreated control, the MRSA population challenged with 
128 µg/ml (MIC) polymyxin B demonstrated approximately 60 % inhibition to the 
quantity of formazan crystals produced. The MRSA populations exposed to 64 
µg/ml (1/2 MIC) F1 with 64 µg/ml (1/2 MIC) polymyxin B and 128 µg/ml (MIC) 
F1 with 128 µg/ml (MIC) polymyxin B both demonstrated approximately 85 and 
90 % blockage of the biological formation of formazan crystals respectively. The 
inhibitory activity of the former combination of strengths of both compounds 
complements the data presented in figure 5.3 from a time-course viability assay, 
wherein a 7 log cfu/ml inoculum population of MRSA was reduced to below 
detectable limits after 8 hours, suggesting cessation of metabolic functions 
preceded the loss of cell viability. The levels of interference of these compounds 
with the activities of bacterial reducing enzymes (NADH and succinate 
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dehydrogenase) seem to bear a correlation with their synergistic effects against 
S. aureus species. 
6.3.4.3 Effect of F1 with polymyxin B upon the biological reducing 
capacity of quinolone-resistant S. aureus 
The figure 6.12 below shows the effect of F1 applied with polymyxin B upon the 
capacity of quinolone-resistant S. aureus (QRSA) to reduce MTT salt into 
formazan.  
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Figure 6.12: Enhanced inhibitory effect of F1 with polymyxin B upon the biological reducing power 
of QRSA. The data were mean values obtained from 3 experiments conducted in duplicate on 
separate days. 
The choice of concentrations of both compounds applied was based on 
information obtained from both chequerboard (table 4.1) and time-course 
viability (figure 5.5) assays. 
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The untreated, solvent-treated and the QRSA populations challenged with 32 
µg/ml F1 demonstrated comparable quantities of formazan crystal production 
over the 80 minutes duration of the experiment. Given that the untreated QRSA 
sample displayed a 100 % production of formazan from the salt, then bacterial 
suspensions challenged with 128 µg/ml (1/2 MIC) polymyxin B alone and in 
combination with 32 µg/ml (MIC) F1 demonstrated approximately 25 and 60 % 
reduction in the quantity of recovered formazan, respectively. 
The enzyme inhibitory activity of these combined compounds at the same 
concentrations above also correlates with their synergistic action against this 
same strain of S. aureus, in a time-kinetic colony counting experiment recorded 
in figure 5.5. Therein, a 7 log cfu/ml population was reduced to below detectable 
limit after 8 hours, suggesting the establishment of cessation of metabolic 
activity in advance of eventual cell death, in the combined agents’ mechanism of 
action against S. aureus. This observation seems to support the speculation that 
a correlation existed between the synergistic action of both compounds and their 
inhibitory effect upon the activities of biological reducing enzymes (such as NADH 
and succinate dehydrogenase), in S. aureus species.  
6.3.5 Evaluation of the effect of F23 with polymyxin B upon bacterial 
metabolism 
Following the outcome above for F1, the activity of polymyxin B when applied 
with the second semi-synthetic agent, F23, against the metabolic action of 
selected bacterial species in the presence of MTT salt was investigated. The data 
obtained is subsequently presented. 
6.3.5.1 Effect of F23 with polymyxin B upon reducing enzymes activity 
of MSSA 
Figure 6.13 demonstrates the effect of F23 applied in combination with 
polymyxin B upon the metabolising activity of MSSA.  
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Figure 6.13: Inhibitory effects of polymyxin B alone and in combination with sub-inhibitory 
concentration of F23 upon the MTT-reducing capacity of S. aureus 6571 (MSSA). The data were 
mean values obtained from 3 experiments conducted in duplicate on separate days. 
As in the previous assays with F1 and polymyxin B, the selection of the 
concentration of both compounds to be used in this protocol was made based on 
the information collected from chequerboard (table 4.2) and time-kinetic colony 
counting (figure 5.8) assays. In both assays, as well as in an MBC-determination 
technique, the combination of 16 µg/ml F23 with 256 µg/ml polymyxin B was 
synergistic against S. aureus 6571. The effect of these same concentrations of 
both compounds upon this bacterial species metabolism was examined in this 
protocol. 
The untreated, solvent-treated and MSSA populations challenged with 16 µg/ml 
F23 demonstrated comparable quantities of formazan crystal production over the 
80 minutes duration of the experiment. In comparison to the untreated bacterial 
suspension, S. aureus challenged with 256 µg/ml (MIC) polymyxin B alone and in 
combination with 16 µg/ml (1/4 MIC) F23, both demonstrated approximately 70 
% inhibition to the quantity of formazan produced over time. This result verified 
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the data reported in sections 6.3.2.2 (figure 6.5) and 6.3.4.1 (figure 6.10) 
wherein 256 µg/ml polymyxin B was seen to have demonstrated about 75 and 60 
% inhibition to the activity of the reducing enzymes in MSSA with the application 
of the same concentration of this polypeptide antibiotic, thereby giving an overall 
average of 68 %. 
Whereas 32 or 64 µg/ml F1 applied with 64 or 256 µg/ml polymyxin B 
respectively both displayed an enhanced blockade of the activity of reducing 
enzymes in MSSA (figure 6.10), 16 µg/ml F23 applied with 256 µg/ml polymyxin 
B demonstrated almost the same degree of impairment with 256 µg/ml of the 
polypeptide antibiotic used alone against the activity of these enzymes. But 
clearly, the degree of metabolic enzyme activity impairment by the latter 
combination is noteworthy whilst F23 had no significant individual impact. 
Further assays involving the use of higher strengths of F23 in combination with 
the polypeptide are required before a conclusion can be reached on the possible 
absence of enhanced impairment of the activity of these reducing enzymes in 
MSSA by both compounds. 
6.3.5.2 Effect of F23 with polymyxin B upon MTT-reducing capacity of 
MRSA 
It was reported in table 4.2 that 32 µg/ml (1/32 MIC) F23 applied with 64 µg/ml 
(1/2) polymyxin B was additive in antibacterial action against MRSA. These 
strengths of both compounds applied together were seen to be synergistic in a 
kinetic colony-counting assay by displaying a >4 log cfu/ml reduction in the 
viability of the same bacterial species after 24 hours (figure 5.9). In order to gain 
an insight into the possible mechanism of action for both agents, the same 
concentration above were used to challenge a population of this bacterial species 
and examined for the blockage of the cells capacity to reduce MTT salt into 
formazan crystals. The data obtained is presented in figure 6.14. 
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Figure 6.14: The effects of sub-inhibitory concentrations of polymyxin B and F23 applied alone as 
well as together upon the capacity of S. aureus 11940 (MRSA) to produce formazan crystals from 
MTT salt. The data were mean values obtained from 3 experiments conducted in duplicate on 
separate days. 
Whereas the untreated, solvent-treated and MRSA populations challenged with 
32 µg/ml (1/32 MIC) F23 demonstrated comparable quantities of formazan 
crystal production over 80 minutes, MRSA suspension challenged with 64 µg/ml 
(1/2 MIC) polymyxin B alone displayed about 45 % blockade to the activity of 
bacterial reducing enzymes. This recorded activity is lower than the 
approximately 60 % inhibition produced by twice this concentration of the 
polypeptide antibiotic in section 6.3.4.2 (figure 6.11). This verified the capacity 
of polymyxin B to impede the actions of enzymes thought to be responsible for 
enforcing biological reduction reactions within MRSA. As can also be seen from 
the results in figure 6.14, an application of 32 µg/ml of this chalcone-derivative 
with 64 µg/ml (1/2 MIC) polymyxin B demonstrated a 60 % reduction in the 
quantity of formazan produced. This observation correlates with the results 
recorded in table 4.2 and figure 5.9 suggesting the impairment of metabolic 
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activity preceded cell death in the possible mechanism of action for the 
combination against this bacterial strain. 
6.3.5.3 Effect of F23 with polymyxin B upon the formazan crystals 
production capacity of quinolone-resistant S. aureus 
Figure 6.15 below shows the effect of a sub-inhibitory concentration of F23 
applied alone and with a sub-inhibitory concentration of polymyxin B upon the 
biological reduction of MTT salt to formazan crystals by QRSA. 
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Figure 6.15: Inhibitory effect of a sub-inhibitory concentration of polymyxin B with a sub-inhibitory 
concentration of F23 applied in combination upon the biological reduction capacity of S. aureus 
1628 (QRSA) in an MTT metabolic assay. The data were mean values obtained from 3 experiments 
conducted in duplicate on separate days. 
The concentrations of both compounds used in this assay were the same as 
those reported as synergistic against quinolone-resistant strain of S. aureus in 
table 4.2 and figure 5.10. The 16 µg/ml (1/2 MIC) F23 that was seen to have 
caused more than 0.5 log cfu/ml loss in the viability of QRSA population within 
24 hours is now observed to induce an approximately 12.5 % blockage to the 
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activity of NADH and succinate dehydrogenase after 80 minutes, with respect to 
the untreated and solvent-treated QRSA controls.  
Similarly, an application of 64 µg/ml (1/2 MIC) polymyxin B that was responsible 
for a 2 log cfu/ml loss in cell viability is also seen to cause a 25 % impairment to 
the activity of the biological reducing enzymes; suggesting a cessation of 
metabolic activity occurred in advance of cell death.  A combined application of 
both compounds at the same strengths previously mentioned demonstrated 
about 40 % impairment to the activity of these enzymes after 80 minutes.  
The fact that the combination of this same 16 µg/ml F23 with 64 µg/ml 
polymyxin B had been reported to have reduced the colonies of this bacterial 
species by about 4.5 log cfu/ml after 8 hours suggests again that the cessation 
of cell metabolism occurred before the killing of these cells. 
The curve for the combination of F23 with the polypeptide antibiotic above is also 
suggestive of a possibility for a continued enhanced impairment of reducing 
enzymes activity and an increment in the amount of recovered formazan 
crystals, if the experiment were extendable beyond 80 minutes. But this cannot 
be achieved because of the deposition and aggregation of the formed crystals 
with the cells, thereby reducing the accessibility of the metabolic enzymes over 
time. 
As already demonstrated for MSSA (figure 6.5), an increase in the concentration 
of polymyxin B may have led to an increase in the degree of impairment upon 
the metabolic enzymes activity in QRSA. A similar speculation is that an increase 
in concentrations of both F23 and polymyxin B in the combination may also have 
yielded a corresponding decrease in the rate and quantity of formazan production 
over time.  
In any case, there is a correlation between the data provided and those 
previously recorded in table 4.2 and figure 5.10. When viewed together, these 
results strongly suggest the blockage of bacterial metabolism (reducing enzymes 
activity) in QRSA, is an eminent mechanism of action for the polypeptide 
combined with F23, which has also been demonstrated for this antibiotic 
combined with F1 (figure 6.12). 
An inconsistency that is noticeable is the use of different wavelengths for the 
measurements of optical densities of formazan crystals and the estimation of 
bacterial populations as the presentation of data was progressing. This variation 
was because the first set of experimentations were conducted using large 
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quantities of materials and the formazan crystals were measured using 1 ml 
transparent disposable cuvette in a spectrophotometer. The experimental 
procedure was later scaled down to permit the use of reduced quantities of 
substrates and the formazan crystals obtained were quantified in a micro-titre 
plate wells using a DTX-880 reader (Molecular Devices). The difference in 
wavelength scales did not interfere with the interpretation of the results data as 
analysis were done in percentages, relative to the untreated control in each set 
of experiment. 
The absence of either MTT reagent or inoculum bacteria led to lack of production 
of formazan as mixtures of bacterial-free broth, test-antimicrobial compound and 
MTT solution incubated at 37 oC for 80 minutes had no formazan crystals, in 
comparison to blank DMSO control. This data indicates there was no interference 
between LBG and MTT in the bacterial metabolic assay as well as that both MTT 
salt and inoculum bacteria were essentially required for the technique. Similarly, 
the combination of MTT, broth and glycerol in the presence of oxygen under ideal 
bacterial growth temperature did not lead to the formation of formazan crystals. 
6.4 Discussion 
6.4.1 General observations in this protocol 
The MIC and minimum bactericidal concentration (MBC) values reported for 
polypeptides against the different bacterial species were almost always the same 
(table 3.5), and the use of either value for a given polypeptide antibiotic can be 
considered almost always interchangeable in this report. The data presented in 
figures 6.1 and 6.2 suggest that the capacity of the bacterial population to 
reduce MTT salt to formazan crystals increases proportionately to cell density, as 
a linear correlation existed between the quantities of formazan produced and cell 
populations within the range of 0.1 to 1.0 unit at OD600. Therefore, the MTT 
metabolic assay was justifiably used to assess the inhibitory effect of polymyxins 
on the reduction capacity of S. aureus species, Ps. aeruginosa and E. coli in 
relation to untreated cell samples. The untreated cell suspensions and negative 
controls devoid of either MTT reagent or bacterial inoculum consistently formed 
the highest and lowest amounts of formazan crystals respectively within the 80 
minutes time-course.   
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Formazan production rate will drop if the assay is continued infinitely after 80 
minutes due to enzyme saturation and exhaustion of available units of 
dehydrogenases. Absorbance readings for formazan production were monitored 
at 550 nm because formazan crystal-bacterial complex dissolved in DMSO gives 
broad peak between 510 and 570 nm, with a single absorption maximal at 550 
nm (Wang et al. 2010b).  
6.4.2 Effect of colistin and polymyxin B upon bacterial reducing enzymes 
activity 
Cationic antimicrobial peptides interact with the polyanionic outer surfaces 
created by the presence of cell-wall associated teichoic and lipoteichoic acids in 
Gram-positive as well as the lipopolysaccharide (LPS) in Gram-negative bacterial 
species (Hale and Hancock 2007). For the latter class of organisms, the initial 
electrostatic attraction between these agents and the cell surface is followed by a 
self-promoted translocation (Hancock 1997a, Hancock 1997b). This may explain 
why colistin and polymyxin B have greater antibacterial potency against most 
Gram-negative than Gram-positive organisms. These antibiotics appear to 
display a relatively higher affinity for lipopolysaccharide than for teichoic and 
lipoteichoic acids (Hancock 1997b). Their affinity for the LPS is so strong that 
these agents competitively displace native Mg2+ and Ca2+ ions, causing a local 
destabilisation that facilitates trans membrane bilayer uptake of more peptides, 
as well as allied molecules (Hale and Hancock 2007). But in addition to the 
absence of this outer bilayer in Gram-positive cells, the presence of a thicker 
peptidoglycan layer may also be limiting the antibacterial action of these 
polypeptides (Zhang, Rozek and Hancock 2001a, Hancock and Rozek 2002a, 
Vaara et al. 2008), considering that this latter structure functions as a form of 
exoskeleton and scaffolding that further strengthens this latter class of 
organisms (Lorian  2005). 
Since both colistin and polymyxin B demonstrated a greater inhibition to the 
metabolic activity of reducing enzymes in Gram-positive S. aureus than those of 
Gram-negative Ps. aeruginosa and E. coli in the data recorded from the MTT-
reduction assays, these results seem to suggest that the two latter bacterial 
species can transition between aerobic and anaerobic respiration, unlike the 
former, thereby enhancing their capacity to better evade this mechanism of 
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action. For whilst polymyxin B concentrations up to 0.625 µg/ml (20 x MIC) only 
showed a partial blockade to the metabolic activity of E. coli (figures 6.3 and 
6.4), strengths of this antibiotic equivalent to the 256 µg/ml (MIC), 1.024 mg/ml 
(4 x MIC) and 2.56 mg/ml (10 x MIC) were seen to display about 75, 100 and 
100 % cessation respectively to the biological MTT-reduction capacity of S. 
aureus in figure 6.5. Since enzymes are proteins that are universal irrespective 
of the bacterial species, the heavy amounts of this antibiotic employed against 
the reducing enzymes of S. aureus reported in the latter data have undoubtedly 
contributed to the significant inhibitory action against these proteins activity. But 
the activity of this polypeptide reported against these same reducing enzymes 
actions for Ps. aeruginosa, another Gram-negative organism was also partial 
(supporting this species’ capacity for respiratory transitioning), despite the use of 
lesser amounts in comparison to that applied against S. aureus. Concentrations 
equivalent to 1 µg/ml (MIC), 4 µg/ml (4 x MIC) and 20 µg/ml (20 x MIC) applied 
against this organism were seen to exhibit only partial inhibitions to the activity 
of NADH and succinate dehydrogenase (figure 6.6). A speculation is that larger 
quantities of this antibiotic, as those applied against S. aureus, may have yielded 
more impairment (perhaps a complete blockage), given that the actions of this 
compound against the reducing enzymes were concentration-dependent, as 
indicated by the curves in figure 6.6. But such an assay would mean the use of 
concentrations that were grossly disproportionate from the MIC value of 
polymyxin B against Ps. aeruginosa. As a follow on, the action of colistin against 
the metabolic activity of these bacterial species above may be considered 
comparable to that of polymyxin B. The degree of inhibitory actions of equivalent 
multiples of MIC of this latter antibiotic against the activity of bacterial reducing 
enzymes were also seen to be greater in S. aureus than in both Ps. aeruginosa 
and E. coli, which may be explained by the fact that the latter two bacterial 
species can undergo respiratory flexibility (Richardson  2000) by transitioning 
from aerobic to anaerobic respiration (Hassett et al. 2002), thereby minimising 
the potential damage upon the cells metabolic capacity by colistin. A number of 
electron acceptors are utilised, including oxygen, nitrate, nitrite, nitric oxide and 
fumarate (Hassett et al. 2010).The production of succinate dehydrogenase in E. 
coli exposed to noxious agent and undergoing dual-phase fermentation, has been 
shown to be dependent upon the time of transitioning from aerobic to anaerobic 
respiration (Vemuri, Eiteman and Altman 2002).  
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Concentrations of polymyxin B equivalent to 0.125 µg/ml (4 x MIC) were seen to 
display a partial blockage of the enzyme-reduction capability of E. coli (figure 
6.3). A concentration equivalent to 0.625 µg/ml (20 x MIC) polymyxin B also 
only demonstrated ~ 25 % impairment to the biological reduction capacity of this 
organism (figure 6.4). Whereas, this antibiotic also demonstrated about 50 % 
loss to the reduction activity of metabolising enzymes in Ps. aeruginosa at 
strengths equivalent to 20 µg/ml (20 x MIC) and much less at concentrations 
equivalent to 4 µg/ml (4 x MIC) and 1 µg/ml (MIC). Considering that both 
compounds are selectively and rapidly bactericidal against Gram-negative 
bacterial pathogens in kinetic-colony counting assays (Tam et al. 2005, Li et al. 
2005b), the data presented in figure 6.3, 6.6, 6.7 and 6.9 wherein both 
compounds were only partially effective at high concentrations in blocking 
biological reducing enzymes in these organisms suggest E. coli and Ps. 
aeruginosa may be evading metabolic impairment by undergoing a rapid 
transition from aerobic to anaerobic respiration (Poole and Cook 2000). The 
cellular physiologies as well as metabolic pathways for both routes of bacterial 
respiration are vast and diverse (Sawers 1999). With the aerobic growth phase, 
E. coli produces CO2 as the main extracellular by-product whilst a mixed acid 
fermentation is undertaken with anaerobic growth leading to the accumulation of 
formate, lactate, acetate, ethanol as well as relatively small quantities of 
succinate (Vemuri, Eiteman and Altman 2002). Succinate dehydrogenase enzyme 
contributes to the biological reduction of MTT salt to formazan crystals (Berridge, 
Herst and Tan 2005a). And under this circumstance above, certain genetic 
manipulations can increase succinate yield (Vemuri, Eiteman and Altman 2002). 
Such genetic engineering manoeuvres include the deletions of ldhA (that encodes 
fermentative lactate dehydrogenase) (Bunch et al. 1997, Jiang, Nikolova and 
Clark 2001), as well as pyruvate formate lyase (PfL) (Wendisch, Bott and 
Eikmanns 2006, Leibig et al. 2011); over expression of ppC encoding 
phosphoenolpyruvate (PEP) carboxylase (Millard et al. 1996) as well as the genes 
that code for malic enzyme and pyruvate carboxylase (pyC) (Gokarn, Eiteman 
and Altman 2000).  
Since the anaerobic process for Ps. aeruginosa involves the utilisation of 
alternative electron acceptors such as either NO3ˉ, or NO2ˉ (Hassett et al. 2002). 
This organism can replicate under both (aerobic and anaerobic) conditions but 
robust growth is undertaken via the latter phase respiration through the use of 
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either of these inorganic terminal electron acceptors above or a very slow growth 
through substrate level phosphorylation with arginine (Hassett et al. 2002). The 
NO3ˉ is then reduced either to ammonia and subsequently used as a nitrogen 
source or to nitrogen gas for respiration (Pinzon-Gamez 2009). 
Antimicrobial cationic peptides can display a rapid bactericidal activity against 
susceptible pathogens with greater than 99.999 % reduction to the population of 
the challenged bacterial inoculum within 5 to 120 minutes at concentrations 
equivalent to 4 x MIC (Tam et al. 2005, Hermsen, Sullivan and Rotschafer 2003), 
suggesting the mechanisms of such peptides include inhibition of metabolic 
enzymes as well as impairment of energization  activities (Hancock and Rozek 
2002b). This is in addition to their verified capacity to competitively interact with 
and rapidly disrupt bacterial lipopolysaccharide bilayer (Jenssen, Hamill and 
Hancock 2006a), which by itself can lead to a substantial loss in metabolism 
considering that the bilayer accommodates some enzymes such as cytochrome 
P450 reductase (Wadsater et al. 2012). Such membrane anchored-enzymes can 
catalyse electron transfers from NADPH to cytochrome P450, which is an essential 
enzyme for substrate metabolism (Malonek et al. 2004).  
The data presented from this study showed that concentrations equivalent to 
MIC, 4 x MIC as well as 10 X MIC, colistin and polymyxin B demonstrated a rapid 
onset of suppression of reduction enzyme activity in Gram-positive S. aureus, 
against which both compounds are adjudged to be clinically ineffective (Res  
2003) and are not drugs of choices for infections diseases mediated by such 
pathogens either as primary or opportunistic pathogens (Li et al. 2006). Although 
both polypeptides caused a cessation to the activity of the bacterial reducing 
enzymes in S. aureus species, this action did not translate to a bactericidal effect 
under buffer conditions in vitro (chapter 5), giving an insight to why these 
compounds are not effective clinically against S. aureus species, bearing in mind 
the capacity of this organism to transit from aerobic to anaerobic respiration, 
under biological stress conditions (Martin et al. 1999), producing smaller 
quantities of succinate (Vemuri, Eiteman and Altman 2002). This is an indication 
that the rapid inhibition of NADH and succinate dehydrogenases during bacterial 
aerobic respiration, may not always translate to a rapid loss of cell viability. 
Time-course viability data presented in figures 5.1 and 5.2 show that 256 and 
128 µg/ml polymyxin B, being MICs of this antibiotic against MSSA and MRSA in 
table 3.5, were only bacteriostatic against these organisms, with an approximate 
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1 log cfu/ml reduction to the starting inoculum populations within 24 hours. But 
both concentrations showed a 75 % (figure 6.5) and 60 % (figure 6.11) 
inhibition to the metabolic enzyme activities in S. aureus, within 80 minutes. It is 
therefore possible that the impairment imposed upon the activities of these 
reducing enzymes did not translate to cell death because of the capacity of S. 
aureus to transition between aerobic and anaerobic respiration (Martin et al. 
1999, Malonek et al. 2004).This may suggest that although both antibiotics were 
able to block aerobic respiration, these S. aureus species probably switched over 
to anaerobic respiration which generates lower levels of glucose utilisation 
(Kohler et al. 2003), expressing a decline in the capacity of these organisms to 
form formazan from MTT salt. As such, despite the demonstrated capacity to 
inhibit bacterial reduction activity, polymyxin B is not bactericidal against S. 
aureus species even over an extended period of 24 hours as shown in the time-
course viability data presented in the previous chapter. But in addition, the 
inoculum population of 0.3 units at OD500 (equivalent to ~1 x 108 cfu/ml) used 
for the assays may be considered as a large bio-load, bearing in mind that the 
bactericidal efficacy of polymyxin B is significantly diminished in the presence of 
a high inoculum density (Tam et al. 2005). 
Although the time-course viability data presented for polymyxin B against MSSA, 
MRSA and QRSA in figures 5.1, 5.2 and 5.4 show that strengths of this antibiotic 
equivalent to MIC were at best only bacteriostatic within 24 hours, these 
concentrations were seen to have demonstrated a rapid and profound inhibition 
of formazan production through blockade of the activity of bacterial reduction 
enzyme. The explanation previously suggested that a lack of correlation between 
kinetic viability data and inhibition of MTT-reduction capacity existed is also 
applicable for Ps. aeruginosa. Data published for the time course-viability assay 
of polymyxin B against Ps. aeruginosa show that there was a rapid bactericidal 
action against antibiotic sensitive strains within 2 hours at polymyxin B 
concentrations of 4, 8 as well 16 µg/ml, given a starting inoculum population of 
105 to 107 cfu/ml with an MIC in the range of 0.5 to 1 µg/ml (Tam et al. 2005). 
Findings from the MTT reduction assay presented in this section show that 
concentrations of 1 µg/ml (MIC), 4 µg/ml (4 x MIC) and 20 µg/ml (20 x MIC) 
demonstrated an incomplete inhibition of biological reduction of MTT salt in a 
sensitive strain of Ps. aeruginosa. This observation may suggest that Gram-
negative bacterial species are killed solely by this mechanism. The involvement 
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of this pathway in the killing effect of polymyxins against these bacterial species 
may only have been partial. The involvement of outer membrane disruption as 
the primary mechanism of action of the polymyxins in Gram-negative bacterial 
species has been extensively discussed (Hancock 1997a, Zhang, Rozek and 
Hancock 2001b, Hancock and Rozek 2002a, Hancock and Chapple 1999, Zhang 
et al. 2000,  Jenssen, Hamill and Hancock 2006b). The fact that the impairment 
of bacterial reduction activity remained incomplete even at 20 µg/ml (20 x MIC) 
seems to fortify the speculation for the occurrence of transitioning between 
aerobic and anaerobic respiration (with the use of either NO3ˉ or NO2ˉ in Ps. 
aeruginosa (Hassett et al. 2002), as well as the partial engagement of non-
competitive enzyme impairment in the aerobic pathway). The published data 
(Tam et al. 2005), also show that with the use of broth, the challenged Ps. 
aeruginosa populations began to display extensive re-growth after 4 hours. In 
fact, even the populations challenged with higher strengths of polymyxin B that 
had their densities reduced below detectable levels also demonstrated re-growth 
(Tam et al. 2005). Bearing this in mind whilst viewing data presented in figures 
6.6, 6.3, 6.4, 6.9 and 6.7 (in this order) suggest Gram-negative Ps. aeruginosa 
and E. coli are not  killed primarily through inhibition of their metabolic enzyme 
activity by either polymyxin B or colistin, especially considering that the 
organisms can undergo a transition to an alternate respiratory pathway. The 
inhibition of reduction enzyme activity is therefore only partially effected upon 
the cells in the entire challenged population. A weakness in the analysis may be 
attributed to the high inoculum density employed as although this was essential 
to allow the formation of measurable quantities of formazan, it is uncertain if this 
factor may be negating the correct interpretation of the data given that the 
antibacterial activity of polymyxins are greatly influenced by cell density 
(Hancock and Rozek 2002a, Tam et al. 2005). 
The pronounced inhibition of biological MTT salt reduction to formazan crystals by 
colistin and polymyxin B in MSSA (figures 6.5, 6.8, 6.10, 6.13), MRSA (figures 
6.11, 6.14) and QRSA (figures 6.12, 6.15) suggest these organisms are probably 
able to switch into an alternative means of respiration as well as ATP generation. 
A srrAB (staphylococcal respiratory response) gene, whose homologue resDE was 
previously identified in B. subtilis, has been determined in S. aureus (Yarwood, 
McCormick and Schlievert 2001). Both genes code for the two-component 
regulatory system, ResD-ResE, implicated for the global regulation of both 
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aerobic and anaerobic respiration (Yarwood, McCormick and Schlievert 2001). 
The induction of stress signals is known to activate anaerobic respiration in S. 
aureus (Hausladen, Gow and Stamler 1998). It appears these polypeptide 
antibiotics can activate stress signals that induce transitioning into anaerobic 
respiration in the organisms examined in this assay. Although both antibiotics 
demonstrated extensive capacity to halt S. aureus conversion of MTT salt to 
formazan through inhibition of these cells conventional (aerobic) respiratory 
pathway, colistin and polymyxin B remain Gram-negative specific antibiotics 
(Falagas, Kasiakou and Saravolatz 2005, Li et al. 2006), and unable to kill Gram-
positive S. aureus probably because of the absence of the occurrence outer 
membrane disruption, which is these compounds primary mechanism of action 
(Vaara  2010). 
This rapid onset of action for the pronounced inhibition of the biological reduction 
process is neither correlated nor reflected in a time-course viability assay for S. 
aureus species. The bacteriostatic effect reported for polymyxin B against some 
species of S. aureus in chapter 5 is unaccountable for by the pronounced 
inhibition of biological reducing enzymes in this species as these organisms are 
able to take advantage of alternative routes of respiration (Richardson, Libby and 
Fang 2008), that by-passes formation of NADH, a biological reducing enzyme. 
This metabolic adaptation involves the production of either stress-induced (Seidl 
et al. 2006) or nitric oxide radical (produced by activated phagocytes) inducible 
L-lactate dehydrogenase, known to have aided S. aureus to become resistant to 
innate antimicrobial defence peptides such as defensins and cathalicidins LL-37 
(Richardson, Libby and Fang 2008, Kraus and Peschel 2008). L-Lactate 
dehydrogenase is thought to catalyse the conversion of pyruvate to lactate when 
S. aureus is grown and stressed/challenged in the presence of rapidly 
catabolizable carbon source (glycerol in this instance), under anaerobic 
respiration (Seidl et al. 2006). If the impairment of the activities of the reducing 
enzymes (NADH and succinate dehydrogenase) by the applied polymyxins made 
S. aureus to transit into anaerobic respiration, the stress induced by the 
presence of these agents probably led to an induced formation of L-lactate 
dehydrogenase, an alternate enzyme. This will translate to an unhindered supply 
of ATP and possibly repair mechanisms that lead to bacterial survival as well as 
insusceptibility to these antibiotics.  The effect of colistin and polymyxin B on 
stress proteins in the challenged bacterial species may be worth examining in 
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subsequent studies. Colonies of Gram-positive bacterial species can also exist as 
biofilms in vivo, precluding access of oxygen to cells within the biofilm, which can 
then switch to alternative mechanisms of sugar metabolism and respiration, 
thereby evading the lethal effects of cationic antimicrobial peptides, as well as 
acting as inoculi for cell propagation (Flemming and Wingender 2010, Burmølle 
et al. 2010). All these factors seem to provide possible explanations for the 
clinical inefficacy of polymyxins against S. aureus species. Considering that 
Gram-positive cells are bereft of an outer membrane bilayer (Lorian 2005), which 
is the primary target of these polypeptides (Falagas, Kasiakou and Saravolatz 
2005), these organisms are advantageously physiological positioned to evade the 
killing effects of these agents. In fact, the inability of polymyxins to induce a 
bactericidal effect upon S. aureus species in colony counting assays at 
concentrations many-fold higher than the MICs (chapter 5) further exposes the 
ineffectiveness of this polypeptide antibiotic against Gram-positive bacterial 
species.  
On the other hand, polypeptides that are bactericidal against Gram-positive 
bacterial species (such as indolicidin (Friedrich et al. 2000)) do so by interacting 
with the phospholipids, teichoic and lipotechoic acids (Scott, Gold and Hancock 
1999, Brogden  2005), by depolarisation of the cytoplasmic membrane (Hancock  
1997b) and by either the induction of some degree of disturbances or formation 
of channels across the bilayer (Brogden  2005) (as indeed is applicable in Gram-
negative species, upon translocation across the outer membrane (Jenssen, 
Hamill and Hancock 2006a)). There seems to be an association between the 
substantial blockade of the reducing enzymes (NADH and succinate 
dehydrogenases) activity by polymyxins with their infringement upon the 
integrity of cytoplasmic membrane, as it has been speculated that pore 
formation across the bilayer alone is insufficient to account for the bactericidal 
action of antimicrobial peptides against Gram-positive bacterial species, but 
necessary for these agents to access other intracellular targets (Friedrich et al. 
2000, Brogden  2005). Although the permeabilization as well as disruption of the 
cytoplasmic membrane permits the self-translocation of these peptides, there is 
another speculation that this action simultaneously leads to an impairment of 
localised enzyme activities and cell de-energization (Zhang, Rozek and Hancock 
2001a). In addition to both latter speculations, is the effect of membrane 
depolarisation which all collectively culminates into a lethal event (Brogden 
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2005). Therefore, the capacity of polymyxins to induce membrane depolarisation 
as well as disruption in S. aureus species should be evaluated in subsequent 
sections of the this study in order to enable a more robust and accurate 
interpretation of the data gleaned from this chapter. The results obtained from 
the MTT-reduction assay for the effect of colistin and polymyxin B upon the 
metabolic reducing enzymes of S. aureus species cannot be comprehensively 
interpreted in isolation as an association is thought to exist between cell 
membrane depolarisation, channelization, essential enzymes activities inhibition 
and cell de-energization (Zhanel et al. 2010, Zhang, Rozek and Hancock 2001a).   
6.4.3 Partial inhibition of biological reducing enzymes activity in E. coli 
and Ps. aeruginosa 
The inhibitory action of polymyxin B and colistin upon E. coli and Ps. aeruginosa 
reducing enzymes activity were therefore concentration-dependent, as reflected 
in the data presented in figures 6.3 to 6.9. These observations conform to 
published reports that demonstrate both antibiotics display concentration-
dependent action against Ps. aeruginosa in time-course colony counting assays 
(Gunderson et al. 2003, Tam et al. 2005, Li et al. 2001a), suggesting that outer 
membrane disruption (Falagas, Kasiakou and Saravolatz 2005), as well as 
cessation of respiration-associated reducing enzymes can probably collectively 
account for the bactericidal action of polymyxins against E. coli and Ps. 
aeruginosa. 
6.4.3.1 Effective drug combinations that impede bacterial enzyme 
activities 
With the assessment of the effect of polymyxin B applied in combination with 
either of the chalcone-derivative upon bacterial metabolism, the semi-synthetic 
compounds were on their own devoid of inhibitory action against the activity of 
the cells reducing enzymes (except about 12.5 % impairment against the 
reducing enzymes activity in QRSA, at 16 µg/ml in figure 6.15). Yet either these 
compounds displayed substantial augmentation to the inhibitory action of 
polymyxin B (or vice versa) against the reducing enzymes activities in species of 
S. aureus. Figures 6.10 to 6.12 show that F1 applied in combination with 
polymyxin B at sub-inhibitory concentrations demonstrated an enhanced 
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impairment to the biological reducing enzymes action in MSSA, MRSA and QRSA. 
The combined application of 32 µg/ml (1/2 MIC) F1 with 64 µg/ml (1/4 MIC) 
polymyxin B showed a greater inhibitory action against the biological reduction 
potency of MSSA (figure 6.10) suggesting that the combination causes an 
enhanced impairment to the activity of NADH and succinate dehydrogenases that 
results in an increase in the rate as well as extent of the inhibition. Given that 
data presented in figure 5.1 showed that 64 µg/ml F1 applied in combination 
with 256 µg/ml polymyxin B also demonstrated a rapid bactericidal activity 
(unlike polymyxin B applied alone) with greater than 4 log cfu/ml reduction to 
inoculum population relative to the solvent treated sample within 8 hours, such a 
rapid activity had been speculated to very likely involve the inhibition of an 
essential metabolic pathway (Hancock and Rozek 2002b) as is now being shown 
in figure 6.10. The observation above may also provide an explanation for the 
rapid synergistic activity of F1 applied in combination with polymyxin B against 
MRSA (figure 5.2) and QRSA (figure 5.4). In fact, time course viability data in 
figure 5.2 showed a greater than 3 log cfu/ml reduction in MRSA suspension 
treated with 128 µg/ml of both F1 and polymyxin B after 2 hours; whilst the 
same concentrations of both compounds applied separately were clearly 
ineffective after 24 hours. These observations strongly suggest the application of 
the chalcone-derivatives with polymyxin B leads to an inhibition of biological 
MTT-reduction process as well as a killing-effect (unlike the single application of 
polymyxin B) because the combination seems to possess the capacity to block 
both aerobic and anaerobic bacterial respiration in these species culminating into 
a complete cessation of all possible pathways for ATP production as well as 
speculatively, the blockage of the biosynthesis of essential proteins, such as 
NADH and succinate dehydrogenases. In such circumstances, it has been 
demonstrated that in a bid for the cells to generate more NADH by any other 
pathway, albeit unsuccessfully, the organisms eventually rapidly expend their 
stock of ATP reserve resulting to a rapid loss of viability (Baker et al. 2004, 
Seidler  2013). Data presented in figure 6.11 showed that although 128 µg/ml 
polymyxin B applied alone demonstrated about 60 % inhibition to the activity of 
the reducing enzyme, 128 µg/ml F1 applied in combination with this same 
concentration of polymyxin B demonstrated 90 % blockade to the activity of the 
enzyme, with a faster onset/rate, suggesting an inhibition of both the 
conventional and alternative metabolic pathways, such as both aerobic and 
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anaerobic respiration mechanisms. It is possible that the activity of enzymes 
such as NADH, succinate as well as L-lactate dehydrogenases that are regulated 
by different pathways have all been impaired. An application of half the 
aforementioned concentrations for both compounds also demonstrated 85 % 
impairment to the activity of reducing enzymes at a fast rate, an indication that 
at lower concentrations, both compounds still enhance each other’s activity when 
applied together. 
Other instances exist wherein the inhibition of vital metabolic process leads to 
and correlates with cell death, sometimes accompanied with rapid onset 
(Hancock and Rozek 2002a), using combinational drug therapy. The anti-
metabolic and synergistic action of trimethoprim applied in combination with 
sulfamethoxazole is established through their direct blockade of the folic acid 
synthetic pathway in two independent positions, leading to bactericidal activity in 
susceptible pathogens (Grim et al. 2005). The development of this effective 
combination has resulted in the successful treatment of acute urinary tract 
infections such as cystitis (Kavatha et al. 2003), even with the application of 
lower synergistic concentrations of both compounds, resulting into a reduced 
potential for adverse events (Knaapen and Barrera 2007). Folic acid is 
structurally composed of para-aminobenzoic acid (PABA), pteridine and 
glutamate (Bermingham and Derrick 2002, Brain et al. 2008). 
Sulphamethoxazole, like other sulphonamides such as sulfisoxazole is structurally 
similar to PABA and both are competitive substrates for the biological enzyme 
dihydropteroate synthetase which is responsible for the addition of PABA to 
pteridine (Grim et al. 2005, Lumb et al. 2009). On the other hand, trimethoprim 
like pyrimethamine, is a structural analogue of pteridine and both are 
competitive substrates for dihydrofolate reductase (Lumb et al. 2009, Basco et 
al. 2000). Co-trimoxazole combinational antibiotic demonstrates selectivity 
(preferential interaction) for bacterial dihydropteroate synthetase with a greater 
than a 1000-fold sensitivity, because unlike mammalian cells, prokaryotic 
organisms synthesize their folic acid requirements and possess genes encoding 
for the latter enzyme (Knaapen and Barrera 2007). 
The improved activity of F1 in combination with polymyxin B against species of 
S. aureus, even at reduced concentrations, is probably due to the blockage of 
these organisms’ respiratory pathways/enzymes. The antibiotic combination, co-
trimoxazole is bactericidal through a mechanism that involves the inhibition of 
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folic acid synthetic pathway at two separate points (Knaapen and Barrera 2007). 
Data presented in this section for the chalcone-derivatives alone correlates with 
those recorded from the time-course viability assays. The chalcone-derivatives 
were almost always inactive against species of S. aureus during individual 
applications, and these agents were also devoid of inhibitory action against the 
activity of NADH and succinate dehydrogenases in the MTT reduction analysis. 
But 16 µg/ml F23 that was bacteriostatic against QRSA with a 2 log cfu/ml loss in 
viability of the exposed population displayed a 12.5 % inhibition to the activity of 
this species reducing enzymes within 80 minutes. This observation suggested the 
antibacterial action of the chalcone-derivatives could be strain related in S. 
aureus as well as the partial inhibition of aerobic and anaerobic respiratory 
metabolic enzymes.  
Another obvious limitation of this study is the inability to make an inference from 
the data provided so far as to whether or not the inhibition of NADH and 
succinate dehydrogenases by the combination of F1 with polymyxin is reversible 
given that the time-course assays were conducted in buffer media and the 
formation of complexes between bacterial cells and formazan crystals in the 
biological MTT reduction analysis prohibits the culturing of the organisms for 
assessment of potential re-growth. Assuming the time-course viability analysis 
were conducted in broth and if cell samples used for the MTT-reduction test were 
cultivable (viable), then the occurrence of bacterial re-growth would have 
verified that the activity of both compounds against these dehydrogenases were 
either partial or reversible. The activity of polymyxin B applied alone against Ps. 
aeruginosa recorded an eminent bacterial re-growth in all the challenged strains 
(Tam et al. 2005), supporting this speculation of the occurrence of either a 
partial or reversible enzyme inhibition. In the presence of polymyxin B 
concentrations equivalent to MIC, 4 x MIC and 10 or 20 x MIC, Ps. aeruginosa 
and S. aureus species probably transited between aerobic and anaerobic 
respiration thereby enabling an incomplete impairment of these organisms 
respiration as well as other essential metabolic mechanisms which facilitates cell 
re-growth in broth.  
The viability and virulence of these organisms are determined by cell 
wall/membrane-associated proteins that are inducible by adverse growth 
conditions and stress (Seidl et al. 2006). The expression of genes responsible for 
resistance to specific antibiotic action is driven by specific and sensitive 
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mechanisms that are often undertaken at the transcriptional level (Bronner, 
Monteil and Prévost 2006). The regulatory factors are influenced by the two 
component regulatory genes such as saeRS and srrAB, that are sensitive to 
environmental signals. For instance, srrAB (srhSR) is known to code for certain 
proteins, including those responsible for energy metabolism and is required for 
fermentative growth of S. aureus wherein the up-regulation of enzymes such as 
alcohol and L-lactate dehydrogenases that are involved in fermentation are 
enabled in anaerobic and stressful conditions (Throup et al. 2001). Therefore, a 
blockage of the activities of NADH and succinate dehydrogenases manifested by 
an inhibition of MTT-reduction to formazan crystals may be insufficient to always 
culminate into a bactericidal action in species of S. aureus and other bacterial 
species. For instance, although gentamicin is bactericidal against E. coli species, 
this agent is known to display weak activity against this organism when 
undergoing anaerobic respiration, especially at reduced pH (Bringer et al. 2007). 
It may therefore be worthwhile to conduct future time-course viability assays for 
the chalcone-derivatives applied in combination with polymyxin B against strains 
of S. aureus (and Ps. aeruginosa) in growth media in order to facilitate a more 
elaborate interpretation of the pool of data. 
The speculation above is also applicable for the data presented in figures 6.14 
and 6.15. Sub-inhibitory concentrations of F23 applied in combination with 
polymyxin caused a greater impediment to formazan production from MTT salt 
suggesting the occurrence of a blockade (of both aerobic as well as anaerobic 
respiratory pathways) to the reducing activity of NADH, succinate, alcohol and L-
lactate dehydrogenases, in MRSA and QRSA. This may have contributed 
substantially to the synergistic activity of both compounds against these bacterial 
species reported in figures 5.9 and 5.10 respectively. 
The concentrations of both compounds applied to challenge the bacterial 
population were selected based on guidance from data previously obtained from 
the chequerboard and time-course-viability studies. The combination of 1/32 MIC 
(32 µg/ml) of F23 with 1/2 MIC (64 µg/ml) polymyxin B demonstrated a 
remarkable inhibition to the reducing enzymes activity of MRSA (figure 6.12), 
similar to 64 µg/ml (1/2 MIC) F1 with 64 µg/ml (1/2 MIC) polymyxin B (figure 
6.9) and in agreement with the synergistic effects reported for the former 
concentrations against the growth of this resistant strain of S. aureus in both a 
chequerboard (table 4.2) and time-course viability assays (figure 5.9) 
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respectively. Considering that these same concentrations of F23 and polymyxin B 
when applied in combination demonstrated a greater than 4 log cfu/ml reduction 
to the MRSA inoculum within 24 hours, the data presented in figure 6.2 may be 
suggesting the mechanisms of action of the combination is not unconnected with 
the inhibition of the bacterial reducing enzymes activity. At a concentration of 64 
µg/ml (1/2 MIC), the polypeptide and Gram-negative specific antibiotic 
polymyxin B was bacteriostatic against MRSA with a 1 log cfu/ml reduction to the 
cell population within 24 hours (figure 5.9), and also demonstrated a remarkable 
cessation of the activity of NADH and succinate dehydrogenase (figure 6.14). The 
onset of action of between 20 and 80 minutes recorded for the impairment of 
enzyme activity is not reflected in the previously reported time-course viability 
bacteriostatic loss in cell count, as no remarkable reduction in colony count is 
noted until after 8 hours. This may suggest that the impairment of 
dehydrogenase activity in isolation is inadequate to induce loss of cell viability, in 
line with a speculation that not all inhibition of biological metabolic processes 
may lead to cell death in bacterial species (Cushnie et al. 2007). It is therefore 
possible that other mechanisms still underlie the activity of the chalcone-
derivatives applied in combination with polymyxin B against various species of S. 
aureus.  For instance, it is thought that an association exists between membrane 
depolarisation, disruption, cell de-energization and antibiotic bactericidal action 
(Zhang, Rozek and Hancock 2001a, Hale and Hancock 2007, Baltz 2009). The 
existence of such a relationship for the activity of the synergistic action of 
polymyxin B with the chalcone-derivatives is worth examining in subsequent 
studies. 
The data presented in figures 6.13 and 5.8 show that 16 µg/ml F23 applied alone 
was ineffective at inhibiting the activity of NADH and succinate dehydrogenase in 
MSSA. This same concentration of F23 applied in combination with 256 µg/ml 
polymyxin B had demonstrated synergistic activity against viable populations of 
MSSA with a greater than 4 log cfu/ml reduction to the challenged inoculum 
population and also demonstrated an approximately 60 % blockade to the 
activity reducing enzymes in this bacterial species. In addition, 256 µg/ml 
polymyxin B applied alone that was previously shown to be bacteriostatic in 
action also showed a 60 % impairment to the activity of the biological reducing 
enzymes suggesting that the action of polymyxin B may have solely prompted 
the obstruction to the activity of NADH and succinate dehydrogenases in MSSA 
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by the combined agents. But considering that polymyxin B single application was 
not bactericidal against S. aureus (MSSA), but that a combined action with F23 
was synergistic against this species (as shown in figure 5.8), it is probable that 
the combination of both agents blocked all alternative respiratory as well as 
metabolic channels in this organism, unlike the single application of the 
polypeptide antibiotic. 
 Data presented in figure 5.10 showed that 64 µg/ml polymyxin B was 
bacteriostatic against QRSA with about 2 log cfu/ml reduction to the inoculum 
population in comparison to the solvent-treated sample. This same polypeptide 
strength showed a 20 % inhibition to the activity of NADH and succinate 
dehydrogenases after 80 minutes (figure 6.15) in the MTT reduction analysis 
suggesting the existence of a correlation and a contributory action to the overall 
mechanism of action for the polypeptide synergism with the chalcone-derivatives 
against QRSA (figure 5.10). This observation also suggests the synergistic action 
of both compounds is related to the enhanced blockage of biological reducing 
enzymes activities of the examined species in the MTT-reduction analysis. 
Similarly in this same figure, 16 µg/ml F23 that displayed about 0.5 log cfu/ml 
loss in viability was later seen to induce about 12.5 % inhibition to the activity of 
biological reducing enzymes. 
6.5 Conclusion 
Colistin and polymyxin B have demonstrated capacity to obstruct the activity of 
the essential metabolic pathways required for bacterial respiration and viability. 
The impairment caused by these agents to the activity of these biological 
reducing enzymes is evidenced by a reduction in the capacity of these cells to 
convert MTT-salt into formazan crystals. The previously tested combined 
synergistic concentrations of chalcone-derivatives and polymyxin B also 
demonstrated potentiated blockage of bacterial respiratory pathway and 
metabolic enzyme reduction capacity. The inhibition of bacterial metabolic 
pathway by polymyxins alone and in combination with chalcone-derivatives 
possibly occurs simultaneously with membrane potential dissipation and integrity 
disruption in susceptible Gram-positive as well as Gram-negative species 
(Falagas, Kasiakou and Saravolatz 2005, Hancock and Chapple 1999, Hancock 
and Lehrer 1998a). Given the need for target specificity in antibacterial action, 
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the fact that these metabolic enzymes are also present in eukaryotic cells and 
that concerns of neuro as well as nephro toxicities in the host were previously 
raised for polymyxin B when applied clinically, there is a great need for toxicity 
analysis to be conducted for the synergistic action of both compounds against 
the selected bacterial species. DMSO-polymyxin B control should be included in 
future studies on the action of polymyxin B either alone or in combination with 
the chalcone-derivatives. The capacity of the combination to induce membrane 
depolarisation and disruption is also to be examined in subsequent sections. 
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Chapter 7 
Examining bacterial membrane potential dissipation and integrity 
disruption by polymyxin B combined with the chalcone-derivatives  
7.1 Introduction 
The cytoplasmic membrane depolarisation capacity of polymyxin B in 
combination with the chalcone-derivatives was examined using fluorimetry as 
well as fluorescent microscopy in the presence of DiOC3(5), a membrane 
potential-sensitive stain, using protocols similar to those employed for the 
investigation of the demonstration of similar actions by β-lactams  (Penyige et al. 
2002) and diverse cationic peptides (Friedrich et al. 2000). Under normal 
polarised conditions, the dye distributes between the cells and medium initially 
then gains intracellular entrance by permeating the bacterial membrane 
according to the electrical potential gradient, aggregating within the cytoplasm 
(Ruissen et al. 2001). Once within the cytoplasm, the stain becomes 
concentrated and self-quenches its fluorescence due to dye aggregation (Farha 
and Brown 2010). Depolarisation of the membrane potential by an external 
agent can cause the disintegration and release of the aggregated dye molecules 
which is accompanied by measurable fluorescence (Silverman, Perlmutter and 
Shapiro 2003). The fluorescence intensity can be assessed with a fluorimeter as 
well as being observed with a suitable fluorescence microscope. The fluorescence 
of this dye is usually neither a reflection of the degree of membrane perturbation 
nor destruction (Poole and Cook 2000) but rather gives the extent of 
depolarisation.  Compounds that have capacity to induce bacterial membrane 
depolarisation include nisin, lantibiotics, daptomycin, oritavancin and some 
peptide antibiotics (Domenech et al. 2009, Hancock and Rozek 2002a, 
Silverman, Perlmutter and Shapiro 2003). 
The membrane bilayer in S. aureus acts as an effective semi-permeable barrier 
that is porous to water (via osmosis) and uncharged organic molecules up to the 
size limit of glycerol, with molecular weight of 92 Daltons (Lorian 2005). The 
mechanisms of substrate uptake through the phospholipid bilayer include either 
simple diffusion, facilitated diffusion (fluoroquinolones like ciprofloxacin) or active 
transport (both primary and secondary systems) (Sengupta and Mukherji 2006). 
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When the integrity of the cell membrane is slightly compromised, small 
substrates like potassium ions with a molecular weight of 32 g/mol, are readily 
extruded either through any fractures or by diffusion and the degree of leakage 
can be quantified with a flame emission spectrophotometer (O'Driscoll  2011, 
Burt  2004, Cushnie and Lamb 2005b). The flame emission spectrophotometer is 
a very sensitive device that can identify a metallic substance in the excited state 
by their atomic weight and the molecules can be quantified with reference to a 
pre-calibrated curve. The difference in the quantity of potassium ion within the 
reaction meliu before and after the cell population was challenged over a defined 
time period can be used to extrapolate the impact of the activity of the 
compound upon bacterial membrane integrity (and viability) (Cushnie and Lamb 
2005b). 
Antibacterial peptides are selectively effective against Gram-negative bacterial 
species due to the presence of an outer membrane bilayer; upon which these 
peptides’ action can cause the formation of protrusions (blebs) following the 
competitive displacement of Ca2+ and Mg2+ cations (Zhang, Rozek and Hancock 
2001a, Hancock and Sahl 2006, Jenssen, Hamill and Hancock 2006a, Hancock 
and Rozek 2002b). This outer membrane disruption capacity has provided an 
explanation for the selective activity of cationic antimicrobial peptides against 
Gram-negative bacterial species, since these compounds are seen to display an 
initial electrostatic interaction with the net negative charge on anionic 
phospholipids and phosphate groups on the lipopolysaccharide layer (Martti  
2010, Hancock and Chapple 1999, Hancock and Rozek 2002b). Peptide 
antibiotics can however also be bound to teichoic acids on the surface of Gram-
positive bacterial species (Scott, Yan and Hancock 1999), and may thereby 
establish a destabilization of the membrane bilayer. Some peptides have 
demonstrable capacity to bind to both Gram-positive and Gram-negative 
structures. Artificial chimeric peptides such as the cecropin/melittin hybrid 
(CEME), produced by recombinant DNA techniques (Piers and Hancock 1994, 
Subhadra  2011), are bactericidal against Ps. aeruginosa by being able to bind 
with strong affinity to lipopolysaccharide, permeabilizing this same structure and 
inhibiting the production of lipopolysaccharide-induced tumour necrosis factor 
(TNF-α) (Piers and Hancock 1994). CEME is likewise able to kill Gram-positive 
organisms by interacting with lipoteichoic acids (Scott, Gold and Hancock 1999).  
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The increasing incidence of sepsis and other infections caused by Gram-positive 
bacterial species provides a strong rationale supporting the need for the 
development of either new antibiotics or combinations of compounds with broad-
spectrum activity against both classes of Gram-positive and Gram-negative 
bacterial species. It is also pertinent for the mechanisms of action of effective 
potential agents to be established. New antimicrobial compounds with either 
novel or multiple mechanisms of action are likely to evade existing antimicrobial 
resistance strategies of bacterial pathogens and thereby provide a longer clinical 
lifespan (Yeaman and Yount 2003, Sibanda and Okoh 2010). 
When a given bacterial population is exposed to an antimicrobial agent in the 
presence of cell impermeable dye such as Sytox Green, the stain is able to 
permeate compromised membranes, interacting with nucleic acids materials to 
fluoresce (Lebaron, Catala and Parthuisot 1998).  The dye is incapable of self-
translocation across intact bacterial membrane bilayer and is therefore non-
emitting. When the cell membrane is disrupted, Sytox Green undergoes a rapid 
passage across the damaged bilayer, binding irreversibly to polyanionic nucleic 
acid materials within the cytoplasm and strongly emitting at a wavelength 
around 525 nm (Roth et al. 1997), thereby establishing the susceptibility of the 
challenged pathogen to the applied antibiotic. The change in intensity of emission 
over time can be used to extrapolate the effect of the applied agent upon 
bacterial membrane integrity.  
The antimicrobial agents applied as controls in this section included the in vitro 
S. aureus aggregator galangin (Cushnie et al. 2007), a quaternary ammonium 
compound benzalkonium chloride (Sütterlin, Alexy and Kümmerer 2008), cell 
wall synthesis inhibitor penicillin G (Rivera and Boucher 2011) and the DNA 
gyrase (as well as topoisomerase II) inhibitor ciprofloxacin (Pankey and Ashcraft 
2005). Galangin is obtainable from the crude alcoholic extracts of the aerial parts 
Helichrysum aureonitens Sch. Bip. (Asteraceae), used as a topical anti-infective 
by indigenous South Africans (Afolayan and Meyer 1997). This flavonol is purified 
and characterised from the acetone extracts of the leaves and within a range of 
100 to 200 µg/ml demonstrates bactericidal action against sensitive as well as 
multi-resistant bacterial species of S. aureus, Enterococcus sp. and Ps. 
aeruginosa (Pepeljnjak and Kosalec 2004, Cushnie and Lamb 2005c, Cushnie and 
Lamb 2006). This flavonoid compound was however previously thought to be 
bereft of activity against Gram-negative organisms, except Enterobacter cloacae 
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(Afolayan and Meyer 1997). Galangin is thought to be bactericidal against S. 
aureus by inducing leakage of intracellular potassium ions (Cushnie and Lamb 
2005c) and enforcing cell aggregation (Cushnie et al. 2007).  
The objectives in this chapter were to assess the impact of polymyxin B alone, as 
well as in combination with a chalcone-derivative upon cell membrane potential 
dissipation and disruption. 
7.2 Materials and Methods 
7.2.1 Membrane potential depolarisation and cell microscopy assays 
A 90 ml aliquot 0.3 unit OD500 S. aureus 11940 suspension in PBS solution 
containing 1 % w/v D-glucose at pH 7.2 was prepared from a 24 hours culture 
(section 2.2.3.2). A 10 ml volume of 1 M KCl was added to the suspension, 
adjusted to a final concentration of 4 µM (2.186 μg/ml) DiOC3(5) (Molecular 
Probes, Life Technologies Ltd, Paisley, UK.) and kept in the dark for 15 minutes, 
to allow for dye up-take in accordance with the manufacturer’s guideline 
(Haugland, Spence and Johnson  2005, Allison, Brynildsen and Collins 2011). 
Five 20 ml aliquots were then prepared from this bacterial suspension, three of 
which were treated with either chalcone-derivative alone, polymyxin B alone or 
both compounds applied together, using suitable volumes of stock required to 
obtain the desired effective either single or combination concentration. The 
fourth and fifth 20 ml aliquot bacterial suspension were used as the untreated 
stained control and 256 μg/ml (4 x MIC) gramicidin-treated control samples 
respectively. All samples were incubated in a static water bath pre-set at 37 oC. 
At time intervals of 0, 15, 30, 60, 120 and 240 minutes, 1 ml sample was 
withdrawn into a glass cuvette and fluorescence was read at excitation of 625 
nm and emission of 690 nm respectively. The reported data represent the mean 
result from three independent assays conducted in duplicate on separate days. 
For the examination of changes in fluorescence intensity of the cells  over time 
using  microscopy, 5 aliquots of 4 ml 0.3 unit OD500 S. aureus 11940 suspension 
in PBS solution containing 1 % w/v D-glucose at pH 7.2 was treated as described 
above and incubated in a Clifton water bath at 37 oC. A 100 µl volume was 
withdrawn from each tube and applied onto a 100 µl 0.5 % w/v agarose gel in a 
hollow glass slide at time intervals of 1, 2, 3 and 4 hours.  Observations of 
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changes in fluorescence intensity were made with a suitable microscope ((Leica 
DMLB, Leica Microsystems, Wetzlar, Mannheim, Germany) set at a magnification 
of x1000 and recordings were made using an attached camera (Leica DC 300F, 
Leica Microsystems, Wetzlar, Mannheim, Germany). The reported data were 
obtained from three independent assays conducted on separate days. 
7.2.2 Quantifying potassium lost from bacterial cytoplasm 
7.2.2.1 Preparation of glassware and utensils 
All glasswares employed in the flame-emission assay were soaked in deionised 
ultra-pure water for 24 hours prior to the assay. This was to enable the removal 
of glass-borne potassium from the surface of the vessels. 
7.2.2.2 Calibration of atomic emission spectrophotometer 
The calibration of the flame spectrophotometer was made following a procedure 
similar to a previously published protocol (O’Driscoll 2011). An analysis aimed at 
quantifying the leakage of intracellular potassium ions was undertaken with a 
flame atomic absorption spectrophotometer (Model AA3110, Perkin Elmer Las 
UK., Beaconfield, UK.). The instrument mode was set for standard flame 
emission for detection of potassium ions at 766.5 nm, slit at 0.2/0.4 nm and was 
powered by air/acetylene gas mixture (B.O.C., Worsley, Manchester, UK.). A 
stock solution of 1000 μg/ml KCl in ultra pure de-ionised water was prepared. 
Five reference standards containing 1.0, 2.0, 3.0, 4.0 and 5.0 μg/ml KCl were 
made from the stock solution by suitable dilutions. The stock solution and the 
reference dilution samples were all prepared in propylene volumetric flasks 
(Azlon; Fisher Scientific). The 5 reference standards were then used to calibrate 
the flame photometer to obtain a reference graph with a correlation coefficient 
≥0.99. The instrument subsequently quantified concentrations of potassium ions 
in actual samples against this reference calibration graph. Actual samples were a 
100-fold dilution of supernatant solutions obtained from bacterial suspensions 
that were challenged with the test compound(s). 
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7.2.2.3 Quantifying leakage of potassium ions from antibiotic-treated S. 
aureus 6571 
A 200 ml S. aureus NCTC 6571 suspension with density of 5 x 108 cfu/ml was 
prepared as previously described in section 2.4. Aliquots of 24 ml were made 
from the bacterial suspension and treated with suitable volumes of the stock 
antimicrobial test compounds needed to obtain the desired final concentrations, 
whose effect on membrane activity were to be examined. All samples were 
incubated in a Clifton shaking water bath at 37 oC and 100 rpm. Then, 1 ml 
volume was withdrawn from each sample at 0, 10, 20, 30, 60 and 120 minutes 
respectively and centrifuged at 12,000 rpm for 1.5 minutes. Hundred-fold 
dilutions of the supernatants were assayed for K+ concentrations using the 
calibrated atomic absorption spectrometer (Perkin Elmer, A Analyst 400, UK.). 
Control samples included negative (untreated) and positive (either 20 μg/ml 
benzalkonium chloride or 5 % v/v chlorhexidine treated) samples.  The data 
obtained were analysed with GraphPad prism software 4 for standard error of 
mean and standard deviation followed with the plotting of a graph of K+ lost 
(µg/µl) against time (minutes). 
7.2.3 Quantifying influx of Sytox Green into bacterial cytoplasm  
7.2.3.1 Preparation of dye stock solution 
A five ml stock solution of 0.5 µM Sytox Green stain (S7020, Invitrogen; 
Molecular Probes, Life Technologies Ltd, Paisley, UK.) was prepared with distilled 
water in McCartney bottle wrapped in an aluminium foil. The solution was stored 
in the dark at -20 oC until required; therein, suitable sub-aliquots of the stock 
required to obtain the desired final concentration were withdrawn. 
7.2.3.2 Preparation of experimental sample 
A 60 ml volume of stock bacterial suspension containing 1 x 108 cfu/ml bacterial 
density in 0.9 % w/v sodium chloride was prepared as previously described in 
section 2.4. The suspension was adjusted to 5 x 107 cfu/ml with same medium 
and treated with a suitable volume of stock test antibacterial compound solution 
to obtain a final 20 ml aliquot that was immediately incubated in a Clifton water 
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bath pre-set at 37 oC and 100 rpm. One millilitre samples were collected at 0, 
15, 30, 60, 120, 180, 240 and 1440 minutes, centrifuged at 12,000 rpm for 2 
minutes and the supernatant carefully removed. The recovered bacterial pellets 
were re-suspended in fresh 1 ml volumes of the same buffer followed by the 
addition of 100 µl volume of stock 5 µM of Sytox Green stain and kept in the 
dark for 15 minutes. Untreated control samples and bacterial suspensions 
treated with established membrane active agents used as controls were included. 
The fluorescence change for the entire cell suspensions over time were measured 
using a 1 ml volume glass cuvette to take readings in a Perkin Elmer LS 
Luminescence Spectrometer, set to take readings at excitation 488 and emission 
523 nm. This method was adapted from protocols published by Mark, Vocadlo 
and Oliver 2011 and Hancock 2001. At the same sampling time intervals 
indicated above, 100 µl volumes of the bacterial suspension were removed for 
cell viability determination by colony counting technique previously described in 
sections 2.3.3, 2.3.4 and 2.4.2. Both assays were conducted in duplicate and 
repeated on three separate days.   
Subsequent fluorescence assays were conducted using a protocol designed for 
the DTX-880 micro-titre plate reader that was pre-calibrated to take readings at 
37 oC, excitation 488 and emission 535 nm. Wells were prepared containing a 
final 200 µl volume of 5 x 107 cfu/ml suspensions of treated and untreated 
bacteria that were stained with a final strength of 0.25 µM of Sytox Green with 
readings taken every 15 minutes for 24 hours. Assays were conducted in 
duplicate and repeated on three separate days (n = 6). 
7.3 Results 
7.3.1 Assessment of bacterial membrane potential depolarisation 
7.3.1.1 Fluorimetry analysis of effect of test compounds upon 
membrane potential   
The ability of either of the chalcone-derivatives applied alone and in combination 
with polymyxin B to induce membrane depolarisation in bacteria was 
investigated and reported in figures 7.1 and 7.2.  
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Figure 7.1: Depolarisation of S. aureus NCTC 11940 membrane potential by combined sub-
inhibitory concentrations of F1 with polymyxin B in the presence of DiOC3(5). The data presented 
were obtained from assays conducted in duplicate and repeated on three separate days (n = 6). 
The concentrations of the compounds applied in this assay were chosen based on 
guidance from the previously conducted micro-broth dilution and chequerboard 
assays (tables 4.1 and 4.2) and were examined for membrane bilayer 
dissipation. As would be expected, cell suspensions exposed to 4 x MIC 
gramicidin (section 3.3.4), a membrane active ionophore used as the positive 
control, displayed the highest extent of staphylococcal membrane depolarisation 
in both charts. Similarly, the activity recorded in samples treated with polymyxin 
B were comparable to those of the untreated bacterial suspension within the first 
30 minutes but subsequently increased steadily. In both instances, cell 
suspension exposed to single applications of 32 µg/ml of this polypeptide 
demonstrated a degree of membrane dissipation equivalent to 50 % after 120 
minute, in comparison to the activity recorded for the positive control. 
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The data recorded in figure 7.1 show that 16 µg/ml (1/8 MIC F1) caused no 
overall alteration to the membrane potential of the exposed cells, in comparison 
to the untreated control. But the combination of 16 µg/ml F1 with 32 µg/ml 
polymyxin B (previously seen to be bactericidal in table 4.1a in both a 
chequerboard and MBC-determination assays), demonstrated a membrane 
depolarisation rate that was slightly higher than that effected by gramicidin for 
the first 30 minutes, although at 120 minutes, this was about 30 % lower in 
extent. Therefore, although polymyxin B demonstrated a notable extent of the 
cell membrane bilayer depolarisation, the combination of this polypeptide with F1 
displayed a much faster onset and an enhanced extent. 
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Figure 7.2: Depolarisation of S. aureus NCTC 11940 membrane potential by combined sub-
inhibitory concentrations of F23 with polymyxin B in the presence of DiOC3 (5). The data presented 
were obtained from assays conducted in duplicate and repeated on three separate days (n = 3). 
The data presented in figure 7.2 also show that 16 µg/ml (1/64 MIC) F23 
displayed no impact upon the MRSA membrane potential for the first 30 minutes. 
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This concentration of the chalcone compound later demonstrated an overall 
extent of bilayer potential dissipation of about 20 %, in comparison to the 
positive control. A combined application of both compounds at the same stated 
concentrations above (equivalent to half their synergistic concentrations recorded 
in table 4.2), exhibited a much more rapid onset of action than the sub-inhibitory 
concentration of polymyxin B alone but a lower rate and extent (about 45 %) of 
action than gramicidin D. 
7.3.1.2 Membrane potential examination using microscopy 
Morphological assessment using fluorescence microscopy was used to 
complement the data obtained from the fluorimetry assay above. But to 
guarantee that dye-uptake occurred during the dark-room incubation period, an 
initial examination was undertaken. 
7.3.1.2.1 Verifying dye-uptake by stained cells 
In order to ascertain that cells in bacterial suspension treated with DiOC3(5) 
experienced dye-uptake and aggregation, a comparative view of S. aureus 11940 
suspensions stained with this stain, as well as the intact-cell membrane 
impermeable Sytox Green was undertaken, after the 15 minutes incubation 
period, using an inverted fluorescence microscope (Leica DMI 4000B, Leica, 
Wetzlar, Mannheim, Germany) and recordings were taken with an attached 
camera (Leica DFC 300 FX, Leica, Wetzlar, Mannheim, Germany). The data 
obtained are presented in figure 7.3.  
The images in 7.3.1a,b suggests Sytox Green was unable to permeate the MRSA 
cell membrane whilst those in 7.3.1 c,d suggests apparent intracellular dye-
uptake and aggregation for DiOC3(5) treated cells. 
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7.3a: MRSA cells stained with Sytox Green  
 
 
7.3b: MRSA cells stained with Sytox Green  
 
 
7.3c: Untreated MRSA cells stained with 
DiOC3(5) 
 
 
7.3d: MRSA cells stained with DiOC3(5). 
Figure 7.3: Inverted fluorescence microscope images taken at x600 of cells stained with (a,b) 
Sytox Green (c,d) DiOC3(5) after 15 minutes dark-room waiting period. 
7.3.1.2.2 Examining changes in fluorescence intensity due to the effect 
of test compounds in bacterial cells 
Polymyxin B, each of the chalcone-derivatives applied alone, as well as together 
with the polypeptide antibiotic and gramicidin D as a control agent, were used to 
challenge defined S. aureus 11940 populations that were subsequently examined 
for changes in fluorescence intensity using a time-lapse microscopy technique. 
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7.3.1.2.3 Time-course assessment of changes in fluorescence intensity 
for stained untreated cells 
Stained but unchallenged cells were initially viewed over time for morphological 
changes with a fluorescence microscope. These control experiments were 
essential to avoid ascribing morphological and structural changes that may occur 
due to cell degradation over time as well as defects that were artefactual in 
origin, to the effect of applied agents. The data obtained when untreated MRSA 
suspensions were simply exposed to DiOC3 over time is recorded in figure 7.4. 
Despite the heavy biomass, the stained cells were barely visible under the 
fluorescent microscope at 15 minute and up to the second hour. As previously 
stated, the cells were viewed at intervals within 4 hours and the recordings taken 
at 15 minute and 3 hours are presented in figure 7.4.  
 
 
 
 
 
 
A: 15 minutes 
 
 
 
 
 
 
B: 3 hours 
Figure 7.4: DiOC3(5) stained and untreated MRSA cells after (a) 15 minutes (b) 3 hours. Images 
were taken at x400 using a fluorescence microscope. 
This observation suggests the dye was not emitting due to lack of adequate 
uptake and dissipation probably due to the existence of a fully functional 
cytoplasmic membrane bilayer with an intact proton motive force. At the third 
hour (figure 7.4b), the cells fluoresced slightly as their cells became relatively 
more visible suggesting the membrane potential of unchallenged MRSA were 
slowly dissipated over time, enabling the desegregation and fluorescence of 
previously accumulated stain. 
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7.3.1.2.4 Changes in fluorescence intensity over time for stained 
gramicidin-treated cells  
S. aureus stained and challenged with gramicidin were overwhelmingly 
depolarised after 5 minutes (figure 7.5) leading to the formation of hazy clumps 
of (colonies) cell. 
 
 
 
 
 
 
A: 5 minutes 
 
 
 
 
 
 
B: 3 hours 
 
 
 
 
 
 
C: 4 hours 
Figures 7.5: DiOC3(5) stained MRSA cells treated with 256 µg/ml gramicidin for (a) 5 minutes  (b) 
3 hours and (d) 4 hours respectively. Images were taken at x400 using a fluorescence microscope. 
The degree of intensity of the stain fluorescence diminished gradually after 2 
hours. After 4 hours, the data presented is suggestive of cells displaying a 
complete collapse of fluorescence, probably due to absolute disintegration of the 
previously aggregated stain. The accumulated stain disintegrates in response to 
changes in the cell membrane potential and confirms gramicidin’s capacity to 
effectively dissipate the proton motive force, as well as to be used as a control 
agent (Penyige et al. 2002).   
7.3.1.2.5 Time-Kinetic changes in fluorescence intensity for stained S. 
aureus treated with polymyxin B 
The data presented in figure 7.6 is for MRSA stained with DiOC3(5) and treated 
with single applications of the polypeptide antibiotic polymyxin B. 
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A: 5 minutes 
 
 
B: 1 hour 
 
 
 
 
 
 
 
 
C: 3 hours 
 
 
 
 
 
 
 
 
D: 4 hours 
Figure 7.6: DiOC3(5) stained MRSA cells treated with 64 µg/ml polymyxin B for (a) 5 minutes (b) 1 
hour (c) 3 hours and (d) 4 hours respectively. Images were taken at x400 using a fluorescence 
microscope. 
The data suggests the dye accumulated and fluoresced within the treated cells 
after 1 hour. It was however noticed that the recorded intensity was increasing 
with time and that the cells appeared depolarised individually after 4 hours. The 
recorded intensity is however much less than that reported for gramicidin D-
treated MRSA, suggesting that the capacity of polymyxin B to dissipate cell 
membrane potential is lower than that of gramicidin D. 
7.3.1.2.6 Time-course changes in fluorescence intensity for bacterial 
cells stained and challenged with both F1 and F23 chalcone-derivatives  
The data shown in figure 7.7 is for MRSA cells that were stained and treated with 
32 µg/ml of either F1 or F23 and examined for membrane depolarisation 
evidenced by dye fluorescence. 
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Figure 7.7: DiOC3(5) stained MRSA cells treated with 32 µg/ml F1 for (a) 5 minutes (b) 1 hour and 
(c) 4 hours; as well as DiOC3(5) stained MRSA cells treated with 32 µg/ml F23 for (d) 5 minutes (e) 
1 and (f) 4 hours. Images were taken at x400 using a fluorescence microscope.  
All the treated samples showed weaker degrees of fluorescence indicating a 
lower capacity of the semi-synthetic agents to depolarize the bilayer barrier to 
promote the intracellular disaggregation and fluorescence of the stain. The 
degrees of observable fluorescence with time appear to be similar to that 
displayed by the untreated bacterial suspension up to the second hour, indicating 
the absence of membrane dissipation. 
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7.3.1.2.7 Monitoring time-course changes in fluorescence intensity for 
for stained cells challenged with F1 in combination with polymyxin B 
The ability polymyxin B when applied with F1 to dissipate the membrane 
potential of MRSA was re-examined using a fluorescence microscope in the 
presence of DiOC3(5) stain. The data obtained is recorded in figure 7.8. 
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Figure 7.8: DiOC3(5)-stained MRSA cells treated with 32 µg/ml F1 applied with 64 µg/ml polymyxin 
B for (a) 5 minutes (b) 1 hour and (c) 4 hours. Images were taken at x400 using a fluorescence 
microscope. 
At the applied concentrations, the combined agents induced a significant degree 
of membrane dissipation and dye fluorescence that became very pronounced 
over time (figures 7.8), being very obvious at the 4th hour (figure 7.8c). The 
intensity of fluorescence caused by the combination of both compounds 
surpassed those seen in samples treated with either polymyxin B (figure 7.6) or 
any of the chalcone-derivatives when applied alone (figures 7.7). This data 
therefore show that the application of both agents demonstrated an enhanced 
capacity to dissipate MRSA membrane potential by the inducement of a degree of 
stain fluorescence that surpasses those produced by either of the agents’ 
individual applications.  
7.3.1.2.8 Morphological time-kinetics for cells stained and treated with 
both F23 and polymyxin B 
MRSA was stained with the same dye and challenged with 64 µg/ml of the 
polypeptide antibiotic with 32 µg/ml of F23, the second chalcone compound that 
was examined in this project. These concentrations represent the strengths that 
were effective synergistically against the same bacterial species in both a 
chequerboard and MBC-determination assays (as recorded in table 4.2). The 
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data obtained from the examination of the cells using a fluorescence microscope 
is presented in figure 7.9. 
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Figure 7.9: DiOC3(5) stained MRSA cells treated with 32 µg/ml F23 with 64 µg/ml polymyxin B for 
(a) 5 minutes (b) 1 hour (c) 3 hours and (d) 4 hours. Images were taken at x400 using a 
fluorescence microscope. 
In comparison to the action of the polypeptide applied with F1, this latter 
combination demonstrates a lower degree of fluorescence. In this case, the 
induced fluorescence made the cells more visible after 3 (figure 7.9c) and up to 
after 4 hours (figure 7.9d) respectively. The data presented in both figures is 
strongly suggestive of cells with depolarised membrane potential and 
fluorescence especially after 3 and 4 hours.  
7.3.1.2.9 Summary of data findings from microscopic changes in cells 
fluorescence intensity 
Another comparative analysis of the data in this section indicates the untreated 
and polymyxin B–treated cells were seen to undergo degrees of depolarisation 
over time, producing cells with dissipated membrane potentials that appeared as 
distinguishable colonies. On the other hand, gramicidin treated cells were 
recorded as clumped up and hazy colonies, indicating wide-spread dissipation of 
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their membrane potential; whilst cells treated with combinations of polymyxin B 
with the chalcone-derivatives were recorded as having both distinct and smaller 
diameter hazy-clumped, dissipated colonies, indicating a lesser degree of 
depolarisation than gramicidin-treated control. Cell suspensions treated with F1 
and polymyxin B displayed a greater degree of their membrane-bilayer 
dissipation than those treated with the combination of F23 with polymyxin B. Cell 
suspensions stained with the dye and treated with either F1 or F23 alone did not 
show signs of any significant dissipation of their membrane potential after 4 
hours as illustrated in the data previously presented in figure 7.7. 
7.3.2 An assessment of the effect of selected compounds upon bacterial 
membrane integrity through measurement of leaked intracellular K+  
7.3.2.1 Effect of benzalkonium chloride upon bacterial membrane 
integrity 
In order to verify the approach using the flame emission spectrophotometer, the 
rate of potassium ion leakage from a S. aureus 6571(MSSA) population 
challenged with benzalkonium chloride in ultra-pure de-ionised water was 
assessed and the data obtained is shown in figure 7.10.  
The assay results give an indication of the rate and quantity of leakage of 
intracellular K+ from the bacterial cells due to the membrane activity of this 
quaternary ammonium compound. The MSSA samples treated with 4 and 20 
µg/ml benzalkonium chloride demonstrated a rapid and profound onset of cell 
membrane disruption evidenced by the quick release of intracellular potassium 
ions. The MSSA suspension challenged with 20 µg/ml of this antimicrobial agent 
was seen to display the highest level of intracellular cation release and was 
subsequently used as the positive control during the evaluation of the activity of 
polymyxin B with the chalcone-derivatives. 
The untreated bacterial sample released about 0.3 µg/ml intracellular potassium 
ions after 5 as well as 15 minutes and the amount of released cations increased 
to about 0.5 µg/ml after 60 minutes. 
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Figure 7.10: Intracellular potassium ion leakage from 1 x 108 cfu/ml S. aureus 6571 cells treated 
with benzalkonium chloride and analysed with the flame emission analysis. These data represent 
the mean result from three independent assays conducted in duplicate. 
The release of intracellular potassium ion from bacterial samples that were not 
challenged is an indication that the cations were either undergoing diffusion from 
the intracellular space due to concentration gradient or membrane bilayer 
perturbation since the cells were suspended in de-ionised water rather than a 
buffer solution.   
A complementary plate count determination was undertaken (figure 7.11) and 
demonstrates a rapid as well as profound bactericidal activity for 20 µg/ml 
benzalkonium chloride against the inoculum population. After 30 minute, this 
concentration of quaternary ammonium compound had caused a complete loss of 
viability to the exposed population. This observation is corroborated by the fact 
that these samples suspensions displayed a sustained maximum release of 
potassium after this same period in figure 7.10 as detected by the flame 
photometer. The bacterial sample challenged with 4 µg/ml benzalkonium chloride 
demonstrated an approximately 75 % release of intracellular potassium ion 
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(figure 7.10) and a reduction of their cell colony count from 8 to 6 log cfu/ml (an 
approximate loss of 10 million colonies) after 60 minutes (figure 7.11).  
 
Figure 7.11: Time-kinetic viability assay for the 1 x 108 cfu/ml S. aureus 6571 suspension exposed 
to concentrations of the quaternary ammonium compound. Samples for the latter analysis were 
withdrawn concurrently with those used for the flame emission analysis. These data represent the 
mean result from three independent assays conducted in duplicate. 
Both data appear to suggest that the degree of membrane bilayer disruption 
induced by this latter concentration of benzalkonium chloride was lesser than 
that caused by 20 µg/ml of this same agent. The membrane activity of the 
quaternary compound was therefore concentration-dependent and the degree of 
cell cytoplasmic bilayer damage was reflected by the percentage of potassium ion 
loss and mirrored by the extent of loss in cell viability. Future time course 
viability studies with benzalkonium chloride should be conducted with a 
neutraliser such as tween 80 in order to avoid potential drug carry-over effect. 
The untreated cells suspended in de-ionised water did not demonstrate 
appreciable loss in viability probably due to the short duration of the assay. 
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7.3.2.2 Effect of polymyxin B with the chalcone-derivatives upon cell 
membrane integrity  
The data presented in figures 7.12 and 7.13 show the rate and extent of leakage 
of potassium ions leaked from MSSA populations challenged with polymyxin 
alone and in combination with F1. The release of 4 µg/ml K+ from the 20 µg/ml 
benzalkonium chloride-treated control population indicates an increase of 1.5 
µg/ml over that previous value obtained from a lower MSSA density of 1 x 108 
cfu/ml that was treated with the same concentration of this quaternary 
ammonium compound.  
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Figure 7.12: Inducement of potassium ion leakage in S. aureus 6571 populations challenged with 
128 µg/ml of both F1 and polymyxin B. The cell density used was A500 0.50 MSSA that was washed 
once and re-suspended in ultra pure deionised water. Upon agar plate count, this inoculum 
population was equivalent to ~5.25x108 cfu/ml. The data represent the mean result from three 
separate experiments that were conducted in duplicate, n = 6. 
This observation indicates an increase in the population of the challenged 
bacterial suspension leads to an increase in the amount of leaked potassium. In 
comparison to the untreated bacterial suspension, MSSA challenged with only 
polymyxin B displayed a release of 45, 75 and 82 % K+ after 10, 20 and 60 
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minutes respectively whilst another aliquot suspension treated with a single 
application of F1 released intracellular ions to an extent of 32, 32 and 50 % 
(figure 7.12). An equivalent bacterial population challenged with F1 and 
polymyxin B together showed an enhanced leakage of potassium ions. This cell 
population released about 60, 75 and 100 % of potassium ions at the defined 
time periods above. As noted previously in the calibration assays with control 
agents, the MSSA suspension in de-ionised ultra-pure water also released some 
amount of K+, probably due to the cation concentration gradient and some 
degree of membrane perturbation. An analysis from 2 way ANOVA with the 
Bonferroni post test show that at p > 0.05 there was no significant difference 
between all the treated samples and the untreated control at time 0 but a 
significant difference existed for both 20 µg/ml benzalkonium chloride and F1-
polymyxin B treated samples between 5 and 120 minutes of the assay at p < 
0.0001. However, both samples treated with polymyxin and F1 separately also 
demonstrated a non-significant difference in comparison to the untreated control 
after 5 minutes, with p > 0.05. 
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Figure 7.13: Inducement of potassium ion leakage in S. aureus 6571 populations challenged with 
128 µg/ml of both F23 and polymyxin B. The cell density used was A500 0.50 MSSA that was 
washed once and re-suspended in ultra pure deionised water. Upon agar plate count, this inoculum 
population was equivalent to ~5.25x108 cfu/ml. The data represent the mean result from three 
separate experiments that were conducted in duplicate, n = 6. 
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In figure 7.13, the amount of potassium ions released by bacterial suspension 
treated with 20 µg/ml benzalkonium chloride was also used as the reference. 
MSSA population challenged with a single application of 128 µg/ml F23 displayed 
a released 8, 12.5 and 37.5 % potassium ions after 10, 30 and 60 minutes 
respectively. Cells exposed to only 128 µg/ml polymyxin B were seen to have 
leaked much higher amounts of approximately 45, 75 and 82 % at the same 
time intervals. 
Although cell populations exposed only to polymyxin B, as well as those treated 
with both compounds were seen to have released about the same amount of the 
intracellular cation after 20 minutes. The augmentative action of the combined 
agents induced the release of about 105 % of the cation after 120 minutes whilst 
cell suspensions treated with only 128 µg/ml polymyxin B leaked only 90 %, but 
there was a significant difference at p < 0.0001 with the use of a 2 way analysis 
of variance with the Bonferroni post test. The same statistical analysis show that 
at p > 0.05 there was also no significant difference between all the treated 
samples and the untreated control at time 0 and between F23-treated sample 
and the latter reference up to after 30 minute with p value >0.05. Menawhile, all 
the other treated bacterial suspensions expressed a significant difference 
between 5 and 120 minutes with p < 0.0001. 
In this assay, bacterial suspensions were prepared in ultra-pure de-ionised water 
in order to avoid contamination from extraneous particulate materials and 
dissolved ions as these can interfere with data obtained from flame 
spectrophotometry. This device is highly sensitive with known capacity to detect 
microscopic levels of free ions. In comparison to the previous data obtained 
during the verification of the protocol of the spectrophotometer, after 60 
minutes, the untreated sample had no appreciable loss in viability but was seen 
to have released potassium ion concentration equivalent to 12.5 %. After 120 
minutes, this same sample had demonstrated a release of intracellular potassium 
ion equivalent to 28 %. 
7.3.3 Examining cell membrane disruption with fluorimetry analysis 
The degree of cell cytoplasmic membrane disruption enforced upon S. aureus 
species challenged with established as well as test antibacterial compounds was 
assessed with the use of fluorescing dyes in fluorimetry. 
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7.3.3.1 Calibration of the fluorimeter and testing of the protocol 
A calibration of the fluorimetry protocol for assessing bacterial membrane 
integrity upon the challenge of a given cell population was conducted by 
evaluating the effect of already established antimicrobial compounds upon MSSA. 
The data obtained is presented in figure 7.14.  
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Figure 7.14: An assessment of the impact of representative antimicrobial compounds upon 
membrane integrity of S. aureus 6571 (MSSA) populations. n = 6. 
The peak emission demonstrated by MSSA population challenged with 
benzalkonium chloride after 24 hours was taken to equivalent to a 100 % 
fluorescence. This quaternary ammonium compound was seen to have displayed 
a 30, 35 and 55 % emission at 15, 60 and 240 minutes respectively. Polymyxin 
B displayed 12, 9, 24 and 30 % emission at 15, 30, 60, 240 and 1440 minutes. 
These data imply both compounds disrupted MSSA cytoplasmic membrane 
integrity to such an extent that enabled the influx of Sytox Green into the 
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bacterial cytoplasm for binding to nucleic acid and fluorescing of the dye (Salas-
Vidal 2004). On the other hand, MSSA populations challenged with penicillin, 
ciprofloxacin and galangin displayed emission levels that were below 12 % all 
through the 24 hours period. In addition, the lowest recorded value of about 1.7 
% was displayed by the flavonol compound all through the analysis. This 
observation suggests the mechanism of action of all of these four compounds is 
unconnected with disruption of bacterial membrane integrity. 
The data presented in figure 7.15 illustrate about a 2.5 log reduction in viability 
of MSSA populations challenged with the same strengths of galangin, polymyxin 
B and benzalkonium chloride applied in the examination of membrane integrity, 
in a complementary assay. 
0 30 60 90 120 150 180 210 240
1
2
3
4
5
6
7
8
1024 µg/ml polymyxin B
0.125 µg/ml
(4xMIC) penicillin G 128 µg/ml (4xMIC) ciprofloxacin
4 µg/ml (4xMIC) benzalkonium chloride
Untreated Control
240 1440
125 mg/ml (MIC) galangin
Time (minutes)
S.
 a
ur
eu
s 
vi
ab
ili
ty
 (l
og
 c
fu
/m
l)
 
Figure 7.15: Data from a time-course viability assay for the 5 x 107 cfu/ml S. aureus 6571 (MSSA) 
populations challenged with 128 µg/ml (4 x MIC) ciprofloxacin, 0.125 µg/ml (4 x MIC) penicillin G, 
1.024 mg/ml polymyxin B and 4 µg/ml (4 x MIC) benzalkonium chloride. Samples for viability 
determinations were collected at the same time as those for the fluorimetry analysis following 
challenge of the cell sample. The data was mean of values obtained from experiments conducted in 
duplicate and repeated on three separate days. 
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This indicates that at the applied concentrations, these three agents were 
bacteriostatic with about a 500-fold reduction to the high biomass of 5 x 107 
cfu/ml. The data in figure 7.14 show a rapid onset in the influx of Sytox Green 
(within 15 minutes) for bacterial populations challenged separately with 
benzalkonium chloride and polymyxin B. But the data obtained from the time-
course viability analysis presented in figure 7.15 suggest that the decline in 
population of viable cells in these samples were relatively slow in onset and only 
became notable as from 180 minutes. This observation was despite the 
occurrence of a prompt as well as steadily increasing membrane disruption, 
verified by influx of Sytox Green into cells treated with benzalkonium chloride 
and polymyxin B in figure 7.14, suggesting that membrane disruption may not 
always translate to an immediate loss in viability. Similar to the data previously 
presented in figure 7.10 for the leakage of intracellular potassium ions, S. aureus 
suspension exposed to 4 µg/ml (4 x MIC) benzalkonium chloride demonstrated a 
notable influx and fluorescence of the intact-membrane impermeable stain, as 
well as a 2.5 log cfu/ml loss in viability after 24 hours. Both information verified 
the previous data that this concentration of the quaternary ammonium 
compound disrupted the cytoplasmic membrane bilayer of S. aureus, permitting 
the leakage of potassium ions and in addition gives an insight into the degree of 
assault upon the membrane bilayer by enabling the intracellular influx, binding 
and fluorescing of the cationic stain (molecular weight 600 g/mol (Saugar et al. 
2006)) to polyanionic nucleic acids. The information also verifies the suitability of 
the use of this protocol for examination of the membrane activity of the 
synergistic action of the combined application of polymyxin B with the chalcone-
derivatives.  
7.3.3.2 Assessing the degree of membrane disruption caused by 
polymyxin B with the chalcone-derivatives  
The fact that an application of polymyxin B with the chalcone-derivatives caused 
cytoplasmic membrane disruption in S. aureus has been evidenced by the 
leakage of intracellular potassium ions. But the degree of this damage still needs 
to be verified since this cation is considered to be small in size, having a 
molecular weight of 32 g/mol. The effect of the combined application of the 
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polypeptide antibiotic with either of the chalcone derivatives upon bacterial 
membrane integrity was determined by quantifying the intra-cellular influx of 
Sytox Green over time, after challenging S. aureus suspensions with defined 
strengths of both compounds. As stated previously, this stain with a molecular 
weight of about 600 g/mol is unable to permeate intact cytoplasmic membranes 
and would fluoresce only upon binding to nucleic acid materials (Vives‐Rego, 
Lebaron and Nebe‐von Caron 2000). The data presented in figures 7.16 to 7.18 
show the effect of various concentrations of control as well as single and 
combined applications of test compounds upon the membrane integrity of 
equivalent MSSA populations, measured as a reflection of the intensity of Sytox 
Green emission.  
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Figure 7.16: Determination of the membrane integrity of S. aureus 6571 (MSSA) challenged with 
concentrations of benzalkonium chloride, polymyxin B, F1 alone and F1 applied in combination with 
polymyxin B at varying strengths. All data are means of duplicate experiments that were repeated 
three times on separate days. Statistical evaluations were by 2-way ANOVA and post hoc 
investigations were by Bonferonnis test of multiple comparisons where all the samples were 
analysed relative to the untreated control at  p < 0.001. 
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The data presented from all three figures suggest Sytox Green was unable to 
permeate the membrane of untreated MSSA reflected by the near-zero level 
emission perpetually recorded from this sample all through the assay period. In 
figure 7.16, the 4 µg/ml benzalkonium chloride treated bacterial suspension 
demonstrated a gradual incremental uptake of the dye whilst cell suspension 
treated with 20 µg/ml of this cationic surface active agent shows a pronounced 
and rapid onset of emission within 5 minutes indicating a very substantial 
disruption of the cell membrane by this cationic surface active agent, thereby 
permitting the rapid intracellular influx of the stain. The data from subsequent 
assays were interpreted based on the premise that cells exposed to 20 µg/ml 
benzalkonium chloride displayed a 100 % membrane disruption and Sytox Green 
emission. Further standardisation of the protocol was carried out by examining 
the influx of the stain into cells treated with various strengths of polymyxin B 
alone. The data presented in figure 7.16 also contains curves for cell suspensions 
exposed to varying concentrations of this polypeptide showing that although this 
agent demonstrated membrane action, membrane disruption that was 
accompanied by the influx of the dye became pronounced approximately after 4 
hours for all the examined strengths within the range of 32 to 256 µg/ml.  The 
degree of disruption appears to be time and concentration dependent in 
character. The membrane activity of the highest concentration of this polypeptide 
antibiotic peaked at about 48 % at 10 hours whilst that of the lowest 
concentration tested was 32 % after 24 hours of exposure. 
The data presented in figure 7.17 show that bacterial suspensions treated with 
single applications of the chalcone-derivative F1 produced curves with lower 
degrees of fluorescence in comparison to that from cells exposed to the control 
surface active agent, thereby indicating a relatively lesser degree of membrane 
activity reflected by the lower onset as well as extent of dye emission. The 
membrane disruption activities of the semi-synthetic agents were also in a 
concentration-dependent order. MSSA cells treated with 128 µg/ml F1 
demonstrated the highest emission followed by those challenged with 64 and 32 
µg/ml (figure 7.17). 
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Figure 7.17: Determination of the membrane integrity of S. aureus 6571 (MSSA) challenged with 
concentrations of benzalkonium chloride, polymyxin B, F1 alone and F1 applied in combination with 
polymyxin B at varying strengths. All data are means of duplicate experiments that were repeated 
three times on separate days. 
Similarly, cells exposed to 128 F23 displayed the highest degree of emission 
followed by 64 and 32 µg/ml (figure 7.18) respectively. The data presented in 
figure 7.17 also clearly show a potentiated membrane disruption activity between 
various concentrations of F1 with polymyxin B as the curves express higher 
degrees of fluorescence that are comparable to that caused by 20 µg/ml 
benzalkonium chloride. This latter concentration of the control agent produced a 
membrane bilayer disruption action that remarkably surpassed (in both rate and 
extent) the bilayer assault caused by 4 µg/ml of this same compound (figure 
7.16).  With reference to the 20 µg/ml benzalkonium chloride control, cell 
suspensions exposed to 32 µg/ml of both compounds applied together showed 
the lowest degree of activity that was followed by 64 and 128 µg/ml of both 
compounds. However, a combination of 32 µg/ml F1 with 256 µg/ml polymyxin B 
demonstrated the highest activity of 105 % amongst all the combinations. 
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Figure 7.18: Determination of the membrane integrity of S. aureus 6571 (MSSA) challenged with 
concentrations of benzalkonium chloride, polymyxin B, F23 alone and F23 applied in combination 
with polymyxin B at varying strengths. All data are means of duplicate experiments that were 
repeated three times on separate days. 
Although the activity of benzalkonium chloride peaked after about 4 hours, that 
of this latter combination was at optimum after 10 hours, in addition to 
demonstrating the most rapid onset of action which was only closely followed by 
that of the combination of 128 µg/ml of both compounds. The activity of this 
latter combination of both agents was seen to be at optimum after about 20 
hours. Therefore a combination of 32 µg/ml F1 with 256 µg/ml displayed the best 
overall onset of action amongst all the strengths and combinations examined 
fluorimetrically with an extent of action that surpassed that displayed by the 
surface active agent used as control. This was closely followed by the activity of 
128 µg/ml F1 combined with 128 µg/ml polymyxin B that displayed an extent of 
action which also exceeded that of benzalkonium chloride. This latter 
combination demonstrated a remarkable potentiated membrane disruption, 
exceeding that displayed by the individual compounds. Colony counting assay 
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data presented in chapter 5 showed this same combination displayed 
tremendous synergistic actions by reducing 1 x 107 cfu/ml populations of both 
MSSA and MRSA to below detectable levels after 8 hours clearly indicating the 
existence of a correlation between membrane activity and inducement of loss in 
viability by the combined application of both agents. 
The data presented in figure 7.18 suggest the application of 32 µg/ml F23 with 
256 µg/ml polymyxin B was superior in extent of activity over other strengths of 
both compounds examined in combination against MSSA. It is again interesting 
to note that the extent of membrane disruption displayed by this combination 
was better than that reported for 128 µg/ml F23 applied with 128 µg/ml 
polymyxin B; emphasizing that with a small fraction of this semi-synthetic agent, 
the antibiotic action of polymyxin B against Gram-positive organism is 
augmented partly through the enhanced disruption of the cytoplasmic membrane 
integrity. Another important observation is that 32 µg/ml F23 applied in 
combination with 256 µg/ml polymyxin B that induced the highest rate and 
extent of loss in S. aureus viability (figure 5.8) also demonstrated the highest 
rate and extent of influx of the fluorescing dye after 24 hours. This again 
emphasizes the possibility that cytoplasmic membrane bilayer disruption is 
amongst the core mechanisms of action of polymyxin B combined with the 
chalcone-derivatives against Gram-positive S. aureus. 
In figure 7.18, in comparison to the action of 20 µg/ml benzalkonium chloride, 
MSSA challenged with 128 µg/ml of both polymyxin B and F23 that were singly 
applied displayed about 48 % stain emission that peaked after about 10 and 24 
hours respectively. A concurrent view of figures 7.16, 7.17 and 7.18 suggest that 
applications containing only polymyxin B gave emissions with a faster rate and 
onset of action than those singly treated with either F1 or F23. The cells 
challenged with a combination of 128 µg/ml F23 and 128 µg/ml polymyxin B 
demonstrated about 55 % membrane disruption with an action that was slightly 
more rapid in onset, which peaked after 4 hours like cells challenged with only 
polymyxin B but exhibited a peak that is lower than was obtained with the 
combined application of 32 µg/ml F23 with 256 µg/ml polymyxin B as well as 
that of the cationic surface active agent control. As previously mentioned, 32 
µg/ml (1/2 MIC) F23 applied with 256 µg/ml (MIC) polymyxin B demonstrated 
the fastest onset and extent of bactericidal action in the kinetic-colony count 
presented in figure 5.8. The fact that the bactericidal activity demonstrated by 
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this combined concentrations of both compounds is higher than that shown by 
the combined application of 128 µg/ml of both agents (as is indeed also shown 
for F1 in figure 7.17), verifies that only a small fraction of either of the chalcone-
derivatives was required to be applied with polymyxin B in order to elicit 
augmented activity against strains of Gram-positive S. aureus. Overall, these 
data give an insight into a potential mechanism for the bactericidal action of 
combinations of both agents against S. aureus as previously reported from a 
chequerboard and time-kinetic assays. 
7.4 Discussion 
7.4.1 Membrane depolarisation and the release of S. aureus intracellular 
K+ by the combination of polymyxin B with the chalcone-derivatives 
There are variations in the definitions and descriptions of bacterial membrane 
damage as well as arguments on the correct order of events that lead to cell 
death caused by antimicrobial agents. But certainly, these events are all likely 
related in a cascade. The dissipation of trans membrane potential, formation of 
ion channels, trans membrane pores and membrane rupture should be viewed as 
a chain of events rather than as completely different mechanisms (Dathe and 
Wieprecht 1999). In terms of sequence of events, there is a strong rationale 
behind the opinion that the distortion of membrane-potential as well as the pH-
gradient by agents such as gramicidin, valinomycin, nisin, etc., certainly 
precedes all other events and are likely to be accompanied by impairment of 
osmotic regulation, formation of trans membrane pores and inhibition of bacterial 
respiration (Matsuzaki et al. 1997, Dathe et al. 2002). The data presented in 
figure 7.1 and 7.2 show induced depolarisation of MRSA membrane potential by 
the combinations of sub-inhibitory concentrations of the chalcone derivatives (F1, 
F23) with polymyxin B within 30 to 60 minutes. This dissipation is likely to have 
occurred before the extensive loss of the membrane bilayer integrity in cells 
exposed to the combinations, evidenced by the massive influx of Sytox Green 
within the first 75 minutes, as recorded in figures 7.16 to 7.18.  
The formation of peptide-induced ultra structural lesions has been noted to lag 
behind loss in cell viability (Brogden 2005). The reported data suggest whereas 
substantial loss in viability by S. aureus species challenged with the combinations 
203 
 
of polymyxin B with the chalcone-derivatives in time-kinetic colony counting 
assays were recorded between 2 and 8 hours (chapter 5), membrane 
depolarisation (figures 7.1 and 7.2), leakage of intracellular K+ (figures 7.12 and 
7.13), blockade of essential metabolic enzyme function (chapter 6) and extensive 
membrane disruption (figures 7.16 to 7.18) were seen to occur much earlier. 
Although the treatment of E. coli with megainin 2 leads to immediate release of 
intracellular potassium ion that is accompanied by prompt cell death (Matsuzaki 
et al. 1997), this was not the case for the combined application of polymyxin B 
with the chalcone-derivatives against S. aureus as a time-lag existed between 
the occurrence of both events. 
It is notable that lower concentrations of these compound combinations (than 
those used for time-kinetic colony counting assays) demonstrated these agents 
capacity to depolarise S. aureus membrane potential. The antimicrobial peptide 
cecropin A has been shown to dissipate the lipid ion gradients in lipid vesicles at 
concentrations much lower than is required to cause extensive membrane 
damage following the release of encapsulated calcein (Silvestro et al. 1997). The 
antibacterial action of lower strengths of this antimicrobial peptide is therefore 
attributed to the mechanistic dissipation of trans membrane electrochemical ion 
gradients.  
The dissipation of trans membrane electrochemical potential in MRSA  
by as low as 16 µg/ml of either of F1 applied with 32 µg/ml of polymyxin B 
complemented the synergistic activity of this same combination recorded in table 
4.1 and in addition suggests membrane depolarisation occurred in advance of 
actual cell death, being initiated at less than 30 minutes in figures 7.1 and 7.2. 
The rapid onset of bacterial membrane potential depolarisation in S. aureus 
species membrane is responsible for triggering a cascade of sub-cellular events 
that may eventually lead to bactericidal effects (Penyige et al. 2002, Mirzoeva, 
Grishanin and Calder 1997).  
The release of intracellular potassium ions has largely been described as the first 
sign of impairment to the cytoplasmic membrane integrity as evidenced by the 
immediate release of this cation upon the application of certain antimicrobial 
agents such as the ionophore valinomycin, as well as daptomycin (Silverman, 
Perlmutter and Shapiro 2003). The leakage of intracellular cations may be 
accompanied by the release of inorganic phosphates, a pool of amino acids as 
well as materials absorbing at 260 nm (nucleic acids and proteins) (Maillard  
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2002). If quickly halted, these destructive actions may lead to only a 
bacteriostatic effect if the bacterial cell is able to initiate and effect the repair of 
the membrane bilayer as well as other measures that counteract the action of 
the noxious agent (Maillard 2002). The data presented in figures 7.12 and 7.13 
showing that polymyxin B caused an inducement of the leakage of intracellular 
potassium ions from exposed S. aureus cells does not therefore always 
automatically translate to a bactericidal action (> 3 log cfu/ml loss in cell viability 
(Petersen et al. 2006)). This assertion was corroborated by data presented in 
figures 5.1 to 5.10 wherein varying concentrations, including 128 µg/ml, of 
polymyxin B were at best only bacteriostatic against species of S. aureus but 
demonstrated the capacity to induce the intracellular leakage of this cation 
(figures 7.12 and 7.13) and enabled the influx of the intact-membrane 
impermeable dye (figures 7.16 to 7.18). The molecular weight and size of 
potassium ion is so small that any minor infringement on the intactness of the 
bilayer membrane results into leakage of this cation (Lambert and Hammond 
1973). Bacterial suspensions in de-ionised water may also lose viability over time 
because of a perturbation of the membrane bilayer due to the difference in 
osmotic pressure between the extracellular and intracellular fluid.  
However, a massive and unobstructed leakage of this cation followed by the 
cascade of events previously described, often leads to a bactericidal effect. Data 
presented in figures 7.12 and 7.13 showing  the inducement of enhanced 
leakage of cytoplasmic cation by the action of either F1 or F23 applied with 
polymyxin B against S. aureus correlates with the synergistic action of both 
compounds reported in figures 5.1 to 5.10. This observation also corroborated 
the enhanced anti-metabolic action of the application of both compounds against 
various strains of this bacterial species reported in figures 6.10 to 6.15. Although 
massive induced leakage of the cation was seen to have occurred from the initial 
time of exposure up to 120 minute of the assay, substantial cell deaths for these 
bacterial species were only recorded between 2 and 8 hours in the colony-
counting assay. This is in order with published opinions that sometimes the 
timing for the occurrence of ultra-structural lesions caused by certain harmful 
agents, including antimicrobial peptides, may be seen to lag behind the period 
wherein loss of cell viability was noted (Brogden  2005). 
Upon the application of sufficient negative potential to an artificial planar lipid 
bilayer, the introduction of the antimicrobial peptides HNP-1 and rabbit NP-1 to 
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the opposite side causes formation of trans membrane pores (Kagan, Ganz and 
Lehrer 1994). It is therefore thought that the interaction of polymyxin B-
chalcone derivatives with lipoteichoic acid of Gram-positive S. aureus possibly 
caused a depolarisation of the cells that triggered the formation of trans 
membrane pores that is accompanied by the massive outflow of cytoplasmic 
materials as well as the blockage of essential metabolic enzyme activities 
(chapter 5) and loss of cell viability.  
The combination of polymyxin B with the chalcone-derivatives demonstrated a 
rapid blockage of the activity of biological metabolic enzymes (chapter 6), which 
may have eventually lead to an impairment of ATP production (Dinning et al. 
1998, Zhang et al. 2003). It may be worthwhile to verify the inhibition of the 
activity of this essential adenosine-derived nucleotide in future studies. Nisin has 
been reported to cause a time and concentration-dependent decline in internal 
ATP levels in treated M. bovis strain bacillus Carmette Guerin treated without the 
detection of ATP efflux (Chung, Montville and Chikindas 2000), suggesting the 
inhibition of ATP production mechanisms occurs almost simultaneously with the 
onset of pore-formation and the utilisation of energy reserve in unsuccessful 
attempts to generate essential metabolites. But M. bovis is also seen to 
demonstrate the maintenance of a fairly constant level of ATP during the initial 
treatment period despite a decline in both components of the proton motive force 
(membrane potential, ∆ψ and ∆pH) (Chung, Montville and Chikindas 2000). 
Therefore, despite the dissipation of membrane potential, blockage of bacterial 
metabolic action in the MTT-reduction assay and membrane disruption evidenced 
by the fluorescence of nucleic acid bound stain, additional assays are required to 
ascertain whether the combination of polymyxin B with the chalcone-derivatives 
alters ATP/ATPase levels.  
It is also pertinent to investigate whether the polypeptide combined with these 
semi-synthetic agents inhibits the activity of genes encoding for efflux 
mechanisms in S. aureus as this would amount to a more rapid accumulation of 
both compounds to facilitate their potential destructive effects within the cell 
(Kumar and Schweizer 2005). 
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7.4.2 S. aureus membrane disruption and influx of Sytox Green stain 
The assay involving the interaction and binding of unsymmetrical and 
polycationic intact-membrane impermeable Sytox Green stain (Roth et al. 1997) 
to polyanionic nucleic acid, gave an insight into the possible degree of membrane 
disturbances caused by the assault of the combined agents application. The 
degree of membrane disturbance/disruption may be estimated to be minor if it 
only permitted the leakage of K+ (MW. 32 g/mol), but prevented the outflow of 
the pool of amino acids as well as nucleic acids and disallowed the influx of the 
stain. On the other hand, the degree of membrane disturbance/disruption 
enforced upon cell membrane bilayer would be estimated to be major if the 
disturbance permitted either the influx of the dye into the cells or an unhindered 
outflow of nucleic acids demonstrated by the binding and fluorescing of the stain 
(bearing in mind that the molecular weight of Sytox Green is 600 g/mol (Saugar 
et al. 2006)). The antimicrobial peptide alamethicin forms trans membrane pores 
using the barrel-stave model wherein the hydrophobic regions of the compound 
align with the lipid core regions of the bilayer whilst the hydrophilic regions of the 
agent form the interior region of the pore which can contain 3 – 11 parallel 
helical molecules (He et al. 1995, Ludtke et al. 1996). The inside and outside 
diameters of the pore were found to be ~1.8 and 4.0 nm (Spaar, Münster and 
Salditt 2004). The sizes of toroidal trans membrane pores induced by magainin 
are observed to be bigger with more variable sizes than those formed by 
alamethicin (Yang et al. 2001). These pores measure 3.0 – 5.0 and ~7.0 – 8.4 
nm in inner and outer diameter respectively and each can accommodate either 
4-7 molecules of magainin or approximately 90 lipid molecules (Matsuzaki et al. 
1998). The polycationic Sytox Green stain with a larger molecular weight (600 
g/mol) than the compounds mentioned above (Saugar et al. 2006), 
demonstrates great affinity for RNA as well as DNA but an inability to permeate 
intact bacterial membranes, whilst this stain can flow freely across compromised 
cytoplasmic bilayers (Lebaron, Catala and Parthuisot 1998, Joux and Lebaron 
2000).  The data presented in figure 7.16 suggests that various concentrations of 
polymyxin B were able to disrupt S. aureus membrane integrity to a degree that 
allows either the outflow of the intracellular contents or influx of Sytox Green 
stain only after about 300 minutes. The combinations of the chalcone-derivatives 
with this same polypeptide were however seen to cause an immediate 
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impairment of membrane integrity to allow for the occurrence of the same 
process reflected by the prompt fluorescence of the stain (figure 7.17 and 7.18), 
sometimes to an extent that exceeded the emission induced by benzalkonium 
chloride. 
The data presented in this assay shows that the release of intracellular 
potassium ions is not a guarantee for the stain to fluoresce as the extent of 
membrane disturbance caused by the action of an antimicrobial agent may not 
be sufficient to either permit the outflow of DNA and RNA or the influx of the 
stain. The formation of pores with smaller diameters has been noted to be able 
to prevent the release of the pool of intracellular amino acids (Daniel R. Marshak 
1996). Considering the high inoculum population of 5 x 107 cfu/ml, galangin at 
125 µg/ml demonstrated as much as 2.5 log cfu/ml reduction in the cell viability 
after 24 hours (figure 7.15) with only 1.7 % fluorescence intensity of the dye 
over the same period (figure 7.14). But this flavonol causes damage to the 
cytoplasmic membrane of S. aureus, evidenced by the leakage of intracellular 
potassium ions (Cushnie and Lamb 2005b). It can therefore by speculated, going 
by the findings in this report that the damage to the cytoplasmic bilayer of S. 
aureus instituted by the action of galangin was not sufficient to either permit the 
influx of Sytox Green or enable the outflow of nucleic acid containing materials. 
There may be a desire in the future, to determine the actual size/width of the 
trans membrane infringements that are instituted by galangin’s action. It is a 
well established fact the primary mechanism of action of the other control 
antibiotics penicillin G and ciprofloxacin involves the blockade of the synthesis of 
peptidoglycan (Anderl, Franklin and Stewart 2000) and DNA replication (Pankey 
and Ashcraft 2005) respectively. Both compounds function via a membrane non-
lytic mechanism of action. 
The antibacterial activities of β-lactams and fluoroquinolones are diminished in 
non-growing cells and by high inoculum densities (Mizunaga et al. 2005). Both 
conditions were factored into the experiment for control purposes. The data show 
penicillin G and ciprofloxacin at four times and twenty times their MICs 
demonstrated less than 0.5 log cfu/ml reduction to the inoculum population of 
MSSA. The data also show the combinations of the chalcone-derivatives with 
polymyxin B demonstrated enhanced entry and binding to nucleic acid for Sytox 
Green indicating a potentiated membrane permeabilization and influx for both 
compounds. 
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It has been suggested that the use of Sytox Green for membrane integrity 
analysis should be considered with caution and restricted to the evaluation of 
antibiotic susceptibility of bacteria with undamaged nucleic acids (Lebaron, 
Catala and Parthuisot 1998). Considering that the organisms employed in this 
project were not in starvation mode, neither were they obtained from the natural 
habitat, these bacterial species may be assumed to have undamaged as well as 
the normal proportion of nucleic acids, unlike cell samples collected from the 
Mediterranean Sea (Roth et al. 1997). There is also another assumption that the 
combination of polymyxin B with these chalcone-derivatives does not destroy 
nucleic acids. If both compounds were later found to kill bacteria by mechanisms 
that include destruction of RNA and DNA, then the reported degree of 
fluorescence by the stain upon the combined application of both compounds may 
need to be reviewed. The use of Sytox Green for determining the fraction of dead 
cells amongst marine oligotrophic bacterial species has been restricted by the 
fact that the degree of nucleic acids containing cells may be some times lower 
than 50 % (Karner and Fuhrman 1997). For the same reason, the use of this 
stain in the determination of the fraction of dead cells in natural habitats is 
limited. In the presence of a background stain for live cells, Sytox Green is 
unable to effectively differentiate live from dead cells when the sample is 
obtained from the Mediterranean Sea because of an inadequate supply of RNA 
and DNA (Lebaron, Catala and Parthuisot 1998). In this project however, the use 
of background stain was avoided, preferring colony counting assay that is a more 
reliable means of ascertaining cell viability (Moriarty, Elborn and Tunney 2005, 
Tunney et al. 2004). The adoption of the latter technique also made the 
interpretation of the data from the stain unambiguous since determination of the 
intactness of the bacterial membrane bilayer and viability were simultaneously 
ascertained by two different mechanisms. 
7.4.3 Monitoring changes in fluorescence intensity in S. aureus using 
microscopy 
The data presented in figures 7.4 and 7.5 show clearly that the controls put in 
place for the fluorescence microscopy assay were reliable. The DiOC3(5) stained 
but untreated S. aureus cells did not fluoresce in for the first three hours, 
indicating the absence of membrane depolarisation within this period. The 
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stained cells fluoresced with greater intensity for gramicidin-treated bacterial 
suspensions indicating dye disaggregation within the intracellular space, after 15 
minutes of exposure. This ionophore antibiotic has demonstrable capacity to 
dissipate bacterial cytoplasmic membrane potential thereby enabling dye 
disaggregation that caused the recorded intense fluorescence (Suller, Stark and 
Lloyd 1997). The use of such stains has been adapted in flow cytometry analysis 
for the prompt assessment of antibiotic susceptibility through determination of 
membrane depolarisation, integrity impairment and loss in bacterial viability 
(Kirk et al. 1998, Shapiro 2001). Data presented in figure 7.7 suggests the cells 
exposed to either of the chalcone-derivatives alone demonstrated higher degrees 
of changes in fluorescence intensity over time in comparison to the untreated 
cells but that was higher in intensity when viewed in relation to samples treated 
with the latter agents in combination with polymyxin B. The data presented in 
figures 7.3 to 7.8 likewise suggests firmly that the application of polymyxin B 
with either of the chalcone-derivatives caused a depolarisation of the S. aureus 
bilayer that enabled the disaggregation and notable fluorescence of the stain. 
With the use of a similar stain, and likewise gramicidin as a control, valinomycin 
has been shown to demonstrate complete membrane depolarisation in S. aureus 
(MSSA) as well as MRSA evidenced by intense fluorescence. Understandably, 
methicillin is unable to induce an emission in stained MRSA cells (Suller, Stark 
and Lloyd 1997). Effective β-lactam antibiotics are thought to be able to induce 
depolarisation of membrane potential, inhibition of cell wall biosynthesis and an 
induction of cell wall autolysis that are both dose and bacterial-growth phase 
related (Penyige et al. 2002).  
Sometimes, alterations and damage to cell structures are expected to occur at 
the same time with loss of viability during mechanistic studies for antibacterial 
compounds, in order to correlate cause and effect. But data from some studies 
have shown that this is not always the case. But the timing for the occurrence of 
cellular damage caused by antimicrobial peptides may lag substantially behind 
that for recorded cell death; one study concluded a reported induced ultra-
structural damage may have been artefactual (Brogden 2005).  In other 
instances, the morphological and structural defects caused by the application of 
such agents continue to increase even after the establishment of a killing action. 
E. coli cells treated with the polypeptide, HNP, are seen to increase the formation 
of membranous blebs even after a substantial decrease in colony count is noted 
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(Lehrer et al. 1989). The interpretation of data from that publication was that cell 
death was not caused by bleb formation but rather an event that occurred 
afterwards (Hancock and Lehrer 1998a). Similarly, although a complete loss in 
viability was recorded for E. coli cells exposed to another peptide DEFB118 after 
15 minutes of exposure, morphological and structural damage are seen to 
continue 30 to 120 minutes later (Yenugu et al. 2004). Data reported in figures 
7.5 to 7.13 show that although gramicidin D induced prompt MRSA membrane 
depolarisation that was evidenced by an immediate and intense fluorescence of 
the stain, this was not the case with the combination of polymyxin B with either 
of the semi-synthetic agents. This combination required 3 to 4 hours for notable 
fluorescence which tallied with the timing needed for initiation of substantial loss 
in viability against various strains of this organism (figures 5.1, 5.3, 5.5, 5.8, 5.9 
and 5.10). The occurrence of the reported bactericidal effects for both 
compounds lagged behind the timing for the induced leakage of intracellular 
potassium ions, which was very rapid in onset (figures 7.12 and 7.13). 
7.4.4 Combined discussion of the data in this chapter 
Published data show that sub-inhibitory concentrations of the cAMP myeline 
could dissipate the membrane potential of the cytoplasmic membranes of Ps. 
aeruginosa and S. aureus species, as well as disrupt the outer membrane of the 
former organism (Rasul et al. 2010), following an initial electrostatic interaction 
with both of these cells surfaces (Zhang et al. 2000). It was observed however 
that the major cell damaging/killing effect for both bacterial species was the 
impact of the agent’s destructive effect upon their cytoplasmic membranes. For 
whilst a rapid dissipation of cytoplasmic membrane potential demonstrated by a 
quicker release of DiSC3(5) stain (previously aggregated within the cytoplasm) 
correlates with the timing of the loss of cell viability in Ps. aeruginosa (Rasul et 
al. 2010), all the concentrations used to challenge S. aureus, including the non-
killing concentrations in this report demonstrated a comparable extent and rate 
of intracellular release of this stain. This suggests that membrane depolarisation 
and release of the dye in S. aureus may not always result into an immediate loss 
of cell viability. The data presented in this section although show existence of a 
correlation between the disaggregation of this stain, membrane depolarisation, 
leakage of intracellular cations and loss viability in MRSA suspension challenged 
211 
 
with the combination of polymyxin B with the chalcone-derivative; however the 
timing of the former events preceded that of the latter (chapter 5). Moreover, 
the timing for the rapid loss in intracellular potassium ions tallied with that 
recorded earlier for the blockage of bacterial metabolic activity in chapter 6. 
Previously published data from an agar dilution technique demonstrated galangin 
had MICs in the range of 25 – 50 µg/ml against various strains of S. aureus 
including MSSA (S. aureus NCTC 6571) (Cushnie and Lamb 2005c, Cushnie, 
Hamilton and Lamb 2003) and that this flavonol was bactericidal in action by 
causing a 100,000-fold decrease in inoculum population within 2 hours in time-
course viability studies through rapid cell aggregation (Cushnie et al. 2007) as 
revealed by light microscopy. Although it was thought that the cell aggregation 
effected by galangin was due to the compounds action upon the cytoplasmic 
membrane (Cushnie et al. 2007), data presented in figures 7.12 and 7.13 show 
that Sytox Green is unable to permeate MSSA cytoplasmic barrier when 
challenged with 125 µg/ml of this agent for 24 hours strongly suggesting that the 
integrity of the treated cells were intact during this period despite a ≥ 2.5 log 
cfu/ml reduction in inoculum population. Time-kinetic data not shown from this 
study demonstrated 125 µg/ml was the concentration of galangin required for 
optimum activity against MSSA. 
The inability of Sytox Green to permeate S. aureus cytoplasmic membrane upon 
treatment with galangin, that indicated cell membrane intactness, did not 
however dismiss the possibility for the occurrence of leakage of potassium ions 
due to either infringed minor disturbances upon the bilayer or induced activation 
and/or formation trans membrane channels  (Cushnie and Lamb 2005b). It is 
therefore possible for a given agent to induce pore formation and leakage of 
intracellular cations, without actually causing a killing effect through membrane 
disruption and cell lysis. Indeed, daptomycin causes the leakage of potassium 
ions from S. aureus upon the insertion of the compounds lipophilic acyl tail into 
the cytoplasmic membrane (Rasul et al. 2010). The bleeding of cytoplasmic 
potassium ion could lead to an imbalance in the ionic concentration gradient that 
causes membrane depolarisation, inhibition of protein, DNA, RNA synthesis and 
eventually cell death (Silverman, Perlmutter and Shapiro 2003). Although 
galangin has been shown to cause bacterial death through cell aggregation 
(Cushnie et al. 2007), it may be worth investigating whether the loss of 
intracellular potassium ion induced by the flavonol (Cushnie and Lamb 2005b) is 
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caused by an imbalance in ionic concentration, membrane depolarisation and the 
sub-cellular cascade of events that results to cell death, alongside the induced 
aggregation. 
The data above also therefore suggests that the inability of Sytox Green to pass 
through cytoplasmic membrane may not always imply absolute intactness of the 
bilayer structure as the molecular weight of potassium ion makes this element 
small enough to permit its leakage across such barriers that are effective against 
the polycationic dye. Understandably, the loss of potassium ion is the first sign 
and primary indication of bacterial membrane damage, leading to a chain of 
events that could terminate in cell death (Johnston et al. 2003, Castillo et al. 
2006), even in the absence of cell lysis (Cotroneo et al. 2008). Daptomycin is 
rapidly bactericidal in vitro against S. aureus (Thorne and Alder 2002) through a 
cascade of sub-cellular events that is initiated with the insertion of the 
compounds lipophilic region that seems to initiate membrane depolarisation and 
the leakage of cytoplasmic potassium ions (Silverman, Perlmutter and Shapiro 
2003, Benvenuto et al. 2006) but without the occurrence of cell lysis (Cotroneo 
et al. 2008). 
At various concentrations, polymyxin B demonstrated the capacity to permeate 
S. aureus cytoplasmic membrane and permit the influx of Sytox Green stain. This 
agent has a reputation for self-promoted uptake across bacterial membrane 
bilayer (Hancock 1997b). Antimicrobial peptides with such characteristics are 
also known to promote the uptake of hydrophobic antibiotics across bacterial 
bilayer barriers and act synergistically with these agents (Vaara and Porro 1996, 
Sánchez-Gómez et al. 2011). Therefore, it is being speculated that polymyxin B 
probably promoted the entry of the chalcone derivatives, through which both 
compounds demonstrated augmented bactericidal effect against several Gram-
positive as well as Gram-negative species.  
Cationic antimicrobial peptides (cAMPs) have been known to function as anti-
infective agents through permeabilization of bacterial membranes (Zhang, Rozek 
and Hancock 2001a) and have now been overwhelmingly suggested to also 
function through alternative mechanisms and as such via multiple routes 
(Jenssen, Hamill and Hancock 2006a). The renewed clinical interest in some 
cAMPs such as colistin and polymyxin B, apart from the shortfall in supply of new 
effective agents, is due to their efficacy against multi-resistant Gram-negative 
bacterial species, rapid onset of action and low potential for the emergence of 
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mutant-resistant strains during their applications (Gordon, Romanowski and 
McDermott 2005). Data obtained from this study suggest the combination of the 
chalcone derivatives with polymyxin B can extend the latter’s spectrum of 
activity to include Gram-positive species such as S. aureus through enhanced 
depolarisation and permeabilization of cytoplasmic membrane, increased rate 
and extent of leakage of intracellular potassium ions, blockage of respiratory 
metabolic enzymes (chapter 6) and cell death (chapter 5).  
7.5 Conclusion 
The data presented in this chapter strongly suggest the combination of 
polymyxin B with the chalone-derivatives elicits multiple mechanisms of action 
against S. aureus. 
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Chapter 8 
Erythrocyte lysis assay for polymyxin B combined with either of 
the chalcone derivatives 
8.1 Introduction 
The sensitivity of erythrocytes to the polymyxin B applied alone and in 
combination with either of the chalcone-derivatives were also assessed, as a 
measure of haemolysis. This is thought to be able to give an insight into the 
outcome of possible interactions between potential formulations delivering 
synergistic concentrations of both compounds with these mammalian cells (Plank 
et al. 1994, Miwa et al. 2002). Given the available literature information 
concerning the dose-related nephrotoxicity of polymyxin B alone and the 
aqueous solubility challenges affiliated with the use of the chalcone-derivatives, 
potential future formulations will be likely inclined towards external formulations 
such as ointments, creams, powders for skin ulcers, as well as nebulised 
inhalations that can be applied directly into the lungs in ailments such as cystic 
fibrosis which is normally mediated by multi-resistant Gram-negative organisms 
such as Ps. aeruginosa (Schurek, Breidenstein and Hancock 2012). 
The aims of this section are to examine the sensitivity of mammalian red blood 
cells to the presence of various concentrations of polymyxin B alone and in 
combination with various synergistic strengths of either F1 or F23. 
8.2 Materials and Methods 
8.2.1 Erythrocyte lysis assay 
Erythrocytes were recovered from defribinated horse blood by centrifuging six 1 
ml volumes at 10,000 rpm for 2 minutes. The recovered pellets were washed in 
phosphate buffer solution three times and all were combined in a conical flask. 
The pellets were re-suspended and diluted 20-fold in the same buffer. Following 
on, 4 ml of the suspension, in a non-adherent disposable plastic 20 ml vial 
(Fisher Scientific), was treated with suitable volumes of the stock solutions of 
chalcone-derivative and polymyxin B separately and together, in order to obtain 
the desired final concentrations. All the vials were incubated for 1 hour in a water 
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bath previously set at 37 oC, following which haemolysis was assessed by 
measuring the optical densities of the suspensions at OD540. A four ml aliquot of 
erythrocyte suspension challenged with 5 % w/v sodium dodecyl sulphate (SDS) 
and an equivalent untreated volume were used as controls, representing 0 and 
100 % haemolysis, respectively. This assay was developed by adaptations from 
procedures described by (Fernandez-Lopez et al. 2001) and (Lee and Oh 2000). 
8.3 Results 
8.3.1 Effect of the test compounds on erythrocyte membrane integrity 
The haemolytic effect of the chalcone-derivatives applied alone and in 
combination with polymyxin B upon the membrane integrity of erythrocytes was 
examined and the data obtained are presented in figures 8.1 and 8.2. 
 
Figure 8.1: Data for erythocyte cells treated with various concentrations polymyxin B alone and in 
combination with F1. SDS represents sodium dodecyl sulphate. Results are from experiments 
conducted in duplicated and repeated twice. 
The data expresses the effect of different concentrations of single polymyxin B 
concentrations and treatments made in conjunction with varying concentrations 
of either of the chalcone-derivatives against erythrocytes and showed that this 
polypeptide did not induce membrane lysis upon mammalian cells, even at 
extremely high concentrations of up to 2048 µg/ml, in comparison to 
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216 
 
unchallenged cells. Although 5 % w/v SDS used as the positive control displayed 
a 100 % haemolysis, the applications of different synergistic combination 
concentrations of polymyxin B with either of the chalcone-derivatives 
demonstrated varying degrees of haemolysis. 
 
Figure 8.2: Data for erythocyte cells treated with various concentrations polymyxin B alone and in 
combination with F23. SDS represents sodium dodecyl sulphate. Results are from experiments 
conducted in duplicated and repeated twice. 
In comparison to the action of SDS, the combination of 128 µg/ml of either of 
the chalcone-derivatives with the same concentration of polymyxin B displayed 
80.4 % of unlysed cells (the combination with lowest toxicity), whilst being 
notably synergistic (figure 5.1, 5.3), inducing profuse and rapid leakage of 
intracellular potassium ions (figures 7.12 and 7.13), haven’t ruptured S. aureus 
cytoplasmic membrane to an extent that permitted the inflow of Sytox Green 
stain (figures 7.16 to 7.18) and caused the blockage of the activities of metabolic 
enzymes (figure 6.9). The degree of haemolysis caused by the latter combination 
concentrations was followed by a 28 % haemolysis effected by 32 µg/ml of either 
of the chalcone-derivatives applied with 256 µg/ml polymyxin B. This 
combination had demonstrated the most rapid onset as well as extent of 
cytoplasmic membrane disruption (figure 7.17 and 7.18) and was the most 
synergistic concentration combination against S. aureus species (figure 5.8). It 
was noted that the combination of 64 µg/ml polymyxin B with 64 µg/ml F1 as 
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well as that of 64 µg/ml polymyxin B with 32 µg/ml F1 demonstrated more 
deleterious effects against the exposed cells in the data presented in figure 8.1 
by leaving behind 72 % unruptured cells after the treatment period and that this 
was also consistent with the findings recorded in figure 8.2 for the combined 
action of equivalent concentrations of both F23 with this same antibiotic.  
Therefore, the combination of 128 µg/ml of polymyxin B with either of the 
chalcone compounds appears to have the optimum activity if considerations 
between efficacy and safety was undertaken on the basis of the information 
obtained so far. At the moment, this finding seems ambiguous and would require 
further analysis as lower strengths of antibiotics are expected to display lesser 
adverse effects as has been noted with the dose-related nephrotoxicity syndrome 
of polymyxins (Schurek, Breidenstein and Hancock 2012).  
Combinations containing these concentrations demonstrated a notable 
bactericidal effect against Gram-positive S. aureus and displayed the lowest lysis 
of red blood cells. The combination of 64 µg/ml of both F1 and polymyxin B that 
demonstrated an enhanced inhibition of the activity of metabolic enzymes 
activity in S. aureus (figure 6.9), also displayed a 28 % haemolytic effect. Also, 
the combination of 32 µg/ml F1 with 64 µg/ml polymyxin B displayed as high as 
approximately 40 % haemolysis and was the highest degree of haemolysis 
recorded in this assay. This latter combination concentration instituted the 
blockage of the activity of S. aureus metabolic enzymes (figure 6.8) and induced 
membrane bilayer depolarisation (figure 7.8). The data obtained with the 
combination of polymyxin B with F23 were comparable at some points to those 
from the combination of this same antibiotic with F1. But the combination of 16 
µg/ml F23 with 64 µg/ml polymyxin B induced only about 17 % haemolysis 
(unlike with same concentration of F1 which was 30 %). This combination of F23 
with polymyxin B was synergistic against S. aureus species in the chequerboard 
(table 4.2) as well as in the time-kinetic colony counting (figures 5.8 and 5.9) 
assays. The combinations of either 32 or 64 µg/ml F23 with 64 µg/ml polymyxin 
B induced the same degree of haemolysis (36 %). The combined application of 
32 µg/ml F23 with 64 µg/ml polymyxin B was bactericidal in table 4.2 and figure 
5.9 and induced a notable degree of cell depolarisation in figure 7.9 in S. aureus 
species. The haemolysis action effected by the 5 % w/v SDS positive control was 
approximately twice the value instituted by the most haemolytic combination 
concentration of polymyxin B with either of the semi-synthetic compounds. It 
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appears that red blood cells displayed the lowest level of sensitivity to the 
presence the combination of 128 µg/ml polymyxin B with 128 µg/ml of either of 
both chalcone-derivatives, which had also incidentally demonstrated very notable 
antibacterial actions. If further investigations are warranted in the future, 
controls samples examining the haemolytic activities of F1, F23, strengths of 
DMSO used as solvent in their single applications as well as DMSO-polymyxin B 
should be included in the analysis.  
8.4 Discussion 
8.4.1 Haemolytic effect of polymyxin B with the chalcone-derivatives 
The enhanced haemolytic activity of the application of the chalone-derivatives 
with polymyxin B in vitro may make it necessary to investigate whether this 
combination may show preference for binding with either sodium dodecyl 
sulphate (SDS) or 3-[(3-cholamidoprpyl) dimethylammonio]-1-propanesulphonic 
acid (CHAPS). Cationic antimicrobial peptide antibiotics which prefer interacting 
with SDS over CHAPS are expected to exhibit low haemolytic activity (Rasul et 
al. 2010). Upon independent application, polymyxins have preferential binding 
for Gram-negative bacterial membranes over mammalian cell bilayers (Giuliani, 
Pirri and Nicoletto 2007, Ding et al. 2004, Gregory and Mello 2005) and also 
display an overall preference for prokaryotic membranes, especially at lower 
doses (Giuliani, Pirri and Nicoletto 2007), a desired characteristic of an ideal 
antibiotic. The data in figures 8.1 and 8.2 also suggest mammalian red blood 
cells displayed a very high degree of insensitivity to the presence of polymyxin B, 
even at extremely high concentrations, emphasizing the selective toxicity 
attribute of this agent when applied alone. When applied with varying 
concentrations of the chalcone-derivatives, erythrocytes demonstrated increased 
sensitivity to certain combinations that had shown notable antibacterial actions in 
other sessions. The data presented suggest the combination of 128 µg/ml of 
polymyxin B with either of the chalcone-derivatives had both notable synergistic 
action and the lowest lysis of red blood cells. 
In the past, the concentration-dependent adverse effects of nephrotoxicity 
caused by polymyxins have necessitated studies aimed at improving 
antimicrobial activity whilst enhancing selectivity by varying the number of 
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positive charges (Vaara et al. 2008), hydrophobic interactions with membrane 
bilayers (Dathe et al. 1996) and helicity (Dathe et al. 1997) of the molecule. But 
most of the investigations produced compounds that demonstrated enhanced 
activity with reduced selectivity (Dathe et al. 1997), just like it became clearer 
that helicity and planar orientation at membrane surfaces are also crucial for 
bilayer translocation and antibacterial action (Giuliani, Pirri and Nicoletto 2007, 
Vaara et al. 2008, Vaara  2010, Brogden  2005).  A strong correlation however 
also exists between the helicity of cationic amphiphatic model peptides and 
haemolytic activity which seems to verify the hypothesis that helicity significantly 
contributes to haemolysis (Dathe et al. 2002, Dathe et al. 1997). It may be 
worth investigating whether the combined application of polymyxin B with lower 
concentrations of these chalcone-derivatives causes an increase in haemolytic 
tendency through alteration to the hydrophobic moment and planar orientation of 
both compounds when in contact with mammalian (erythrocyte) cell membranes; 
and whether a further increase in the amount of the semi-synthetic agents leads 
to helical movements that effect lower degrees of disruption against these 
bilayers. 
8.5 Conclusion 
Certain combinations of polymyxin B with the chalone-derivatives, which were 
previously reported to be synergistic in action against the various bacterial 
species, displayed lower degrees of lysis of mammalian red blood cells. 
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Chapter 9  
General discussion and future works 
9.1 The need for new agents and combinations of antibiotics with 
either novel or multiple mechanisms of action 
In view of the prevailing universal crises and continually emerging patterns of 
microbial resistance to antibiotics (Zhang et al. 2006, DiazGranados, Cardo and 
McGowan 2008, Kumarasamy et al. 2010, Johnson et al. 2012), there remains a 
strong rational need for the discovery and development of new effective 
antimicrobial agents with either uncommon or multiple mechanisms of action 
(Fischbach and Walsh 2009). Newly introduced agents that do not belong to the 
existing classes of antibiotics, possessing either novel or multiple mechanisms of 
action will ensure a prolonged delay in the time required by susceptible 
organisms to develop resistance strategies (Gould 2007). Research efforts must 
therefore be aimed at the search for either unfamiliar molecular structures with 
antibiotic activities or new combinational approaches that yield synergistic 
outcomes, entailing the applications of established antimicrobial compounds with 
novel agents, such as semi-synthetic flavonoids (Cushnie and Lamb 2011, 
Anderson et al. 2005). 
The methods described in this thesis were used to evaluate the antibacterial 
activity of the synthetic hydrophobic compounds, F1 and F23.  The chequerboard 
method used for preliminary investigations aided the detection and evaluation of 
their synergistic action with polymyxin B. Although the use of this technique is 
considered adequate for the examination of synergistic action amongst cationic 
antimicrobial peptides (cAMPs) (Yan and Hancock 2001), the data obtained 
showing synergism between the applied agents, were verified using more reliable 
time-course viability assays (Lewis et al. 2002). The modified bacterial MTT-
reduction protocol also gave demonstrable insight into possible mechanisms of 
action by polymyxins against selected bacterial species through the inhibition of 
the cells respiratory metabolic pathway. The timing of the latter event shows it 
occurred in advance of the loss of cell viability, suggesting metabolic enzyme 
inhibition is amongst the initial mechanisms of action for the synergistic 
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combinations of polymyxin B with the chalcone-derivatives against Gram-positive 
S. aureus species. 
Although the chalcone-derivatives were ineffective as antimicrobial agents alone, 
a combination of either F1 or F23 with polymyxin B induced a notable 
antibacterial effect. Similarly, although polymyxin B alone is known to be 
ineffective against Gram-positive bacterial species, the combination of this 
polypeptide antibiotic with either of the semi-synthetic agents elicited an 
extended spectrum of activity, resulting in antibacterial actions against both 
Gram-positive and negative bacterial species. 
The predominant reason for using antibiotic combinational therapy, especially 
during an empirical treatment, includes the need for a wider spectrum of 
coverage (Viscoli and Castagnola 2002), improved action against multiple-drug 
resistant strains (Nicas, Zeckel and Braun 1997), a reduction in the potential for 
dose-related adverse events due to the use of lower doses of the combined drugs 
(Pal and Mitra 2006) and an improvement in the antibiotic pharmacokinetic 
profile (Roling et al. 2002a). Although a combined application of different 
antibiotics can result in competitive antagonism if the agents share either a 
common mechanism of action or are acting on the same target site (Roling et al. 
2002b), the use of polymyxin B with the chalcone-derivatives (either F1 or F23), 
elicited an enhanced bactericidal effect. Considering that the molecular structures 
presented in figure 1.5 show the absence of a net-charge in the chalcone-
derivatives and that these compounds are hydrophobic, these agents may on 
their own be possessing low membrane activity and were also to have been 
antagonistic in action with the polymyxins, whose primary target is the disruption 
of the cell membrane (Vaara  2010).  
Previous studies have shown that the antibacterial activity of aminoglycosides 
and daptomycin are affected by media composition (König, Schwank and Blaser 
2001), including the addition of Ca2+ (Barry, Fuchs and Brown 2001). The extent 
of the interference caused by these factors varies with the class of organism such 
that Gram-negative species have been shown to be more sensitive to both 
antibiotics in vivo, in the presence of externally added Ca2+ (Benvenuto et al. 
2006, da Cunha Camargo et al. 2008,Baltz  2009, Kotra, Haddad and Mobashery 
2000). This observation is thought to be associated with the preferential binding 
of these cationic agents to the lipopolysaccharide layer and competitive 
displacement of native Ca2+ as well as Mg2+ from the membrane bilayer surface 
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(Zhang, Rozek and Hancock 2001a, Hancock and Rozek 2002a). Variation in 
media content has been shown to significantly influence the degree of action of 
some antibiotics, especially those with weak basic molecular structures such as 
daptomycin, which has a pKa value of approximately 7.5 as well as about 50 % 
ionisable functional side-chains at pH 7 (Chopra  2007). The addition of 20 % 
albumin and 50 mg/ml Ca2+ significantly improves the antibacterial action of 
daptomycin (Thorne and Alder 2002) through mechanisms thought to involve the 
reduction of the quantity of free divalent cations in the test medium, thereby 
promoting competitive binding of daptomycin to the anionic lipopolysaccharide 
which in turn results in depolarisation and disruption of the outer membrane 
structure (Baltz  2009). One lapse in the present study was that the effect of 
growth media on the activity of the semi-synthetic chalcone-derivatives was 
conducted with only Mueller-Hinton broth, such that the effect of media-content 
variation on the antibacterial action of these chalcone derivatives with polymyxin 
B remains to be determined. So the effect of pH fluctuation, broth content 
variation and presence of cations like Ca2+, Mg2+ and Zn2+. on the antibacterial 
activity of effective combination concentrations of polymyxin B with the 
chalcone-derivatives would be worth investigating in future. Furthermore, the 
effect of nutrients present in Mueller-Hinton broth on the activity of chalcone-
derivatives was considered only against Gram-positive S. aureus. Such an 
analysis should be extended to cover Gram-negative organisms in order to give a 
balanced view and a more reliable interpretation of the entire data. 
Polysorbate 80 enhances the concentration-dependent antibacterial activity of 
oritavancin when assessed by in vitro time-kinetic assays (Belley et al. 2009, 
McKay et al. 2009a) by functioning as a surfactant that promotes solubilisation of 
this oligopeptide antibiotic whilst minimising the adherence of this drug to 
experimental vessel walls. The effect of this pharmaceutical excipient (Gourley et 
al. 2007) on the antibacterial activity of both chalcone-derivatives alone and 
their effective combinations with other agents should be considered in the future, 
since DMSO was used as a solvent for the analysis of these semi-synthetic 
compounds. 
A systematic review of PubMed and Scopus databases on the studies conducted 
so far to determine the comparative effectiveness of polymyxins either as a 
monotherapy or as a combinational treatment with other antibiotics such as 
rifampicin and carbapenems was undertaken (Petrosillo, Ioannidou and Falagas 
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2008). This review found 16 studies that had previously evaluated the 
effectiveness of these agents. All the studies were carried out using Gram-
negative bacterial species giving an impression that their objectives included a 
view towards improving the action of this polypeptide agent against resistant 
strains of this class of organisms, with a particular emphasis on Ps. aeruginosa, 
Acinetobacter baumannii and E. coli (Petrosillo, Ioannidou and Falagas 2008), 
whilst preserving the clinical lifespan of this antibiotic class (Falagas, Kasiakou 
and Saravolatz 2005). On the other hand, the data presented in this report 
primarily focused  on extending the antibacterial coverage of polymyxin B to 
include Gram-positive organisms through a combined application with chalcone-
derivatives whilst also improving the efficacy of polymyxin B against Gram-
negative organisms. The finding that F1 applied in combination with polymyxin B 
demonstrated an augmented activity against MSSA, MRSA, QRSA, C. violaceum, 
E. coli and Ps. aeruginosa in both a chequerboard and time-course colony 
counting assays is therefore noteworthy. 
The antibacterial action of the combination of the polypeptide antibiotic with 
either of the chalcone-derivatives may not be attributable to one specific 
mechanism, as there are several possible targets which include dissipation of 
membrane potential, disruption of membrane integrity, blockage of cell wall 
synthesis, interaction with nucleic acids as well as impairment of the activity of 
metabolic and essential enzymes, (Carson, Mee and Riley 2002). Although these 
represent the most likely targets, some of these potential sites may not be 
affected in isolation due to the triggering of a cascade of events. The locations 
within bacterial cells thought to be the sites of action upon which the 
combination of polymyxin B with the chalcone compounds act include membrane 
depolarisation, especially in Gram-positive organisms, as has been demonstrated 
in published data for S. aureus challenged with daptomycin (Silverman, 
Perlmutter and Shapiro 2003). The blockage of cell wall synthesis by the 
combined agents, especially under bacterial growth conditions, may also be a 
possibility considering that these compounds have demonstrated the capacity to 
prevent the multiplication of S. aureus in broth under suitable growth conditions 
(figure 5.4). Similarly, the impairment of cell wall synthesis is a proven 
mechanism of action with β-lactams, glycopeptides and others (Rivera and 
Boucher 2011, Pinho and Errington 2005).  
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Leakage of intracellular potassium ions is one of the first signs of a damaged 
bacterial membrane (Johnston et al. 2003, Ioannou, Hanlon and Denyer 2007). 
Data provided in this study show that the application of polymyxin B with the 
chalcone-derivatives demonstrated an enhanced leakage of intracellular 
potassium ions. The occurrence of this event, like the cessation of respiratory 
metabolic activity, preceded the loss of cell viability in S. aureus species. The 
simultaneous occurrence of membrane depolarisation, leakage of intracellular 
cations and either interference with cell wall expansion and synthesis or an 
outright damaging of existing cell wall structures have been noted with 
vancomycin, teicoplanin, daptomycin and oritavancin (Howden et al. 2010, Kim 
et al. 2008, Domenech et al. 2009, Baltz  2009). But an area that was clearly not 
investigated in this study is the capacity of the combined agents (polymyxin B 
with chalcone-derivatives) to induce damage to membrane proteins. Damage to 
membrane proteins especially by reactive oxygen species and oxidative stress 
are recognised mechanisms of bacterial destruction by antibiotics (Cabiscol, 
Tamarit and Ros 2010). There is little possibility that the combination of 
polymyxin B with either of the chalcone-derivatives can impede the activities cell 
proteins within the cytoplasmic membrane as seen with other antimicrobial 
peptides, which are able to impair septum formation in bacterial binary fission 
(Kois et al. 2009), but there is a strong speculation that the induction of pore 
formation in the cytoplasmic bilayer (Brogden  2005) may be involved. The data 
provided from bacterial metabolic assays showing a cessation of the activity of 
reducing enzymes in S. aureus by the combination of polymyxin B with either F1 
or F23 may also be supporting another speculation for the existence of a 
simultaneous impairment of the activity of other enzymes such as ATPase, 
located within the cytoplasmic membrane (Fekkes and Driessen 1999, Qu and 
Sharom 2002). This needs to be further investigated. 
The combination of polymyxin B with the chalcone-derivatives may have led to 
the production of a partly lipophylic entity that can be attached/accumulated in 
the lipid bilayer, causing a distortion of either the lipid-lipid or lipid-protein 
interaction. Because the newly assembled moiety may have an amphiphilic 
character, the lipophilic component of this structure could have exercised a direct 
engagement with the hydrophobic areas of the bacterial bilayer proteins (Denich 
et al. 2003), potentially causing a depletion of the proton-motive force. The 
depletion of the proton-motive force by the activity of certain antibiotics [such as 
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lactosporins, bacteriocins, megainin, etc., (Riazi, Dover and Chikindas 2012)], 
and by nisin in species of mycobacterium (Chung, Montville and Chikindas 2000) 
is well established. Nisin causes a time and concentration dependent reduction of 
cytoplasmic ATP levels without any evidence of ATP efflux in M. bovis-BCG by 
decreasing both components of the proton motive force (membrane potential, 
∆ψ and ∆pH) (Chung, Montville and Chikindas 2000). The depletion of ATP can 
lead to catastrophic events that culminate in cell death (Nicholls and Budd 1998).  
Similarly depletion of NAD+, an important co-factor in bacterial metabolism, is 
known to occur through hyper-activation of PARP-1 following DNA damage 
through the activity of alkylating agents (Grahnert et al. 2011). This leads to the 
reduction in the amount of NAD+ within the cytoplasm, a cessation of glycolysis 
as well as depletion of the intracellular ATP pool and eventually cell death (Blank 
and Shiloh 2007). This form of induced cell apoptosis occurs because, in a bid to 
re-synthesize more NAD+, the bacterial species consume the reserve stock of 
ATP, thereby exacerbating the energy crisis that leads to cell death (Pieper et al. 
1999).  
The data provided in this study clearly shows polymyxin B (and colistin) 
exhibited capacities to initiate sub-cellular events that led to the impairment of 
the activities of essential metabolic respiratory enzymes in species of S. aureus, 
Ps. aeruginosa and E. coli. The combination of polymyxin B with the chalcone-
derivatives demonstrated an extension of the activity of polymyxin B to cover 
Gram-positive S. aureus through an enhanced membrane depolarisation, 
increased leakage of intracellular content as well as an augmented impairment of 
the activity of biological reducing enzymes.  
9.2 Enhanced uptake may be a vital step for the synergistic actions of 
polymyxin B with the chalcone-derivatives 
The possible means by which polymyxin B undergoes self-promoted uptake 
across bacterial membranes have been extensively studied (Hancock 1997b, 
Brogden 2005). The barrel-stave method appears most suitable for explaining 
the uptake of polymyxin B with the chalcone-derivatives since the trans 
membrane pore formation would more likely facilitate a continuous translocation 
of both compounds. It can be speculated that polymyxin B was being synergistic 
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with these semi-synthetic hydrophobic compounds through their promoted up-
take across the outer (in Gram-negative bacterial cells) and cytoplasmic 
membrane barriers. The antimicrobial activity of hydrophobic compounds is 
greatly impeded because of a reduction of access to their intracellular target sites 
due to the barrier instituted by the presence of the lipopolysaccharide layer in 
Gram-negative bacterial species, as well as by highly effective efflux pumps 
mechanisms (Hancock 1997c, Hancock and Chapple 1999). It is possible that 
their poor aqueous solubility makes it more difficult for these semi-synthetic 
agents to permeate bacterial outer and cytoplasmic membranes despite their 
relatively modest molecular weights (figure 1.5) and in addition, a great fraction 
of hydrophobic compounds are extruded by the activity of efflux pumps 
(Fernández, Breidenstein and Hancock 2011, Hancock 1997d). More so, both F1 
as well as F23 appear to bear no net surface charge and may consequently not 
be exhibiting enough physical and ionic interactions with either the polyanionic 
lipopolysaccharide outer bilayer in Gram negative bacterial species or teichoic 
and lipoteichoic acids in Gram-positive species, limiting their trans-location 
capacities. Such physical and chemical ionic interactions are prerequisites for 
enhanced antibiotic uptake and actions which can ultimately result in cell death, 
especially those initiated through membrane depolarisation and disruption 
(Falagas, Kasiakou and Saravolatz 2005, Hancock and Sahl 2006).  
Unlike chalcone-derivatives, polymyxins are amphipatic compounds with 
hydrophobic fatty acyl regions attached to their amino terminus (Tsubery et al. 
2000, Giacometti et al. 2000). Polymyxin-like peptide, ranalexin, enhances the 
entry of several hydrophobic substrates into both Gram-positive and Gram-
negative bacterial cells (Giacometti et al. 2000). Hydrophilic cAMPs applied 
together with hydrophobic fluorescent compounds increase the diameter of the 
outer membrane porins and inadvertently enhance the influx of hydrophobic 
fluorescent probes (Delcour 2009). Therefore both ranalexin and polymyxins can 
act in a manner that potentiates the antibacterial action of lipophilic and 
amphiphilic agents such as rifampicin, erythromycin, fusidic acid and novobiocin 
against Ps. aeruginosa (Hancock 1997c, Giacometti et al. 2000, Vaara and Porro 
1996). In addition, the application of polycationic peptides (ranalexin) in 
combination with polymyxins yields synergistic antimicrobial action (Knoetze 
2006). This is understandable considering that both compounds have similar 
mechanisms of interacting with the phospholipids of cell membranes, increasing 
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bilayer permeability and disrupting osmotic integrity (Giacometti et al. 2000, 
Giacometti et al. 1999). 
Compared to Gram-positive cells, Gram-negative species possess a layer of 
peptidoglycan with a reduced thickness and an outer membrane in addition to 
the cytoplasmic membrane that exists in both classes of bacteria (Pagès, James 
and Winterhalter 2008). The outer-membrane functions as a selective sieve and 
a permeability barrier, bearing additional efflux mechanisms as well as a 
periplasmic space that can accommodate β-lactamase enzymes (Hancock and 
Rozek 2002b). All these factors collectively function to make Gram-negative 
bacteria intrinsically more resistant to most antibiotics (Li, Zhang and Poole 
2000). But, Gram-negative bacterial species are more susceptible to colistin and 
polymyxin B because these agents competitively interact with the anionic 
lipopolysaccharide, underging a self-promoted uptake (Hancock 1997b), and 
causing disruption of this polyanionic outer membrane bilayer that is completely 
absent in Gram-positive organisms (Falagas, Kasiakou and Saravolatz 2005). 
Therefore, the observation that the combination of polymyxin B with the 
chalcone-derivatives was bactericidal against Gram-positive S. aureus species 
became very crucial in this study. 
The thicker peptidoglycan layer in Gram-positive bacteria may also be partly 
responsible for making species of S. aureus particularly insusceptible to the 
activities of some antibiotics, including the polymyxins (Lorian 2005, Russell 
1998, Epand et al. 2006). Vancomycin-intermediate resistant S. aureus (VISA) 
isolated from patients with previous exposure to vancomycin have been noted for 
their exceptionally thicker cell wall (Appelbaum  2007) developed in response to 
an altered composition of the peptidoglycan layer (Sieradzki, Pinho and Tomasz 
1999). This altered morphology creates an environment enabling the 
continuation of cell wall synthesis even in the presence of glycopeptides due to 
the inability of these agents to gain sufficient access to these target sites, due to 
entrapment of a large fraction of the administered dose within the enlarged wall 
structure (Sieradzki, Pinho and Tomasz 1999). Findings in this study suggest that 
although the chalcone-derivatives were weak in antibacterial actions on their 
own, their effectiveness may be greatly improved with increased translocation 
across bacterial membrane bilayer barrier.  
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9.3 Inhibition of efflux mechanisms as a potential mechanism of 
polymyxin B combined with the chalcone-derivatives 
Although the inhibition of bacterial efflux mechanisms, such as the blockage of 
the activities of the ABC transporters involved in the extrusion of tetracyclines by 
reserpine and verapamil (Mahamoud et al. 2007), has not been previously 
ascribed to the polymyxins, it may be worthwhile investigating the possibility of 
this combination of this latter agent with the chalcone-derivatives to act through 
this mechanism. The combination of MC-207,110 with laevofloxacin against Ps. 
aeruginosa and E. coli caused a reduction of intrinsic resistance of these 
organisms to fluoroquinolone (Lomovskaya et al. 2001b). An 8-fold reduction in 
the intrinsic resistance of both organisms was induced by the drug combination 
through the potentiating action of MC-207,110, a broad spectrum efflux pump 
inhibitor effective against all three Mex efflux pumps in Ps. aeruginosa and their 
homologues AcrAB-TolC in E. coli (Lomovskaya et al. 2001b). It may be worth 
investigating whether the potentiated action of polymyxin B with the chalcone-
derivatives against Gram-negative species of Ps. aeruginosa and C. violaceum is 
due to an inhibitory effect upon mechanisms responsible for an early efflux of the 
combined agents. Regardless of how the synergistic action is imparted, the 
antibacterial activity of polymyxin B singly applied against S. aureus (MSSA, 
MRSA and QRSA), C. violaceum as well as Ps. aeruginosa was potentiated from 
being bacteriostatic to bactericidal with the addition of small fractions of either of 
the semi-synthetic agents. The activity of ciprofloxacin when combined with the 
semi-synthetic agents was also augmented against S. aureus in a chequerboard 
assay. 
But apart from efflux, bacterial resistance to fluoroquinolone antibiotics can also 
occur by target mutations, occurring mainly in quinolone-resistant determining 
regions (QRDRS) (Piddock  1995, Hartmann et al. 1998), in DNA gyrase (gyrA 
and gyrB) and topoisomerase IV (parC and parE). It would be important to 
investigate in future whether the chalcone derivatives are able to block the 
activity of efflux pumps through the inactivation of QRDR in S. aureus when 
applied with polymyxin B. In this regard, reserpine is a known MDR pump 
inhibitor for Gram-positive bacteria, mammalian cells and p-glycoproteins 
(Markham 1999), with an additional capacity to suppress the emergence of 
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ciprofloxacin-resistant mutants in S. aureus and S. pneumonia (Markham 1999, 
Markham and Neyfakh 1996). It may be worthwhile to examine whether the 
chalcone derivatives are able to inhibit NorA MDR efflux pump activity in S. 
aureus. Such an investigation may be extended to cover whether the activity of 
the chalcone-derivatives, when combined with polymyxin B involves the 
inhibition of MexAB-OprM, MexCD-OprJ and MexEF-OprN efflux mechanisms in 
Ps. aeruginosa. Such an action is known to be able to significantly improve the 
antibiotic activity of complement compounds via a decrease in intrinsic 
resistance, reversal of acquired resistance as well as a reduction in the potential 
for the emergence of mutant strains (Lomovskaya et al. 2001b). 
9.4 The semi-synthetic flavonoids (F1 and F23) demonstrated a 
potential to synergistically extend the spectrum and improve the efficacy 
of polymyxin B   
Although polymyxins are ineffective against Gram-positive species, an extension 
of their antibacterial spectrum through the complementary activity of the 
chalcone-derivatives would be a development with clinical advantage. But on 
their own, the polymyxins are effective agents against Gram-negative bacterial 
species and are reserved for multi-resistant strains (Falagas, Kasiakou and 
Saravolatz 2005). Published data show that colistin was rapidly bactericidal with 
as much as a 5 log cfu/ml reduction to strains of Ps. aeruginosa within 2 hours 
(Gunderson et al. 2003, Li et al. 2001a). However, cell re-growth occurs after 
about 8 hours. The data presented from this study (chapters 4 and 5) show that 
the combination of polymyxin B with the chalcone-derivatives demonstrated 
improved/synergistic activity against Ps. aeruginosa under buffer environment. 
Such studies should be repeated with polymyxin B applied with either of the 
chalcone-derivatives in broth. In the event of an absence of re-growth, this 
would verify that it could be advantageous to use polymyxin B with these semi-
synthetic agents. It is worth mentioning at this point that these chalcone-
derivatives were synthesized through a one-step microwave assisted 
heterocyclisation pathway (Abdel Ghani et al. 2008), making it relatively simple 
for these compounds to be produced. Hence if the combined application with 
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polymyxin B is considered to be clinically useful, a continuous supply of the 
chalcone-derivatives at a reasonable cost is guaranteed. 
Cationic antimicrobial peptides (cAMPs) that are bactericidal with kill rates as 
high as 99.99 % within a short duration are thought to cause depolarisation of 
membrane potential (Baltz  2009, Cotroneo et al. 2008), disruption of the bilayer 
structure (Hancock and Rozek 2002b), as well as cell de-energization (Hancock 
and Rozek 2002a, Tam et al. 2005, Steinberg et al. 1997). The data presented 
from this study strongly suggests that these polycationic agents are able to block 
the activity of enzymes responsible for essential metabolic processes. The 
capacity of these agents to dissipate the membrane bilayer was previously 
exemplified with the accumulation of triphenymethylphosphonium and safranine 
O by E. coli membrane vesicles in the presence of suitable electron donors, which 
is regarded as an indication of membrane depolarisation (Sakai, Houdebert and 
Matile 2003), as this process occurs only in response to an induced intracellular 
potassium ion gradient. But the ability of the combination of polymyxin B with 
the chalcone-derivatives to induce the leakage of intracellular potassium ions 
from S. aureus demonstrated in this study (figures 7.12 and 7.13), may have 
been preceded by membrane depolarisation through the dissipation of trans 
membrane ∆pH and ∆ψ across the bilayer. 
With Ps. aeruginosa, the suppression of ATP generation and utilisation might 
have been temporary or else the organism developed a by-pass mechanism 
enabling the transitioning from aerobic to anaerobic respiration (Hassett et al. 
2002) and thereby overcoming the effect of the inhibition of essential metabolic 
pathways. This speculation may provide an explanation for the re-growth 
recorded with higher cell densities challenged with single applications of colistin 
(Gunderson et al. 2003) and polymyxin B (Tam et al. 2005) for assays conducted 
in broth. The synergistic action recorded for the combination of 128 µg/ml of 
polymyxin B with either of the chalcone-derivative that demonstrated an 
excellent reduction of the S. aureus colonies should be re-evaluated under 
bacterial growth conditions. This combination concentration that displayed an 
excellent antibacterial action alongside a weak haemolytic effect should also be 
noted for further analysis. Like the commencement of antibiotic action of 
daptomycin (Castanheira et al. 2008, Cotroneo et al. 2008), it is possible that 
the combined application of both compounds stated above interacted with the 
acyl portion of the bacterial membrane bilayer to institute the depolarisation as 
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well as cause an alteration of the surface membrane structure in a manner that 
enables the inward permeation of more of both drug entities, similar to the 
barrel-stave analogy (Bradshaw 2003, Brogden 2005). This speculation is based 
on the knowledge that antimicrobial peptides always associate with membrane 
lipid head groups (Brogden 2005). There is no evidence at the moment as to 
whether or not pore formation ensues, but the data provided strongly suggest 
the occurrence of cytoplasmic membrane depolarisation (figures 7.1 and 7.2), as 
well as disruption, which is evidenced by the leakage of intracellular K+ (figures 
7.12 and 7.13), influx and emission of the intact membrane bilayer-impermeable 
Sytox Green stain (figures 7.16 to 7.18), followed by cell death (chapter 5). This 
is almost the same sequence of events for daptomycin, albeit with emphasis on 
the occurrence of membrane depolarisation as a prerequisite (Silverman et al. 
2005, Silverman, Perlmutter and Shapiro 2003).  
The disruption of the trans membrane electrochemical gradient by daptomycin in 
B. megaterium leads to the blockage of active transport of cell wall amino acids, 
formation of sugar-peptide precursors and peptidoglycan synthesis (Wagenlehner 
and Naber 2004). Although Jung and colleagues have shown evidence that 
membrane depolarisation can occur after cell death upon bacterial exposure to 
daptomycin (Jung et al. 2004b), the data provided in this study for the 
membrane activity of polymyxin B with the chalcone-derivatives suggest 
depolarisation preceded cell death for challenged S. aureus species. For whilst 
membrane depolarisation and inhibition of metabolic activity were seen to occur 
within 60 minutes (figures 7.1 and 7.2; chapter 6), significant loss in viability 
were often recorded beyond 120 minutes (chapter 5). The bactericidal action of 
daptomycin and vancomycin is optimal when cells are challenged in the 
logarithmic rather than stationary growth phase (Snydman et al. 2000), unlike 
with oritavancin (Mercier, Stumpo and Rybak 2002). It is yet to be ascertained 
as to whether or not the combined action of the chalcone-derivative with 
polymyxin B is growth-phase specific. However, an equivalent of 8 x MIC F1 only 
application was seen to demonstrate bacteriostatic action against species of S. 
aureus in both broth and buffer. The data provided in this study also suggest 
that, like the action of daptomycin against S. aureus (Sauermann et al. 2008), 
the antibiotic effect of the combined application of the semi-synthetic agents with 
polymyxin B was concentration-dependent. Therefore, should in vivo studies be 
warranted in future, the efficacy of the combinations would best be correlated 
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with either the peak concentration (Cmax) or a 24 hours area under the 
concentration versus time curve (AUC), in relation to the MIC demonstrated 
against the given bacterial strain (Thorne and Alder 2002, Dandekar et al. 2004, 
Safdar, Andes and Craig 2004), since this will give a clearer indication of the 
bioavailability profiles for both agents in relation to their activity over time. 
Also in the future, further toxicity studies will be required given that the 
combination of either of the chalcone derivatives with polymyxin B has been 
suggested to cause a blockage of the activity of reducing enzymes such as NADH 
and succinate dehydrogenase, which are present in both prokaryotic and 
mammalian host cells. But a more specific toxicity study should focus on the 
potential of these polymyxin B chalcone-derivatives combinations to aggravate 
the neuro and nephro toxicities that were previously associated with the former 
antibiotic. Structural studies to improve the aqueous solubility of these semi-
synthetic flavonoids may include the addition of either gallate or citrate sub-
group to the chromone-ring of these compounds. This sort of structural 
modification improved solubility, hydrolytic stability and enhanced the 
antibacterial action of both (-)-epicatechin (as the gallate) (Stapleton et al. 
2007). This might speculatively lower their MICs to sub-microgram values and 
encourage the undertaking of other molecular biology experimentations as well 
as formulation studies. Considerations may latter be given to potential 
formulations containing polymyxin B with either of the chalcone-derivatives in 
the form of external applications such as ointments, lotions, nebulised powders 
(for cystic fibrosis), dusting powders for skin ulcers and as either sanitizers or 
disinfectants. 
9.5 Conclusion 
In addition to membrane bilayer depolarisation and disruption, another plausible 
mechanism for the antibacterial action of polymyxins demonstrated in this study 
is the inhibition of essential bacterial enzymes activity, displayed by their 
capacity to block cell respiratory metabolism. The combination of polymyxin B 
with either of the chalcone-derivatives (F1 and F23), demonstrated a potential 
extended spectrum to include Gram-positive species of S. aureus, as well as an 
enhanced efficacy against Ps. aeruginosa and C. violaceum, by this decapeptide 
antibiotic. The combination of both agents dissipated cell membrane potential, 
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induced leakage of intracellular cations as well as enabled the influx of Sytox 
Green thereby indicating the infliction of major membrane disruption. 
Furthermore, the combination of either of both compounds caused the cessation 
of metabolic activity and eventually led to cell death. Future optimisation through 
structural activity modifications as well as formulation studies are needed to 
develop suitable and effective therapeutic combinations of the chalcone-
derivatives with polymyxin B against clinical strains of Gram-positive and 
negative bacterial species.  
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11 
Appendices 
11.1 List of the examined chalcone-derivative compounds  
Code Chemical Structure 
F1 
O
O
O
C17H20O3
Mol. Wt.: 272.339
2-(cyclohexylmethyl)-6-methoxy-4H-chromen-4-one  
F2 
O
O
Br
C16H17BrO2
Mol. Wt.: 321.209
6-bromo-2-(cyclohexylmethyl)-4H-chromen-4-one
 
F3 
O
O
O
C17H20O3
Mol. Wt.: 272.339
2-(cyclohexylmethyl)-7-methoxy-4H-chromen-4-one
 
F4 
O
O
Br
CF3
C16H8BrF3O2
Mol. Wt.: 369.133
6-bromo-2-(4-(trifluoromethyl)phenyl)-4H-chromen-4-one  
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F5 
O
O
O
CF3
C17H11F3O3
Mol. Wt.: 320.263
2-(4-(trifluoromethyl)phenyl)-6-methoxy-4H-chromen-4-one  
F6 
O
O
CF3
F
C16H8F4O2
Mol. Wt.: 308.227
7-fluoro-2-(4-(trifluoromethyl)phenyl)-4H-chromen-4-one  
F7 
O
O
Cl
F
C15H8ClFO2
Mol. Wt.: 274.674
2-(4-chlorophenyl)-7-fluoro-4H-chromen-4-one  
F8 
O
O
F Cl
C15H8ClFO2
Mol. Wt.: 274.674
2-(3-chlorophenyl)-7-fluoro-4H-chromen-4-one  
F9 
O
O
F
Cl
C15H8ClFO2
Mol. Wt.: 274.674
2-(2-chlorophenyl)-7-fluoro-4H-chromen-4-one  
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F10 
O
O
F
C15H15FO2
Mol. Wt.: 246.277
2-cyclohexyl-7-fluoro-4H-chromen-4-one  
F11 
O
O
OF
C13H7FO3
Mol. Wt.: 230.191
7-fluoro-2-(furan-2-yl)-4H-chromen-4-one  
F12 
O
O
F
F
C15H8F2O2
Mol. Wt.: 258.22
7-fluoro-2-(4-fluorophenyl)-4H-chromen-4-one  
F13 
O
O
F
CF3
CF3
C17H7F7O2
Mol. Wt.: 376.225
2-(3,5-bis(trifluoromethyl)phenyl)-7-fluoro-
4H-chromen-4-one  
F14 
O
O
N
C20H25NO2
Mol. Wt.: 311.418
2-cyclohexyl-7-(piperidin-1-yl)-4H-chromen-4-one  
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F15 
O
O
N
C20H19NO2
Mol. Wt.: 305.37
2-phenyl-7-(piperidin-1-yl)-4H-chromen-4-one  
F16 
O
O
N
N
CF3C21H19F3N2O2
Mol. Wt.: 388.383
2-(4-(trifluoromethyl)phenyl)-7-(4-methylpiperazin-1-yl)-4H-chromen-4-one  
F17 
O
O
N
O
ClC19H16ClNO3
Mol. Wt.: 341.788
2-(4-chlorophenyl)-7-morpholino-4H-chromen-4-one  
F18 
O
O
N O
C18H17NO3
Mol. Wt.: 295.332
2-(furan-2-yl)-7-(piperidin-1-yl)-4H-chromen-4-one  
F19 
O
O
N
O
C19H23NO3
Mol. Wt.: 313.391
2-cyclohexyl-7-morpholino-4H-chromen-4-one  
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F20 
O
O
HO
MW. 258.31
2-(cyclohexylmethyl)-6-hydroxy-
4H-chromen-4-one  
F21 
O
O
O
C13H12O3
Mol. Wt.: 216.2326
2-cyclopropyl-6-methoxy-4H-chromen-4-one  
F22 
O
O
Br
6-bromo-2-cyclopropyl-4H-chromen-4-one
C12H9BrO2
Mol. Wt.: 265.1027
 
F23 
MeO
O
O
F23: C16H18O3
MW. 258.31 g/mol
2-cyclohexyl-6-methoxy-4H-chromen-4-
one  
Table 11.1: Chemical structure, molecular weight and scientific names of the examined chalcone 
derivatives 
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11.2 Calibration curves for S.aureus strains 
 
Figure 12.1: Calibration curves for S. aureus 6571 (MSSA) 
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Figure 12.2: Calibration curves for S. aureus 11940 (MRSA) 
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